{"100-1.\n\u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c2010\u5e74\u7f8e\u570b\u5fc3\u81df\u5354\u6703(American Heart Association)\u9812\u4f48\u7684\u5c08\u5bb6\u6703\u8b70\u5efa\u8b70\uff0c\u4e0b\u5217\u6709\u95dc\u9662\u5916\u5fc3\u81df\u9589\u6b62(Out-Hospital Cardiac Arrest, OHCA)\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u6b63\u78ba\uff1f\nA. \u5916\u884c\u4eba(Lay person)\u65bd\u884cCPR\u4ecd\u61c9\u9075\u5faa\u80f8\u8154\u58d3\u7e2e(Chest compression)\u53ca\u6301\u7e8c\u6216\u4e2d\u65b7\u6027\u4eba\u5de5\u547c\u5438(Ventilation)\nB. \u53ef\u53ea\u65bd\u884c\u80f8\u8154\u58d3\u7e2e\uff0c\u4ee5\u865f\u53ec\u66f4\u591a\u7684\u5916\u884c\u4eba\u5bb9\u6613\u53c3\u8207CPR\nC. \u53ef\u53ea\u65bd\u884c\u4eba\u5de5\u547c\u5438\uff0c\u4ee5\u865f\u53ec\u66f4\u591a\u7684\u5916\u884c\u4eba\u5bb9\u6613\u53c3\u8207CPR\nD. \u65b0\u5f0f\u7684\u6cbb\u7642-\u4f4e\u6eab\u6cbb\u7642(Therapeutic hypothermia)\u3001\u7d93\u76ae\u51a0\u8108\u963b\u4ecb(PCI)\u53ca\u7559\u7f6e\u5fc3\u81df\u53bb\u986b\u5668(ICD)\u7b49\u4e26\u7121\u5be6\u8cea\u7642\u6548\nE. \u904e\u5ea6\u5f37\u8abf\u55ae\u4e00\u7684\u4eba\u5de5\u547c\u5438\u6216\u80f8\u8154\u58d3\u7e2e\uff0c\u6050\u5f0a\u591a\u65bc\u5229\n": "(B)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u5167\u819c\u708e(Infective Endocarditis)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. \u9032\u6b65\u570b\u5bb6\u7684\u5fc3\u5167\u819c\u708e\u8fd1\u5e74\u591a\u589e\uff0c\u56e0\u975e\u6cd5\u4f7f\u7528\u7981\u85e5\u3001\u591a\u7528\u5fc3\u5167\u5668\u68b0(Intracardiac device)\u3001\u591a\u589e\u9000\u5316\u6027\u5fc3\u74e3\u819c\u75c5\u4eba\u3001\u53ca\u91ab\u8b77\u76f8\u95dc\u7684\u611f\u67d3\u75c5\u4e5f\u589e\u591a\nB. \u8d05\u751f\u7269(Vegetation)\u96c6\u8840\u5c0f\u677f\u3001\u7e96\u7dad\u7d20\u3001\u75c5\u83cc\u53ca\u5c11\u6578\u7684\u767c\u708e\u7d30\u80de\uff0c\u591a\u898b\u65bc\u4f4e\u58d3\u8154\u5ba4\u7684\u5fc3\u81df\u7d50\u69cb\nC. \u80c3\u8178\u606f\u8089\u6216\u61a9\u5ba4(Diverticuli)\u5e38\u662f\u93c8\u7403\u83cc\u682a\u7684\u4f86\u6e90\uff0c\u800c\u5927\u8178\u7403\u83cc(Enterococci)\u5e38\u4f86\u81ea\u6ccc\u5c3f\u9053\nD. \u793e\u5340\u611f\u67d3\u5fc3\u5167\u819c\u708e\u591a\u56e0\u93c8\u7403\u83cc(S. viridian)\u3001Staphylococci\u53caHACEK\u75c5\u83cc\u800c\u8d77\nE. \u98df\u9053\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u53ef\u63d0\u9ad8\u5fc3\u5167\u819c\u708e\u7684\u8a3a\u65b7\n": "(A)", "100-3.\n\u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u75c5\u5f8c\uff0c\u767c\u751f\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u6642\uff0c\u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u4e0b\u5217\u4f55\u8005\u6c92\u6709\u7f6e\u653e\u6c38\u4e45\u6027\u5fc3\u5f8b\u8abf\u6574\u5668(Permanent pacemaker implantation)\u7684\u5fc5\u8981\uff1f\nA. \u6301\u7e8c\u6027\u7b2c\u4e8c\u6216\u4e09\u5ea6His\u6c0f\u675f\u4ee5\u4e0b\u4e4b\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\nB. \u77ed\u9663\u6027\u7b2c\u4e8c\u6216\u4e09\u5ea6AV node\u4ee5\u4e0b\u4e4b\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\uff0c\u540c\u6642\u4f34\u6709\u675f\u679d\u50b3\u5c0e\u963b\u6eef(BBB)\nC. \u77ed\u9663\u6027\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u540c\u6642\u4f34\u6709\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef(Left anterior fascicular block)\nD. \u6301\u7e8c\u6027\u4e14\u6709\u75c7\u72c0\u7684\u7b2c\u4e8c\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\nE. \u6301\u7e8c\u6027\u4e14\u6709\u75c7\u72c0\u7684\u7b2c\u4e09\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\n": "(C)", "100-4.\n\u816b\u7624\u75c5\u4eba\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u65e5\u591a\uff0c\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u85e5\u7269\u4e4b\u5fc3\u8840\u7ba1\u6bd2\u5bb3\u7684\u5be6\u8b49\u91ab\u5b78\u8ad6\u9ede\uff0c\u54ea\u4e9b\u662f\u932f\u8aa4\u7684\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u6bcf\u7a2e\u816b\u7624\u6cbb\u7642\u85e5\u7269\u90fd\u5177\u540c\u6a23\u5fc3\u81df\u6bd2\u5bb3\r\n2. \u51fa\u73fe\u6bd2\u5bb3\u8207\u5e74\u9f61\u7121\u95dc\r\n3 .\u6bd2\u5bb3\u7684\u7522\u751f\u8207\u5291\u91cf\u7684\u5927\u5c0f\u53ca\u670d\u7528\u7684\u6642\u9593\u9577\u77ed\u6709\u95dc\r\n4 .\u4f7f\u7528Beta-Blockers\u53ef\u6539\u5584\u5fc3\u81df\u529f\u80fd\r\n5.\u5118\u65e9\u4f7f\u7528Angiotensin converting enzyme inhibitors\u53ef\u9810\u9632\u5fc3\u808c\u75c5\u8b8a\u4e4b\u767c\u751f\nA. 1+2+3\nB. 1+3+5\nC. 1+2\nD. 2+3\nE. 3+5\n": "(C)", "100-5.\n\u4e0b\u5217\u7684\u5e8a\u908a\u5c64\u6b21\u5fb5\u5146\uff0c\u54ea\u4e9b\u4e0d\u8db3\u4f5c\u70ba\u5224\u5b9a\u50e7\u5e3d\u74e3\u819c\u72f9\u7a84(Mitral stenosis)\u56b4\u91cd\u5ea6\u4e4b\u6839\u64da\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u7b2c\u4e8c\u5fc3\u97f3(P2)-open snap(OS)\u6642\u9593\u5ef6\u9577\r\n2. \u51fa\u73fe\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u540c\u6642\u5408\u4f75\u5fc3\u5ba4\u5feb\u61c9(Rapid ventricular response)\r\n3. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6e2c\u5b9a\u4e4b\u50e7\u5e3d\u74e3\u53e3\u9762\u7a4d(Mitral valvular area)\u5c0f\u65bc1cm2\r\n4. \u51fa\u73fe\u80ba\u52d5\u8108\u9ad8\u58d3(Pulmonary hypertension)\u540c\u6642\u6709\u4e09\u5c16\u74e3\u9589\u92b7\u4e0d\u5168(Tricuspid regurgitation)\r\n5. \u51fa\u73feAustin-Flint murmur\nA. 1+2+3\nB. 1+3+5\nC. 1+3\nD. 1+5\nE. 2+4\n": "(D)", "100-6.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u81e8\u5e8a\u6307\u5f15(Guideline)\u61c9\u5305\u62ec\u4e0b\u5217\u8af8\u9ede\u6025\u8a3a\u8655\u7f6e\uff0c\u4f46\u4f55\u8005\u9664\u5916\uff1f\nA. \u6aa2\u50b7\u5206\u985e\u4ee5\u78ba\u4fdddoor-to-needle time\u5c0f\u65bc30\u5206\u9418\u6216door-to-balloon time\u5c0f\u65bc90\u5206\u9418\nB. \u4f7f\u7528Aspirin\nC. \u9664\u4f4e\u8840\u58d3\u3001\u5fc3\u8df3\u5c0f\u65bc60/min\u53ca\u91cd\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u5916\uff0c\u61c9\u4f7f\u7528Beta-Blockers\u6cbb\u7642\nD. \u9664\u4f4e\u8840\u58d3\u53ca\u53f3\u5fc3\u5ba4\u5fc3\u808c\u6897\u585e\uff0c\u820c\u4e0bNitroglycerin\u78ba\u6709\u4f7f\u7528\u7684\u9700\u8981\nE. \u53ef\u4ee5dihydropyridines\u9223\u96e2\u5b50\u963b\u65b7\u5291\u64f4\u5f35\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u4ee5\u6539\u5584\u5fc3\u808c\u8840\u6db2\u5faa\u74b0\n": "(E)", "100-7.\n\u5973\u6027\u75c5\u4eba68\u6b72\u5728\u6d17\u814e\u4e2d\uff0c\u6709\u982d\u660f\u3001\u5168\u8eab\u7121\u529b\u3001\u51b7\u6c57\u53ca\u5fae\u5598\u6c23\uff0c\u4e43\u8f49\u6025\u8a3a\u8655\u7f6e\u3002\u9019\u4f4d\u592a\u592a\u670910\u5e74\u9ad8\u8840\u58d3\u53ca20\u591a\u5e74\u7684\u7cd6\u5c3f\u75c5\u53f2\uff0c\u4e5f\u5728\u6578\u5e74\u524d\u56e0\u51a0\u5fc3\u75c5\u66fe\u63a5\u53d7\u7d93\u76ae\u51a0\u8108\u4ecb\u5165\u6cbb\u7642(PCI)\uff0c\u4e8c\u5e74\u524d\u56e0\u814e\u75c5\u672b\u671f\uff0c\u6bcf\u9031\u4e09\u6b21\u8840\u6db2\u900f\u6790(Hemodialysis)\u3002\u7406\u5b78\u6240\u898b\uff0cBT\uff1a35.4\u00b0C, RR\uff1a16 min, HR\uff1a43 min, BP\uff1a84/50 mmHg\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u6709\u8ca7\u8840\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u80f8\u90e8\u6709\u6fd5\u56c9\u97f3\uff0c\u5de6\u5fc3\u64f4\u5927\uff0cS1\u504f\u5f31\uff0c\u5728\u5fc3\u5c16\u8655\u6709Gr II Systolic murmur\uff0c\u672a\u8f49\u79fb\uff0c\u4e5f\u7121S3\u6216S4\uff0c\u8179\u90e8\u5fae\u80d6\uff0c\u809d\u813e\u672a\u89f8\u89ba\uff0c\u96d9\u8173\u8f15\u5ea6\u6c34\u816b\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8\uff38\u5149\u5982\u5716\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Uremic cardiomyopathy\nB. Acute myocardial infarction\nC. Hyperkalemia\nD. Complete AV block\nE. Sick sinus syndrome\n": "(C)", "100-8.\n27\u6b72\u7537\u6027\u4e00\u5411\u5065\u5eb7\u53c8\u6d3b\u8e8d\uff0c\u8fd1\u65e5\u4e26\u7121\u50b7\u98a8\u6216\u611f\u5192\uff0c\u8207\u6578\u4f4d\u597d\u53cb\u805a\u9910\u98f2\u9152\uff0c\u6642\u8fd1\u5348\u591c\uff0c\u7a81\u7136\u5931\u53bb\u77e5\u89ba\u5012\u5730\uff0c\u5927\u5925\u4e00\u9663\u614c\u5f35\uff0c\u4f46\u4ecd\u9032\u884cCPR\uff0c\u5f8c\u6025\u96fb\u6551\u8b77\u8eca\u8f49\u9001\u6700\u8fd1\u6025\u8a3a\u8655\uff0c\u7dca\u6025\u6551\u8b77\u54e1\u63a5\u7e8c\u6025\u6551\uff0c\u4e03\u5206\u9418\u9001\u62b5\u91ab\u9662\uff0c\u4f9d\u7167Out-Hospital Cardiac Arrest(OHCA)\u8655\u7f6e\u3002Pupil\uff1a5/5 \u660f\u8ff7\u6307\u6578\uff1aE1V1M1\uff1b\u8eab\u9ad8\uff1a160cm\uff1b\u9ad4\u91cd\uff1a70kg\uff1b\u9ad4\u6eab\uff1a37.2\u2103\uff1b\u7121\u5fc3\u8df3\uff0c\u7121\u8840\u58d3\u53ca\u7121\u547c\u5438\u3002\u8840\u6db2\u53ca\u751f\u5316\u6aa2\u67e5\uff1a WBC\uff1a24000/uL\uff1bHb\uff1a15.2 gm/dL\uff1bPlt:378000/uL\uff1bSeg/Lym\uff1a40.6%/52.3%\uff1bBUN\uff1a10.9 mg/dL\uff1bCr\uff1a1.23 mg/dL\uff1bGOT:58 IU/L\uff1bGlucose\uff1a309 mg/dL\uff1bNa/K/Cl/Mg\uff1a140/3.1/103/0.8 mol/L\uff1bCa7.7\r\nmg/dL\uff1bCKMB/CPK\uff1a2.6/87 U/L Tropnin I 0.19ng/mL\uff1bABG:PH\uff1a6.928\uff1bPCO2\uff1a89.9mmHg\uff1b PO2\uff1a154.6mmHg\uff1bHCO3\uff1a18.4 mEq/L\uff1bSaO2\uff1a97.2%\u3002\u7d93\u6025\u6551\u5f8c\uff0c\u5448\u73fe\u9ad8\u71d2>42\u2103\uff0c\u5fc3\u8df3120bpm\u53ca\u8840\u58d3BP117/76 mmHg\u53ca\u6bcf\u520640\u6b21\u4e4b\u6025\u4fc3\u547c\u5438\uff0c\u5fc3\u97f3\u5fae\u5f31\uff0c\u6574\u500b\u80ba\u547c\u5438\u8072\u6fc1\uff0c\u56db\u80a2\u8edf\u5f31\u3002\u5fc3\u96fb\u5716\u5982\u793a\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684OHCA\u539f\u56e0\u662f\uff1a\nA. Acute anterior myocardial infarction\nB. Acute myocarditis\nC. Alcoholic intoxication\nD. Brugada's syndrome\nE. Long QT syndrome\n": "(D)", "100-9.\n56\u6b72\u7537\u6027\u516c\u52d9\u4eba\u54e1\u56e0\u7a81\u767c\u5fc3\u80f8\u524d\u5340\u5287\u75db\uff0c\u6709\u5de6\u624b\u7684\u8f49\u79fb\u9178\u75bc\uff0c\u4e26\u5b58\u5192\u6c57\u53ca\u81c9\u8272\u84bc\u767d\uff0c\u96a8\u5373\u62b5\u9054\u6025\u8a3a\u8655\u8a3a\u7642\uff0c\u75c5\u4eba\u6709\u4e09\u5341\u5e74\u6bcf\u59291.5\u5305\u9999\u7159\u53ca\u4e09\u5e74\u8f15\u5ea6\u7cd6\u5c3f\u75c5\uff0c\u8fd1\u4e09\u500b\u6708\u6709\u9593\u6b47\u6027\u5fc3\u7d5e\u75bc\u767c\u751f\u3002\u7406\u5b78\uff1a\u6025\u75c5\u72c0\uff0c\u8840\u58d3165/106 mmHg\uff1b \u5fc3\u8df396/min\uff1b\u9ad4\u6eab36.7\u2103\uff0c\u5176\u4ed6\u4e26\u7121\u986f\u8457\u7570\u5e38\u3002\u5fc3\u96fb\u5716\u5982\u793a\uff0c\u8acb\u554f\u9019\u5f35\u5fc3\u96fb\u5716\u6240\u8868\u73fe\u6700\u53ef\u80fd\u7684\u51a0\u72c0\u52d5\u8108\u5b8c\u5168\u963b\u585e\u4f4d\u7f6e\u662f\uff1a\nA. Left main coronary artery\nB. Left anterior descending artery proximal to septal branch\nC. Proximal left circumflex artery\nD. Proximal right coronary artery\nE. Left anterior descending artery to Diagonal branch\n": "(D)", "100-10.\n\u4e0b\u5217\u6709\u95dc\u7121\u75c7\u72c0\u9ad8\u8840\u58d3(>180/120mmHg)\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r\n1. \u6b63\u898f\u4f7f\u7528\u6cbb\u7642\u91cf\u7684\u591a\u7a2e\u964d\u8840\u58d3\u85e5\u7684\u75c5\u4eba\u4ecd\u820a\u7121\u6548\uff0c\u5176\u9ad8\u8840\u58d3\u591a\u56e0\u651d\u53d6\u98df\u9e7d\u9ad8\u6240\u800c\u8d77\uff0c\u61c9\u5f37\u5236\u9650\u7528\u98df\u9e7d\u98f2\u98df\r\n2. \u4ecd\u61c9\u7dca\u6025\u964d\u4f4e\u8840\u58d3\u5230160/100mmHg\u4ee5\u4e0b\uff0c\u4ee5\u7b56\u5b89\u5168\r\n3. \u4f7f\u7528\u820c\u4e0bNifedipine\u964d\u58d3\u662f\u9019\u985e\u75c5\u4eba\u4e4b\u9996\u9078\r\n4. \u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u5b55\u5a66\u7684\u9ad8\u8840\u58d3\u61c9\u5373\u6ce8\u5c04\u975c\u8108Nicardipine\r\n5. \u4e0d\u61c9\u7acb\u5373\u4f4f\u9662\nA. 1+2+3\nB. 2+3+4\nC. 1+3+5\nD. 1+4\nE. 1+5\n": "(E)", "100-11.\n\u5fc3\u8840\u7ba1\u7cfb\u7d71\u7406\u5b78\u6aa2\u67e5\u4e4b\u7368\u7279\u6027\u70ba\u8996\u8a3a (\u5167\u9838\u975c\u8108)\u3001\u89f8\u8a3a (\u9838\u52d5\u8108\u6216\u6a48\u9aa8\u8108\u640f)\u8207\u807d\u8a3a\u53ef\u540c\u6b65\u57f7\u884c (\u6240\u8b023\u54081\u6aa2\u67e5)\u3002\u4e0b\u5217\u5fc3\u96fb\u5716 (1 - 4) \u6240\u793a\u4e4b\u4e0d\u6574\u8108,\u5982\u53ea\u9760\u52d5\u8108\u628a\u8108\uff0c\u4f55\u8005\u6703\u88ab\u8aa4\u5224\u70ba\u7ac7\u623f\u6027\u5f90\u8108 (sinus bradycardia)?\nA. 1\nB. 2\nC. 3\nD. 4\nE. 1-4 \u7686\u6703\u88ab\u8aa4\u5224\u70ba\u7ac7\u623f\u6027\u5f90\u8108\n": "(E)", "100-12.\n\u80f8\u90e8\u2169\u5149\u4e0b\u5217\u7570\u5e38\u6240\u898b\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u5de6\u5fc3\u623f\u64f4\u5927\nB. \u5de6\u5fc3\u5ba4\u64f4\u5927\nC. \u53f3\u5fc3\u5ba4\u64f4\u5927\nD. \u80ba\u975c\u8108\u58d3\u4e0a\u6607\nE. \u80ba\u4e3b\u52d5\u8108\u64f4\u5927\n": "(B)", "100-13.\n\u4e00\u4f4d40\u6b72\u7537\u6027\u60a3\u6709 primary pulmonary hypertension, \u56e0\u5e73\u6642\u547c\u5438\u56f0\u96e3\u3001\u8173\u6d6e\u816b\u670d\u7528\u5229\u5c3f\u5291\u3002\u56e0\u6700\u8fd1\u5169\u9031\u8d70\u8def\u6642\u4e0a\u8179\u90e8\u6f32\u75db\u63d0\u524d\u81f3\u9580\u8a3a\u8907\u8a3a\u3002\u554f\u8a3a\u767c\u73fe\u5176\u8179\u90e8\u75c7\u72c0\u8173\u816b\u52a0\u5287\u6642\u66f4\u660e\u986f\uff0c\u53cd\u4e4b\u5982\u52a0\u91cd\u4f7f\u7528\u5229\u5c3f\u5291\u6d6e\u816b\u6e1b\u8f15\u5f8c\u5247\u6539\u5584\u3002\u75c5\u4eba\u7121\u809d\u75c5\u6216\u809d\u529f\u80fd\u7570\u5e38\u4e4b\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u610f\u8b58\u6e05\u6670\uff0c\u8840\u58d3118/76 mmHg\uff0c\u8108\u640f\u6bcf\u5206\u941898\u3001\u898f\u5247\uff0c\u547c\u5438\u7a0d\u6dfa\u5feb\u3001\u624b\u8173\u7a0d\u51b0\u51b7\uff0c\u5750\u4f4d\u6642\u53f3\u8033\u5782\u96a8\u5fc3\u6536\u7e2e\u671f\u640f\u52d5\u3002\u5fc3\u81df\u53f3\u5fc3\u5ba4\u64f4\u5927 (\u80f8\u9aa8\u4e0b\u5de6\u7de3\u81f3\u5fc3\u5c16\u90e8\u4f4d\uff0c\u7030\u6f2b\u6027\u6536\u7e2e\u671f\u640f\u52d5(systolic heave)\uff0c\r\n\u7b2c\u4e8c\u5fc3\u97f3P2\u4ea2\u9032\uff0c\u80f8\u9aa8\u5de6\u7de3\u4e0b\u7b2c\u4e09\u5ea6\u6536\u7e2e\u671f\u96dc\u97f3\u96a8\u5438\u6c23\u589e\u5f37\u3002\u80ba\u90e8\u7121\u660e\u986f\u56c9\u97f3\uff0c\u809d\u660e\u986f\u816b\u5927\u8868\u9762\u5e73\u6ed1\u3001\u96a8\u5fc3\u6536\u7e2e\u671f\u640f\u52d5\u3001\u7a0d\u6709\u58d3\u75db\u3002\u6709\u95dc\u6b64\u75c5\u4eba\u75c5\u60c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u6709\u53f3\u5fc3\u5ba4\u8870\u7aed\u53ca\u56b4\u91cd\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\uff0c\u809d\u975c\u8108/\u6bdb\u7d30\u7ba1\u975c\u6c34\u58d3\u4e0a\u5347\uff0c\u5c0e\u81f4\u809d\u5145\u8840 (congested liver) \u3002\r\n2.\u6709\u52de\u4f5c\u6027\u72f9\u5fc3\u75c7 (exertional angina)\u3002\r\n3.\u9810\u671f\u6b64\u75c5\u4eba\u809d\u529f\u80fd\u6aa2\u67e5\u7570\u5e38AST\u3001ALT\uff0c\u4e14ALT\u4e0a\u5347\u8f03AST\u4e0a\u5347\u591a\r\n4.\u4e0a\u8ff0\u809d\u529f\u80fd\u6aa2\u67e5\u7570\u5e38\u8207 shock liver\u6642\u96f7\u540c\u3002\r\n5.\u6709\u57f7\u884c\u809d\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e4b\u9069\u61c9\u75c7\u3002\nA. 1+3+4\nB. 1+2+3+4+5\nC. 1+3+4+5\nD. 1+2+3+4\nE. 1+5\n": "(A)", "100-14.\n\u4ee5\u4e0b\u53ef\u80fd\u9020\u6210\u4ea4\u4e92\u4f5c\u7528(interaction) \u4e4b\u914d\u5c0d\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Amiodarone - calcium channel blocker.\nB. Statin - grape fruits (\u8461\u8404\u67da)\nC. Amiodarone - warfarin\nD. Nitrates - sildenafil\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "100-15.\n50\u6b72\u7537\u6027\uff0c\u60a3\u6709\u7cd6\u5c3f\u75c5\uff0c\u80f0\u81df\u764c\u53ca\u6050\u614c\u75c7\uff0c\u56e0\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u81f3\u6025\u8a3a\u6c42\u8a3a\u3002\u75c5\u60a3\u4e26\u7121\u660e\u986f\u80f8\u75db\u6216\u5192\u51b7\u6c57\uff0c\u610f\u8b58\u6e05\u695a\u4f46\u60c5\u7dd2\u7dca\u5f35\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab36.5\u2103\uff0c\u8840\u58d3 145/95 mmHg\uff0c\u8108\u535a112/min\u7bc0\u5f8b\u898f\u5247, \u547c\u5438 24/min\u5feb\u4e14\u6df1\uff1b\u56db\u80a2\u51b0\u51b7\u6709\u8f15\u5fae\u767c\u7d3a\u73fe\u8c61\u3002\u9838\u975c\u8108\u58d312 cm H2O\uff0c\u7121\u660e\u986f\u5fc3\u96dc\u97f3\u3002\u547c\u5438\u97f3\u96d9\u5074\u6b63\u5e38\uff0c\u8179\u90e8\u5e73\u5766\u7121\u58d3\u75db\uff0c\u56db\u80a2\u6d3b\u52d5\u6b63\u5e38\u4ea6\u7121\u6c34\u816b\u3002\u8b77\u7406\u4eba\u54e1\u7d66\u4e88\u8108\u885d\u8840\u6c27\u5b9a\u91cf\u8a08 (pulse oximeter) \u5075\u6e2c\u767c\u73feSpO2 84%\uff0c\u6025\u8a3a\u91ab\u5e2b\u96a8\u5373\u6307\u793a\u4f7f\u7528Venturi mask O2 35%\u3002\u7d04\u534a\u5c0f\u6642\u5f8c\uff0c\u75c5\u4eba\u81ea\u89ba\u75c7\u72c0\u7565\u70ba\u6e1b\u7de9\uff0c\u6b64\u6642\u4e4b\u52d5\u8108\u6c23\u9ad4\u5206\u6790: PH 7.50, PaO2 70mmHg, PaCO2 25 mmHg, HCO3 23\r\nmEq/L, one touch blood glucose 320 mg/dl. EKG\u9664\u7ac7\u6027\u983b\u8108\u5916\u5176\u9918\u6b63\u5e38\uff0c\u80f8\u90e8\u2169\u5149\u5982\u9644\u5716\uff0c\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd?\nA. Acute pulmonary embolism\nB. Panic disorder related hyperventilation syndrome\nC. Diabetic ketoacidosis\nD. Endobronchial foreign body\nE. Bronchial asthma\n": "(A)", "100-16.\n\u4e0b\u5217\u6709\u95dc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 (obstructive sleep apnea, OSA) \u6240\u7522\u751f\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u5bb9\u6613\u5f15\u767c\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u5982\u8166\u4e2d\u98a8\u548c\u5fc3\u808c\u6897\u585e\nB. \u8207\u4ee3\u8b1d\u75c7\u5019\u7fa4\u4e2d\u7684\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\u7121\u95dc\nC. OSA\u4e5f\u548c\u9ad8\u8840\u58d3\u53ca\u80ba\u52d5\u8108\u9ad8\u58d3\u76f8\u95dc\nD. OSA\u5f15\u8d77\u4e4b\u5fc3\u5f8b\u4e0d\u6574\uff0c\u6700\u5e38\u898b\u70ba\u623f\u5ba4\u963b\u65b7\u53ca\u5fc3\u623f\u986b\u52d5 (Atrial fibrillation)\nE. \u56b4\u91cd\u4e4bOSA\u7d93\u9023\u7e8c\u547c\u5438\u9053\u6b63\u58d3\u547c\u5438\u5668 (CPAP) \u6210\u529f\u6cbb\u7642\u5f8c\uff0c\u5fc3\u808c\u6897\u585e\u53ca\u8166\u4e2d\u98a8\u4e4b\u98a8\u96aa\u53ef\u6062\u5fa9\n": "(B)", "100-17.\n\u75c7\u72c0\u4e4b\u8d77\u59cb\u767c\u4f5c\u578b\u614b (mode of onset) \u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u6975\u70ba\u91cd\u8981\uff0c\u4e0b\u5217\u53ef\u80fd\u4ee5\u80f8\u75db\u8868\u73fe\u4e4b\u6025\u75c7\u4e2d\uff0c\u5176\u75db\u4e4b\u8d77\u59cb\u767c\u4f5c\u578b\u614b\u70ba\u8d85\u6025\u6027(abrupt or dramatic onset) - \u5373\u5176\u75db\u7a81\u7136\u767c\u751f\uff0c\u5176\u7a0b\u5ea6\u77ac\u9593\u6216\u8fc5\u901f\u9054\u5230\u6975\u9ede (\u6674\u5929\u9739\u9742\u5f0f) \u8005\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f\nA. \u6025\u6027\u5fc3\u808c\u6897\u585e\nB. \u4e3b\u52d5\u8108\u525d\u96e2\u75c7\nC. \u6c23\u80f8 (pneumothorax)\nD. Boerhaave's syndrome\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(A)", "100-18.\n\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u5f15\u8d77\u4e4b\u547c\u5438\u56f0\u96e3\u7684\u767c\u75c5\u578b\u614b (onset mode) \u662f\u70ba\u7a81\u767c\u6027 (sudden onset)? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. Pneumothorax\r\n2. Acute pulmonary embolism\r\n3. Acute severe mitral regurgitation due to chordae tendineae rupture\r\n4. Panic disorder related hyperventilation syndrome\r\n5. ARDS (acute respiratory distress syndrome)\nA. 1+2\nB. 1+2+3\nC. 1+2+3+4\nD. 1+2+3+4+5\nE. 1+2+4\n": "(C)", "100-19.\n\u80ba\u6c34\u816b\u7684\u75c5\u614b\u751f\u7406\u5b78\uff0c\u5c0e\u56e0\u65bc\u6c34/\u9209\u96e2\u5b50\u7559\u6eef\u5728\u6bdb\u7d30\u7ba1\u5916\u9593\u8cea\u5167\u6240\u5f15\u8d77\u3002\u4f9d\u7167\u5176\u539f\u56e0\u53ef\u5206\u70ba\u5169\u5927\u985e\uff0c\u5373\u5fc3\u56e0\u6027 (cardiogenic) \u548c\u975e\u5fc3\u56e0\u6027 (non-cardiogenic)\uff0c\u6cbb\u7642\u65b9\u5411\u4e0d\u76e1\u76f8\u540c\uff0c\u6545\u5176\u9451\u5225\u8a3a\u65b7\u6975\u70ba\u91cd\u8981\u3002\u4e0b\u5217\u5404\u7a2e\u75be\u75c5\u5f15\u8d77\u4e4b\u80ba\u6c34\u816b\u70ba\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (Acute respiratory distress syndrome)\r\n2. \u6bd2\u7269\u5438\u5165\u5f15\u8d77\u4e4b\u80ba\u640d\u50b7 (toxic inhalation lung injury)\r\n3. \u518d\u64f4\u5f35\u6027\u80ba\u6c34\u816b (re-expansion pulmonary edema)\r\n4. \u9ad8\u5c71\u75c7\r\n5. \u4e8c\u5c16\u74e3\u72f9\u7a84\r\n6. \u5de6\u5fc3\u5ba4\u8870\u7aed\nA. 1+2\nB. 1+2+3\nC. 1+2+3+4\nD. 1+2+3+4+5\nE. 1+2+3+4+5+6\n": "(C)", "100-20.\n\u59ff\u52e2\u8207\u9ad4\u4f4d\u7684\u8b8a\u5316\u6703\u9020\u6210\u5fc3\u81df\u524d\u8ca0\u8377\u8207\u7cfb\u7d71\u6027\u52d5\u8108\u8840\u7ba1\u963b\u529b (systemic vascular resistance) \u4e4b\u6539\u8b8a\u3002\u4e0b\u5217\u5404\u7a2e\u60c5\u6cc1\u8207\u751f\u7406\u5b78\u4e4b\u914d\u5c0d\u4f55\u8005\u6709\u8aa4?\nA. \u7576\u75c5\u4eba\u767c\u751fVasovagal syncope\u6642\uff0c\u8b93\u75c5\u4eba\u5e73\u8eba\u4e26\u4f7f\u5176\u5448knee-chest position (\u819d\u84cb\u5411\u80f8\u53e3\u5f4e\u66f2) \u53ef\u5e6b\u52a9\u75c5\u4eba\u7526\u9192\nB. \u80a5\u539a\u6027\u963b\u585e\u578b\u5fc3\u808c\u75c5\u8b8a (hypertrophic obstructive cardiomyopathy) \u7684\u75c5\u4eba\uff0c\u4ee4\u5176\u8e72\u4e0b\uff0c\u53ef\u4f7f\u5f8c\u8ca0\u8377\u6e1b\u5c11\u800c\u8b93\u96dc\u97f3\u6e1b\u5f31\nC. \u6cd5\u6d1b\u6c0f\u56db\u5408\u75c7 (tetralogy of Fallot) \u4e4b\u75c5\u7ae5\uff0c\u7576\u5176\u767c\u751fhypoxic spell (\u7f3a\u6c27\u6027\u767c\u4f5c) \u547c\u5438\u56f0\u96e3\u3001\u767c\u7d3a\u60e1\u5316\u6642\uff0c\u5e38\u81ea\u4e3b\u6027\u8e72\u4e0b\uff0c\u56e0\u4f7f\u53f3\u5fc3\u5ba4\u524d\u8ca0\u8377\u589e\u52a0\u4e14\u5de6\u3001\u53f3\u5fc3\u5ba4\u58d3\u529b\u589e\u52a0\u800c\u80ba\u8840\u6d41\u589e\u52a0\uff0c\u81f3\u5de6\u5fc3\u5ba4\u5206\u6d41\u6e1b\u5c11\uff0c\u4ee5\u6e1b\u7de9\u75c7\u72c0\nD. \u5fc3\u7d5e\u75db\u4e4b\u75c5\u4eba\u82e5\u7ad9\u7acb\u6642\u4f7f\u7528\u785d\u9178\u9e7d\u820c\u4e0b\u542b\u9320\u53ef\u80fd\u5c0e\u81f4\u6688\u53a5\uff0c\u662f\u7531\u65bc\u59ff\u52e2\u6539\u8b8a\u53ca\u975c\u8108\u64f4\u5f35\uff0c\u9020\u6210\u524d\u8ca0\u8377\u6025\u907d\u6e1b\u5c11\u6240\u9020\u6210\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(B)", "100-21.\n\u5fc3\u623f\u986b\u52d5 (atrial fibrillation) \u70ba\u6700\u5e38\u898b\u4e4b\u6301\u7e8c\u6027\u983b\u8108 (sustained tachycardia) \uff0c\u5176\u767c\u751f\u7387\u96a8\u5e74\u9f61\u800c\u589e\u52a0\u3002\u6709\u95dc\u8001\u5e74\u4eba\u767c\u751f\u5fc3\u623f\u986b\u52d5\u6642\u4e4b\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u5e38\u60a3\u6709\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u529f\u80fd\u7570\u5e38 (left ventricular dysfunction)\uff0c\u800c\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u9806\u61c9\u6027\u964d\u4f4e\uff0c\u56e0\u6b64\u8108\u5dee(pulse deficit) \u6bd4\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u529f\u80fd\u6b63\u5e38\u8005\u76f8 \u5c0d\u589e\u52a0\nB. \u4f7f\u7528\u63a7\u901f\u85e5\u7269\uff0c\u5291\u91cf\u8abf\u6574\u61c9\u4ee5\u9069\u7576\u5fc3\u5ba4\u7387\u70ba\u6e96\nC. \u56e0\u5e38\u53ef\u80fd\u814e\u529f\u80fd\u7570\u5e38\uff0c\u4f7f\u7528amiodarone\u63a7\u901f\uff0c\u61c9\u76e3\u63a7\u5176\u8840\u4e2d\u6fc3\u5ea6\nD. \u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 (hyperthyroidism) \u6709\u53ef\u80fd\u55ae\u4ee5\u5fc3\u623f\u986b\u52d5\u8868\u73fe\nE. \u82e5\u6709\u767c\u751ftransient ischemia attack\uff0c\u5247\u5efa\u8b70\u4f7f\u7528Warfarin.\n": "(C)", "100-22.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic Shock, CS)\u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba\u7684?\nA. \u5fc3\u96fb\u5716\u53ef\u80fd\u770b\u5230 Q wave \u53ca ST elevation>2mm\u6216LBBB\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u76f8\u95dc\u4e4bCS\u56e0\u65e9\u671f\u8840\u7ba1\u8108\u518d\u901a(Revascularization)\u5176\u767c\u751f\u7387\u5df2\u5f9e20%\u964d\u523010%\u4ee5\u4e0b\nC. \u61c9\u96a8\u5373\u65bd\u884c\u8d85\u97f3\u6ce2\u5fc3\u5716\u4ee5\u78ba\u5b9a\u75c5\u56e0\nD. \u4f9d\u64daSHOCK Trial, Coronary artery bypass graft surgery(CABGS)\u6216Percutaneous intervention(PCI)\u6bd4IABP(Intra aoric balloon counterpulsation)\u4f75\u7528\u8840\u6813\u6eb6\u89e3\u6cbb\u7642\u70ba\u4f73\nE. \u5927\u65bc75\u6b72\u4e0d\u9069\u5b9c\u65bd\u884cCABG\u6216PCI\n": "(E)", "101-1.\n\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u4e0d\u9069\u5fc3\u81df\u78c1\u6838\u5171\u632f\u5f71\u50cf(Cardiovascular magnetic resonance imaging)\u6aa2\u67e5\uff1f\nA. \u51a0\u8108\u7ba1\u5167\u652f\u67b6(Coronary stents)\nB. \u6b98\u7559\u5fc3\u81df\u51672000\u5e74\u5f8c\u4e4b\u5fc3\u5f8b\u8abf\u6574\u5668\u7684\u7ba1\u7dda(Pacemaker leads)\nC. \u80f8\u9aa8\u5207\u88c2\u91d1\u5c6c\u5d4c\u5408\u7dda(Sternotomy wires)\nD. \u80f8\u8154\u5167\u8840\u7ba1\u9257\u593e(Vascular clip)\nE. \u751f\u7269\u6027\u53ca\u91d1\u5c6c\u6027\u4eba\u5de5\u5fc3\u81df\u74e3\u819c(Bioprosthetic & mechanical heart valve)\n": "(E)", "101-2.\n\u4fb5\u5165\u6027\u7684\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u67093-7%\u767c\u751f\u986f\u5f71\u5291\u5c0e\u767c\u814e\u75c5\u8b8a(Contrast-induced nephropathy)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u9810\u9632\u8655\u7f6e\u932f\u8aa4\uff1f\nA. \u5728\u8853\u524d\u53ca\u8853\u5f8c\u7d66\u4e88Normal saline 50 cc/hour x 24 hours\nB. \u8853\u524d\u4e8c\u5929\u958b\u59cb Acetylcysteine 600 mg bid\nC. \u7cd6\u5c3f\u75c5\u4eba\u6212\u7528Metformin\nD. \u4f7f\u7528\u53e3\u670d\u4f4e\u6fc3\u5ea6\u9e7d\u9178\u4ee5\u589e\u52a0\u986f\u5f71\u5291\u4e4b\u6eb6\u89e3\u5ea6\uff0c\u65e9\u671f\u6392\u51fa\u9ad4\u5916\nE. \u4f7f\u7528\u4f4e\u6ef2\u900f\u58d3\u986f\u5f71\u5291(Low-osmolar contrast media)\uff0c\u9650\u91cf\u5728100 cc \u4ee5\u4e0b\n": "(D)", "101-3.\n\u8a3a\u65b7\u50e7\u5e3d\u74e3\u72f9\u7a84(Mitral stenosis)\u4e4b\u56b4\u91cd\u5ea6\u9664\u5305\u62ec\u81e8\u5e8a\u7684\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3\u3001\u5fc3\u60b8\u53ca\u8840\u75f0\u5916\uff0c\u53ca\u7406\u5b78\u986f\u73fe\u7684\u53f3\u5fc3\u64f4\u5927\uff0c\u5f37\u5ea6S1\uff0c\u5f37\u5ea6\u5fc3\u8212\u4e2d\u671f\u9686\u55da\u96dc\u97f3(Mid-diastolic rumbling murmur)\u53ca\u5fc3\u7e2e\u524d\u671f\u96dc\u97f3\u3002\u5f9e\u8840\u884c\u529b\u5b78\u7684\u89d2\u5ea6\uff0c\u4ee5\u4e0b\u5217\u4f55\u8005\u6700\u6703\u5f71\u97ff\u50e7\u5e3d\u74e3\u72f9\u7a84\u4e4b\u81e8\u5e8a\u75c7\u72c0\u7684\u56b4\u91cd\u5ea6\uff1f\nA. \u5fc3\u8df3(Heart rate)\nB. \u7a7f\u8d8a\u50e7\u5e3d\u74e3\u8840\u58d3\u95a5\u5dee(Trans-mitral valvular pressure gradient)\nC. \u5fc3\u81df\u6392\u8840\u91cf(Cardiac output)\nD. \u50e7\u5e3d\u74e3\u958b\u53e3\u9762\u7a4d(Mitral valvular area)\nE. S2 to OS(Open snap)\u6642\u9593\u7e2e\u77ed\n": "(A)", "101-4.\n\u75c5\u4eba82\u6b72\u8001\u592a\u5927\u56e0\u7a81\u6f38\u56b4\u91cd\u6027\u547c\u5438\u56f0\u96e3\u800c\u4f4f\u9662\uff0c\u5979\u4e09\u5341\u5e74\u524d\u5c31\u6709\u5fc3\u96dc\u97f3\u53ef\u805e\u77e5\uff0c\u552f\u672a\u66fe\u9032\u4e00\u6b65\u8a3a\u7642\u3002\u5f9e\u4e94\u5e74\u524d\u958b\u59cb\u5c31\u6709\u904b\u52d5\u96e3\u53d7\uff0c\u4f34\u6709\u904b\u52d5\u6027\u5fc3\u60b6\uff0c\u6642\u5728\u516c\u4fdd\u4e2d\u5fc3\u78ba\u8a8d\u5fc3\u81df\u64f4\u5927\uff0c\u5728\u4ee5\u5f8c\u7684\u6b72\u6708\uff0c\u75c7\u72c0\u9010\u6f38\u52a0\u5287\uff0c\u7279\u5225\u5728\u904b\u52d5\u6216\u6500\u767b\u6a13\u68af\u4e2d\uff0c\u4f11\u606f\u5373\u53ef\u6539\u5584\u3002\u4f4f\u9662\u524d\u4e09\u65e5\uff0c\u7a81\u7136\u5728\u51cc\u6668\u767c\u4f5c\u547c\u5438\u56f0\u96e3\u3002\u6642\uff0cT/P/R\uff1a36.4/90/16\uff1b BP\uff0c110/62 mmHg\uff1bjugular vein engorgement\uff1bbilateral basal chest with crackles\uff1bheart\uff0cnormal heart border\uff0cGr.III systolic murmur over RUSB with carotid transmission\uff0cS2 diminished\uff1botherwise unremarkable\u3002 Chest X- ray &\rECG\u5982\u57164-1\u53ca\u57164-2\u6240\u793a\u3002\r\u8acb\u554f\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u50e7\u5e3d\u74e3\u72f9\u7a84(Mitral stenosis)\nB. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\nC. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(Aortic stenosis)\nD. \u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168(Aortic regurgitation)\nE. \u6b63\u5e38\u5fc3\u81df\n": "(C)", "101-5.\n\u6709\u95dc\u51a0\u5fc3\u75c5\u8fd1\u56db\u5341\u5e74\u7684\u6d41\u884c\u75c5\u5b78\u6f14\u5316\uff0c\u6709\u4e0b\u5217\u8af8\u9ede\u4e4b\u6027\u5225\u5dee\u7570(Gender difference)\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u51a0\u5fc3\u75c5\u4e4b\u767c\u751f\uff0c\u4e00\u5411\u7537\u591a\u65bc\u5973\nB. \u7d93\u5e74\u9f61\u6821\u6b63(Age-adjusted)\u5f8c\uff0c\u5973\u6027\u75c5\u4eba\u7684\u5fc3\u8840\u7ba1\u75c5\u6b7b\u4ea1\u7387\u8f03\u4f4e\nC. \u4ee5\u904b\u52d5\u5fc3\u96fb\u5716\u8a3a\u65b7\u51a0\u5fc3\u75c5\uff0c\u7537\u6027\u75c5\u4eba\u6709\u8f03\u9ad8\u7684\u53ef\u9760\u5ea6\nD. \u5973\u6027\u4e4b\u51a0\u5fc3\u75c5\u767c\u751f\u6a5f\u8f49\u591a\u8207\u767c\u708e\u3001\u80a5\u80d6\u3001\u7cd6\u5c3f\u75c5\u53ca\u4ee3\u8b1d\u75c7\u5019\u7fa4\u6709\u95dc\nE. \u5973\u6027\u7684\u51a0\u5fc3\u75c5\u591a\u56e0\u51a0\u8108\u5fae\u5faa\u74b0(micro-circulation)\u5931\u80fd\u800c\u8d77\n": "(B)", "101-6.\n\u6709\u95dc\u6211\u570b\u96d9\u8449\u6027(bicuspid)\u4e3b\u52d5\u8108\u74e3\u7684\u81ea\u7136\u75c5\u53f2\u4e4b\u7814\u7a76\u5c1a\u5c6c\u6b20\u7f3a\uff0c\u552f\u4f9d\u64da\u7f8e\u570bMayo Clinic\u5728Olmstead County\u768441,687\u4f4d\u5c45\u6c11\u6b77\u6642\u4e09\u5341\u5e74\u4e4b\u7cfb\u5217\u8ffd\u8e64\uff0c\u6709\u4e0b\u5217\u8af8\u591a\u7279\u9ede\u53ef\u8cc7\u53c3\u8003\uff0c\u4f46\u4f55\u8005\u7684\u8ad6\u8ff0\u662f\u932f\u8aa4\u7684\uff1f\nA. \u65e5\u5f8c\u767c\u751f\u4e3b\u52d5\u8108\u525d\u96e2(aortic dissection)\u4f75\u767c\u75c7\u4e4b\u76f8\u5c0d\u5371\u96aa\u5ea6\u9ad8\u90548.4\u500d\nB. \u65e5\u5f8c\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(aortic stenosis)\u7684\u767c\u751f\u7387\u6bd4\u4e3b\u52d5\u8108\u74e3\u9589\u92b7\u4e0d\u5168(aortic regurgitation)\u591a\u8fd1\u4e00\u500d\nC. \u96d9\u8449\u6027\u4e3b\u52d5\u8108\u74e3\u75c5\u591a\u898b\u65bc\u7537\u6027\u75c5\u4eba\nD. \u4e00\u65e6\u4f34\u767c\u4e3b\u52d5\u8108\u7624(Aortic aneurysm)\uff0c\u5982\u5176\u76f4\u5f91\u5927\u65bc50 mm \u6642\uff0c\u5e38\u6613\u81f4\u8840\u7ba1\u7834\u88c2\nE. \u96d9\u8449\u6027\u4e3b\u52d5\u8108\u74e3\u8005\u591a\u898b\u56ca\u80de\u6027\u4e2d\u5c64\u58de\u6b7b(Cystic medial necrosis)\n": "(B)", "101-7.\n\u75c5\u4eba67\u6b72\u5973\u6027\uff0c\u4f4f\u5b89\u990a\u8001\u4eba\u9662\uff0c\u4e0b\u5e8a\u8dcc\u50b7\u53f3\u8173\uff0c\u4e94\u5929\u5f8c\u56e0\u610f\u8b58\u4e0d\u6e05\u4f34\u6709\u6c23\u4fc3\u3001\u767c\u71d2\u3001\u5bd2\u986b(chills)\u800c\u4f4f\u9662\u3002\u75c5\u4eba\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\uff0c\u4e5f\u6709\u9ad8\u8840\u58d3\u5408\u4f75\u5fc3\u81df\u8870\u7aed\u7684\u75c5\u53f2\u3002\u4f4f\u9662\u6642\uff0cGCS E2V2M3\uff1bBP\uff0c112/57 mmHg\uff1bHR\uff0c85/min\uff0cregular\uff1bRR\uff0c25/min\uff1b\u9ad4\u6eab\uff0c\u651d\u6c0f37\u5ea6\uff1b\u5fc3\u81df\u5448\u73fe\u898f\u5f8b\uff0c\u4f46\u5728\u5fc3\u5c16\u90e8\u6709Gr.III/VI Systolic murmur\uff1b\u5728\u80ba\u57fa\u8655\u6fc1\u6fd5\u547c\u5438\u8072\uff1b\u56db\u80a2\u591a\u8655\u7600\u8840\uff0c\u6b64\u5916\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002\u5be6\u9a57\u5ba4\u6240\u898b\uff1a\u767d\u8840\u7403\uff0c15350/\u03bcL\uff1bC-\u53cd\u61c9\u86cb 44.20 mg/dl(\u6b63\u5e38<1.9)\uff1b\u808c\u9178\u9150 0.98mg/dl\uff1b\u4f4f\u9662\u7b2c\u4e8c\u5929\u6709\u5169\u5957\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u5448\u73fe\u9769\u862d\u967d\u6027\u75c5\u83cc\u3002\u81e8\u5e8a\u8a3a\u65b7\u70ba\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(infective\rendocarditis)\u5f8c\uff0c\u8acb\u554f\u5728\u6b64\u523b\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u70ba\u5b9c\uff1f\nA. \u9032\u884c\u4ecb\u5165\u6027\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\nB. \u5916\u79d1\u624b\u8853\u4ee5\u7372\u5f97\u7d44\u7e54\u8a3a\u65b7\nC. \u4f7f\u7528 IV dopamine 0.5 \u03bcgkg/min \u6ce8\u5c04\uff0c\u4ee5\u589e\u52a0\u5c3f\u91cf\nD. \u4f5c24\u5c0f\u6642\u5fc3\u96fb\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u5f8b\u4e0d\u6574\nE. \u4f5c\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u81df\u75c5\u8b8a\n": "(E)", "101-8.\n\u75c5\u4eba\u662f28\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u66fe\u6709\u5b55\u671f\u9ad8\u8840\u58d3\u53ca\u6d41\u7522\u5169\u6b21\u3002\u4f4f\u9662\u524d\u6709\u4e00\u500b\u591a\u6708\u958b\u59cb\u547c\u5438\u56f0\u96e3\uff0c\u5176\u5f8c\u9010\u6f38\u52a0\u91cd\u4e14\u4f34\u6709\u98df\u617e\u4e0d\u632f\uff0c\u5076\u6709\u7aef\u7acb\u6027\u547c\u5438\u56f0\u96e3\uff0c\u54b3\u55fd\uff0c\u7d42\u81f3\u96d9\u8173\u6c34\u816b\u53ca\u6e1b\u5c11\u5c3f\u91cf\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c98/54 mmHg\uff1b\u5fc3\u8df3\uff0c131/min\uff1b\u9ad4\u6eab\uff0c37.3\u5ea6\uff1b\u547c\u543836/min\uff1b\u6025\u75c5\u72c0\uff0c\u8ca7\u8840\u773c\u77bc\uff1b\u96d9\u5074\u80ba\u90e8\u6709\u6fd5\u56c9\u8072\uff1b\u5fc3\u81df\u64f4\u5927\uff0c\u6709Gr.III/VI pansystolic murmur\u5728apex\u53caGr.II/IV early diastolic murmur over right upper sternal\rborder\uff0c\u6709S3\u53ef\u805e\uff1b\u8179\u90e8\u672a\u6709\u809d\u813e\u816b\u5927\uff1b\u96d9\u8173\u6c34\u816b\uff0c\u76ae\u819a\u51b7\u6c57\uff0c\u6709\u7d2b\u6591\u53ca\u51fa\u8840\u75d5\u6591\uff0c\u5982\u57168-1\u53ca\u57168-2\u6240\u793a\u3002\u5728\u6025\u6027\u5fc3\u5167\u819c\u708e(IE)\u4e4b\u81c6\u8a3a\u4e0b\uff0c\u4e43\u5728\u4e09\u5c0f\u6642\u5167\u5206\u5225\u5728\u5de6\u53f3\u624b\u63a2\u8840\u7d30\u83cc\u57f9\u990a\u90fd\u5448\u73fe\uff1aviridans streptococci\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4f9d\u64daDuke Criteria\u8a3a\u65b7IE\u7684\u6839\u64da\u662f\uff1a\nA. 2 major criteria\nB. 1 major criterion &  3 minor criteria\nC. 1 major criterion &  2 minor criteria\nD. 1 major criterion &  1 minor criterion\nE. 2 major criteria &  2 minor criteria\n": "(B)", "101-9.\n\u7537\u6027\u75c5\u4eba\uff0c72\u6b72\uff0c\u56e0\u5c16\u92b3\u6027\u4e0a\u80cc\u90e8\u75bc\u75db\u7a81\u7136\u767c\u4f5c\uff0c\u540c\u6642\u4f34\u6709\u6025\u4fc3\u547c\u5438\u53ca\u7729\u6688\uff0c\u4e43\u5f80\u6025\u8a3a\u6c42\u6cbb\u3002\u6642\uff0c\u8840\u58d3149/91 mmHg\uff1b\u5fc3\u8df3\uff0c70/min; RR, 20/min\uff1b\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u4efb\u4f55\u7570\u5e38\u3002\u75c5\u4eba\u6bcf\u5929\u62bd\u7159\u4e00\u5305\uff0c\u5df2\u6709\u4e94\u5341\u591a\u5e74\u3002Chest X-ray\u3001ECG\u53caCT\uff0c\u5982\u57169-1\u3001\u57169-2\u3001\u57169-3A\u53ca\u57169-3B\u5f8c\uff0c\u53ca\u5176\u521d\u6b65\u8655\u7f6e\uff0c\u5f8c\u8f49\u9001\u52a0\u8b77\u75c5\u623f\u9014\u4e2d\uff0c\u53c8\u7a81\u767c\u5f8c\u80cc\u75bc\uff0c\u540c\u6642\u96d9\u8173\u9ebb\u53ca\u75bc\u75db\uff0c\u4e26\u5448\u73fe\u96d9\u8173\u767c\u7d3a\uff0c\u4e43\u6025\u7167\u53e6\u6b21CT\u5982\u57169-4\u6240\u793a\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u6c7a\u7b56\u4e0d\u6070\u7576\uff1f\nA. \u63a7\u5236\u5fc3\u6536\u7e2e\u8840\u58d3\u5728100-120 mmHg\u53ca\u5fc3\u8df360-80/min\nB. \u975c\u8108\u6ce8\u5c04Labetalol 30 mg/min\nC. \u53e3\u670dPropranolol 20 mg tid po\nD. \u53e3\u670dAspirin 100 mg qd \u53caClopidogrel 75 mg qd\nE. \u5916\u79d1\u6703\u8a3a\uff0c\u7dca\u6025\u624b\u8853\n": "(D)", "101-10.\n\u75c5\u4eba62\u6b72\u7537\u6027\uff0c\u65bc9\u67084\u67083:30AM\u56e0\u7a81\u767c\u6027\u5fc3\u80f8\u524d\u5340\u75bc\u75db\u4e00\u500b\u5c0f\u6642\u800c\u6c42\u6551\u6025\u8a3a\uff0c\u6642\u4f34\u6709\u51b7\u6c57\u3001\u81c9\u8272\u84bc\u767d\u3002\u6642\uff0c\u8840\u58d3\uff0c135/82\uff1b\u5fc3\u8df3\uff0c76/min\uff1b\u547c\u5438\uff0c18/min\uff1b\u9ad4\u6eab\uff0c35.9\u5ea6\uff1b\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u75c5\u4eba\u6709\u9ad8\u8102\u8840\u75c5\u53f2\uff0cStatin\u6cbb\u7642\u4e2d\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\u9175\u7d20\u6aa2\u67e5\uff0c\u5982\u571610-1\u3001\u571610-2\u3001\u571610-3\u6240\u793a\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4e4b\u51a0\u72c0\u52d5\u8108\u963b\u585e\u75c5\u8b8a\u6700\u53ef\u80fd\u7684\u4f4d\u7f6e\u662f\uff1a\nA. \u5de6\u4e3b\u5e79\nB. \u5de6\u524d\u4e0b\u884c\u679d\nC. \u5de6\u8ff4\u65cb\u679d\nD. \u53f3\u51a0\u8108\u679d\nE. \u6b63\u5e38\u51a0\u72c0\u52d5\u8108\n": "(D)", "101-11.\n\u75c5\u4eba82\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u6709\u5bd2\u986b(chills)\u53ca\u6f38\u9032\u6027\u547c\u5438\u56f0\u96e3\u7684\u5169\u5929\u75c5\u7a0b\uff0c\u540c\u6642\u4f34\u6709\u5496\u5561\u8272\u5614\u5410\u7269\u3002\u4ed6\u6709\u9ad8\u8840\u58d3\u3001\u5de6\u8ff4\u65cb\u679d\u652f\u67b6\u7f6e\u653e\u4e4b\u51a0\u5fc3\u75c5\u53ca\u8166\u4e2d\u98a8\u800c\u5de6\u534a\u908a\u9ebb\u75fa\u7684\u591a\u5e74\u75c5\u53f2\u3002\u8840\u58d3 125/64\uff1b\u5fc3\u8df3 100/min\uff1b\u9ad4\u6eab 38.6\u5ea6\uff1b\u547c\u5438 24/min\uff1b\u5fc3\u5c16\u90e8\u6709Gr 4/6 systolic murmur\uff1b\u80ba\u90e8\u6709\u6fd5\u6027\u6fc1\u97f3\uff0c\u96d9\u8173\u6c34\u816b\uff1b\u5176\u4ed6\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u5be6\u9a57\u5ba4\uff1aWBC 9610/mm3\uff0csegment neutrophils 88%\uff1bHb 10.0 g/dL\uff1bC-Reactive protein 1.69 ng/mL\uff1bCK 221 ng/mL\uff1b CK-MB 16 U/L\uff1bTroponin I 1.36\r\u03bcg/L\uff1b\u5c3f\u6aa2\u6709\u86cb\u81ea\u5c3f(++)\uff0c\u5927\u4fbf\u6f5b\u8840\uff0c(++)\uff1b\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u571611-1\u53ca\u571611-2\u6240\u793a\u3002\u4e09\u3001\u516b\u53ca\u5341\u4e8c\u5c0f\u6642\u5f8c\u4e4bCK\u53caCK-MB\uff0c\u5206\u5225\u70ba1340\u30011462\u30011422\u53ca40\u300144\u300138\u3002\u4e14\u5728\u7fcc\u65e5\u8ffd\u8e64\u80f8\u90e8X\u5149\u5982\u571611-3\u6240\u793a\u3002\u96a8\u5373\r(1).\u9015\u884c\u8840\u6db2\u53ca\u75f0\u7d30\u83cc\u57f9\u990a\u53ca\u555f\u7528Unasyn 1g q8h\u53caazithromycin 500 mg qd\r(2)\u8f382u packed cell RBC\r(3).\u975c\u8108\u6ce8\u5c04Furosemide 20 mg\r(4)\u4f7f\u7528Clopidogrel 150 mg & then 75 mg qd \u53caAspirin 80 mg qd\r(5)Heparin25,000 u/day\r(6)\u6703\u8a3a\u5fc3\u81df\u79d1\r\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u7d44\u7684\u8655\u7f6e\u8f03\u6070\u7576\uff1f\nA. (1)+(2)+(5)\nB. (1)+(3)+(6)\nC. (1)+(4)+(6)\nD. (2)+(5)+(6)\nE. (3+(4)+(5)\n": "(B)", "101-12.\n\u4e86\u89e3\u5fc3\u81df\u7d50\u69cb\u6709\u52a9\u65bc\u57f7\u884c\u5fc3\u81df\u5224\u8b80\u7406\u5b78\u6aa2\u67e5\u4e26\u5224\u8b80\u5fc3\u96fb\u5716\u53ca\u5f71\u50cf\u6aa2\u67e5(\u5305\u62ec\u80f8\u90e8X\u5149\u3001CT\u53ca\u5fc3\u81df\u8d85\u97f3\u6ce2\u7b49)\u4e4b\u6240\u898b\u3002\u6709\u95dc\u4e0b\u5217\u5fc3\u81df\u69cb\u9020\u4e4b\u76f8\u5c0d\u4f4d\u7f6e\u95dc\u4fc2\u4f55\u8005\u932f\u8aa4?\nA. \u4e09\u5c16\u74e3\u4f4d\u65bc\u4e8c\u5c16\u74e3\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0b\u65b9\nB. \u53f3\u5fc3\u623f\u4f4d\u65bc\u5de6\u5fc3\u623f\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0b\u65b9\nC. \u53f3\u5fc3\u5ba4\u4f4d\u65bc\u5de6\u5fc3\u5ba4\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\nD. \u80ba\u52d5\u8108\u74e3\u4f4d\u65bc\u4e3b\u52d5\u8108\u74e3\u4e4b\u524d\u65b9\u3001\u5de6\u65b9\u53ca\u4e0a\u65b9\nE. \u80ba\u52d5\u8108\u74e3\u4f4d\u65bc\u4e3b\u52d5\u8108\u74e3\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0a\u65b9\n": "(E)", "101-13.\n\u975e\u767c\u7d3a\u6027\u6775\u72c0\u6307 (non-cyanotic clubbing fingers)\u53ef\u80fd\u51fa\u73fe\u5728\u6162\u6027\u5fc3\u3001\u80ba\u75be\u75c5\u4e4b\u75c5\u60a3\u3002\u4e0b\u5217\u4f55\u8005\u9664\u5916?\nA. Subacute infective endocarditis\nB. Non-small cell lung cancer\nC. Bronchiectasis\nD. Atrial myxoma\nE. Atrial septal defect\n": "(E)", "101-14.\n\u808b\u819c\u8154\u7a4d\u6c34\u70ba\u5de6\u5fc3\u8870\u7aed\u5f15\u8d77\u4e4b\u5fc3\u56e0\u6027\u80ba\u6c34\u816b(cardiogenic pulmonary edema) \u5e38\u898b\u7684\u4f75\u767c\u75c7\uff0c\u82e5\u7121\u75c7\u72c0\u4e0d\u4e00\u5b9a\u9700\u8981\u80f8\u8154\u7a7f\u523a\u5f15\u6d41\u6216\u6aa2\u67e5\uff0c\u4f46\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u5373\u4f7f\u7121\u75c7\u72c0\u4e5f\u5efa\u8b70\u9700\u8981\u80f8\u8154\u7a7f\u523a\u6aa2\u67e5?\r(1)\u96d9\u5074\u808b\u819c\u7a4d\u6c34\r(2)\u55ae\u7368\u53f3\u5074\u808b\u819c\u7a4d\u6c34\r(3)\u55ae\u7368\u5de6\u5074\u808b\u819c\u7a4d\u6c34\r(4).\u591a\u9694\u9593\u6027 (multi-loculated ) \u808b\u819c\u7a4d\u6c34\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (2)+(4)\nE. (1)+(3)\n": "(C)", "101-15.\n64\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u5df2\u77e5\u5fc3\u80ba\u75be\u75c5\uff0c\u56e0\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u81f3\u6025\u8a3a\u6c42\u8a3a\u3002\u75c5\u60a3\u4e26\u7121\u660e\u986f\u80f8\u75db\u6216\u5192\u51b7\u6c57\uff0c\u610f\u8b58\u6e05\u695a\u4f46\u60c5\u7dd2\u7dca\u5f35\uff0c\u521d\u6b65\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab37.2\u2103\uff0c\u8840\u58d3 150/95 mmHg\uff0c\u8108\u535a110/min\u7bc0\u5f8b\u898f\u5247,\u547c\u5438\u5feb(24/min)\u4e14\u6df1\uff1b\u56db\u80a2\u8f15\u5fae\u51b0\u51b7\u6709\u767c\u7d3a\u73fe\u8c61\u3002\u9838\u975c\u8108\u58d313 cm H2O\uff0c\u8108\u885d\u8840\u6c27\u5b9a\u91cf\u8a08 (pulse oximeter) \u5075\u6e2c\u767c\u73feSpO2 83%\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd?\nA. Panic disorder related hyperventilation syndrome\nB. Metabolic acidosis\nC. Pneumothorax\nD. Acute pulmonary embolism\nE. Bronchial asthma\n": "(D)", "101-16.\n\u4ee5\u4e0b\u53ef\u80fd\u548cWarfarin\u9020\u6210\u4ea4\u4e92\u4f5c\u7528 (drug interaction) \u4e4b\u85e5\u7269\u4f55\u8005\u932f\u8aa4?\nA. Amiodarone\nB. Herb drugs - ginkgo etc.\nC. Antiepileptic-phenytoin\nD. Cimetidine\nE. Digoxin\n": "(E)", "101-17.\n\u5728\u6b63\u5e38\u4eba\uff0c\u4e0b\u5217\u975c\u8108\u8840:1) \u51a0\u72c0\u975c\u8108\u7ac7(coronary sinus); 2)\u814e\u975c\u8108(renal veins); 3) \u4e0a\u8154\u975c\u8108 (superior vena cava); and 4) \u4e0b\u8154\u975c\u8108 (inferior vena cava) \u8840\u4e2d\u4e4b\u7d05\u8840\u7403\u8840\u7d05\u7d20\u6c27\u6c23\u98fd\u548c\u5ea6(hemoglobin O2 saturation)\u9ad8\u4f4e\u4f9d\u5e8f\u70ba?\nA. 4) > 1) > 3) > 2)\nB. 2) > 4) > 3) > 1)\nC. 2) > 3) > 4) > 1)\nD. 1) > 2) > 3) > 4)\nE. 2) > 4) > 1) > 3)\n": "(B)", "101-18.\n\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 (obstructive sleep apnea, OSA)\u8207\u4e0b\u5217\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u95dc\u806f\u6027\u7522\u751f\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u8166\u4e2d\u98a8\u3001\u5fc3\u808c\u6897\u585e\nB. \u4ee3\u8b1d\u75c7\u5019\u7fa4\u4e2d\u7684\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\nC. \u9ad8\u8840\u58d3\u3001\u80ba\u52d5\u8108\u9ad8\u58d3\nD. \u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation)\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-19.\n\u4e00\u4f4d36\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u60a3\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032(hyperthyroidism)\uff0c\u4e8c\u9031\u524d\u958b\u59cb\u670d\u7528propylthiouracil\uff0c\u56e0\u8207\u4ee5\u524d\u7570\u6a23\u4e4b\u5fc3\u60b8(\u4e0d\u898f\u5247\u5feb\u901f\u8df3\u52d5\u7684\u611f\u89ba)\u6c42\u8a3a\u3002\u807d\u8a3a\u767c\u73fe\u5fc3\u8df3\u6578\u6bcf\u5206\u9418150\uff0c\u5b8c\u5168\u4e0d\u898f\u5247(irregularly irregular)\uff0c\u540c\u6b65\u89f8\u8a3a\u6a48\u9aa8\u52d5\u8108 (radial pulse)\uff0c\u8108\u640f\u6578\u6bcf\u5206\u9418110\uff0c\u9838\u52d5\u8108\u8996\u8a3a\u7121a\u6ce2\u3002\u70ba\u63a7\u5236\u5fc3\u901f\u7387\u4e0b\u5217\u85e5\u7269\u6700\u9069\u5408\u8005\u70ba?\nA. Verapamil\nB. Diltiazem\nC. Propranolol\nD. Digoxin\nE. \u4ee5\u4e0a\u7686\u9069\u5408\n": "(C)", "101-20.\n\u6025\u6027\u7f3a\u8840\u6027\u809d\u75c5\u8b8a (ischemic liver) -\u5305\u62ec\u7531\u6025\u6027\u53f3\u5fc3\u8870\u7aed\u5c0e\u81f4\u4e4b\u9b31\u8840\u6027\u809d\u75c5\u8b8a(congestive liver)\u53ca\u4f4e\u8840\u58d3\u5f15\u767c\u4e4b\u4f11\u514b\u6027\u809d\u75c5\u8b8a (shock liver)\uff0c\u5176\u809d\u529f\u80fd\u7570\u5e38\u6709\u5225\u65bc\u75c5\u6bd2\u6027\u6025\u6027\u809d\u708e\u4e4b\u809d\u529f\u80fd\u7570\u5e38\u3002 \u7f3a\u8840\u6027\u809d\u75c5\u8b8a\u809d\u529f\u80fd\u7570\u5e38\u4e4b\u4e0b\u5217\u7279\u5fb5\uff0c\u4f55\u8005\u932f\u8aa4?\nA. AST \u53ca ALT\u6607\u9ad8\uff0c\u800c\u6bd4\u7387\u4e0aALT(\u7d30\u80de\u8cea\u9175\u7d20)\u9ad8\u65bcAST(\u7c92\u817a\u9ad4\u9175\u7d20)\u3002\nB. Bilirubin \u7e3d\u6578\u503c\u7570\u5e38\u6607\u9ad8\uff0c\u800c indirect bilirubin \u6bd4\u7387\u4e0a\u9ad8\u65bc direct bilirubin\u3002\nC. \u4e0a\u8ff0B\u9805\u7570\u5e38\u8d77\u56e0\u65bcuridine diphosphate glucuronosyltransferase \u529f\u80fd\u56e0\u7f3a\u6c27\u800c\u529f\u80fd\u964d\u4f4e\u3002\nD. \u53f3\u5fc3\u8870\u7aed\u6216\u4f11\u514b\u7d93\u6cbb\u7642\u6539\u5584\u5f8c\uff0c\u809d\u529f\u80fd\u7570\u5e38\u4ea6\u96a8\u4e4b\u5feb\u901f\u6539\u5584\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-21.\n\u5fc3\u623f\u9707\u986b (atrial fibrillation) \u60a3\u8005\u53ef\u4ee5\u5229\u7528CHADS2\u91cf\u8868\u8a55\u4f30\u767c\u751f\u4e2d\u98a8\u98a8\u96aa\uff1a\u4ee5\u4e0aC\uff0cH\uff0cA\uff0cD\u54041\u5206\uff0c\u6709S\u5247\u4ee52\u5206\u8a08\uff0c\u5f9e\u52a0\u7e3d\u5f8c\u7684CHADS2\u5206\u6578\u5373\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\u98a8\u98a8\u96aa\u3002\u82e5\u5206\u6578\u662f0\u5206\u5c31\u5c6c\u4f4e\u98a8\u96aa\uff1b1\u5206\u662f\u4e2d\u5ea6\u98a8\u96aa\uff1b\u22672\u5206\uff0c\u5247\u5c6c\u91cd\u5ea6\u8166\u4e2d\u98a8\u96aa\u60a3\u8005\u3002\u5982\u679cCHADS2\u5206\u6578\u662f0\u62161\u5206\uff0c\u53ef\u4ee5\u53ea\u7528 aspirin \u9810\u9632\uff0c\u5982\u679c\u5206\u6578 \u22672\u5206\uff0c\u5247\u61c9\u8a72\u9577\u671f\u670d\u7528warfarin \u4ee5\u6e1b\u4f4e\u8166\u4e2d\u98a8\u6a5f\u6703\u3002\u8acb\u554f CHADS\u5404\u5b57\u6bcd\u6240\u4ee3\u8868\u4e4b\u610f\u7fa9\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4?\nA. C\u4ee3\u8868Congestive heart failure (\u5fc3\u8870\u7aed)\nB. H\u4ee3\u8868Hyperlipemia\uff08\u9ad8\u8840\u8102\uff09\nC. A\u4ee3\u8868Age (\u5e74\u7d00)7 5\u6b72\u4ee5\u4e0a\nD. D\u4ee3\u8868Diabetes (\u7cd6\u5c3f\u75c5)\nE. S\u4ee3\u8868 Stroke\uff08\u4e2d\u98a8\uff09\u53f2\u6216\uff0c\u66ab\u6642\u6027\u8166\u7f3a\u8840(TIA)\n": "(B)", "101-22.\n\u60a3\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032(hyperthyroidism)\u60a3\u8005\u6240\u4f5c\u5fc3\u96fb\u5716\u4e2d\u9664\u6700\u5e38\u898b\u4e4b\u7ac7\u6027\u983b\u8108(sinus tachycardia)\u5916\uff0c\u9084\u53ef\u80fd\u6709\u4e0b\u5217\u4e4b\u8868\u73fe\uff0c\u4f55\u8005\u9664\u5916?\nA. \u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (atrial fibrillation)\nB. \u75c5\u4eba\u4ee5\u4e0a\u3001\u4e0b\u80a2\u8fd1\u7aef\u7121\u529b(proximal muscle weakness)\u8868\u73fe\u6642\uff0c\u6709\u4f4e\u8840\u9240\u4e4b\u6240\u898b\nC. \u9577\u671f\u5de6\u5fc3\u5ba4\u5bb9\u91cf\u8ca0\u8377\u589e\u52a0(chronic volume overload)\uff0c\u5c0e\u81f4\u4e4bLVH (left ventricular hypertrophy)\nD. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7(PAH)\u5c0e\u81f4\u4e4bRVH (right ventricular hypertrophy)\nE. \u4ee5\u4e0a\u7686\u53ef\u80fd\n": "(E)", "102-1.\n\u4e0b\u5217\u6578\u5247\u6709\u95dc\u5fc3\u623f\u64b2\u52d5(Atrial flutter) \u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u767c\u751f\u5fc3\u623f\u64b2\u52d5\u7684\u5fc3\u623f\u6027\u5feb\u8df3\u6a5f\u8f49\u901a\u5e38\u662f\u529f\u80fd\u6027\u7684\r\n (functional)\uff0c\u800c\u4e0d\u662f\u5668\u8cea\u6027(organic)\nB. \u5178\u578b\u5fc3\u623f\u64b2\u52d5\u591a\u898b\"sawtooth\" \u5f62\u72c0,\u5728II,III,aVF\u53caV1\u5448\u6b63\u5411\u6216\u8ca0\u5411\u6ce2\nC. \u5fc3\u623f\u64b2\u52d5\u53ef\u5728\u4f7f\u7528\u6297\u5fc3\u5f8b\u4e0d\u6574\u85e5\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation,AF)\u5f8c\u767c\u751f\nD. \u5fc3\u623f\u64b2\u52d5\u4e5f\u53ef\u5728\u5de6\u5fc3\u623f\u71d2\u707c\u624b\u8853\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(AF)\u5f8c\u51fa\u73fe\nE. \u96fb\u6fc0\u65b9\u5f0f(electric cardioversion)\u70ba\u6cbb\u7642\u5fc3\u623f\u64b2\u52d5\u6700\u6709\u6548\u7684\u65b9\u6cd5\n": "(A)", "102-2.\n\u4f9d\u64da\u4eca\u5e74ACCF/AHA guideline for the management of heart failure\uff0c\u5176\u6307\u5f15\u5c0e\u5411\u5167\u79d1\u7642\u6cd5(Guideline-directed medical therapy)\u6709\u8af8\u9ede\u91cd\u8981\u4fee\u6b63\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6307\u5f15\u4e3b\u5f35?(1)ACE inhibitors, Angiotensin-II receptor blockers, \u53ca\u03b2-blockers\u4ecd\u820a\u662f\u5408\u5b9c\u5167\u79d1\u7642\u6cd5  (2)B-type naturetic peptide(BNP)\u53ef\u4f5c\u70ba\u9810\u5f8c\u53ca\u75c5\u50b7\u5206\u985e\u4e4b\u6839\u64da\uff0c\u5c24\u5176\u6cbb\u7642\u5f8cBNP\u7684\u964d\u4f4e, \u66f4\u53ef\u4f5c\u9810\u5f8c\u7684\u53c3\u8003 (3)\u53ea\u6709\u6c34\u816b\u75c5\u4eba\u624d\u9700\u8981\u56b4\u683c\u9650\u5236\u9e7d\u5206 (4)\u61c9\u8a72\u4f7f\u7528Inotropic therapy (5)Cardiac resynchronization therapy\u9650\u5b9a\u5728\u5fc3\u8870\u7aedFunction class 3\u4ee5\u4e0a\u53caLBBB\r>150msec\u7684\u75c5\u4eba\uff0c\u624d\u6709\u7f6e\u653e\u7684\u9069\u61c9(indications)\u689d\u4ef6 \u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(D)", "102-3.\n\u4e0b\u5217\u6709\u95dcDigoxin\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u5be6\u8b49\u91ab\u5b78\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. Digoxin\u53ef\u6291\u5236\u5fc3\u808c\u7d30\u80de\u819cNa-K ATPase pump\uff0c\u589e\u52a0\u7d30\u80de\u6f3f\u6db2(Cytosol)\u5167Ca++\uff0c\u800c\u589e\u5f37\u5fc3\u808c\u6536\u7e2e\u529b(Inotropism)\uff0c\u56e0\u6b64\u98fd\u548c\u5291\u91cf\u662f\u6025\u6ce8\u539f\u5247\nB. \u4f9d\u64daDIG\u81e8\u5e8a\u8a66\u9a57\uff0c\u5728\u975e\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u75c5\u4eba\uff0c\u7d93Digoxin \u6cbb\u7642\u5f8c\uff0c\u4e26\u672a\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\u6216\u4f4f\u9662\u65e5\u6578\nC. \u5728\u81e8\u5e8a\u4e0aDigoxin\u4e26\u975e\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u4e3b\u8ef8\uff0c\u53ea\u80fd\u8207\u03b2-blocker, diuretic, Angiotensin converting enzyme inhibitor \u6216Angiotensin receptor blockade\u4f75\u7528\nD. Digoxin\u53ef\u7528\u65bc\u5fc3\u8870\u7aed\u4f75\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u5fc3\u64f4\u5927\u8005\nE. Digoxin \u4e2d\u6bd2\u4e4b\u81e8\u5e8a\u8868\u73fe\uff0c\u4ee5\u5fc3\u5f8b\u53ca\u5fc3\u50b3\u5c0e\u7570\u5e38\u6700\u591a\u898b\uff0c\u80c3\u8178\u75c7\u72c0\u6b21\u4e4b\n": "(A)", "102-4.\n\u75c5\u4eba78\u6b72\u9000\u4f11\u7684\u7537\u516c\u52d9\u54e1\uff0c\u4e3b\u8a34\u5fc3\u60b8\u6709\u516b\u5c0f\u6642\u4e4b\u4e45\uff0c\u4e26\u6709\u8d77\u4f0f\u4e0d\u5b9a\u4e4b\u9ad8\u8840\u58d3\u8b8a\u5316\uff0c\u4e43\u6025\u901f\u9001\u91ab\u9662\u6c42\u8a3a\u3002\u5c31\u8a3a\u6642\uff0c\u75c5\u4eba\u8868\u73fe\u614c\u5f35\u4e0d\u5b89\u3002\u64da\u7a31\u6709\u4e00\u5e74\u4e4b\u9ad8\u8840\u58d3\uff0c\u53c8\u6709\u80ba\u6c23\u816b\uff0c\u6bcf\u5929\u670d\u7528Theophylline 200 mg\uff1b\u8166\u90e8\u6709Lacunar infarct\uff0c\u6bcf\u5929\u670d\u7528Clopidogrel 75 mg\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3166/86 mmHg\uff1b\u5fc3\u8df395/ min\uff1b\u9918\u7121\u4e0d\u6b63\u5e38\u3002\u5fc3\u96fb\u5716\u5982\u5716\u793a\u3002\u8840\u6db2\u6aa2\u67e5\uff1aSugar\uff0c165 mg/dL\uff1bCPK\uff0c74 IU/L\uff1bCK-MB\uff0c1.2U/L\u53caTroponin I\uff0c0.02 ng/mL\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u9ad8\u8840\u58d3\nB. STEMI(ST Elevation Myocardial Infarction)\nC. NSTEMI(Non ST Elevation Myocardial Infarction)\nD. Brugada syndrome\nE. Long QT syndrome\n": "(D)", "102-5.\n\u75c5\u4eba\u73fe\u5e7468\u6b72\u7537\u6027\u8fb2\u592b\uff0c\u65bc\uff16\u6708\uff17\u65e5\u6e05\u6668\u7a81\u6709\u80f8\u60b6\uff0c\u540c\u6642\u4f34\u6709\u5641\u5fc3\u3001\u5614\u5410\u3001\u5fc3\u60b8\u53ca\u51b7\u6c57\uff0c\u4e43\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u75c5\u4eba\u6bcf\u5929\u62bd\u83f8\u4e8c\u5305\uff0c\u5df2\u6709\u4e09\u5341\u591a\u5e74\uff0c\u7121\u9ad8\u8840\u58d3\u3001\u9ad8\u8102\u8840\u6216\u7cd6\u5c3f\u75c5\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5TPR \uff1a35.6/82/16\uff1bBP\uff1a146/93 mmHg\uff0c\u610f\u8b58\u6e05\u695a\uff0c\u5fc3\u81df\u5927\u5c0f\u53ca\u5fc3\u97f3\u6b63\u5e38\uff0c\u80ba\u90e8\u7121\u6fd5\u56c9\u97f3\uff0c\u5176\u4ed6\u90e8\u4f4d\u4ea6\u7121\u7570\u5e38\u6240\u898b\u3002CKMB 35 U/L \u6b63\u5e38\u503c[7-25] \uff0cTroponin-T 0.009 ng/ml\uff0cCreatinine(\u8840) 1.0 mg/dL\uff0ceGFR 79 mL/min/1.73M2\u3002 \u80f8\u90e8\uff38\u5149\u6b63\u5e38\uff0c\u5176\u5fc3\u96fb\u5716\u5982\u5716\u793a\uff0c\u8acb\u554f\u6700\u6b63\u78ba\u75be\u75c5\u8a3a\u65b7\u662f\uff1a\nA. Angina pectoris\nB. Non-ST Elevation Myocardial infarction\nC. Right coronary artery occlusion with inferior ST-elevation infarction\nD. Left circumflex artery occlusion with posterior ST-elevation infarction\nE. Left anterior descending artery occlusion with anterior myocardial ischemic injury\n": "(C)", "102-6.\n48\u6b72\u7537\u6027\u5f9e\u6628\u65e5\u4e0b\u53484:30 pm\u7a81\u767c\u5de6\u80f8\u75db\uff0c\u4e26\u6709\u5f8c\u80cc\u50b3\u75db\uff0c\u4f34\u6709\u51b7\u6c57\u3001\u6c23\u4fc3\u53ca\u547c\u5438\u56f0\u96e3\u7b49\u75c7\u72c0\uff0c\u5df2\u6b77\u7d93\u4e00\u5929\u672a\u7de9\u89e3\uff0c\u4e43\u65bc7 PM\u9001\u9054\u91ab\u9662\u6c42\u6cbb\u3002\u75c5\u4eba\u4e00\u5411\u5065\u58ef\uff0c\u672a\u6709\u9ad8\u8840\u58d3\u6216\u5176\u4ed6\u51a0\u5fc3\u75c5\u76f8\u95dc\u5371\u96aa\u56e0\u7d20\u3002\u7406\u5b78\u6240\u898b\uff1a\u6025\u75c5\u72c0\uff0c\u5de6\u53f3\u5169\u624b\u8840\u58d3\u5206\u5225\u70ba182/126\u53ca193/125 mmHg\uff0c\u5de6\u53f3\u5169\u817f\u8840\u58d3\u70ba211/112\u53ca205/112 mmHg\uff1b\u5fc3\u8df371/min\uff0c\u6b63\u5e38\u5f8b\u52d5\uff0c\u5fc3\u81df\u5fae\u5927\uff0c\u7121\u7570\u5e38\u96dc\u97f3\u53ef\u805e\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\uff0c\u751f\u5316\u6aa2\u67e5CK\u3001CK-MB\u53caTroponin I\u90fd\u6b63\u5e38\uff1bBNP,246 pg/mL\u5fae\u9ad8\u3002\u75c5\u4eba\u6b64\u523b\u4e4b\u75be\u75c5\u8a3a\u65b7\u53ca\u5176\u8655\u7f6e\uff0c\u4ee5\u4f55\u8005\u6700\u59a5\u9069?\nA. Acute myocardial infarction, anteroseptal STEMI\nB. Hypertensive cardiovascular disease complication\nC. Acute pericarditis\nD. Hyperkalemia\nE. Myocarditis\n": "(B)", "102-7.\n\u75c5\u4eba\u7537\u602765\u6b72\u751f\u610f\u4eba\uff0c\u6709\u4e00\u5929\u7684\u80f8\u9aa8\u4e0b\u80f8\u60b6\uff0c\u9010\u6f38\u52a0\u5287\uff0c\u540c\u6642\u53c8\u6709\u51b7\u6c57\u3001\u7729\u6688\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u5f80\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u7121\u4efb\u4f55\u75be\u75c5\uff0c\u50c5\u53ea\u62bd\u83f8\u6bcf\u5929\u4e00\u5305\u670920\u5e74\uff0c\u6212\u83f8\u5df210\u5e74\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3110/67\uff1b\u5fc3\u8df345/min\uff1b\u5fc3\u81df\u898f\u5247\u5f8b\u8df3\uff0c\u7121\u5fc3\u96dc\u97f3\uff1b\u5176\u4ed6\u6240\u898b\u4e26\u7121\u4efb\u4f55\u4e0d\u6b63\u5e38\u3002\u5176\u751f\u5316\u6aa2\u67e5\uff1aCK,622 IU/L\uff1bCKMB, 32.6IU/L\uff1bTroponin I, 2.30 ng/ml\uff1bSugar,105 mg/dL\uff1bCholesterol,161 mg/dL\uff1bLDL-C,93 mg/dL\uff1bHDL-C,37  mg/dL\uff0c\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\u3002\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u8a3a\u65b7\uff0c\u75c5\u4eba\u63a5\u53d7\u4e0b\u5217\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. iv Atropine, 0.5 mg\u53ca Aspirin,100 mg qd p o\nB. Atorvastatin 10 mg qd / hs\nC. Clopidogrel 300 mg followed by 75 mg qd\nD. Enoxaparin 60 mg subcutaneous injection\nE. Carvedilol (6.25 mg),1# bid po\n": "(E)", "102-8.\n\u75c5\u4eba\u5973\u6027\u73fe\u5e7444\u6b72\uff0c\u6709\u5168\u8eab\u6d6e\u816b2\u500b\u6708\u3002\u81ea2010\u5e74\u5c31\u56e0\u96d9\u8173\u6c34\u816b\u6c42\u91ab\uff0c\u5176\u5f8c\u5169\u5e74\u9593\u5148\u5f8c\u56e0\u8179\u6c34\u3001\u5168\u8eab\u6c34\u816b\u53ca\u9ad4\u91cd11\u516c\u65a4\u7684\u6025\u5287\u589e\u52a0\uff0c\u4f4f\u9662\u6aa2\u67e5\u767c\u73fe\u809d\u786c\u5316\u53ca\u4f4e\u8840\u6e05\u767d\u86cb\u767d(1.2-1.6 g/dL)\u3002\u6700\u8fd1\u534a\u5e74\u66f4\u6709\u6c34\u6027\u8179\u7009\u3001\u8179\u75db\u548c\u591c\u9593\u547c\u5438\u56f0\u96e3\uff0c\u662f\u4e43\u4f4f\u9662\u8a3a\u7642\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c108/71\rmmHg\uff1b\u5fc3\u8df3\uff0c88/min\uff0c\u4e0d\u898f\u5247\uff1b\u9838\u975c\u8108\u6012\u5f35\uff1b\u96d9\u5074\u80ba\u90e8\u6709\u6fd5\u6fc1\u547c\u5438\u8072\uff1b\u5fc3\u81df\u64f4\u5927\uff0c\u5728\u5fc3\u5c16\u53ca\u5de6\u4e0b\u80f8\u7de3(LLSB)\u6709\u4e09\u5ea6\u5fc3\u7e2e\u6027\u96dc\u97f3\u53caS3\u53ef\u805e\uff1b\u8179\u90e8\u6709\u5fae\u91cf\u8179\u6c34\u53ca\u8f15\u5ea6\u809d\u816b\uff1b\u96d9\u8173\u4e2d\u5ea6\u6c34\u816b\uff0c\u4f46\u5176\u52d5\u8108\u8108\u8df3\u5c1a\u5c6c\u6b63\u5e38\u3002\u8178\u5167\u8996\u93e1\u53ef\u898b\u6dcb\u5df4\u7ba1\u6d6e\u816b(lymphangiectasia)\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u662f\uff1a\nA. \u5fc3\u5167\u819c\u708e(Endocarditis)\nB. \u5fc3\u808c\u708e(Myocarditis)\nC. \u7a84\u7e2e\u6027\u5fc3\u5305\u819c\u708e(Constrictive pericarditis)\nD. \u51a0\u5fc3\u75c5(Coronary artery syndrome)\nE. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\n": "(C)", "102-9.\n\u75c5\u4eba53\u6b72\u7537\u6027\uff0c\u6709\u547c\u5438\u56f0\u96e3\u4f75\u6709\u591a\u75f0\u3001\u591c\u9593\u54b3\u55fd\u53ca\u591c\u9593\u547c\u5438\u56f0\u96e3\u3001\u80f8\u60b6\u53ca\u8173\u816b\u7b49\u6b77\u6642\u4e00\u500b\u591a\u6708\u4e0d\u89e3\u3002\u75c5\u4eba\u6709\u591a\u5e74\u5fc3\u667a\u9072\u920d\uff0c\u4e26\u6709\u7cd6\u5c3f\u75c5\u53ca\u9ad8\u8840\u58d3\u7684\u81f3\u5c11\u4e00\u5e74\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3103/56 mmHg\uff1b\u5fc3\u8df398/min;\u547c\u543818/min\uff1b\u9838\u975c\u8108\u6b63\u5e38\uff1b\u5fc3\u81df\u5fae\u5927\uff0c\u5fc3\u97f3\u6b63\u5e38\uff0c\u7121\u96dc\u97f3\uff1b\u80f8\u90e8\u5de6\u5f8c\u5074\u6fd5\u6fc1\u547c\u5438\u97f3\uff0c\u809d\u4e26\u7121\u816b\u5927\uff0c\u4f46\u96d9\u8173\u6d6e\u816b\u3002\u751f\u5316\u6aa2\u9a57\uff1aCK,204 U/L\uff1bCK-MB,35 U/L\uff1bTroponin I,0.655 mg/L\uff1bSugar,216 mg/dl\uff1bHbA1C,8.0%\uff1bBUN,18 mg/dL\uff1bcreatinine,0.84mg/dL\uff1bALT,90 IU/L\uff1bTriglyceride,100 mg/dL\uff1bHDL-C,58.5 mg/dL\uff1bLDL-C,178.1\rmg/dL\u3002\u5176\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u53ca\u51a0\u8108\u651d\u5f71\u5982\u5716\u793a\u3002\u8acb\u554f\u6b64\u75c5\u4eba\u5728\u73fe\u968e\u6bb5\uff0c\u5f9e\u5e74\u9f61\u3001\u6027\u5225\u3001\u51a0\u5fc3\u75c5\u5371\u96aa\u56e0\u7d20\u53ca\u81e8\u5e8a\u75c7\u72c0\u7b49\u8003\u91cf\uff0c\u6700\u5177\u91ab\u5b78\u5be6\u8b49\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\uff1a\nA. \u63a1\u7528\u6700\u5408\u9069\u7684\u5167\u79d1\u7642\u6cd5(Optimal medical therapy)\nB. \u63a1\u7528\u7d93\u51a0\u8108\u963b\u4ecb(PCI),\u7f6e\u653e\u652f\u67b6(Coronary stent)\nC. \u63a1\u7528\u5916\u79d1\u7e5e\u9053\u624b\u8853(CABGS)\nD. \u5148\u4ee5\u6700\u5408\u9069\u5167\u79d1\u7642\u6cd5\uff0c\u723e\u5f8c\u4f9d\u75c5\u60c5\u518d\u63a1\u884cPCI\nE. \u5148\u4ee5\u6700\u5408\u9069\u5167\u79d1\u7642\u6cd5\uff0c\u723e\u5f8c\u4f9d\u75c5\u60c5\u518d\u63a1\u884cCABGS\n": "(E)", "102-10.\nWPW syndrome\u6709\u5fc3\u60b8\u3001\u7729\u6688\u3001\u660f\u53a5\u53ca\u731d\u6b7b\u5371\u96aa\uff0c\u6709\u95dc\u5c0e\u7ba1\u71d2\u707c\u624b\u8853(Catheter ablation)\u6cbb\u7642\u7684\u9069\u61c9\u75c7\uff0c\u6709\u8af8\u591a\u7814\u7a76\u5be6\u8b49\uff1a(1)\u6709\u5fc3\u5feb\u8df3\u75c7\u72c0\u8005 (2) \u7121\u75c7\u72c0\uff0c\u4f46\u65b7\u65b7\u7e8c\u7e8c\u51fa\u73fepreexcitation(short PR & delta wave) (3)WPW syndrome \u75c5\u4eba\u4f34\u6709\u96e3\u6cbb\u7684\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(atrial fibrillation) (4)WPW syndrome \u75c5\u4eba\u7d93\u96fb\u751f\u7406\u5b78\u6aa2\u8a98\u767c\u5fc3\u5feb\u8df3\u8005 (5)\u7121\u75c7\u72c0\uff0cpreexcitation \u767c\u751f\u5728\u904b\u52d5\u54e1\u3001\u98db\u884c\u54e1\u53ca\u5e7c\u5b69\u3002\r\u4e0b\u5217\u4f55\u9805\u624d\u662f\u6b63\u78ba\u4e4b\u9078\u64c7?\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (2)+(3)+(4)\n": "(C)", "102-11.\n\u75c5\u4eba46\u6b72\u5361\u8eca\u53f8\u6a5f\uff0c\u56e0\u6025\u767c\u80f8\u75bc\u4e09\u5c0f\u6642\u6c42\u91ab\u3002\u75c5\u4eba\u7121\u91cd\u5927\u75be\u75c5\u3002\u65e9\u6668\u767b\u5c71\u4e2d\u7a81\u7136\u80f8\u75db\u4f34\u6709\u5de6\u80a9\u9178\u75db\u8207\u6ce0\u6c57\u3002\u5c31\u8fd1\u91ab\u9662\u6c42\u8a3a\uff0c\u5fc3\u96fb\u5716\u5982\u5716\u793a\uff0c\u8840\u6e05CPK=240\uff0c \u4e00\u5929\u5f8c\u4e0a\u5347\u81f34224IU/L\uff0cCK-MB=9.8U/L\uff0c\u4e00\u5929\u5f8c\u4e0a\u5347\u81f3172.5U/L\u3002\u8840\u58d3\uff0c117/76 mmHg\uff1b\u5fc3\u8df3,56/min\uff0c\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\uff0c\u8655\u7f6e\u5f8c\u8f49\u9001\u91ab\u5b78\u4e2d\u5fc3\u3002\u8acb\u554f\u6b64\u91ab\u9662\u7684\u4f55\u7d44\u8655\u7f6e\uff0c\u624d\u7b26\u5408\u6307\u5f15\u898f\u5b9a\u4e4b\u521d\u59cb\u8655\u7f6e(Initial management)\uff1f(1)Carvedilol 3.125 mg qd / po (2)Atorvastatin 20 mg qd (3)Aspirin 80 mg qd and Clopidogrel 300 mg loading followed by 75 mg qd (4)IV nitroglycerin (5)IV Heparin 5000 u\rbolus followed by 1000u/hr (6)rTissue plasminogen activator IV, 15mg bolus followed by 85 mg / 90 min\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (2)+(3)+(5)\nD. (3)+(4)+(5)\nE. (4)+(5)+(6)\n": "(C)", "102-12.\n\u4e0b\u5217\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u5e74\u8f15\u7684\u5fc3\u5167\u819c\u708e\u75c5\u4eba\u4ee5\u5973\u6027\u70ba\u591a\nB. \u91ab\u8b77\u7167\u9867\u76f8\u95dc\u7684\u5fc3\u5167\u819c\u708e(healthcare-associated)\u4ee5S. aureus \u70ba\u6700\u3002\u793e\u5340\u6027\u5fc3\u5167\u819c\u708e(community-acquired endocarditis)\u5247\u4ee5Streptococcal species \u6700\u5e38\u898b\nC. \u50e7\u5e3d\u74e3\u819c\u5fc3\u5167\u819c\u708e\u5f9e\u4f86\u6700\u591a\u898b\nD. \u74e3\u819c\u7f6e\u63db\u8853\u5f8c>12\u6708\u7684\u4eba\u5de5\u5fc3\u74e3\u819c\u5fc3\u5167\u819c\u708e\uff0c\u4ee5S aureus\u6700\u591a\u898b\nE. Enterococcal septicemia\u53ef\u5728\u793e\u5340\u6027\u53ca\u91ab\u8b77\u7167\u9867\u76f8\u95dc\u5fc3\u5167\u819c\u708e\u51fa\u73fe\n": "(D)", "102-13.\n\u5a66\u7522\u79d1\u8f49\u4f86\u4e00\u4f4d\u7522\u5a66\uff0c\u5728\u5979\u9806\u5229\u5730\u7528\u81ea\u7136\u7522\u751f\u4e0b\u7b2c\u4e8c\u500b\u5bf6\u5bf6\u4e4b\u5f8c\u4e00\u500b\u6708\uff0c\u5979\u51fa\u73fe\u4e86\u5bb9\u6613\u75b2\u4e4f\u548c\u8f15\u5ea6\u904b\u52d5\u5c31\u6703\u5f88\u5598\u7684\u60c5\u6cc1\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u9838\u975c\u8108\u64f4\u5f35\uff0c\u96d9\u5074\u4e0b\u80a2\u6709\u6c34\u816b\uff0c\u6700\u5927\u5fc3\u640f\u9ede(PMI)\u4e5f\u5411\u5916\uff0c\u5411\u4e0b\u4f4d\u79fb\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5de6\u5fc3\u5ba4\u640f\u51fa\u7387\u662f30%\uff0c\u5fc3\u5ba4\u6709\u64f4\u5927\u3002\u95dc\u65bc\u5979\u7684\u60c5\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6070\u7576\uff1f\nA. \u9019\u7a2e\u60c5\u6cc1\u53ef\u4ee5\u5728\u751f\u7522\u6578\u5e74\u4e4b\u5f8c\u624d\u7a81\u7136\u51fa\u73fe\nB. \u5927\u7d04\u4e00\u534a\u7684\u985e\u4f3c\u60a3\u8005\u6703\u75ca\u7652\nC. \u9019\u7a2e\u60c5\u5f62\u4e00\u65e6\u51fa\u73fe\uff0c\u4e26\u4e0d\u6703\u589e\u52a0\u4e0b\u4e00\u80ce\u61f7\u5b55\u6216\u662f\u751f\u7522\u9031\u671f\u7684\u5fc3\u8870\u7aed\u98a8\u96aa\nD. \u6b64\u60c5\u6cc1\u7684\u6cbb\u7642\u65b9\u5f0f\u4e0d\u540c\u65bc\u5176\u4ed6\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u60a3\u8005\nE. \u8a3a\u65b7\u6b64\u60c5\u6cc1\u4e00\u5b9a\u8981\u9032\u884c\u5fc3\u808c\u63a1\u6a23(Endomyocardial biopsy)\n": "(B)", "102-14.\n68\u6b72\u7537\u6027\u60a3\u8005\u6709\u7cd6\u5c3f\u75c5\u548c\u5fc3\u8870\u7aed\u7684\u6b77\u53f2\uff0c\u6700\u8fd1\u5e38\u56e0\u591c\u9593\u60b6\u8207\u5598\u800c\u9192\u4f86\uff0c\u4ed6\u5e73\u6642\u56e0\u70ba\u6703\u5598\u800c\u7121\u6cd5\u9023\u7e8c\u884c\u8d7050\u516c\u5c3a\u4ee5\u4e0a\uff0c\u82e5\u722c\u6a13\u68af\u8d85\u904e\u4e00\u5c64\u6a13\u4e5f\u6703\u5f88\u5598\u3002\u6aa2\u67e5\u6642\u767c\u73fe\u8840\u58d3\u6b63\u5e38\uff0c\u96d9\u5074\u80ba\u5e95\u6709\u56c9\u97f3\uff0c\u9838\u975c\u8108\u9f13\u8139\u3002\u4e0a\u500b\u6708\u4ed6\u525b\u63a5\u53d7\u4e86\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u767c\u73fe\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387\u662f30%\uff0c\u76ee\u524d\u4ed6\u670d\u7528\u4e59\u578b\u963b\u65b7\u5291\u3001\u5229\u5c3f\u5291\u3001\u8f49\u5316\ufffdC\u6291\u5236\u5291(Angiotensin Coverting enzyme inhibitor)\u548c\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u3002\u4f9d\u64da\u75c5\u60a3\u7684\u7279\u6027\u8207\u76ee\u524d\u7684\u72c0\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u53ef\u80fd\u662f\u9020\u6210\u9019\u4f4d\u60a3\u8005\u5fc3\u8870\u7aed\u7684\u539f\u56e0\uff1f\nA. \u6bd2\u6027\u7269\u8cea\u6216\u85e5\u7269\nB. \u6d78\u6f64\u6027\u75be\u75c5\nC. \u51a0\u72c0\u52d5\u8108\u75be\u75c5\nD. \u74e3\u819c\u6027\u5fc3\u81df\u75c5\nE. \u611f\u67d3\u6027\u75be\u75c5\n": "(C)", "102-15.\n\u4e00\u4f4d48\u6b72\u6709\u8f15\u5fae\u9ad8\u8840\u58d3\u548c\u62bd\u83f8\u7684\u7537\u6027\u60a3\u8005\uff0c\u56e0\u70ba\u6e05\u6668\u7a81\u767c\u6027\u80f8\u53e3\u58d3\u8feb\u75bc\u75db\u5408\u4f75\u5641\u5fc3\u8207\u5192\u6c57\uff0c\u547c\u5438\u8b8a\u5598\uff0c\u7d93\u7531\u6025\u8a3a\u5165\u9662\u3002\u5728\u525b\u5230\u9054\u6025\u8a3a\u7684\u5fc3\u96fb\u5716\u6709\u80f8\u524d\u6975\u5c0e(precordial leads)\u7684ST\u7bc0\u6bb5\u4e0a\u5347\uff0c\u7cfb\u5217\u62bd\u8840\u7684\u5fc3\u81df\u9175\u7d20\u503c\u6b63\u5e38\uff0c\u75c5\u4eba\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u767c\u73fe\u5de6\u524d\u4e0b\u964d\u679d\u51a0\u72c0\u52d5\u810825%\u72f9\u7a84\uff0c\u75c5\u4eba\u6c92\u6709\u9032\u884c\u652f\u67b6\u653e\u7f6e\u6216\u6c23\u7403\u64f4\u5f35\u6cbb\u7642\uff0c\u5f8c\u7e8c\u7684\u4f4f\u9662\u904e\u7a0b\u4e2d\u4e5f\u6c92\u6709\u51fa\u73fe\u5371\u96aa\u6027\u7684\u5fc3\u5f8b\u4e0d\u6574\u3002\u4e0b\u5217\u7684\u8655\u7f6e\uff0c\u54ea\u4e00\u9805\u662f\u9069\u5408\u4e5f\u53ef\u4ee5\u6e1b\u5c11\u672a\u4f86\u53cd\u8986\u767c\u751f\u985e\u4f3c\u80f8\u75db\u7684\u60c5\u6cc1\uff1f\nA. \u653e\u7f6e\u5857\u85e5\u652f\u67b6(drug-eluting coronary artery stent)\u5728\u51a0\u72c0\u52d5\u8108\u4e0a\nB. \u653e\u7f6e\u975e\u5857\u85e5\u652f\u67b6\u5728\u51a0\u72c0\u52d5\u8108\nC. \u958b\u59cb\u4f7f\u7528\u8f49\u5316\ufffdC\u6291\u5236\u5291(ACEI)\u85e5\u54c1\u6cbb\u7642\nD. \u958b\u59cb\u4f7f\u7528\u4e59\u578b\u963b\u65b7\u5291\u6cbb\u7642\nE. \u958b\u59cb\u4f7f\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291\u6cbb\u7642\n": "(E)", "102-16.\n\u9580\u8a3a\u4f86\u4e86\u4e00\u4f4d15\u6b72\u7684\u7537\u5b78\u751f\uff0c\u966a\u540c\u7684\u6559\u7df4\u8868\u793a\u4ed6\u5728\u6628\u5929\u7684\u4f8b\u884c\u6392\u7403\u6821\u968a\u8a13\u7df4\u4e2d\u5148\u662f\u611f\u89ba\u982d\u6688\uff0c\u7136\u5f8c\u6688\u5012\u4e26\u8dcc\u843d\u5730\u9762\uff0c\u540c\u6642\u55aa\u5931\u610f\u8b58\u5927\u7d041\u5206\u9418\uff0c\u6c92\u6709\u5168\u8eab\u62bd\u6410\u6216\u662f\u53e3\u5410\u767d\u6cab\u3002\u4eca\u5e74\u662f\u4ed6\u52a0\u5165\u6821\u968a\u7684\u7b2c\u4e00\u5e74\uff0c\u4ed6\u4e4b\u524d\u4e26\u4e0d\u66fe\u6688\u5012\uff0c\u56e0\u70ba\u4ed6\u53d7\u4eba\u9818\u990a\uff0c\u5bb6\u65cf\u53f2\u6c92\u6709\u9032\u4e00\u6b65\u7684\u8cc7\u8a0a\u3002\u8eab\u9ad4\u6aa2\u67e5\u4e2d\u4f60\u767c\u73fe\u4e86\u5de6\u80f8\u9aa8\u7de3\u5230\u5fc3\u5c16\u6709\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u5fc3\u96fb\u5716\u6aa2\u67e5\u662f\u7ac7\u6027\u5fc3\u5f8b\uff0c\u4f46\u6709\u5de6\u5fc3\u5ba4\u80a5\u5927\u3002\u4f9d\u64da\u524d\u8ff0\u72c0\u6cc1\u5224\u65b7\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u7406\u5b78\u6aa2\u67e5\u6703\u662f\u6bd4\u8f03\u5408\u7406\u7684\u65b9\u5f0f\u4f86\u9032\u4e00\u6b65\u91d0\u6e05\u9019\u500b\u904b\u52d5\u54e1\u5728\u904b\u52d5\u8a13\u7df4\u4e2d\u6688\u5012\u548c\u5fc3\u96dc\u97f3\u51fa\u73fe\u7684\u53ef\u80fd\u539f\u56e0\uff1f\nA. \u5fc3\u5c16\u5340\u57df\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u6e1b\u5c11\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u589e\u52a0\nB. \u6536\u7e2e\u4e2d\u671f\u7684\u6ef4\u7b54\u97f3(systolic click)\u548c\u6536\u7e2e\u96dc\u97f3\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u63d0\u65e9\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u5ef6\u5f8c\nC. \u6536\u7e2e\u5168\u6642\u671f\u7684\u96dc\u97f3\u5728\u5fc3\u5c16\u807d\u5f97\u6700\u6e05\u695a\uff0c\u6703\u50b3\u5230\u5de6\u814b\u4e0b\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u589e\u5f37\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u6e1b\u5c11\nD. \u5439\u6c23\u578b\u6536\u7e2e\u671f\u96dc\u97f3(Blowing systolic murmur)\u51fa\u73fe\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u589e\u5f37\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216Valsalva maneuver\u800c\u6e1b\u5c11\nE. \u51fa\u73fe\u4f4e\u983b\u6536\u7e2e\u4e2d\u671f\u5fc3\u96dc\u97f3\u6703\u50b3\u5230\u9838\u52d5\u8108\u5340\u57df\n": "(A)", "102-17.\n\u9580\u8a3a\u6709\u4e00\u4f4d\u5bb9\u6613\u5fc3\u60b8\u768436\u6b72\u5973\u6027\u60a3\u8005\uff0c\u5979\u525b\u63a5\u53d7\u4e86\u6392\u5b9a\u768424\u5c0f\u6642\u5fc3\u96fb\u5716\u6aa2\u67e5\uff0c\u5831\u544a\u5448\u73fe\u5979\u6709\u5c11\u91cf\u7684\u5fc3\u5ba4\u671f\u5916\u6536\u7e2e\u548c\u5fc3\u623f\u671f\u5916\u6536\u7e2e\uff0c\u6c92\u6709\u5176\u4ed6\u7684\u5fc3\u5f8b\u4e0d\u6574\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u640f\u51fa\u7387\u5927\u65bc60%\uff0c\u6c92\u6709\u5176\u4ed6\u74e3\u819c\u6216\u5c40\u90e8\u6536\u7e2e\u529f\u80fd\u7570\u5e38\uff0c\u75c5\u4eba\u6c92\u6709\u5176\u4ed6\u7684\u7cfb\u7d71\u6027\u75be\u75c5\uff0c\u4e5f\u4e0d\u66fe\u6688\u5012\u3002\u91dd\u5c0d\u5979\u7684\u72c0\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u6bd4\u8f03\u5408\u9069\uff1f\nA. \u7d66\u4e88\u6297\u7126\u616e\u85e5\u54c1\nB. \u7d66\u4e88\u4e59\u578b\u963b\u65b7\u5291\nC. \u7d66\u4e88\u6bdb\u5730\u9ec3(Digoxin)\nD. \u7d66\u4e88\u594e\u5be7(Quinidine)\nE. \u7d66\u4e88\u518d\u4fdd\u8b49\uff0c\u5efa\u8b70\u89c0\u5bdf\uff0c\u76ee\u524d\u4e0d\u7528\u7d66\u85e5\u3002\n": "(E)", "102-18.\n\u4e00\u4f4d80\u6b72\u6709\u9577\u671f\u7f3a\u8840\u6027\u5fc3\u81df\u8870\u7aed\u7684\u7537\u6027\u60a3\u8005\u56e0\u70ba\u5931\u4ee3\u511f\u7684\u5fc3\u8870\u7aed\uff08Decompensated congestive heart failure\uff09\u4f4f\u9032\u52a0\u8b77\u75c5\u623f\uff0c\u5fc3\u96fb\u5716\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u8207\u5de6\u5074\u675f\u679d\u50b3\u5c0e\u963b\u65b7\u3002\u80f8\u90e8X\u5149\u6709\u514b\u96f7\u6c0fB\u7dda(Kerley's B-lines)\u548c\u96d9\u5074\u80ba\u6ce1\u6d78\u6f64\u8b8a\u5316(Alveolar infiltrates)\u3002\u5728\u7406\u5b78\u6aa2\u67e5\u4e0a\u61c9\u8a72\u53ef\u4ee5\u767c\u73fe\u4e0b\u5217\u54ea\u4e00\u500b\u7d44\u5408\uff1f(1)\u7b2c\u4e8c\u5fc3\u97f3\u5206\u88c2\u97f3  (2)\u7b2c\u56db\u5fc3\u97f3  (3)\u7b2c\u4e09\u5fc3\u97f3  (4)\u4e0d\u898f\u5247\u7684\u8108\u640f  (5)\u9838\u975c\u8108\u51fa\u73fe\u898f\u5247\u7684a\u6ce2\nA. (1)+(2)+(4)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(3)+(4)\n": "(E)", "102-19.\n\u6709\u4e00\u4f4d75\u6b72\u7537\u6027\u5373\u5c07\u63a5\u53d7\u5e38\u898f\u8ffd\u8e64\u7684\u51a0\u72c0\u52d5\u8108\u5c0e\u7ba1\u6aa2\u67e5\uff0c\u76ee\u7684\u662f\u8a55\u4f30\u4ed6\u5c0d\u65bc\u53e3\u670d\u85e5\u54c1\u53cd\u61c9\u4e0d\u592a\u597d\u7684\u72f9\u5fc3\u75c7\u3002\u4ed6\u554f\u5230\u6709\u95dc\u65bc\u51a0\u72c0\u52d5\u8108\u651d\u5f71\u6aa2\u67e5\u6700\u5e38\u898b\u5230\u7684\u4f75\u767c\u75c7\uff0c\u4f9d\u64da\u4e0a\u8ff0\u60c5\u6cc1\uff0c\u4f60\u8a8d\u70ba\u4e0b\u5217\u54ea\u4e00\u9805\u7684\u6bd4\u4f8b\u6700\u9ad8\uff1f\nA. \u6025\u6027\u814e\u8870\u7aed\nB. \u7de9\u6162\u6027\u5fc3\u5f8b\u4e0d\u6574(Bradyarrhythmias)\nC. \u5fc3\u808c\u6897\u585e\nD. \u8840\u7ba1\u6ce8\u5c04\u90e8\u4f4d(vascular access site)\u51fa\u8840\nE. \u5feb\u901f\u6027\u5fc3\u5f8b\u4e0d\u6574\n": "(D)", "102-20.\n\u4e0b\u5217\u54ea\u4e00\u9805\u76ee\u60c5\u6cc1\uff0c\u5728\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u7684\u60a3\u8005\uff0c\u76ee\u524d\u4ecd\u4e0d\u666e\u904d\u88ab\u7576\u4f5c\u662f\u8166\u8840\u7ba1\u4e2d\u98a8\u7684\u5371\u96aa\u56e0\u5b50\uff1f\nA. \u5de6\u5fc3\u623f\u5927\u5c0f4.0\u516c\u5206\nB. \u7cd6\u5c3f\u75c5\nC. \u66fe\u6709\u9b31\u8840\u6027\u5fc3\u8870\u7aed\nD. \u6709\u9ad8\u8840\u58d3\nE. \u66fe\u7d93\u6709\u8166\u8840\u7ba1\u4e2d\u98a8\n": "(A)", "102-21.\n\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u5728\u6bcf\u4f4d\u60a3\u8005\u8eab\u4e0a\u7684\u81e8\u5e8a\u8868\u73fe\u5dee\u7570\u5f88\u5927\uff0c\u5728\u5177\u6709\u4e0b\u5217\u5e7e\u7a2e\u81e8\u5e8a\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u5982\u679c\u4ed6\u5011\u8eab\u4e0a\u5982\u679c\u51fa\u73fe\u4e86\u65b0\u7684\u6301\u7e8c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff0c\u54ea\u4e00\u7a2e\u6703\u6709\u76f8\u5c0d\u66f4\u660e\u986f\u7684\u75c7\u72c0(\u4f8b\u5982\uff1a\u5598)\uff1f\nA. \u6025\u6027\u9152\u7cbe\u4e2d\u6bd2\nB. \u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\nC. \u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\nD. \u4f4e\u9ad4\u6eab\nE. \u958b\u80f8\u624b\u8853\u5f8c\u7684\u75c5\u4eba\n": "(B)", "102-22.\n\u6709\u95dc\u5fc3\u81df\u74e3\u819c\u75be\u75c5\u9700\u63a5\u53d7\u74e3\u819c\u7f6e\u63db\u624b\u8853\u7684\u60c5\u6cc1\uff0c\u4e0b\u5217\u8aaa\u660e\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f(1)\u8207\u6a5f\u68b0\u74e3\u819c\u6bd4\u8f03\uff0c\u751f\u7269\u74e3\u819c(Bioprosthetic valve) \u6bd4\u8f03\u4e0d\u6703\u7522\u751f\u8840\u6813 (2)\u540c\u6a23\u4f7f\u7528\u6a5f\u68b0\u74e3\u819c\uff0c\u653e\u7f6e\u5728\u4e3b\u52d5\u8108\u74e3\u4f4d\u7f6e\u7684\u74e3\u819c\u6bd4\u653e\u7f6e\u5728\u4e8c\u5c16\u74e3\u7684\u74e3\u819c\u8840\u6813\u7522\u751f\u6a5f\u6703\u66f4\u9ad8 (3)\u5982\u679c\u60a3\u8005\u60f3\u8981\u61f7\u5b55\u751f\u5b50\uff0c\u6574\u9ad4\u7684\u8eab\u9ad4\u72c0\u6cc1\u53ef\u4ee5\u63a5\u53d7\uff0c\u4f7f\u7528\u6a5f\u68b0\u74e3\u819c\u6703\u6bd4\u751f\u7269\u74e3\u819c\u66f4\u597d (4)\u8003\u616e\u4f7f\u7528\u8010\u4e45\u6027\uff0c\u5728\u5e74\u8f15\u4eba\u8eab\u4e0a\u61c9\u4f7f\u7528\u751f\u7269\u74e3\u819c\u6703\u6bd4\u6a5f\u68b0\u74e3\u819c\u66f4\u597d (5)\u96d9\u76e4\u5f0f\u7684\u6a5f\u68b0\u74e3\u819c(Double-disk valves)\u6bd4\u7403\u72c0\u74e3\u819c(Ball valve)\u6709\u6bd4\u8f03\u597d\u7684\u8840\u884c\u52d5\u529b\u5b78\u8868\u73fe(Hemodynamic parameters)\nA. (1)+(4)\nB. (2)+(5)\nC. (1)+(5)\nD. (3)+(4)\nE. (2)+(3)\n": "(C)", "103-1.\n\u4f9d\u64da2014\u5e74\u65b0\u7248\u7684JNC 8\u6cbb\u7642\u9ad8\u8840\u58d3\uff0c\u5f37\u8abf\u5be6\u8b49\u91ab\u5b78\uff0c\u4e0b\u5217\u4f55\u9805\u7684\u8aaa\u6cd5\u4e0d\u662f\u5c08\u5bb6\u5c0f\u7d44\u7684\u5efa\u8b70\uff1f\nA. \u5927\u65bc60\u6b72\u7684\u9ad8\u8840\u58d3\u75c5\u4eba\u4ee5\u4f4e\u65bc160/90 mmHg \u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nB. \u4ecb\u65bc30-59\u6b72\u7684\u9ad8\u8840\u58d3\u75c5\u4eba\u4ee5\u5fc3\u8212\u8840\u58d3\u4f4e\u65bc90 mmHg \u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nC. 60\u6b72\u4ee5\u4e0b\u7cd6\u5c3f\u75c5\u53ca\u6162\u6027\u814e\u75c5\u8b8a\u75c5\u4eba\u7684\u8840\u58d3\u6cbb\u7642\u4ee5140/90 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nD. \u7cd6\u5c3f\u75c5\u4eba\u964d\u58d3\u8d77\u59cb\u6cbb\u7642\u4ee5Angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker\u53caThiazides-type diuretics\u70ba\u9650\u3002\nE. \u964d\u58d3\u5291\u52a0\u7528Angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker\u53ef\u6539\u5584\u6162\u6027\u814e\u75c5\u4eba\u4e4b\u814e\u529f\u80fd\u3002\n": "(A)", "103-2.\n\u6839\u64da\"2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults\"\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u5efa\u8b70\u7684\u6307\u5f15\uff1f\nA. \u5df2\u77e5\u7ca5\u72c0\u786c\u5316\u75c5\u8b8a\u76f8\u95dc\u7684\u5fc3\u8840\u7ba1\u75c5\u4eba\u61c9\u7d66\u4e88\u9ad8\u5f37\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nB. LDL-C >190 mg/dl\u7684\u4eba\u61c9\u7d66\u4e88\u9ad8\u5f37\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nC. \u5e74\u9f6140-75\u7684\u7cd6\u5c3f\u75c5\u4eba\uff0c\u5176LDL-C\u5927\u65bc70 mg/dl\u5c31\u61c9\u7d66\u4e88\u4e2d\u7b49\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nD. \u5e74\u9f6140-75\u75c5\u4eba\uff0c\u5176\u6574\u9ad410\u5e74\u98a8\u96aa\u9ad8\u65bc7.5%\u53caLDL-C 70-189 mg/dl\u5c31\u61c9\u7d66\u4e88\u4e2d\u7b49\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nE. LDL-C\u4e4b\u6cbb\u7642\u76ee\u6a19\uff1a\u5fc3\u8840\u7ba1\u75c5\u4eba\u53ca\u7cd6\u5c3f\u75c5\u4eba\u61c9\u4f4e\u65bc70mg/dl\uff1b\u6709\u5fc3\u8840\u7ba1\u75c5\u5371\u96aa\u56e0\u5b50\u8005\u61c9\u4f4e\u65bc100mg/dl\uff1b\u5176\u4ed6\u8005\u61c9\u4f4e\u65bc160 mg/dl\u3002\n": "(E)", "103-3.\n82\u6b72\u8001\u5a66\u4eba\u5230\u9662\u4e3b\u8a34\u4e94\u5929\u4f86\u6709\u65e5\u8da8\u56b4\u91cd\u7684\u547c\u5438\u56f0\u96e3\u3002\u75c5\u53f2\u986f\u793a30\u5e74\u524d\u5c31\u6709\u91ab\u5e2b\u544a\u77e5\u5fc3\u81df\u96dc\u97f3\uff0c\u56e0\u7121\u75c7\u72c0\uff0c\u672a\u66fe\u6709\u4efb\u4f55\u6cbb\u7642\u3002\u8fd1\u4e94\u5e74\u4f86\u904b\u52d5\u8010\u53d7\u9010\u6f38\u4e0d\u4f73\uff0c\u4e14\u5076\u6709\u7a81\u767c\u6027\u60b8\u52d5\u53ca\u5fc3\u7d5e\u75db\uff0c\u7279\u5225\u5728\u6b65\u884c\u6a13\u68af\u9593\u66f4\u52a0\u60e1\u5316\u3002\u4f4f\u9662\u7576\u65e5\u6e05\u66683\u9ede\u7a81\u7136\u91cd\u5ea6\u547c\u5438\u56f0\u96e3\uff0c\u56e0\u800c\u6025\u8a3a\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3110/62 mmHg\uff1b\u5fc3\u8df390/\u5206\uff1b\u9838\u975c\u8108\u6012\u5f35\u3002\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u4f46\u5728\u53f3\u4e0a\u80f8\u9aa8\u7de3\u53ca\u5fc3\u5c16\u90e8\u6709Gr III/VI systolic murmur, S2\u6e1b\u8f15\uff1a\u5176\u4ed6\u6240\u898b\u5c1a\u7121\u7570\u5e38\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u5fc3\u96fb\u5716\u5982\u5716\u3002WBC,5.2 k/micro L\uff1bAST,21U/L\uff1bCK,111U/L\uff1bCK-MB,14.6U/L\uff1bTroponin I,0.06 ng/ml\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u6700\u6070\u7576?\nA. Percutaneous coronary intervention\nB. Aortic valve replacement\nC. Nitroglycerin IV infusion at the rate of 15mcg/min\nD. Titrate PO carvedilol starting from 3.125 mg and reassess in 3 months\nE. Treating with IV digoxin 0.125mg in conjunction with IV bolus Furosemide 20mg and then 20 mg BID\n": "(B)", "103-4.\n\u75c5\u4eba67\u6b72\u7537\u6027\uff0c\u81ea7\u6708\u8d77\u6709\u8f15\u5ea6\u54b3\u55fd\u53ca\u9593\u65b7\u6027\u767c\u71d2\u9ad8\u905438\u5ea6\uff0c\u574a\u9593\u8a3a\u6240\u8a3a\u65b7\u70ba\u4e0a\u547c\u5438\u9053\u611f\u67d3\u3002\u723e\u5f8c\uff0c\u767c\u71d2\u4ecd\u820a\u8d77\u4f0f\u8b8a\u52d5\uff0c\u5076\u6709\u5bd2\u986b(chillness)\uff0c\u4e26\u6709\u5168\u8eab\u5026\u6020\u53ca\u4e8c\u516c\u65a4\u9ad4\u91cd\u6e1b\u8f15\uff0c\u76f4\u523011\u6708\u624d\u5230\u9662\u6c42\u8a3a\u3002\u75c5\u4eba\u50c5\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u670d\u85e5\u4e2d\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c132/70 mmHg\uff1b\u5fc3\u8df3\uff0c78/\u5206\uff0c\u6b63\u5e38\u5f8b\u52d5\uff1b\u5fc3\u81df\u6709Gr II/IV Systolic murmur over left lower sternum border\uff1b\u5176\u4ed6\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002Blood cultures \u9001\u6aa2\u4e2d\u3002\r\u8acb\u554f\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\u4ee5\u4f55\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. Cardiac MRI\nB. Chest CT\nC. Gallium Scan\nD. Transesophageal echocardiography\nE. Exploratory chest operation\n": "(D)", "103-5.\n\u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u5e38\u6709\u809d\u3001\u814e\u529f\u80fd\u7b49\u591a\u91cd\u5668\u5b98\u7570\u5e38\u53ca\u5e38\u8981\u4f75\u7528\u591a\u7a2e\u85e5\u7269\uff0c\u53ef\u5f71\u97ff\u85e5\u7269\u7684\u5438\u6536\u53ca\u6392\u6cc4\uff0c\u5c0e\u81f4\u7528\u85e5\u4ea4\u4e92\u4f5c\u7528\u7981\u5fcc\u7684\u767c\u751f\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u5f97\u4f7f\u7528?\nA. Thiazolidinediones\nB. Dronedarone\nC. Amlodipine\nD. Cyclooxygenase 2 inhibitors\nE. Metformin\n": "(C)", "103-6.\n72\u6b72\u8001\u5148\u751f\uff0c\u591c\u9593\u7761\u89ba\u4e2d\u7a81\u56e0\u80f8\u75bc\u4f34\u6709\u5bd2\u986b\u3001\u51b7\u6c57\u800c\u9a5a\u9192\uff0c\u75bc\u75db\u9010\u6f38\u52a0\u5287\uff0c\u4e26\u5ef6\u4f38\u5f8c\u80cc\u90e8\uff0c\u4e43\u6025\u8d74\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u7576\u6642\u8840\u58d3\u5de6\u624b176/98 mmHg\uff1b\u53f3\u624b164/97 mmHg\uff1b\u8108\u8df378/\u5206\uff0c\u898f\u5247\u8df3\u52d5\u3002\u75c5\u4eba\u8ffd\u61b6\u8fd1\u500b\u6708\u4f86\uff0c\u6642\u6709\u9593\u6b47\u6027\u7684\u80f8\u75db\uff0c\u6709\u6642\u751a\u81f3\u75db\u904e\u500b\u628a\u5c0f\u6642\u3002 \u75c5\u4eba\u559c\u597d\u62bd\u7159\uff0c\u4f46\u5c1a\u7121\u5176\u4ed6\u75be\u75c5\u3002\u7406\u5b78\u53ea\u898b\u8eab\u9ad8 176 cm\u53ca\u9ad4\u91cd64.6 kg\uff0c\u8840\u58d3\u53ca\u5fc3\u8df3\u5982\u524d\u6240\u8ff0\uff0c\u4e0a\u4e0b\u80a2\u52d5\u8108\u8df3\u52d5\u6b63\u5e38\uff0c\u5176\u4ed6\u90e8\u4f4d\u4e26\u7121\u7570\u5e38\u53ef\u898b\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u96fb\u5716\u53ca\u96fb\u8166\u65b7\u5c64\u5982\u5716\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5982\u4e0b\u3002\u7d93\u4f7f\u7528IV morphine\u53ca\u93ae\u975c\u5291\u5f8c\uff0c\u75c5\u6cc1\u5927\u6709\u6539\u5584\u3002\u8acb\u554f\u6b64\u523b\u75c5\u4eba\u6700\u5408\u5b9c\u7684\u6cbb\u7642\u7b56\u7565\u662f?\nA. Endovascular stenting\nB. Urgent aortic repair\nC. Labetalol IV titration\nD. Catheter-based fenestration\nE. Dopamine IV infusion\n": "(C)", "103-7.\n\u6709\u95dc\u5fc3\u5ba4\u5feb\u8df3(Ventricular tachycardia, VT)\u7684\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u7684\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. Monomorphic VT \u591a\u898b\u65bc\u975e\u5668\u5b98\u8b8a\u7570\u6027\u5fc3\u81df\u75c5\u3002\nB. Polymorphic VT\u5728EP \u5be6\u9a57\u5ba4\u4e0d\u6613\u96fb\u6fc0\u5c0e\u8a98\u767c(Electric stimulation)\u3002\nC. \u8840\u884c\u529b\u5b78\u7570\u5e38\u53ca\u53bb\u986b\u96fb\u6fc0\u6709\u6548\u7684VT\u591a\u662f\u6301\u7e8c\u6027VT(Sustained VT)\u3002\nD. \u5728\u5fc3\u524d\u5340\u96fb\u6975(Precordial leads) \u51fa\u73fe\u540c\u81f4\u6027(Concordant)QRS\u578b\u614b\u3002\nE. Monomorphic VT \u4f7f\u7528\u975c\u6ce8\u7684Procainamide,Lidocaine \u6216Amiodarone \u5c31\u6709\u6548\uff0c\u4e0d\u5fc5\u96fb\u64ca\u3002\n": "(E)", "103-8.\n\u4f9d\u64da\u7f8e\u570b\u91ab\u5e2b\u5b78\u9662(American College of Physicians)\u57fa\u65bc\u91ab\u7642\u6210\u672c\u3001\u81e8\u5e8a\u5be6\u6548\u53ca\u75c5\u4eba\u5b89\u5168\uff0c\u6709\u4e0b\u5217\u8af8\u9805\u7167\u8b77\u8655\u7f6e\uff1a(1)\u4e2d\u5e74\u5973\u6027\uff0c\u6709\u6b63\u5e38\u6708\u7d93\u9031\u671f\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u5fc3\u81df\u75c7\u72c0\uff0c\u672a\u6709\u4e09\u9ad8\u75c5\u53f2\uff0c\u70ba\u65e9\u671f\u8a3a\u65b7\uff0c\u9054\u5230\u5b8c\u5168\u6cbb\u7642\u6548\u679c\uff0c\u61c9\u5efa\u8b70\u96fb\u8166\u65b7\u5c64\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u6aa2\u67e5\uff0c\u4ee5\u77ad\u89e3\u51a0\u8108\u72f9\u7a84\u53ca\u51a0\u72c0\u52d5\u8108\u9223\u5316\u5206\u6578 (2)\u4e8c\u5c16\u74e3\u812b\u5782\u75c5\u4eba\u9032\u884c\u62d4\u7259\u624b\u8853\u6642\uff0c\u9664\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u5916\uff0c\u53ef\u4e0d\u5fc5\u670d\u7528\u6297\u751f\u7d20\u9810\u9632\u5fc3\u5167\u819c\u708e\u4e4b\u767c\u751f (3)\u6162\u6027\u51a0\u5fc3\u75c5\u4eba\uff0c\u5728\u85e5\u7269\u670d\u7528\u4e2d\uff0c\u672a\u6709\u4efb\u4f55\u5fc3\u81df\u75c7\u72c0\u6642\uff0c\u4e0d\u5fc5\u4ee5\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u8ffd\u8e64\u7ca5\u72c0\u786c\u5316\u4e4b\u9032\u5c55\r(4)\u6025\u6027\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\u4f34\u767c\u5b8c\u5168\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\uff0c\u61c9\u5019\u7b49\u6578\u5929\uff0c\u624d\u53ef\u6c7a\u5b9a\u7f6e\u653e\u6c38\u4e45\u6027\u5fc3\u5f8b\u8abf\u6574\u5668 (5)\u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u4f75\u6709\u547c\u5438\u56f0\u96e3\u6642\uff0c\u4ecd\u820a\u61c9\u6709BNP\u6aa2\u6e2c\uff0c\u4ee5\u70ba\u6cbb\u7642\u4e4b\u53c3\u8003\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u7684\u8655\u7f6e\u624d\u6709\u9ad8\u50f9\u503c\u7684\u7167\u8b77\uff1f\nA. (1)+(3)+(5)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "103-9.\n\u6797\u5148\u751f\u5e7427\u6b72\uff0c\u65bc2013\u5e7410\u6708\u521d\u5f9e\u4e2d\u570b\u5de5\u4f5c\u56de\u53f0\u5f8c\uff0c\u958b\u59cb\u6709\u54b3\u55fd\u3001\u9593\u6b47\u6027\u5bd2\u986b\u3001\u7009\u809a\u53ca\u8f15\u5ea6\u547c\u5438\u56f0\u96e3\uff0c\u7d93\u904e\u4e8c\u9031\uff0c\u75c5\u72c0\u65e5\u5287\uff0c\u5168\u8eab\u5026\u6020\uff0c\u4e26\u6709\u7aef\u5750\u547c\u5438\u56f0\u96e3\uff0c\u8179\u8139\u3001\u5641\u5fc3\u53ca\u9ad4\u91cd\u5287\u589e\uff0c\u4e43\u4f4f\u9662\u8a3a\u7642\u3002\u7406\u6aa2\u986f\u793a\uff1a\u8eab\u9ad8\uff0c179\u516c\u5206\uff1b\u9ad4\u91cd\uff0c84.6\u516c\u65a4\uff1b\u9ad4\u6eab36.9\u5ea6\uff1a\u5fc3\u8df3 110/\u5206\uff1b\u547c\u5438 24/\u5206\u53ca\u8840\u58d3 159/119 mmHg\uff1b\u9838\u975c\u8108\u6012\u5f35\uff1b\u96d9\u5074\u80ba\u6709\u6df7\u6fc1\u547c\u5438\u8072\uff1b\u5fc3\u81df\uff0cS3\u53caleft lift\uff0c\u4f46\u7121\u5fc3\u81df\u96dc\u97f3\u53ef\u805e\uff1b\u8179\u90e8\u6709shifting dullness\uff0c\u4f46\u7121\u809d\u816b\uff1b\u96d9\u8173\u6d6e\u816b\u3002\u5176\u5fc3\u96fb\u5716\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\r\u8acb\u554f\u9019\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Acute myocardial infarction\nB. Hypertensive cardiovascular disease\nC. Hypertrophic cardiomyopathy\nD. Acute aortic disease\nE. Acute heart failure\n": "(E)", "103-10.\n\u675c\u5148\u751f73\u6b72\uff0c\u56e0H1N1\u6d41\u884c\u6027\u611f\u5192\u4f75\u767c\u80ba\u708e\u53ca\u547c\u5438\u8870\u7aed\u800c\u65bc1\u670824\u65e5\u4f4f\u9662\u3002\u6709\u62bd\u7159\u75c5\u53f2\uff0c\u4f46\u7121\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u6216\u8840\u8102\u7570\u5e38\u75c5\u53f2\u3002\u4f4f\u9662\u4e2d\u547c\u5438\u4ecd\u820a\u4e0d\u9069\uff0c1\u670826\u65e5\u6e05\u6668\u8840\u6c27\u964d\u4f4e\uff0c\u6642T/P/R 36.8/123/26\uff1bCVP=8mmHg\uff0cBP 140/73mmHg\uff0cbilateral crackles\uff0c\u555f\u7528 PEEP\u8f14\u52a9\u547c\u5438\u3002\u7dca\u6025\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X-\u5149\u6aa2\u67e5\u5982\u5716\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4e4b\u8a3a\u65b7\u662f\uff1a\nA. Acute respiratory failure\nB. Acute lungs edema\nC. STEMI, proximal left anterior descending artery occlusion\nD. STEMI, proximal right coronary artery occlusion\nE. NSTEMI, left circumflex artery occlusion\n": "(C)", "103-11.\n72\u6b72\u7537\u6027\u8001\u4eba\uff0c\u4f4f\u9662\u4e3b\u8a34\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u3002\u75c5\u4eba\u57282007\u5e74\u6709\u9ad8\u8840\u58d3\u670d\u7528Bisoprolol(5mg)1/2 #,qd\u53ca Amlodipine(5mg) 1#,qd\u30022009\u5e747\u67086\u65e5\u8fd1\u4e4e\u660f\u53a5\u6c42\u91ab\uff0c\u5fc3\u96fb\u5716\u5982(A)\u30022003\u5e744\u67081\u65e5\u6709\u5de6\u773c\u5931\u660e\u53ca\u5de6\u624b\u8edf\u5f31\u7121\u529b\uff0c\u6642\u8840\u58d3164/79 mmHg\u53ca\u5fc3\u8df393/min\uff0c\u4e0d\u898f\u5247\u5f8b\u8df3\uff0c\u5fc3\u96fb\u5716\u5982(B)\u3002\u57282014\u5e748\u67086\u65e5\u6e05\u6668\u7a81\u7136\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\uff0c\u64da\u7a31\u75c5\u4eba\u5df2\u6709\u5fc3\u60b8\u3001\u80f8\u60b6\u53ca\u9593\u6b47\u6027\u547c\u5438\u56f0\u96e3\u4e00\u9031\u3002\u7406\u5b78\u6aa2\u67e5\uff1aT/P/R= 36.9/79/18\uff1bBP 119/73 mmHg\uff1b\u6025\u75c5\u72c0\uff0c\u80ba\u90e8\u6df7\u6fc1\u547c\u5438\u97f3\uff0c\u5fc3\u81df\u5927\u5c0f\u5c1a\u53ef\uff0c\u672a\u6709\u5fc3\u96dc\u97f3\u53caS3\u6216S4\uff0c\u9918\u4e4b\u7406\u6aa2\u5c1a\u7121\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716(C)\r\u53ca\u80f8\u90e8X\u5149\u548c\u8840\u6db2\u6aa2\u67e5\u5982\u5716\u3002\u8acb\u554f\u6b64\u75c5\u4eba\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u8a3a\u65b7\u662f\uff1a\nA. Short-run ventricular tachycardia\nB. Torsades de pointes\nC. Atrial fibrillation\nD. Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation\nE. Ventricular fibrillation\n": "(D)", "103-12.\n\u73fe\u5e7452\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u6025\u767c\u80f8\u75bc\u4e26\u6709\u96d9\u8173\u9ebb\u6728\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u6642\u6709\u5408\u4f75\u51b7\u6c57\uff0c\u4f46\u7121\u5641\u5fc3\u6216\u5614\u5410\uff0c\u4e5f\u672a\u6709\u653e\u6563\u6027\u80f8\u75bc\u3002\u8840\u58d365/52mmHg; \u5fc3\u8df352/\u5206\uff1b\u9ad4\u6eab36.7\u5ea6\uff1b\u547c\u543818/\u5206\uff1b\u5176\u4ed6\u7406\u5b78\u6240\u898b\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u75c5\u4eba\u65e2\u5f80\u75c5\u53f2\u6709\u5341\u591a\u5e74\u9ad8\u8840\u58d3\uff0c\u4e0d\u898f\u5247\u7528\u85e5\uff0c\u5bb6\u65cf\u6709\u51a0\u5fc3\u75c5\u3002\u5176\u7dca\u6025\u751f\u5316\u6aa2\u67e5\uff1aCK 78\uff1bCK-MB 26.3\uff1bTroponin I 0.012\u3002\u8acb\u554f\u672c\u75c5\u4eba\u7684STEMI\u6700\u53ef\u80fd\u7684\u51a0\u72c0\u52d5\u8108\u963b\u585e\u4f4d\u7f6e\u5728\uff1a\nA. Proximal left anterior descending artery(LAD)\nB. Proximal LAD beyond septal branch\nC. Posterolateral right coronary artery(RCA)\nD. Proximal RCA with Bezold-Jarish reaction\nE. Proximal left circumflex artery\n": "(D)", "103-13.\n\u4e00\u4f4d42\u6b72\u7684\u7537\u6027\u4e0a\u73ed\u65cf\u4f86\u770b\u9ad4\u6aa2\u5831\u544a\uff0c\u4ed6\u6bcf\u5468\u6162\u8dd1\u4e09\u6b21\uff0c\u6bcf\u6b21\u8dd135\u5206\u9418\uff0c\u8dd1\u6b65\u6642\u4e0d\u66fe\u89ba\u5f97\u80f8\u60b6\u6216\u6c23\u5598\u3002\u5728\u5de5\u4f5c\u58d3\u529b\u5927\u7684\u6642\u5019\u5076\u723e\u6703\u89ba\u5f97\"\u5fc3\u81df\u5c11\u4e86\u4e00\u8df3\"\u7684\u611f\u89ba\uff0c\u800c\u9019\u7a2e\u611f\u89ba\u4e0d\u6703\u6301\u7e8c\uff0c\u4e5f\u4e0d\u6703\u6709\u982d\u6688\u3002\u4ee5\u524d\u6c92\u6709\u4f4f\u9662\u6216\u958b\u5200\uff0c\u81ea\u5df1\u611f\u89ba\u5065\u5eb7\uff0c\u6c92\u6709\u62bd\u83f8\u6216\u559d\u9152\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3 126/72 mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u941868\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941814\u6b21\uff0c\u8eab\u9ad4\u8cea\u91cf\u6307\u6578(BMI)\u662f23 kg/m2\u3002\u5fc3\u97f3\u807d\u8a3a\u5728\u5de6\u4e0b\u80f8\u9aa8\u908a\u7de3\u6709\u4e0d\u6703\u653e\u5c04\u7684\u7b2c2/6\u5ea6\u6536\u7e2e\u5fc3\u96dc\u97f3\uff0c\u80ba\u90e8\u547c\u5438\u97f3\u6b63\u5e38\uff0c\u56db\u80a2\u8108\u640f\u5c0d\u7a31\u6b63\u5e38\uff0c\u5fc3\u96fb\u5716\u6aa2\u67e5\u6b63\u5e38\u3002 \u4e0b\u4e00\u6b65\u8981\u5b89\u6392\u7684\u6aa2\u67e5\u662f\uff1f\nA. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nB. \u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\nC. \u80f8\u524d\u5fc3\u81df\u8d85\u97f3\u6ce2\nD. \u904b\u52d5\u5fc3\u96fb\u5716\nE. \u4e0d\u7528\u9032\u4e00\u6b65\u6aa2\u67e5\n": "(E)", "103-14.\n63\u6b72\u7537\u6027\u6709\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u548c\u9ad8\u8840\u58d3\uff0c\u540c\u6642\u6709\u9663\u767c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u7684\u75c5\u53f2\u800c\u63a5\u53d7\u5305\u542b\u6709metoprolol\uff0cmetformin\u548cwarfarin\u7684\u85e5\u7269\u6cbb\u7642\u3002\u56e0\u70ba\u7cde\u4fbf\u6f5b\u8840\u7be9\u6aa2\u967d\u6027\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u56e0\u70ba\u53ef\u80fd\u6703\u6709\u63a1\u6aa2 (biopsy)\u7684\u9700\u8981\uff0c\u8981\u5148\u505c\u7528warfarin\u3002\u4ed6\u4e0d\u66fe\u62bd\u83f8\uff0c\u6c92\u6709\u4e2d\u98a8\u6216\u56db\u80a2\u52d5\u975c\u8108\u8840\u7ba1\u963b\u585e\u7684\u904e\u53bb\u53f2\uff0c\u9ad4\u6aa2\u6642\u8840\u58d3\u5fc3\u8df3\u5728\u6b63\u5e38\u503c\uff0c\u5fc3\u5f8b\u5247\u5448\u73fe\u4e0d\u898f\u5247(irregularly irregular)\uff0c\u62bd\u8840\u6aa2\u67e5INR\u662f2.3\u3002\u5728\u6b64\u6642\u9700\u8981\u505c\u6b62warfarin\u7684\u60c5\u6cc1\u4e0b\uff0c\u6703\u63a1\u53d6\u7684\u8f03\u6070\u7576\u6b65\u9a5f\u662f\uff1f\nA. \u6539\u7528aspirin\nB. \u6539\u7528clopidogrel\nC. \u6539\u7528\u4f4e\u5206\u5b50\u91cf\u809d\u7d20(low molecular weight heparin)\nD. \u6539\u7528\u809d\u7d20(unfractionated heparin)\nE. \u4e0d\u9808\u4f7f\u7528\u66ab\u6642\u7684\u66ff\u4ee3\u85e5\u54c1\n": "(E)", "103-15.\n70\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u56b4\u91cd\u7684\u5931\u4ee3\u511f\u9b31\u8840\u6027\u5fc3\u8870\u7aed(decompensated congestive heart failure)\u4f4f\u9662\u63a5\u53d7\u6cbb\u7642\uff0c\u56e0\u70ba\u7a81\u767c\u6027\u7684\u5fc3\u5ba4\u7e96\u7dad\u986b\u52d5(Vf)\u6b63\u5728\u9032\u884c\u6025\u6551\uff0c\u76ee\u524d\u525b\u9032\u884c\u5b8c200\u7126\u8033\u7684\u975e\u540c\u6b65\u9ad4\u5916\u53bb\u986b\u96fb\u64ca\uff0c\u7dca\u63a5\u8457\u53bb\u986b\u96fb\u64ca\u4e4b\u5f8c\u7acb\u523b\u9032\u884c\u8f03\u6070\u7576\u7684\u52d5\u4f5c\u662f\uff1f\nA. \u7e7c\u7e8c\u9ad4\u5916\u6309\u6469CPR\nB. \u7d66\u4e88epinephrine\nC. \u7d66\u4e88amiodarone\nD. \u78ba\u8a8d\u8108\u640f\nE. \u7d66\u4e88vasopressin\n": "(A)", "103-16.\n52\u6b72\u6709\u9ad8\u8840\u58d3\u7684\u7537\u6027\u60a3\u8005\uff0c\u6392\u5c3f\u6b63\u5e38\uff0c\u56e0\u70ba\u5927\u65bc\u4e00\u5468\u7684\u96d9\u4e0b\u80a2\u6c34\u816b\u548c\u547c\u5438\u6703\u5598\uff0c\u722c2\u5c64\u6a13\u68af\u66f4\u5598\u800c\u4f4f\u9662\u6cbb\u7642\u3002\u4f4f\u9662\u6642\u4ed6\u63a5\u53d7\u975c\u8108\u6ce8\u5c04\u5229\u5c3f\u5291furosemide\u4e4b\u5f8c\u75c7\u72c0\u9032\u6b65\uff0c\u4e94\u5929\u5f8c\u85e5\u7269\u8abf\u6574\u5230\u53e3\u670d\u7684 enalapril\u548cfurosemide\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5de6\u5fc3\u5ba4\u5c04\u51fa\u738735%\uff0c\u6c92\u6709\u74e3\u819c\u75be\u75c5\uff0c\u6574\u500b\u5de6\u5fc3\u5ba4\u904b\u52d5\u4e0d\u826f(global hypokinesia); \u6838\u5b50\u91ab\u5b78\u704c\u6d41\u6aa2\u67e5\u6c92\u6709\u660e\u986f\u7684\u5c40\u90e8\u7f3a\u8840\u3002\u76ee\u524d\u4ed6\u7684\u8840\u58d3\u662f136/88mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u941880\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941815\u6b21\uff0c\u8eab\u9ad4\u6aa2\u67e5\u6c92\u6709\u9838\u975c\u8108\u6012\u5f35\uff0c\u6c92\u6709\u7b2c\u4e09\u5fc3\u97f3\uff0c\u6c92\u6709\u80ba\u90e8\u56c9\u97f3(moist\rrales)\uff0c\u96d9\u4e0b\u80a2\u5df2\u7d93\u6c92\u6709\u6c34\u816b\u3002\u7532\u72c0\u817a\u6578\u503c\u6b63\u5e38\uff0c\u5fc3\u96fb\u5716\u6b63\u5e38\u7ac7\u6027\u7bc0\u5f8b\uff0c\u6c92\u6709\u75c5\u7406\u6027Q\u6ce2\u3002\u6b64\u6642\u52a0\u4e0a\u4e0b\u5217\u54ea\u4e00\u7a2e\u85e5\u7269\u8f03\u5408\u9069\uff1f\nA. Amlodipine\nB. Carvedilol\nC. Hydralazine + isosorbide dinitrate\nD. Doxazosin\nE. Spironolactone\n": "(B)", "103-17.\n76\u6b72\u5973\u6027\u9ad8\u8840\u58d3\u75c5\u4eba\u7d93\u6b77\u80f8\u53e3\u75bc\u75db\u4e09\u5929\u4e4b\u5f8c\u7531\u5bb6\u4eba\u966a\u540c\u5c31\u91ab\uff0c\u7576\u5979\u5230\u91ab\u9662\u6025\u8a3a\u6642\u80f8\u75db\u5df2\u7d93\u7de9\u89e3\uff0c\u521d\u6b65\u767c\u73fe\u5979\u6709ST\u7bc0\u6bb5\u4e0a\u5347\u578b\u524d\u58c1\u5fc3\u808c\u6897\u585e\u3002\u5230\u9662\u5169\u5c0f\u6642\u4e4b\u5f8c\u5979\u7a81\u7136\u767c\u751f\u547c\u5438\u4e0d\u9806\uff0c\u5287\u70c8\u5598\u606f\u548c\u8840\u58d3\u4e0b\u964d\u800c\u7dca\u6025\u9032\u884c\u6c23\u7ba1\u63d2\u7ba1\uff0cX\u5149\u6aa2\u67e5\u767c\u73fe\u66f4\u64f4\u5927\u7684\u5fc3\u81df\u8207\u80ba\u6c34\u816b\uff0c\u4e26\u9700\u8981\u7528Dopamine\u958b\u59cb\u5e6b\u5fd9\u7dad\u6301\u8840\u58d3\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3\u662f90/60mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418122\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941816\u6b21\uff0c\u5728\u5979\u7684\u5de6\u53f3\u80f8\u9aa8\u908a\u7de3\u807d\u5230\u7b2c4/6\u7d1a\u5168\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u53ef\u4ee5\u89f8\u8a3a\u5230\u9707\u986b(thrill)\uff0c\u96d9\u5074\u80ba\u90e8\u51fa\u73fe\u56c9\u97f3(rales)\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u8a3a\u65b7\u6bd4\u8f03\u53ef\u80fd\u8981\u5148\u8003\u616e\uff1f\nA. \u4e3b\u52d5\u8108\u525d\u96e2\nB. \u5de6\u5fc3\u5ba4\u7624\nC. \u5fc3\u5ba4\u4e2d\u8188\u7f3a\u640d\nD. \u53f3\u5fc3\u5ba4\u6897\u585e\nE. \u5fc3\u5305\u586b\u585e(cardiac tamponade)\n": "(C)", "103-18.\n68\u6b72\u5973\u6027\u60a3\u8005\u56e0\u70ba\u7a81\u7136\u51fa\u73fe\u7684\u5fc3\u60b8\u5408\u4f75\u982d\u6688\uff0c\u547c\u5438\u6703\u5598\u7b49\u72c0\u6cc1\u4f86\u5230\u6025\u8a3a\u5ba4\u3002\u5979\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u53f2\uff0c\u524d\u4e00\u500b\u6708\u525b\u9032\u884c\u7684\u6aa2\u67e5\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\uff0c\u5fc3\u8df3\u662f\u7ac7\u6027\u5fc3\u5f8b\u3002\u76ee\u524d\u6b63\u4f7f\u7528ACE inhibitor\uff0c\u5229\u5c3f\u5291\u548c\u963f\u65af\u5339\u9748\u6cbb\u7642\u3002\u5e73\u65e5\u8840\u58d3\u63a7\u5236\u5728\u6b63\u5e38\u6578\u503c\u3002\u7576\u5979\u5230\u9054\u6025\u8a3a\u6642\uff0c\u6e2c\u5f97\u7684\u751f\u547d\u5fb5\u8c61\uff1a\u8840\u58d380/60mmHg\uff0c\u5fc3\u8df3150\u6b21/\u5206\u9418\uff0c\u547c\u543830\u6b21/\u5206\u9418\uff0c\u4f7f\u752840%\u6c27\u6c23\u9762\u7f69\u7684SpO2\u662f80%\u3002\u5fc3\u81df\u7684\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u4e0d\u898f\u5247\u7684\u5feb\u901f\u5fc3\u8df3\uff0cS1\u5fc3\u97f3\u807d\u8a3a\u6642\u8072\u97f3\u51fa\u73fe\u5927\u5c0f\u8b8a\u5316\uff0c\u96d9\u5074\u4e0b\u4e09\u5206\u4e4b\u4e00\u7684\u80ba\u90e8\u6709\u6fd5\u56c9\u97f3\uff0c\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u3002\u6b64\u6642\u7684\u7dca\u6025\u8655\u7406\u4e0b\u5217\u6bd4\u8f03\u5408\u9069\u7684\u4e00\u9805\u662f\uff1f\nA. Adenosine\nB. Amiodarone\nC. Cardioversion\nD. Diltiazem\nE. Metoprolol\n": "(C)", "103-19.\n60\u6b72\u7684\u7537\u6027\u56e0\u70ba\u5de6\u5074\u808b\u819c\u75bc\u75db\u611f\u89ba\u800c\u5c31\u91ab\uff0c\u4ed6\u7684\u75bc\u75db\u51fa\u73fe\u5927\u7d04\u4e00\u9031\u4e86\uff0c\u6bcf\u6b21\u767c\u751f\u6642\u6703\u75db\u6578\u500b\u5c0f\u6642\uff0c\u5982\u679c\u8eba\u4e0b\u6703\u66f4\u75bc\u75db\u3002\u4ed6\u66fe\u8a66\u8457\u670d\u7528\u666e\u62ff\u75bc\uff0c\u53ea\u80fd\u7a0d\u5fae\u6e1b\u8f15\u75bc\u75db\u611f\uff0c\u4f46\u4ed6\u767c\u73fe\u5982\u679c\u5750\u8457\u5c07\u4e0a\u534a\u8eab\u50be\u5411\u524d\u65b9\u80fd\u66ab\u6642\u8b93\u75bc\u75db\u611f\u6d88\u5931\u3002\u4ed6\u56de\u61b6\u81ea\u5df1\u5728\u4e03\u500b\u6708\u4e4b\u524d\u66fe\u88ab\u8a3a\u65b7\u6709\u6025\u6027\u5fc3\u5305\u819c\u708e\uff0c\u90a3\u6642\u5403\u4e86\u91ab\u5e2b\u958b\u7684\u6b62\u75db\u85e57\u5929\u4e4b\u5f8c\u5c31\u597d\u4e86\u3002\u60a3\u8005\u5728\u6700\u8fd1\u4e09\u5929\u6709\u8f15\u5fae\u767c\u71d2\uff0c\u4f46\u6c92\u6709\u54b3\u55fd\u6216\u6d41\u9f3b\u6c34\uff0c\u4e5f\u6c92\u6709\u65c5\u884c\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u751f\u547d\u5fb5\u8c61\uff1a\u8840\u58d3128/68mmHg\uff0c\u547c\u543816\u6b21/\u5206\u9418\uff0c\u5fc3\u8df398\u6b21/\u5206\u9418\uff0c\u6c92\u6709\u9838\u975c\u8108\u9f13\u8139\uff0c\u4f46\u6709\u5de6\u5074\u80f8\u9aa8\u7de3\u807d\u5230\u6709\u4e8c\u500b\u7d44\u6210\u6210\u4efd\u7684\u5fc3\u5305\u6469\u64e6\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u6c92\u6709\u54ee\u9cf4\u97f3\uff0c\u624b\u8173\u6c92\u6709\u6c34\u816b\uff0c\u5fc3\u96fb\u5716\u662f\u7ac7\u6027\ufffd\r\u8456\u8144A\u6c92\u6709ST\u7bc0\u6bb5\u8b8a\u5316\u3002\u6b64\u6642\u6703\u8003\u616e\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f55\u8005\u6bd4\u8f03\u6070\u7576\uff1f\nA. \u6aa2\u67e5\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u5fc3\u5305\u5207\u9664\u8853\nC. Azathioprine\nD. Prednisolone\nE. Colchicine\u548caspirin\n": "(E)", "103-20.\n73\u6b72\u5973\u6027\u6709\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\uff0c\u9ad8\u8840\u58d3\uff0c\u9ad8\u8840\u8102\u597d\u591a\u5e74\u4e86\uff0c\u5979\u524d\u4f86\u56de\u8a3a\u770b\u6700\u8fd1\u7684\u6aa2\u67e5\u5831\u544a\u3002\u76ee\u524d\u5979\u6b63\u63a5\u53d7olmesartan, metformin\u548cpravastatin\u7684\u6cbb\u7642\u3002\u5979\u6709\u63a5\u53d7\u91ab\u5e2b\u7684\u5efa\u8b70\u7dad\u6301\u56fa\u5b9a\u904b\u52d5\uff0c\u9ad8\u7e96\u4f4e\u8102\u98f2\u98df\uff0c\u540c\u6642\u5e38\u651d\u53d6\u6c34\u679c\u8207\u852c\u83dc\u3002\u6c92\u6709\u85e5\u7269\u904e\u654f\u53f2\u3002\u56de\u8a3a\u6642\u751f\u547d\u5fb5\u8c61\u662f\uff1a\u8840\u58d3122/72mmHg\uff0c\u5fc3\u8df372\u6b21/\u5206\u9418\uff0c\u547c\u543815\u6b21/\u5206\u9418\uff0c\u5fc3\u3001\u80f8\u3001\u8179\u90e8\u8207\u56db\u80a2\u7684\u8eab\u9ad4\u6aa2\u67e5\u5247\u6c92\u6709\u7279\u6b8a\u767c\u73fe\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u6578\u503c\u5982\u4e0b\uff1aHbA1c :\r6.5%\uff0c\u7e3d\u81bd\u56fa\u9187116mg/dL\uff0c\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187(LDL-C)51mg/dL\uff0c\u9ad8\u5bc6\u5ea6\u81bd\u56fa\u9187(HDL-C)57mg/dL\uff0c\u4e09\u9178\u7518\u6cb9\u8102(TG)40mg/dL\u3002\u75c5\u4eba\u5e0c\u671b\u63a5\u53d7\u5b8c\u5584\u7684\u7167\u9867\uff0c\u8acb\u554f\u6703\u7d66\u4e88\u7684\u7528\u85e5\u5efa\u8b70\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u4f73\uff1f\nA. \u4f7f\u7528clopidogrel\nB. \u589e\u52a0\u964d\u8840\u8102\u7684\u85e5\u7269\nC. \u4f7f\u7528aspirin\u548cdipyridamole\nD. \u4f7f\u7528aspirin\nE. \u4f7f\u7528aspirin\u548cclopidogrel\n": "(D)", "103-21.\n50\u6b72\u7684\u5973\u6027\u66fe\u572813\u5e74\u524d\u56e0\u4e73\u764c\u63a5\u53d7\u624b\u8853\u5207\u9664\u53f3\u5074\u4e73\u623f\u4ee5\u53ca\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5728\u5916\u79d1\u8853\u5f8c\u7684\u898f\u5247\u8ffd\u8e64\u88e1\uff0c\u5979\u7684\u72c0\u6cc1\u7a69\u5b9a\uff0c\u6c92\u6709\u8b8a\u5316\u3002\u76f4\u5230\u5979\u6700\u8fd1\u4e09\u500b\u6708\u88e1\uff0c\u5979\u611f\u5230\u904b\u52d5\u6642\u6703\u7565\u70ba\u80f8\u60b6\uff0c\u6700\u8fd1\u4e8c\u500b\u6708\u5167\u5247\u6162\u6162\u51fa\u73fe\u722c\u4e09\u5c64\u6a13\u68af\u6642\u6709\u4e00\u9ede\u5598\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u5979\u7684\u9ad4\u6eab\u6b63\u5e38\uff0c\u8840\u58d3\uff1a150/43mmHg\uff0c\u5fc3\u8df380\u6b21/\u5206\u9418\uff0c\u547c\u543814\u6b21/\u5206\u9418\u3002\u9838\u975c\u8108\u6c92\u6709\u9f13\u8139\uff0c\u4f46\u6703\u89c0\u5bdf\u5230\u52a0\u5f37\u800c\u5feb\u901f\u7684\u9838\u52d5\u8108\u6ce2\u4e0a\u5347\u8207\u4e0b\u964d\uff0c\u5fc3\u97f3\u767c\u73fe\u6e1b\u5c0f\u7684S2\u5fc3\u97f3\uff0c\u4f46\u6c92\u6709S3\uff0c\u5de6\u5074\u7b2c\u4e09\u808b\u9593\u80f8\u9aa8\u7de3\u5247\u51fa\u73fe\u9ad8\u983b\u7387\uff0c\u7b2c2/6\u7d1a\u7684\u8212\u5f35\u671f\u6f38\u6e1b\u6027\u5fc3\u96dc\u97f3\uff0c\u6700\u5927\u5fc3\u5c16\u640f\u52d5\u9ede\u5247\u5411\u5916\u5411\u4e0b\u504f\u79fb\uff0c\u6c92\u6709\u51fa\u73fe\u809d\uff0d\u9838\u975c\u8108\u53cd\u5c04\u6ce2(Hepatojugular\rreflux)\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u60c5\u6cc1\u8f03\u80fd\u89e3\u91cb\u524d\u8ff0\u767c\u73fe\uff1f\nA. \u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41(Aortic valve regurgitation)\nB. \u5fc3\u5305\u586b\u585e(Cardiac tamponade)\nC. \u9650\u5236\u6027\u5fc3\u808c\u75c5\u8b8a(Constrictive pericarditis)\nD. \u4fb7\u9650\u6027\u5fc3\u5305\u819c\u708e(Restrictive cardiomyopathy)\nE. \u56b4\u91cd\u4e09\u5c16\u74e3\u8ff4\u6d41(Severe tricuspid valve regurgitation)\n": "(A)", "103-22.\n22\u6b72\u7684\u7537\u6027\uff0c\u51fa\u751f\u6642\u662f\u500b\u65e9\u7522\u5152\uff0c\u4ed6\u8a18\u5f97\u7236\u6bcd\u8aaa\u4ed6\u5f9e\u5c0f\u5c31\u88ab\u91ab\u5e2b\u8a3a\u65b7\u6709\u5fc3\u96dc\u97f3\u4f46\u6c92\u6709\u958b\u904e\u5200\uff0c\u4f46\u6c42\u5b78\u4e2d\u8207\u540c\u73ed\u5b78\u751f\u5728\u9ad4\u80fd\u904b\u52d5\u4e0a\u7684\u8868\u73fe\u76f8\u8fd1\uff0c\u6c92\u6709\u7279\u5225\u7684\u5730\u65b9\uff0c\u4e0d\u66fe\u56e0\u80f8\u90e8\u7684\u75c7\u72c0\u6216\u4e0d\u8212\u670d\u770b\u904e\u75c5\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u8840\u58d3\uff1a116/82mmHg\uff0c\u6700\u5927\u5fc3\u5c16\u640f\u52d5\u9ede\u6c92\u6709\u660e\u986f\u4f4d\u79fb\uff0c\u5728\u5de6\u5074\u80f8\u9aa8\u7de3\u7b2c\u4e8c\u808b\u9593\u8655\u6709\u4e00\u500b\u7b2c3/6\u7d1a\u7684\u9023\u7e8c\u7684\uff0c\u50cf\u6a5f\u68b0\u7684( continuous-machinery )\u7684\u8072\u97f3\u51fa\u73fe\uff0c\u9019\u500b\u8072\u97f3\u8de8\u8d8a\u4e86\u6536\u7e2e\u548c\u8212\u5f35\u671f\uff0c\u9019\u500b\u8072\u97f3\u5728\u5de6\u5074\u9396\u9aa8\u4e0b\u65b9\u4e5f\u53ef\u4ee5\u807d\u898b\u3002\u4ed6\u7684\u624b\u8173\u8108\u640f\u5f37\u5f31\u662f\u6b63\u5e38\u5c0d\u7a31\uff0c\u4e5f\u6c92\u6709\u51fa\u73fe\u8108\u640f\u5ef6\u9072\uff0c\u6c92\u6709\u6775\u72c0\u6307\u6216\u767c\u7d3a\u3002\u80f8\u90e8X\u5149\u548c\u5fc3\u96fb\u5716\u6aa2\u67e5\u5247\u6b63\u5e38\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u72c0\u6cc1\u8f03\u7b26\u5408\u9019\u500b\u767c\u73fe\uff1f\nA. Ventricular septal defect\nB. Aortic coarctation\nC. Atrial septal defect\nD. Aortic valve stenosis\nE. Patent ductus arteriosus\n": "(E)", "104-1.\n\u6709\u95dc\u5fc3\u81df\u807d\u8a3a(Cardiac auscultation)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684?\nA. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\u3001\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168(Aortic regurgitation)\u53ca\u5fc3\u5ba4\u4e2d\u9694\u7f3a\u640d(Ventricular septal defect) \u7b49\u5fc3\u81df\u96dc\u97f3\u90fd\u53ef\u56e0\u8840\u7ba1\u64f4\u5f35\u5291\u4e4b\u975c\u6db2\u6ce8\u5c04\u5f8c\u800c\u66f4\u52a0\u589e\u5f37\nB. \u8e72\u5750(Squatting)\u53ef\u81f4\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\u6240\u81f4\u5fc3\u81df\u96dc\u97f3\u66f4\u8da8\u5f37\nC. \u5f9e\u81e5\u8eba\u800c\u7ad9\u7acb\u5f8c\uff0c\u4e8c\u5c16\u74e3\u812b\u5782(Prolapse of mitral valve)\u6240\u81f4\u5fc3\u7e2e\u671f\u6572\u64ca\u6027\u5fc3\u97f3(Systolic click)\u66f4\u8da8\u8fd1\u7b2c\u4e00\u5fc3\u97f3(S1)\nD. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(Aortic stenosis) \u7684\u5fc3\u7e2e\u671f\u96dc\u97f3\u5e38\u5728\u8e72\u5750\u5f8c\u5fc3\u96dc\u97f3\u66f4\u5f37\u5316\nE. \u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u5fc3\u96dc\u97f3\u5e38\u5728\u6df1\u5438\u6c23\u6642\u66f4\u52a0\u5f37\u5316\n": "(A)", "104-2.\n\u6709\u95dc\u51a0\u5fc3\u75c5\u7684\u5e7e\u7a2e\u8aaa\u6cd5\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7576\u4eca\u5be6\u8b49\u91ab\u5b78\u7684\u8aaa\u6cd5 ?\nA. \u7537\u6027\u6bd4\u5973\u6027\u8f03\u591a\u56e0\u5fc3\u8840\u7ba1\u75c5\u800c\u6b7b\u4ea1\nB. \u8fd1\u6578\u5341\u5e74\u5728\u7537\u6027\u56e0\u5fc3\u8840\u7ba1\u800c\u6b7b\u4ea1\u4eba\u6578\u5df2\u5927\u5e45\u5ea6\u964d\u4f4e\uff0c\u4f46\u5973\u6027\u75c5\u4ea1\u4eba\u6578\u537b\u4e0d\u6e1b\u53cd\u5347\nC. \u51a0\u5fc3\u75c5\u4e4b\u767c\u751f\u5e38\u8207\u51a0\u8108\u5fae\u5faa\u74b0(Coronary microcirculation)\u4e4b\u7570\u5e38\u6709\u95dc\uff0c \u5c24\u65bc\u5973\u6027\u75c5\u4eba\u6700\u70ba\u56b4\u91cd\nD. \u5973\u6027\u8f03\u7537\u6027\u597d\u767c\u51a0\u5fc3\u75c5\uff0c\u7814\u7a76\u986f\u793a\u8207\u80a5\u80d6\u3001\u7cd6\u5c3f\u75c5\u3001\u767c\u708e\u53ca\u4ee3\u8b1d\u75c7\u5019\u7fa4\u7b49\u51a0\u5fc3\u75c5\u5371\u96aa\u56e0\u7d20\u4e4b\u591a\u767c\u6709\u95dc\nE. \u5973\u6027\u904b\u52d5\u5fc3\u96fb\u5716\u6709\u8f03\u591a\u7684\u507d\u967d\u6027\u7f3a\u6c27\u8b8a\u5316\uff0c\u4ee5\u81f4\u81e8\u5e8a\u8a3a\u7642\u5e38\u898b\u8aa4\u8a3a\n": "(A)", "104-3.\n77\u6b72\u8001\u592a\u592a\u4e00\u5411\u5065\u6717\uff0c\u672a\u6709\u4efb\u4f55\u4e0d\u9069\u75c7\u72c0\uff0c\u56e0\u4e3b\u52d5\u8108\u5340\u6709\u5fc3\u7e2e\u6027\u5fc3\u96dc\u97f3\u800c\u8f49\u8a3a\u5167\u79d1\u3002\u7406\u5b78\u6aa2\u67e5\uff1aHeight: 160cm/ Weight: 55kg; BP:142/82 mmHg; T/P/R: 36.2 /60 /20, SpO2: 99% under room air; Pulsus paradoxicus (-),PMI: 5th ICS, around left mid-clavicular line, aortic ejection sound (+),Gr. III/VI Mid-systolic murmur over Aortic area and left lower sternal border, no neck radiation; Lungs: No crackles; No hepatosplenomegaly and no ascites; No legs edema. \u5176\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u5fc3\u5c0e\u7ba1\u5831\u544a\u5982\u5217\u3002\r\u672c\u75c5\u4eba\u96a8\u5373\u6709\u4e0b\u5217\u8af8\u9805\u81e8\u5e8a\u6c7a\u7b56\uff1a\r(1)\u521d\u6b65\u8a3a\u65b7\u662f\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5\r(2)\u521d\u6b65\u8a3a\u65b7\u662f\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u5fc3\u81df\u75c5\r(3)\u5728\u73fe\u968e\u6bb5\u6700\u597d\u7684\u5167\u79d1\u6cbb\u7642\u662f\u9069\u91cf\u7684Beta-blocker,Calcium channel blocker,ACE inhibitors or Angiotensin receptor blocker\uff0c\u4ee5\u964d\u4f4e\u8840\u58d3\r(4)\u7531\u65bc\u672a\u6709\u660e\u986f\u7684\u5fc3\u7d5e\u75db\u3001\u7729\u6688\u6216\u547c\u5438\u56f0\u96e3\uff0c\u5728\u73fe\u968e\u6bb5\u6700\u6070\u7576\u7684\u6cbb\u7642\u662f\u4ee5Statin\u3001Angiotensin receptor blocker\u53ca Beta-blocker\u70ba\u5b9c\r(5)\u5167\u79d1\u53ca\u5916\u79d1\u7684\u6cbb\u7642\uff0c\u5c0d\u5176\u9810\u5f8c\u7121\u6709\u6539\u9032\uff0c\u672c\u75c5\u4eba\u7684\u552f\u4e00\u9078\u64c7\u662f\u4e3b\u52d5\u8108\u74e3\u819c\u7f6e\u63db\u624b\u8853\u6216\u7d93\u5c0e\u7ba1\u4e3b\u52d5\u8108\u74e3\u819c\u7f6e\u653e\u624b\u8853\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u6c7a\u7b56\u662f\u6b63\u78ba\u7684 ?\nA. (1)+(3)+(5)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(C)", "104-4.\n\u5433\u5148\u751f\u73fe\u5e7420\u6b72\uff0c\u4e00\u5411\u5065\u58ef\uff0c\u5f9e\u4e8b\u5efa\u7bc9\u7c97\u5de5\uff0c\u65bc3\u670822\u65e5\u6709\u611f\u5192\u6d41\u9f3b\u6c34\u3001\u767c\u71d2\u53ca\u54b3\u55fd\u75c7\u72c0\uff0c\u4e09\u5929\u5f8c\u66f4\u6709\u5168\u8eab\u5026\u6020\u53ca\u6688\u53a5\uff0c\u4e43\u81f3\u5fc3\u75bc\uff0c\u56e0\u5fc3\u96fb\u5716\u53ca\u80f8X\u5149\u7570\u5e38(\u5982\u5716)\uff0c\u800c\u5f9e\u6025\u8a3a\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\uff1aConsciousness: drowsy, E3VTM4;T:37.5 P:93 R:16\u53caBP:82/65 mmHg; \u9838\u975c\u8108\u6012\u5f35; \u80f8\u90e8\u6709\u6fd5\u6fc1\u547c\u5438\u97f3; \u5fc3\u81df\u672a\u6709\u64f4\u5927\uff0c\u5fc3\u97f3\u7565\u70ba\u5fae\u5f31\uff0c\u5c1a\u7121S3\u6216S4\u53ca\u5fc3\u81df\u96dc\u97f3\u53ef\u805e; \u8179\u90e8\u672a\u6709\u8179\u6c34\u6216\u809d\u813e\u816b\u5927; \u96d9\u8173\u672a\u898b\u6c34\u816b\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\uff1aWBC,8.37 K/uL;RBC,4.35 M/uL;Plt,128 K/uL; Hb, 13.0 gm/dL;CK,514 U/L;CK-MB,43 U/L; Troponin I, 2.6 ug/L; CRP, 5.6 mg/dL\u3002\r\u672c\u75c5\u4eba\u96a8\u5373\u9032\u884c\u4e0b\u5217\u81e8\u5e8a\u6c7a\u7b56\uff1a\r(1) Continuous IV infusion of Dopamine at the dose of 7.8 mcg/kg/min\uff0c\u4ee5\u7a69\u5b9a\u8840\u58d3\u53ca\u5fc3\u8df3\u53ca\u8840\u6c27\r(2) \u4f7f\u7528IV Heparin at the dose of 1000 u/hour\uff0c\u4ee5\u9810\u9632\u8840\u6813\u7684\u5f62\u6210\r(3) 3\u670827\u65e5\u56e0\u6301\u7e8c\u6027Ventricular tachycardia\uff0c\u63a1\u7528Electric cardioversion\u4e0d\u76e1\u6709\u6548\uff0c\u800c\u7f6e\u653eV-A ECMO\u53caIABP\r(4) 3\u670828\u65e5\u9032\u884cLeft ventricular assisted device\uff0c\u4ee5\u7dad\u6301\u5de6\u5fc3\u5ba4\u529f\u80fd\r(5) 3\u670829\u65e5Myocardial biopsy\u4e4b\u75c5\u7406\u78ba\u8a3a\u5f8c\uff0c\u4f7f\u7528IVIG\uff0c\u4e5f\u4f7f\u7528Prednisolone\u3001Cyclosporine\u53caAzathioprine\r(6) \u75c5\u60c5\u57283\u670831\u65e5\u5f8c\u65bc\u7109\u7a69\u5b9a\r\u5f9e\u8a3a\u65b7\u53ca\u8655\u7f6e\uff0c\u672c\u75c5\u4f8b\u7684\u8655\u7f6e\u5c1a\u7a31\u6210\u529f\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u624d\u662fEvidence-based management?\nA. \u5f9e\u75c5\u53f2\u3001\u7406\u5b78\u6aa2\u67e5\u53caTroponin I \u6216CRP\u7684\u6578\u503c\u53ef\u78ba\u5b9a\u8a3a\u65b7\nB. \u5f9e\u80f8\u90e8X\u5149\u53ca\u5fc3\u96fb\u5716\u53ef\u78ba\u5b9a\u8a3a\u65b7\nC. \u5f9e\u75c5\u7a0b\u8840\u884c\u529b\u5b78\u4e4b\u4e0d\u7a69\u5b9a\uff0c\u61c9\u9015\u884cMyocardial biopsy\nD. \u4f7f\u7528Immunosuppressive agents:Prednisolone\u53caCyclosporine\u662f\u672c\u4f8b\u6cbb\u7642\u6210\u529f\u7684\u91cd\u8981\u56e0\u7d20\nE. \u4f7f\u7528IVIG(Intravenous immunoglobulin)\u624d\u662f\u6551\u547d\u7684\u8981\u8a23\n": "(C)", "104-5.\n\u75c5\u4eba\u7537\u602759\u6b72\u65bc\u5348\u591c24\u6642\uff0c\u7a81\u56e0\u80f8\u60b6\u4e26\u6709\u7259\u5e8a\u7dca\u75bc\uff0c\u4e43\u76f4\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\uff0c\u6642\u75c5\u4eba\u4e4bT/P/R = 35.1/51/18, BP 137/74 mmHg; \u7406\u5b78\u6aa2\u67e5\uff0c\u672a\u898b\u4efb\u4f55\u7570\u5e38\u3002\u75c5\u53f2\u8ffd\u5c0b\uff0c\u672c\u75c5\u4eba\u66fe\u7d93\u91ab\u5e2b\u78ba\u5b9a\u9ad8\u8840\u58d3\u3001\u9ad8\u8102\u8840\u3001\u7cd6\u5c3f\u75c5\u53ca\u651d\u8b77\u817a\u80a5\u5927\uff0c\u552f\u50c5\u53ea\u670d\u7528Bisoprolol 2.5 mg/day\u3002\u7d93\u7dca\u6025\u6aa2\u67e5\uff1a\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u986f\u793a\u5982\u5716\uff1a\u751f\u5316\u6aa2\u67e5: CK,96 U/L;CK-MB,20 U/L;TnI <0.0012 ng/ml;Sugar 252 mg/dL; Na,137 mmol/L; K, 3.7 mmol/L; TG,182 mg/dL and Total cholesterol, 222 mg/dL ; \u8840\u6db2\u6aa2\u67e5: Hb,13.9 g/dl; Platelet, 203 K/uL; WBC,9.45 K/uL; Cre,1.3 mg/dL\r\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u6025\u8a3a\u8a3a\u65b7\u662f\uff1a\nA. Printzmetal's angina\nB. Aortic dissection\nC. Acute anterior myocardial infarction\nD. Hypertension\nE. Acute periodontitis disease\n": "(C)", "104-6.\n\u4f9d\u64da\u4eca\u5e741\u6708\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u9ad8\u8840\u58d3\u5b78\u6703\u6240\u516c\u544a\u4e4b\u9ad8\u8840\u58d3\u8655\u7f6e\u6307\u5f15 (2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684?\nA. \u53f0\u7063\u7684\u9ad8\u8840\u58d3\u8655\u7f6e\u6307\u5f15\u8207\u6700\u8fd1\u6b50\u6d32\u53ca\u7f8e\u570b\u7684\u6307\u5f15\u4e0d\u76e1\u76f8\u540c\nB. 80\u6b72\u4ee5\u4e0a\u7684\u8001\u5e74\u4eba\u964d\u58d3\u4ee5\u4f4e\u65bc150/90 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\nC. \u7cd6\u5c3f\u75c5\u3001\u51a0\u5fc3\u75c5\u3001\u6162\u6027\u814e\u75c5\u8b8a\u4f75\u6709\u86cb\u767d\u5c3f\u75c5\u4eba\u4e4b\u9ad8\u8840\u58d3\uff0c\u4ee5\u4f4e\u65bc140/80 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\nD. \u670d\u7528\u6297\u8840\u6813\u85e5\u7269\u9632\u6cbb\u8166\u4e2d\u98a8\u767c\u4f5c\u4e4b\u964d\u58d3\u76ee\u6a19\uff0c\u4ee5\u4e0d\u9ad8\u65bc130/80 mmHg\nE. \u6240\u6709\u75c5\u4eba(40-80\u6b72)\u4e4b\u9ad8\u8840\u58d3\u6cbb\u7642\u76ee\u6a19\u5728140/90 mmHg\u4ee5\u4e0b\n": "(C)", "104-7.\n\u4e00\u5411\u4e3b\u5c0e\u5168\u4e16\u754c\u9ad8\u8102\u8840\u8655\u7f6e\u4e4bNCEP ATP III\uff0c\u65bc2013\u5e7411\u6708\u516c\u5e03\u65b0\u7684\u6307\u5f15\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u65b0\u7684\u898f\u5b9a?\nA. \u6709\u51a0\u5fc3\u75c5\u3001\u8166\u8840\u7ba1\u6216\u9031\u908a\u8840\u7ba1\u75c5\u4e4b\u75c5\u4eba\u61c9\u670d\u7528Statin\u6cbb\u7642\nB. 40-75\u6b72\u7684\u4eba\u53ea\u8981LDL-C\u9ad8\u65bc190 mg/dL\u61c9\u670d\u7528Statin\u6cbb\u7642\nC. 40-75\u6b72\u7cd6\u5c3f\u75c5\u4eba\u61c9\u670d\u7528Statin\u6cbb\u7642\nD. \u6240\u6709\u75c5\u4eba\u4e4b\u8840\u8102\u6fc3\u5ea6\uff1aLDLC\u4ee5\u4f4e\u65bc100 mg/dL\uff0c\u800cCholesterol 180 mg/dL\u70ba\u6cbb\u7642\u76ee\u6a19\nE. \u53ea\u9650\u5b9aStatin\u4e00\u85e5\uff0c\u6392\u9664Fibric acid \u53caCholestyramine \u70ba\u964d\u8102\u8840\u85e5\u7269\n": "(D)", "104-8.\n\u81e8\u5e8a\u8655\u7f6e\u6307\u5f15\u5e38\u4f9d\u64da\u5be6\u8b49\u4fee\u8a02\uff0c\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis) \u6709\u4e0b\u5217\u8af8\u591a\u7684\u8a18\u8ff0\uff1a\r(1)\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u61c9\u572824\u5c0f\u6642\u5167\u63a1\u8840\u4e09\u6b21\uff0c\u5728\u4e0d\u540c\u8840\u7ba1\u8655\u63a1\u8840\uff0c\u4e14\u61c9\u76f8\u9694\u81f3\u5c11\u4e00\u5c0f\u6642\u5be6\u65bd\r(2)\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u5fc5\u8981\u7684\u8a3a\u65b7\u5de5\u5177\uff0c\u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u9069\u7528\u65bc\u5fc3\u808c\u81bf\u816b\u3001\u74e3\u819c\u7834\u6d1e\u3001\u5fc3\u5167\u5ed4\u7ba1\u53ca\u4eba\u5de5\u74e3\u819c\u5fc3\u5167\u8108\u708e\u7684\u8a3a\u65b7\r(3)\u4e8c\u5c16\u74e3\u812b\u5782\u75c5\u4eba\u63a5\u53d7\u7259\u79d1\u6cbb\u7642\u61c9\u4f5c\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r(4)\u6709\u767c\u7d3a\u5148\u5929\u6027\u5fc3\u81df\u75c5\u4eba\u3001\u4eba\u5de5\u74e3\u819c\u7f6e\u63db\u624b\u8853\u5f8c\u75c5\u4eba\u3001\u66fe\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u53ca\u63db\u5fc3\u4eba\u6709\u4e3b\u52d5\u8108\u74e3\u75c5\u8b8a\u8005\u61c9\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r(5)\u75c5\u4eba\u88dd\u7f6eICD(Intra-cardiac device) \u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\u61c9\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u6b63\u78ba\u7684\u8655\u7f6e\u6307\u5f15?\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(B)", "104-9.\n\u7537\u6027\u75c5\u4eba\u73fe\u5e7460\u6b72\uff0c\u65bc\u6e05\u66686\u6642\u7a81\u7136\u80f8\u60b6\u3001\u51b7\u6c57\uff0c\u81ea\u89ba\u4f34\u6709\u5f8c\u80cc\u53ca\u8179\u90e8\u9178\u75bc\uff0c\u75c5\u4eba\u7531\u5bb6\u5c6c\u6025\u9001\u91ab\u9662\u3002\u75c5\u4eba\u6709\u591a\u5e74\u9ad8\u8840\u58d3\u53ca\u75db\u98a8\u75c5\uff0c\u670d\u7528Losartan(50mg) 1tabQD; Amlodipine(5mg) 1tabQD;Colchicine(0.5mg)1 tabQD;Benzbromarone(100mg) 1tabQD;Atorvastatin 0.5 Tab /HS\u7b49\u85e5\u4e2d\u3002\u8eab\u9ad4\u6aa2\u67e5\uff0c\u5448\u73fe\u6025\u75c5\u72c0\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u9ad4\u6eab: 36.2\u2103\uff0c\u8108\u8df3: 66/min\uff0c\u547c\u5438: 23/min\uff1bBP: 252/114mmHg\uff1b\u610f\u8b58\u6e05\u695a\uff1b\u80f8\u90e8\u53ca\u8179\u90e8\u5c1a\u7121\u7570\u5e38\uff0c\u5fc3\u5f8b\u6b63\u5e38\uff0cS1\u53caS2\u6b63\u5e38\uff0c\u672a\u6709S3\u6216S4\uff0c\u7121\u5fc3\u81df\u96dc\u97f3\u53ef\u805e\uff0c\u4e5f\u7121paradoxical split of S2\uff0c\u795e\u7d93\u6aa2\u67e5\u6b63\u5e38\u3002\u5176\u6642\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5982\u5716\u8868\u3002\u4e0b\u5217\u4f55\u8005\u662f\u6b63\u78ba\u7684\u8a3a\u65b7?\nA. Acute myocardial infarction\nB. Aortic dissection\nC. Hypertensive crisis\nD. Pulmonary embolism\nE. Aortic stenosis\n": "(B)", "104-10.\n\u5973\u6027\u75c5\u4eba\u73fe\u5e7447\u6b72\uff0cG2P2\uff0c\u4e3b\u8a34\u8fd1\u4f86\u4e00\u500b\u6708\u9593\u6642\u6709\u982d\u660f\uff0c\u4e26\u6709\u6f38\u9032\u5f0f\u547c\u5438\u56f0\u96e3\u3002\u4f4f\u9662\u524d\u56db\u5929\u75c7\u72c0\u66f4\u5f62\u60e1\u5316\uff0c\u662f\u4e43\u7d93\u6025\u8a3a\u4f4f\u52a0\u8b77\u75c5\u623f\u3002\u7406\u5b78\u6240\u898b: \u8eab\u9ad8163cm; \u9ad4\u91cd 67.4kg; BMI = 25.37; \u9ad4\u6eab:36.5\u2103 ;BP(mmHg): 128/60; PR(/min): 104; RR(/min): 24; \u81c9\u8840\u84bc\u767d; \u5fc3\u8df3\u5feb\u901f\u4f46\u6b63\u5e38\u5f8b\u52d5, \u5728\u4e09\u5c16\u74e3\u5340\u6709Grade 3/6 systolic murmur\u53ef\u805e \uff0c\u5176\u4ed6\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u548cComputer tomography\u5982\u5716\u3002\rD-Dimer, 3.56 mg/L;Blood gas:pH,7.534;PaO2,57 mmHg;PaCO2,20.9 mmHg;HCO2 std 22.0 mmol/L;\u75c5\u4eba\u4f4f\u9662\u5f8c\u96a8\u5373\u975c\u6ce8\u5927\u65b9\u5291\u91cf(Bolus dose) Unfractionated Heparin 3000u \u53ca\u6bcf\u5c0f\u66421000u\u975c\u8108\u8f38\u6ce8\u3002\u75c5\u7a0b\u4e2d\u5148\u5f8c\u9032\u884c\u4e0b\u5217\u8655\u7f6e\uff1a\r(1)\u901a\u77e5\u5fc3\u81df\u79d1\u555f\u52d5PCI\u5718\u968a\r(2) \u67e5Protein C \uff0cProtein S\u548canti-thrombin III, \u548cAnticardiolipin IgG\r(3)Tumor biomarkers :CEA, CA-199,CA-125,CA-153\r(4)Heparin bolus 3000 unitIV stat and then IV pump 6~12 U/kg/hr according to the aPTT\r(5)Digoxin o.25 mg + 20% glucose in water for IV to control tachycardia\r\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8655\u7f6e\u624d\u662f\u6b63\u78ba\u7684?\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "104-11.\n\u75c5\u4eba\u662f\u4f4d47\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u81ea7\u6b72\u8d77\u5c31\u8a3a\u65b7\u6709\u5fc3\u81df\u75c5\uff0c18\u6b72\u61f7\u5b55\u751f\u6709\u4e00\u5b50\uff0c\u904e\u7a0b\u5c1a\u7a31\u9806\u5229\uff0c\u8fd1\u5341\u5e74\u4f86\u5076\u6709\u5fc3\u60b8\u53ca\u80f8\u60b6\uff0c\u8fd1\u4e8c\u5e74\u66fe\u6709\u4e94\u6b21\u660f\u53a5\uff0c\u56e0\u6b64\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\u53ca\u751f\u5316\u6aa2\u9a57\u90fd\u6b63\u5e38\u3002\u80f8X\u5149\u53ca\u5fc3\u96fb\u5716(\u5982\u5716)\u3002\u672c\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Supraventricular tachycardia\nB. WPW syndrome with AVRT\nC. Long QT syndrome with Torsade de pointes\nD. Monomorphic ventricular tachycardia from outflow tract\nE. Polymorphic ventricular tachycardia with Torsade de pointes\n": "(D)", "104-12.\n38\u6b72\u5973\u6027\u56e0\u70ba\u5f88\u5bb9\u6613\u51fa\u73fe\u904b\u52d5\u5598\u800c\u4f86\u6aa2\u67e5\uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u8eab\u9ad4\u6aa2\u67e5\u7684\u767c\u73fe\u6700\u5bb9\u6613\u61f7\u7591\u662f\u5426\u6709\u80ba\u52d5\u8108\u9ad8\u58d3\uff1f\nA. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5fc3\u97f3S1\uff0cS2\u6b63\u5e38\u3002\u5728\u53f3\u4e0a\u80f8\u9aa8\u7de3\u6709 II/VI\u7b49\u7d1a\u7684\u8212\u5f35\u671f\u5fc3\u96dc\u97f3\u3002\nB. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5927\u8072\u7684S2\u5fc3\u97f3\u3002\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\u6709 II/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nC. \u9838\u975c\u8108\u9f13\u8139\uff0c \u5927\u8072\u4e14\u56fa\u5b9a\u800c\u5206\u88c2\u7684S2\u5fc3\u97f3\u3002\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\u6709 III/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nD. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5410\u6c23\u6642S2\u5fc3\u97f3\u5206\u88c2\u3002\u5728\u5de6\u4e0a\u80f8\u9aa8\u7de3\u6709 \u5927\u8072\u800c\u5c16\u92b3\u7684II/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nE. \u9838\u975c\u8108\u9f13\u8139\uff0c\u6876\u578b\u80f8\u8154\u8b8a\u5f62\u3002\u547c\u5438\u9031\u671f\u7684\u5410\u6c23\u671f\u7279\u5225\u9577\u3002\n": "(B)", "104-13.\n60\u6b72\u5973\u6027\u56e0\u70ba\u9010\u6f38\u51fa\u73fe\u7684\u5598\u6c23\u9020\u6210\u7121\u6cd5\u884c\u8d70\u6b63\u5e38\u8ddd\u96e2\u800c\u5230\u6025\u8a3a\uff0c\u4ed6\u6c92\u6709\u80f8\u75db\u3001\u652f\u6c23\u7ba1\u54ee\u5598\u3001\u75f0\u6216\u662f\u767c\u71d2\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u80ba\u52d5\u8108\u64f4\u5f35\uff0c\u5de6\u5fc3\u623f\u64f4\u5927\uff0c\u96d9\u5074\u80ba\u90e8\u6c92\u6709\u6d78\u6f64\u73fe\u8c61\u3002\u5fc3\u96fb\u5716\u51fa\u73feV1\u5c0e\u6975\u6709\u9ad8\u7684R\u6ce2\uff0c\u5fc3\u8ef8\u53f3\u504f\u3002\u6b64\u6642\u5e6b\u60a3\u8005\u9032\u884c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u6700\u53ef\u80fd\u6703\u51fa\u73fe\u4e0b\u9762\u54ea\u4e00\u7a2e\u8b8a\u5316\uff1f\nA. \u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41\nB. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\nC. \u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u4f4e\u4e0b\nD. \u4e8c\u5c16\u8108\uff08\u50e7\u5e3d\u74e3\uff09\u74e3\u72f9\u7a84\nE. \u4e8c\u5c16\u8108\uff08\u50e7\u5e3d\u74e3\uff09\u74e3\u8ff4\u6d41\n": "(D)", "104-14.\n\u9ad8\u8840\u9240\u7684\u5fc3\u96fb\u5716\u8b8a\u5316\uff0c\u8acb\u5728\u4e0b\u5217\u9805\u76ee\u4e2d\u9078\u64c7\u6700\u9069\u5408\u7684\u767c\u73fe\uff1a(1) P\u6ce2\u8b8a\u5e73\u800c\u53ef\u80fd\u6d88\u5931 ; (2) ST segment\u5ef6\u9577 ; (3) U\u6ce2\u660e\u986f\u8b8a\u5927 ; (4) QRS\u6ce2\u8b8a\u5bec ; (5) T\u6ce2\u8b8a\u9ad8 ; (6) PR interval\u7e2e\u77ed\nA. (3)+(5)+(6)\nB. (1)+(2)+(3)\nC. (3)+(4)+(6)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(D)", "104-15.\n\u6240\u8b02\u300c\u5b8c\u6574\u7684\u5fc3\u81df\u75c5\u8a3a\u65b7\u300d(Complete cardiac diagnosis)\r\u61c9\u4f9d\u5e8f\u5305\u62ec\u54ea\u4e9b\u9805\u76ee\u7d44\u5408?\nA. \u75c5\u56e0\u3001\u75c5\u7406\u3001\u751f\u5316\u53ca\u529f\u80fd\u7570\u5e38(Functional disability)\u7684\u8a3a\u65b7\nB. \u54b3\u8840\u751f\u7406\u3001\u89e3\u5256\u3001\u75c5\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\nC. \u75c5\u7406\u3001\u751f\u7406\u3001\u529f\u80fd\u53ca\u751f\u5316\u7570\u5e38\u7684\u8a3a\u65b7\nD. \u75c5\u56e0\u3001\u89e3\u5256\u3001\u751f\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\nE. \u75c5\u56e0\u3001\u75c5\u7406\u3001\u751f\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\n": "(D)", "104-16.\n\u7576\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u51fa\u73fe\uff0c\u4e0b\u5217\u54ea\u4e00\u4e9b\u56e0\u5b50\u6703\u52a0\u91cd\u60a3\u8005\u7684\u8166\u8840\u7ba1\u8840\u6813\u4e8b\u4ef6\u7684\u53ef\u80fd\u6027\uff1f(1) \u7cd6\u5c3f\u75c5 ; (2) \u5de6\u5fc3\u623f4.2\u516c\u5206 ; (3) \u66fe\u7d93\u6709\u66ab\u6642\u7f3a\u8840\u6027\u8166\u4e2d\u98a8\u767c\u4f5c ; (4) \u9ad8\u8840\u8102 ; (5) \u9b31\u8840\u6027\u5fc3\u8870\u7aed ; (6) \u5e74\u9f6162\u6b72\nA. (1)+(3)+(5)\nB. (2)+(4)+(6)\nC. (1)+(2)+(3)\nD. (4)+(5)+(6)\nE. (2)+(3)+(4)\n": "(A)", "104-17.\n\u9580\u8a3a\u6642\u6709\u4f4d\u64d4\u5fc3\u7684\u6bcd\u89aa\u4f86\u5411\u4f60\u8a62\u554f\u6709\u95dc\u4ed6\u5152\u5b50\u7684\u554f\u984c\uff0c\u5152\u5b50\u5728\u570b\u4e00\u7684\u65b0\u751f\u5165\u5b78\u6aa2\u67e5\u4e2d\u767c\u73fe\u6709\u5fc3\u623f\u4e2d\u9694\u7f3a\u640d\u3002\u95dc\u65bc\u5982\u679c\u6c92\u6709\u4fee\u5fa9\u5fc3\u623f\u4e2d\u9694\u7f3a\u640d\uff0c\u5728\u6210\u5e74\u6216\u591a\u5e74\u4e4b\u5f8c\uff0c\u6700\u4e0d\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u54ea\u4e00\u7a2e\u60c5\u6cc1\uff1f\nA. \u56e0\u70ba\u91ab\u7642\u76ee\u7684\u800c\u9032\u884c\u4e2d\u5fc3\u975c\u8108\u7ba1\u7f6e\u5165\u8853\uff08CVC\uff09\u800c\u7522\u751f\u6c23\u6813\uff08Air emboli\uff09\nB. \u4e0d\u7a69\u5b9a\u6027\u72f9\u5fc3\u75c7\nC. \u6813\u585e\u6027\u8166\u8840\u7ba1\u4e8b\u4ef6\nD. \u80ba\u9ad8\u58d3\nE. \u904b\u52d5\u4e2d\u6c27\u52d5\u8108\u5206\u58d3\u96a8\u4e4b\u4e0b\u964d\n": "(B)", "104-18.\n42\u6b72\u5973\u6027\u5728\u6210\u4eba\u5065\u6aa2\u4e2d\u767c\u73fe\u6709\u6536\u7e2e\u4e2d\u671f\u7570\u5e38\u5fc3\u97f3- Mid-systolic click\uff0c\u6c92\u6709\u767c\u73fe\u5fc3\u96dc\u97f3\u3002\u9664\u6b64\u4e4b\u5916\u7684\u8eab\u9ad4\u6aa2\u67e5\u6b63\u5e38\uff0c\u8840\u6db2\u6aa2\u67e5\u9805\u76ee\u6578\u503c\u6b63\u5e38\uff0c\u5e73\u65e5\u4e5f\u6c92\u6709\u4e0d\u8212\u670d\u3002\u5979\u9084\u662f\u64d4\u5fc3\u76f8\u95dc\u7684\u767c\u73fe\uff0c\u4f9d\u7167\u4e0a\u8ff0\u60c5\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u76f8\u6558\u8ff0\u8f03\u9069\u7576\uff1f\nA. \u8aaa\u660e\u5927\u591a\u6578\u7684\u9019\u985e\u60a3\u8005\u5b58\u6709\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\uff0c\u9032\u884c\u6aa2\u67e5\nB. \u89e3\u91cb\u4e26\u544a\u77e5\u75c5\u4eba\u91dd\u5c0d\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u9032\u884c\u76f8\u95dc\u9632\u7bc4\u63aa\u65bd\nC. \u5927\u90e8\u5206\u6b64\u7a2e\u767c\u73fe\u6703\u4e00\u76f4\u5b58\u5728\uff0c\u4f46\u4e0d\u9700\u6cbb\u7642\nD. \u5efa\u8b70\u5979\u4f7f\u7528Aspirin 100mg/day \u4f86\u9810\u9632\u8840\u6813\u4e8b\u4ef6\nE. \u9019\u985e\u554f\u984c\u7121\u6cd5\u5f9e\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u4e0d\u8981\u8981\u6c42\u505a\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(C)", "104-19.\n\u4e0b\u5217\u54ea\u4e00\u4e9b\u8eab\u9ad4\u6aa2\u67e5\u7684\u767c\u73fe\u6703\u61f7\u7591\u56b4\u91cd\u7684\u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41\uff1f (1) Corrigan's pulse ; (2) Pulsus bigeminus ; (3) Quincke's pulse ; (4) Traube's sign ; (5) Pulsus parvus et tardus ; (6) Pulsus paradoxus\nA. (2)+(4)+(6)\nB. (1)+(2)+(3)\nC. (1)+(3)+(4)\nD. (3)+(5)+(6)\nE. (4)+(5)+(6)\n": "(C)", "104-20.\n78\u6b72\u7537\u6027\uff0c\u6709\u9577\u671f\u5438\u83f8\uff0c\u80a5\u80d6\u548c\u5341\u5e74\u5de6\u53f3\u7684\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u3002\u4ed6\u56e0\u70ba\u6700\u8fd1\u5169\u500b\u6708\u51fa\u73fe\u7684\u904b\u52d5\u5598\u524d\u4f86\u9580\u8a3a\u3002\u76ee\u524d\u4ed6\u4f7f\u7528\u7684\u85e5\u54c1\u5305\u542b aspirin, metformin \u548c\u5076\u723e\u6703\u56e0\u70ba\u95dc\u7bc0\u75bc\u75db\u670d\u7528 ibuprofen\u3002\u4ed6\u7684\u8eab\u9ad4\u6aa2\u767c\u73fe\u5ef6\u9072\u51fa\u73fe-- \u8108\u640f\u5c16\u5cf0\uff08delayed peak in peripheral pulse\uff09\uff0cleft ventricular heave\u3002\u4ed6\u7684\u5fc3\u8df3\u898f\u5247\uff0c\u5728\u5fc3\u81df\u57fa\u5e95\u90e8\u4f4d(cardiac base)\u6709 VI/VI \u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u6b64\u96dc\u97f3\u6703\u50b3\u5411\u9838\u52d5\u8108\u5340\u57df\u3002\u540c\u6642\u51fa\u73fe\u7b2c\u56db\u5fc3\u97f3\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ea\u6709\u56b4\u91cd\u7684\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u3002\u8acb\u554f\u4f9d\u64da\u75c5\u53f2\u8207\u76f8\u95dc\u767c\u73fe\uff0c\u9020\u6210\u9019\u500b\u75c5\u4eba\u5fc3\u81df\u8b8a\u5316\u7684\u6700\u53ef\u80fd\u539f\u56e0\u662f\uff1f\nA. \u5148\u5929\u6027\u4e8c\u74e3\u7684\u4e3b\u52d5\u8108\u74e3\u819c\uff08bicuspid aortic valve\uff09\nB. \u7cd6\u5c3f\u75c5\nC. \u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\nD. \u75c5\u4eba\u6709\u6f5b\u85cf\u7684\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\nE. \u4ee5\u4e0a\u7686\u975e\n": "(B)", "104-21.\n\u7576\u60a3\u8005\u7684\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u6709\u56b4\u91cd\u7684\u4e8c\u5c16\u74e3\u8ff4\u6d41\uff0c\u8003\u91cf\u624b\u8853\u9069\u61c9\u75c7\uff0c\u4f75\u767c\u75c7\u8207\u624b\u8853\u9810\u5f8c\uff0c\u4e0b\u9762\u54ea\u4e00\u500b\u6558\u8ff0\u7684\u60a3\u8005\u6703\u6709\u6700\u4f73\u7684\u8853\u5f8c\u9032\u6b65\u548c\u624b\u8853\u6cbb\u7642\u6548\u679c\uff1f\nA. 52\u6b72\u7537\u6027\uff0cLVEF=25%\uff0c\u5fc3\u8870\u7aed\u75c7\u72c0NYHA class III\uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9160mm\u3002\nB. 54\u6b72\u7537\u6027\uff0cLVEF=30%\uff0c\u5fc3\u8870\u7aed\u75c7\u72c0NYHA class II\uff0c\u6709\u80ba\u9ad8\u58d3\u3002\nC. 63\u6b72\u7537\u6027\uff0c\u7ac7\u6027\u898f\u5247\u5fc3\u5f8b\uff0cLVEF=65%\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u53f3\u5fc3\u5ba4\u5c0e\u7ba1\u6aa2\u67e5\u58d3\u529b\u6b63\u5e38\u3002\nD. 72\u6b72\u5973\u6027\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u65b0\u767c\u73fe\u9663\u767c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff0cLVEF=60%\uff0c \u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9135mm\u3002\nE. 66\u6b72\u5973\u6027\uff0cLVEF=50%\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9145mm\u3002\n": "(E)", "104-22.\n30\u6b72\uff0cBMI=23\uff0c\u5728\u5efa\u7bc9\u5de5\u5730\u5de5\u4f5c\u7684\u7537\u6027\u9ad8\u8840\u58d3\u60a3\u8005\uff0c\u56e0\u70ba\u5df2\u7d93\u670d\u7528\u56db\u7a2e\u85e5\u7269\u4e4b\u5f8c\u4ecd\u51fa\u73fe180/110mmHg\u7684\u8840\u58d3\u524d\u4f86\u9580\u8a3a\u3002\u4f9d\u60a3\u8005\u6240\u8aaa\uff0c\u4ed6\u5f9e17\u6b72\u5c31\u767c\u73fe\u6709\u9ad8\u8840\u58d3\uff0c\u96d6\u7136\u91ab\u5e2b\u5728\u904e\u53bb\u7d66\u4ed6\u56db\u7a2e\u63a7\u5236\u8840\u58d3\u7684\u85e5\u7269\uff0c\u4ed6\u4e26\u6c92\u6709\u89ba\u5f97\u7279\u5225\u4e0d\u8212\u670d\u3002\u5e73\u65e5\u4e0d\u5e38\u91cf\u8840\u58d3\uff0c\u53ea\u5728\u5076\u723e\u767c\u73fe\u8840\u58d3\u5f88\u9ad8\u6642\u5f9e\u85e5\u623f\u52a0\u8cb7\u85e5\u7269\u670d\u7528\u3002\u9580\u8a3a\u6642\u8eab\u9ad4\u6aa2\u67e5\u6c92\u6709\u7570\u5e38\uff0c\u62bd\u8840\u7684\u6578\u64da\u5982\u4e0b\uff1a Na: 145mEq/L; Cl: 110mEq/L; K: 3.0mEq/L; HCO3: 30 mEq/L; Glucose: 90mg/dL\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u5982\u4f55\u8655\u7f6e\u8f03\u6d3d\u7576\uff1f\nA. \u52a0\u7b2c\u4e94\u7a2e\u85e5\u7269\uff0c\u8acb\u60a3\u8005\u5bc6\u5207\u8ffd\u8e64\u8840\u58d3\nB. \u6e2c\u91cf\u5c3f\u6db2\u4e2d\u7684 VMA; metanephrines; catecholamines\nC. \u5b89\u6392\u96d9\u5074\u814e\u52d5\u8108\u7684\u90fd\u535c\u52d2\u8d85\u97f3\u6ce2\u6aa2\u67e5\nD. \u6aa2\u67e5 plasma renin activity (PRA) \u8207 plasma aldosterone concentration (PAC)\nE. \u5b89\u6392\u7761\u7720\u91ab\u5b78\u6aa2\u67e5\n": "(D)", "105-1.\n\u5728\u5fc3\u96fb\u5716\u5448\u73fe\uff1a\u5fc3\u8ef8\u5de6\u504f-45\u5ea6\uff0cqR \u5728I\u53caaVL\u7b49\u8b8a\u5316\u662f\u6240\u8b02\"\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\" (Left anterior fascicular block)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u8aaa\u6cd5\u4e0d\u6b63\u78ba\uff1f\nA. \u5de6\u524d\u675f\u679d\u7d30\u9577\uff0c\u7a7f\u884c\u5de6\u5fc3\u5ba4\u51fa\u53e3\u901a\u9053\u5730\u5e36\uff0c\u6613\u53d7\u5fc3\u7e2e\u58d3\u529b\u50b7\u5bb3\uff0c\u662f\u4ee5\u81e8\u5e8a\u591a\u898b\u3002\nB. \u5de6\u524d\u964d\u652f\u51a0\u8108(Left anterior descending artery)\u4f9b\u8840\u5de6\u524d\u675f\u679d\uff0c\u4e0d\u82e5\u5de6\u5f8c\u675f\u679d\u4f9b\u8840\u4f86\u81ea\u5de6\u53f3\u96d9\u689d\u51a0\u8108\uff0c\u662f\u4ee5\u6613\u56e0\u5fc3\u808c\u7f3a\u8840\u50b7\u8b8a\uff0c\u767c\u751f\u50b3\u5c0e\u963b\u6eef\u3002\nC. \u6025\u6027\u524d\u58c1\u5fc3\u808c\u6897\u585e\u5982\u82e5\u4f34\u767c\u53f3\u675f\u679d\u50b3\u5c0e\u963b\u6eef(RBBB)\u53ca\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\uff0c\u6613\u81f4\u5b8c\u5168\u50b3\u5c0e\u963b\u6eef(Complete heart block)\u3002\nD. \u6240\u8b02\"\u96d9\u675f\u679d\u50b3\u5c0e\u963b\u6eef\"\u6cdb\u6307RBBB + Left anterior fascicular block\u3001RBBB+ Left posterior fascicular block\u6216LBBB\u3002\nE. \u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\u82e5\u4f34\u767c\u7b2c\u4e00\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef(First degree A-V block)\uff0c \u4e5f\u6613\u81f4\u5b8c\u5168\u50b3\u5c0e\u963b\u6eef(Complete heart block)\u3002\n": "(E)", "105-2.\n\u75c5\u4eba\u73fe\u5e7463\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u56e0\u6709\u80f8\u60b6\u53ca\u6c23\u4fc3\u6c42\u91ab\uff0c\u516d\u5e74\u524d\u66fe\u6709\u9152\u7cbe\u6027\u809d\u786c\u5316\uff0c\u809d\u81df\u79fb\u690d\u3002\u4e94\u5e74\u524d\u56e0\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u4ee5\u81f4\u65bd\u884c\u50e7\u5e3d\u74e3\u7f6e\u63db(Hancock 27)\uff0c\u6301\u7e8c\u9580\u8a3a\u8ffd\u8e64\u4e2d\u3002\u8840\u58d3148/109 mmHg\uff1b\u5fc3\u8df3152/min\uff1b\u547c\u5438\u6bcf\u520627\u6b21\uff1b\u9ad4\u6eab37.5\u5ea6\u3002\u5176\u4ed6\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716(A.\u6cbb\u7642\u524d\uff1bB.\u6cbb\u7642\u5f8c)\u5982\u5217\u3002\u6aa2\u67e5\u78ba\u5b9a\u5fc3\u81df\u5feb\u8df3\uff0c\u6709\u4e0b\u5217\u6578\u9805\u8655\u7f6e\u63aa\u65bd\uff1a\r1.\u7dca\u6025\u6ce8\u5c04Adenosine \u6ce8\u5c04\u5291\u91cf150 mg IV\u3002\r2.\u975c\u8108\u6ce8\u8f38 amiodarone 150 mg\u3002\r3.Rapid atrial pacing\u3002\r4.\u7dca\u6025Synchronized cardioversion 50-100 J\u3002\r5.\u7dca\u6025\u7167\u6703\u5fc3\u81df\u79d1\u65bd\u884c\u96f7\u5c04\u71d2\u707c\u624b\u8853 (Radio-frequency catheter ablation)\u3002\r\u4f9d\u64da2015 ACC/AHA/HRS guideline\uff0c\u8acb\u554f\u6709\u95dc\u672c\u75c5\u4f8b\u5feb\u8df3\u4e4b\u8655\u7f6e\uff0c\u4f55\u9805\u6700\u7b26\u5408\" Class of recommendation I\u301e?\nA. 1+2+3\nB. 1+2+4\nC. 1+3+5\nD. 2+3+5\nE. 3+4+5\n": "(B)", "105-3.\n\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u4f7f\u7528\u6297\u8840\u6813\u6cbb\u7642\uff0c\u5728\u81e8\u5e8a\u4e0a\u6709\u8a31\u591a\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. Atrial fibrillation (Af)\u591a\u898b\u8af8\u8001\u4eba\uff0c80\u6b72\u4ee5\u4eba\u7d04\u670910%\u3002\nB. \u5fc3\u81df\u75c5\u4eba\u5982\u82e5\u4f34\u6709Af\uff0c\u90fd\u5c6c\u75c5\u72c0\u56b4\u91cd\u3002\nC. \u6709Af\u75c5\u4eba\uff0c\u8166\u4e2d\u98a8\u591a\u589e\u4e94\u500d\u3002\nD. \u5be6\u8b49\u91ab\u5b78\u8a8d\u5b9aAspirin\u7528\u65bc\u6cbb\u7642\u6c92\u6709\u75c7\u72c0\u7684Af\uff0c\u4e5f\u53ef\u9810\u9632\u8840\u6813\u585e\u3002\nE. \u8001\u5e74\u3001\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u5fc3\u81df\u75c5\u53ca\u547c\u5438\u4e2d\u6b62\u75c7\u90fd\u662fAf\u7684\u5371\u96aa\u56e0\u7d20\u3002\n": "(D)", "105-4.\n\u6709\u95dc\u5fc3\u81df\u8870\u7aed (Heart failure) \u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u6b63\u78ba\uff1f\nA. \u4e0d\u7ba1\u5fc3\u7e2e\u6216\u5fc3\u8212\u6027\u5fc3\u81df\u8870\u7aed\uff0c\u6709\u8fd1\u534a\u75c5\u4eba\u4ecd\u820a\u6709\u6b63\u5e38\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387(Left ventricular ejection fraction,LVEF)\uff0c\u662f\u4ee5\u5c07\u5fc3\u81df\u8870\u7aed\u5206\u62101).HF reduced EF(HFrEF)\u53ca2).HF preserved EF(HFpEF)\u5169\u7a2e\u3002\nB. \u5c31\u63a7\u5236\u5fc3\u81df\u8870\u7aed\u4e4b\u5feb\u8df3(Tachycardia)\uff0cIvabradine\u9060\u6bd4Digoxin\u70ba\u4f73\u3002\nC. \u9811\u56fa\u6027\u5fc3\u81df\u8870\u7aed\u61c9\u540c\u6642\u4f75\u7528Captopril + Valsartan + Carvedilol + Spironolactone\u3002\nD. \u6025\u6027\u5931\u8abf\u6027\u5fc3\u81df\u8870\u7aed(Acute decompensated heart failure\uff0cADHF)\u670930%\u4f75\u767c\u5fc3\u814e\u75c7\u5019\u7fa4(Cardio-renal syndrome)\uff0c\u4f7f\u7528\u5229\u5c3f\u91cf\u589e\u52a0\u6b64\u985e\u75c5\u4eba\u4e4b\u5fc3\u81df\u6392\u8840\u91cf(Cardiac output) \u6cbb\u7642\uff0c\u4e0d\u76e1\u6709\u6548\u3002\nE. \u4f75\u7528ACEI\u53caBeta-blocker\u4e0d\u76e1\u6709\u76ca\u65bc\u91cd\u5ea6ADHF\u4e4b\u6cbb\u7642\u3002\n": "(C)", "105-5.\n\u6709\u95dc\u75c5\u6bd2\u6027\u5fc3\u808c\u708e(Viral myocarditis) \u6558\u8aaa\uff0c\u5728\u81e8\u5e8a\u4e0a\u6642\u6709\u7684\u8a18\u8ff0\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u8aaa\u6cd5\u662f\u6b63\u78ba\u7684\uff1f\nA. \u75c5\u6bd2\u6027\u5fc3\u808c\u708e\u591a\u767c\u751f\u5728\u8001\u5f31\u75c5\u4eba\uff0c\u591a\u7a2e\u75be\u75c5\u7e8f\u8eab\u3002\nB. \u4f34\u767c\u91cd\u5ea6\u547c\u5438\u8870\u7aed\u53ca\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u731b\u66b4\u6027\u5fc3\u808c\u708e(Fulminant myocarditis)\uff0c\u5e38\u6703\u4f75\u767c\u591a\u5668\u5b98\u8870\u7aed\u3002\u4f46\u53ca\u6642\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642\u53ef\u6551\u547d\u904e\u534a\u4ee5\u4e0a\u3002\nC. \u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5(Endomyocardial biopsy)\u78ba\u5b9a\u8a3a\u65b7\u7387\u9ad8\u3002\nD. \u8fc4\u4eca\u70ba\u6b62\u7684\u5be6\u8b49\u91ab\u5b78\u90fd\u8a8d\u5b9a\u6297\u75c5\u6bd2\u85e5\u53ca\u514d\u75ab\u58d3\u5236\u7642\u6cd5(Immunosuppressive therapy)\u662f\u6709\u6548\u7684\u7642\u6cd5\u3002\nE. \u9452\u65bc\u5fc3\u808c\u75c5\u6bd2\u78ba\u5b9a\u4e0d\u6613\uff0c\u53ea\u8981\u4f75\u6709\u808c\u8089\u9178\u75db\u53ca\u547c\u5438\u75c7\u72c0\u7684\u611f\u67d3\uff0c\u540c\u6642\u6709\u5fc3\u808c\u640d\u50b7\u7684\u6aa2\u5b9a\uff0c\u5c31\u53ef\u78ba\u8a3a(Definite diagnosis)\u5fc3\u808c\u708e\u3002\n": "(B)", "105-6.\n\u8acb\u554f\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e(Acute Myocardial Infarction) \u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4ee5\u4e0b\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6c7a\u5b9a\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u5fc3\u96fb\u5716Q\u6ce2\u5728\u75c5\u7406\u5b78\u5fc5\u5b9a\u662f\u5168\u58c1\u6027\u5fc3\u808c\u75c5\u8b8a(Transmural infarction)\u3002\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4e0d\u5b9c\u4f7f\u7528\u77ed\u6548\u7684Dihydropyridine\uff0c\u56e0\u591a\u589e\u6b7b\u4ea1\u7387\u3002\nC. NSTEMI\u7684\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\uff0c\u4e0d\u5b9c\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u5291\u6cbb\u7642(Fibrinolytic therapy)\u3002\nD. \u985e\u56fa\u9187(Glucocorticoid )\u53caNSAID(Non-steroidal anti-inflammatory agents)\u90fd\u4e0d\u5408\u9069\u5728STEMI\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4f7f\u7528\u3002\nE. Coronary care \u7684\u85e5\u7269\u5305\u62ecStatin, Angiotensin receptor blockade, Beta-blockade\uff0c\u9664\u975e\u6709\u7981\u5fcc\u3002\n": "(A)", "105-7.\n\u75c5\u4eba62\u6b72\u7537\u6027\u5546\u4eba\uff0c7:30AM\u65e9\u98ef\u5f8c\u80f8\u75bc\u4f75\u6709\u51b7\u6c57\uff0c\u65bc8:11AM\u5230\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6709\u62bd\u7159\u4e8c\u5341\u5e74\u53ca\u9ad8\u8102\u8840\u7570\u5e38\u7684\u75c5\u53f2\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3138/74 mmHg,\u5fc3\u8df396/\u5206\uff0c\u898f\u5247\uff0c\u5fc3\u81df\u5fae\u5927\uff0cS1\u5fb5\u5f31\uff0c\u6c92\u6709S3\u6216\u5fc3\u81df\u96dc\u97f3\uff0c\u5176\u4ed6\u6240\u898b\u4ea6\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u5982\u5716\uff0c\u751f\u5316\u6aa2\u67e5\u57288:39AM\uff1aCK,204U/L\uff1bCK-MB,12U/L\uff1bTnI,<0.012ng/mL\u3002\r\u8acb\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u6700\u4e0d\u7b26\u5408\u7576\u4eca\u6307\u5f15?\nA. \u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\ufffdC\u90fd\u6b63\u5e38\uff0c\u7559\u89c0\u5373\u53ef\u3002\nB. \u4f7f\u7528Morphine 3 mg IV\u3002\nC. \u5148\u670d\u7528Ticagrelor 180 mg \u4f75 90 mg BID + Chewable Aspirin 300mg loading and then 100 mg QD\u3002\nD. IV Heparin 5000 u bolus and then 600-1000 u/hour, depending on aPTT\u3002\nE. Atorvastatin 20 mg BID\u3002\n": "(A)", "105-8.\n\u75c5\u4eba64\u6b72\u5973\u6027\uff0c\u57284\u670811\u65e5\u6e05\u6668\u6025\u6027\u80f8\u75db\u767c\u4f5c\uff0c4AM\u9001\u9054\u91ab\u9662\uff0c\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u591a\u5e74\uff0c\u85e5\u7269\u6cbb\u7642\u4e2d\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3216/114 mmHg\uff1b\u5fc3\u8df388/\u5206\uff0c\u898f\u5247\uff0c\u5728\u4e3b\u52d5\u74e3\u5340\u6709\u4e8c\u5ea6\u5fc3\u7e2e\u96dc\u97f3\uff0c\u9918\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u751f\u5316\u6aa2\u67e5\uff1aCK 832 U/L, CK-MB 41 U/L, TnI 5.32 ng/mL(\u5fc3\u96fb\u5716\u5982\u5716\u793a)\u3002\u6025\u8a3a\u91ab\u5e2b\u96a8\u5373\u884cDAPT loading\u53caHeparination\uff0c\u4e26\u555f\u52d5PCI\u5718\u968a\u9032\u884c\u51a0\u8108\u8840\u7ba1\u8a3a\u65b7\u53ca\u6cbb\u7642\u3002\u8acb\u554f\u672c\u75c5\u4f8b\u4e4bCulprit lesion \u6700\u53ef\u80fd\u5728\u4f55\u8655\uff1f\nA. Proximal left anterior descending artery\nB. Proximal left circumflex artery\nC. Distal left circumflex artery\nD. Proximal right coronary artery\nE. Distal right coronary artery\n": "(D)", "105-9.\n\u75c5\u4eba22\u6b72\u5973\u6027\u5916\u7c4d\u770b\u8b77\u56e0\u6709\u6578\u5929\u7684\u9593\u6b47\u6027\u5fc3\u60b8\u53ca\u7729\u6688\uff0c\u96c7\u4e3b\u6025\u9001\u6025\u8a3a\u90e8\u6c42\u91ab\u3002\u5176\u8eab\u9ad4\u6aa2\u67e5\uff1a\u6025\u75c5\u7665\uff0c\u8840\u58d3\uff0c88/72mmHg\uff1b\u8108\u8df3\uff0c144/\u5206\uff0c\u4e0d\u898f\u5247\uff1b\u547c\u5438\uff0c28/\u5206\uff1b\u80ba\u90e8\u7121\u6fc1\u97f3\uff1b\u5fc3\u81df\uff0c\u6709RV heaving\uff0cWide-splitting of S2\u53ef\u805e\uff1b\u6307\u5c16\u767c\u7d3a\uff1b\u9918\u5747\u6b63\u5e38\u6240\u898b\u3002\u5fc3\u96fb\u5716\u5982\u5716\u793a\u3002\u8acb\u554f\u4f9d\u64da\u6700\u65b0ACC/AHA/HRS\u4e4bGuideline\uff0c\u6b64\u5feb\u8df3\u5728\u6025\u8a3a\u8655\u7f6e\uff0c\u61c9\u4ee5\u4f55\u7a2e\u8655\u7f6e\u6700\u6070\u7576\uff1f\nA. Electric cardioversion 200 J after sedation\nB. Adenosine 300 mg IV\nC. Verapamil 5 mg IV\nD. Amiodarone 150 mg in 10 min IV\nE. Digoxin 0.25 mg in 5%D/W 20 ml for 5 min\n": "(A)", "105-10.\n\u4f9d\u64da2015 Guideline of Taiwan Society of Cardiology and Taiwan Hypertension Society for the Management of Hypertension\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662fTaiwan Guideline\u7684\u4e3b\u5f35\uff1f\nA. \u9650\u9209\u9e7d\u57282.0 gm/day\u4ee5\u4e0b\u3002\nB. \u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4e4b\u8840\u58d3\uff0c\u61c9\u63a7\u5236\u5728130/80 mmHg\u4ee5\u4e0b\u3002\nC. \u9ad8\u9f61\u8001\u4eba(>80\u6b72)\u7684\u8840\u58d3\u63a7\u5236\u76ee\u6a19\u5f97\u5347\u81f3150/90 mmHg\u3002\nD. \u6709\u86cb\u767d\u5c3f\u7684\u6162\u6027\u814e\u75c5\u4eba\u5b9c\u7dad\u6301\u8840\u58d3\u5728140/90 mmHg \u4ee5\u4e0a\uff0c\u4ee5\u589e\u5f37\u814e\u5c0f\u7403\u904e\u6ffe\u7387(Glomerular filtration rate)\u3002\nE. \u4f7f\u7528\u6297\u8840\u6813\u6cbb\u7642\u7684\u8166\u4e2d\u98a8\u75c5\u4eba\uff0c\u61c9\u63a7\u5236\u8840\u58d3\u5728130/80 mmHg \u4ee5\u4e0b\uff0c\u4ee5\u514d\u8166\u51fa\u8840\u3002\n": "(D)", "105-11.\n58\u6b72\u7537\u6027\u6025\u6027\u767c\u4f5c\u52d5\u5598\u8207\u7aef\u5750\u547c\u5438\u4f86\u6025\u8a3a\uff0c\u75c7\u72c0\u5df2\u6709\u4e09\u5929\uff0c\u8eab\u9ad4\u6aa2\u67e5\u5728\u5fc3\u5c16\u90e8\u4f4d\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3,\u4e26\u8f3b\u5c04\u81f3\u5de6\u5f8c\u80cc.\u80f8\u90e8X\u5149\u7247\u5448\u73fe\u80ba\u6c34\u816b\uff1b\u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u4e8c\u5c16\u74e3\u8d05\u751f\u7269(vegetation)\uff0c \u4e8c\u5c16\u74e3\u8171\u7d22\u65b7\u88c2\u8207\u91cd\u5ea6\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168\uff0c\u8840\u4e2d\u7d30\u83cc\u57f9\u990a3\u5957\u5448\u73feStreptococcus bovis. \u8acb\u554f\u9664\u4e86\u5fc3\u5167\u819c\u708e\u5916\uff0c\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u61c9\u5217\u5165\u8a3a\u65b7\u8003\u91cf?\nA. \u80ba\u764c\nB. \u5927\u8178\u764c\nC. \u7532\u72c0\u817a\u764c\nD. \u9f3b\u54bd\u764c\nE. \u4e73\u764c\n": "(B)", "105-12.\n\u6709\u95dc24\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u591c\u9593\u8840\u58d3\u901a\u5e38\u6bd4\u65e5\u9593\u8840\u58d3\u4f4e10-20%\nB. \u752824\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u8a3a\u65b7\u9ad8\u8840\u58d3\u6642,\u5e73\u5747\u6e05\u9192\u8840\u58d3 (awake average blood pressure)\u662f\u4ee5\u5927\u65bc\u7b49\u65bc135/85 \u6beb\u7c73\u6c5e\u67f1\u70ba\u8a3a\u65b7\u9ad8\u8840\u58d3\u6a19\u6e96\nC. \u752824\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u8a3a\u65b7\u9ad8\u8840\u58d3\u6642,\u5e73\u5747\u7761\u7720\u8840\u58d3(asleep blood pressure) \u662f\u4ee5\u5927\u65bc\u7b49\u65bc130/80\u6beb\u7c73\u6c5e\u67f1\u70ba\u8a3a\u65b7\u9ad8\u8840\u58d3\u6a19\u6e96\nD. 24\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u63d0\u4f9b\u66f4\u591a\u7684\u65e5\u9593\u8207\u591c\u9593\u8840\u58d3\u6578\u503c,\u6bd4\u8a3a\u9593\u8840\u58d3(office blood pressure)\u66f4\u80fd\u53ef\u9760\u9810\u6e2c\u5668\u5b98\u50b7\u5bb3( target organ damage).\nE. \u7576\u591c\u9593\u8840\u58d3\u964d\u5e45(dip)\u6e1b\u5c11\u6642,\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u5347\u9ad8.\n": "(C)", "105-13.\n\u4e59\u578b\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\u53ef\u7528\u65bc\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387\u6e1b\u5c11\u6642\u4e4b\u5fc3\u81df\u8870\u7aed\u85e5\u7269\u6cbb\u7642,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r1. \u53ef\u4ee5\u4f7f\u7528xamoterol\r2. \u53ef\u4ee5\u4f7f\u7528bisoprolol\r3. \u53ef\u4ee5\u4f7f\u7528carvedilol\r4. \u53ef\u4ee5\u4f7f\u7528propranolol\r5. \u7576\u75c5\u4eba\u6c92\u6709\u51fa\u73fe\u4f4e\u8840\u58d3\u5c0e\u81f4\u982d\u6688\u6216\u5026\u6020\u6642,\u6bcf\u9694\u4e00\u9031\u53ef\u4ee5\u5f80\u4e0a\u8abf\u6574\u5291\u91cf\nA. 1+5\nB. 2+3\nC. 2+3+5\nD. 2+4\nE. 3+5\n": "(B)", "105-14.\n\u539f\u767c\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7 (primary aldosteronism)\u5e38\u9020\u6210\u9ad8\u8840\u58d3,\u6709\u95dc\u5176\u8a3a\u65b7\u63cf\u8ff0,\u4f55\u8005\u6b63\u78ba?\r1. \u5728\u975e\u81e5\u5e8a(ambulatory)\u7684\u75c5\u4eba,\u6e05\u6668\u62bd\u8840\u6642; \u8840\u6e05\u4e2d\u919b\u56fa\u916e/\u814e\u7d20\u6d3b\u6027(plasma aldosterone/ plasma renin activity) >30:1\r2. \u5728\u975e\u81e5\u5e8a\u7684\u75c5\u4eba,\u6e05\u6668\u62bd\u8840;\u8840\u6e05\u4e2d\u919b\u56fa\u916e>555pmol/L (>20ng/dL)\r3. \u5728\u6709\u9ad8\u8840\u58d3\u800c\u672a\u4f7f\u7528\u5229\u5c3f\u5291\u75c5\u60a3,\u8840\u6e05\u4e2d\u9240\u96e2\u5b50\u964d\u4f4e\u8005,\u6709\u9ad8\u905490%\u6709\u539f\u767c\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7\r4. \u5728\u62bd\u8840\u524d4~6\u9031\u8981\u505c\u6389\u919b\u56fa\u916e\u62ee\u6297\u5291(aldosterone antagonists)\r5. \u5728\u8840\u6e05\u919b\u56fa\u916e/\u814e\u7d20\u6bd4\u503c\u5347\u9ad8\u60a3\u8005,\u7d66\u4e88\u975c\u8108\u6ce8\u5c042\u516c\u5347\u751f\u7406\u98df\u9e7d\u6c34\u56db\u5c0f\u6642\u5f8c,\u8840\u6e05\u4e2d\u7684\u919b\u56fa\u916e\u964d\u81f3138pmol/L (5ng/dL)\u4ee5\u4e0b\nA. 2+3+4\nB. 1+2+3\nC. 1+2+4\nD. 1+2+5\nE. 1+4+5\n": "(C)", "105-15.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u5fc3\u623f\u986b\u52d5\u5c31\u8a3a,\u8a72\u5fc3\u5f8b\u4e0d\u6574\u75c5\u53f2\u5df2\u67091\u5e74\u4ee5\u4e0a.\u904e\u53bb\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2,\u6700\u8fd1\u6709\u9663\u767c\u6027\u591c\u9593\u547c\u5438\u56f0\u96e3\u8207\u8173\u90e8\u6c34\u816b;\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5c04\u51fa\u5206\u7387\u70ba29%.\u7121\u5fc3\u808c\u6897\u585e,\u4e2d\u98a8\u6216\u9031\u908a\u8840\u7ba1\u963b\u585e\u75be\u75c5\u75c5\u53f2.\u5728\u6c7a\u5b9a\u8981\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u5291\u6642;\u6703\u4f30\u7b97CHA2DS2-VASc \u5206\u6578,\u8acb\u554f\u8a72\u75c5\u60a3\u4e4b\u5206\u6578\u70ba?\nA. 2\nB. 3\nC. 4\nD. 5\nE. 6\n": "(C)", "105-16.\n\u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u60a3,\u56e0\u660f\u53a5\u800c\u9001\u81f3\u6025\u8a3a.\u5728\u6025\u8a3a\u4e4b\u5fc3\u96fb\u5716\u5982\u5716A. \u56de\u9867\u8a72\u75c5\u60a3\u5148\u524d\u9580\u8a3a12\u5c0e\u7a0b\u5fc3\u96fb\u5716\u7684\u7b2c\u4e00\u81f3\u7b2c\u4e09\u80f8\u524d\u5c0e\u5982\u5716B.\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u8d85\u97f3\u6ce2\u7121\u7d50\u69cb\u6027\u5fc3\u81df\u75c5;\u8840\u6e05\u96fb\u89e3\u8cea\u7121\u7570\u5e38,\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u7d66\u4e88\u8a72\u75c5\u60a3flecainide\u6703\u8b93\u7b2c\u4e00\u81f3\u7b2c\u4e09\u80f8\u524d\u5c0e\u7a0bST\u7bc0\u6bb5\u8b8a\u5316\u66f4\u660e\u986f\nB. \u6709\u90e8\u5206\u75c5\u4eba\u6709\u9209\u96e2\u5b50\u901a\u9053(sodium channel)\u7a81\u8b8a\u7570\u5e38\nC. \u75c5\u4eba\u5e38\u56e0\u767c\u71d2\u6216\u7761\u7720\u8a98\u767c\u5fc3\u640f\u505c\u6b62(cardiac arrest)\nD. \u9019\u985e\u75c5\u4eba\u6709\u6642\u9700\u8981\u88dd\u7f6e\u5fc3\u5167\u53bb\u986b\u6574\u6d41\u5668(ICD)\nE. \u9240\u96e2\u5b50\u901a\u9053( potassium channel)\u7570\u5e38\u662f\u7d55\u5927\u90e8\u5206\u7684\u539f\u56e0\n": "(E)", "105-17.\n\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u96dc\u97f3\u807d\u8a3a\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?\r1.\u7576\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u8d8a\u56b4\u91cd,\u7b2c\u4e8c\u5fc3\u97f3A2\u8207\u4e8c\u5c16\u74e3\u958b\u74e3\u97f3(opening snap)\u7684\u9593\u8ddd\u6703\u7e2e\u77ed\r2.\u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u8d8a\u4f86\u8d8a\u72f9\u7a84,\u6703\u5f15\u8d77\u6b21\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3,\u6b64\u6642\u7b2c\u4e8c\u5fc3\u97f3P2\u6703\u8b8a\u5927\u8072\r3.\u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u8d8a\u4f86\u8d8a\u72f9\u7a84,\u6703\u5f15\u8d77\u6b21\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3,\u6b64\u6642A2\u8207P2\u9593\u8ddd\u6703\u8b8a\u5bec\r4.\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u662f\u8212\u5f35\u671f\u96dc\u97f3(diastolic rumble)\r5.Austin-Flint murmur \u662f\u7528\u4f86\u63cf\u8ff0\u4e8c\u5c16\u74e3\u72f9\u7a84\u7684\u96dc\u97f3\nA. 1+3+5\nB. 1+4\nC. 2+3\nD. 3+4\nE. 3+5\n": "(E)", "105-18.\n\u6709\u95dc\u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3(bicuspid aortic  valve)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u60a3\u8005,\u5176\u4e00\u7b49\u89aa\u7f79\u60a3\u8a72\u75be\u75c5\u7684\u76db\u884c\u7387(prevalence)\u70ba10%\nB. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u60a3\u8005\u4e3b\u52d5\u8108\u6703\u64f4\u5927,\u6709\u6642\u5019\u6703\u5f62\u6210\u4e3b\u52d5\u8108\u7624\u6216\u4e3b\u52d5\u8108\u525d\u96e2\nC. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u60a3\u8005\u7684\u4e3b\u52d5\u8108\u75c5\u8b8a\u8207\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u8840\u578b\u529b\u5b78\u7684\u56b4\u91cd\u7a0b\u5ea6\u4e0d\u4e00\u5b9a\u6709\u76f8\u95dc( independent of the severity of hemodynamic severity  of the valve lesions)\nD. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u7537\u5973\u6bd4\u70ba1:2~4\nE. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u6703\u8207\u5176\u4ed6\u5148\u5929\u6027\u5fc3\u81df\u75c5\u5408\u4f75\u767c\u751f\n": "(D)", "105-19.\n\u4e00\u4f4d82\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u9aa8\u982d\u58d3\u75db\uff0c\u5598\u8207\u8173\u816b\u81f3\u9580\u8a3a\u5c31\u8a3a\uff0c\u8840\u58d3\u70ba96/60\u6beb\u7c73\u6c5e\u67f1\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418\u70ba80\u6b21\uff0c\u8eab\u9ad4\u6aa2\u67e5\u5448\u73fe\uff1a\u7d50\u819c\u84bc\u767d\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u5169\u5074\u547c\u5438\u97f3\u6e1b\u5f31\uff0c\u5fc3\u81df\u807d\u8a3a\u5de6\u4e0b\u80f8\u9aa8\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3\uff0c\u4e26\u96a8\u5438\u6c23\u52a0\u91cd\uff0c\u5fc3\u5c16\u90e8\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3\uff0c\u5169\u5074\u4e0b\u80a2\u660e\u986f\u6c34\u816b\u3002\u62bd\u8840\u6aa2\u67e5\u5448\u73feBUN 70 mg/dl, cre 5.5mg/dl, Na 140 mmol/L, K 4.2 mmol/L, calcium 2.8 mmol/L, phosphate 5.3 mg/dL, Hb 10.7 g/dl, MCV 85.2 fL, WBC 9.61 k/uL,  platelet 197 k/uL, albumin 3.1 g/dl, total protein 7.6 g/dl, \u9a57\u5c3f\u5c3f\u86cb\u767d\u5448\u73fe3+, \u982d\u9aa8X\u5149\u5448\u73fe\rpunched-out\u75c5\u7076.\u9aa8\u9ad3\u5207\u7247\u6aa2\u67e5\u5448\u73fe\u660e\u986fplasma cell neoplasm.\u91ab\u5e2b\u61f7\u7591\u5fc3\u81df\u4e5f\u6709\u88ab\u6b64\u75be\u75c5\u6ce2\u53ca.\u8acb\u554f\u4e0b\u5217\u5fc3\u81df\u6aa2\u67e5\u7d50\u679c,\u4f55\u8005\u8207\u9019\u500b\u61f7\u7591\u8f03\u4e0d\u543b\u5408?\nA. \u5fc3\u96fb\u5716A\nB. \u5fc3\u96fb\u5716B\nC. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u5fc3\u808c\u80a5\u539a\u8207sparkling\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u51fa\u73ferestrictive filling pattern\nE. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u4e2d\u81f3\u91cd\u5ea6\u4e09\u5c16\u74e3\u819c\u9589\u9396\u4e0d\u5168\n": "(B)", "105-20.\n\u6709\u95dc\u65b0\u578b\u53e3\u670d\u6297\u51dd\u8840\u5291\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. apixaban\u662f\u4f5c\u7528\u5728thrombin\nB. rivaroxaban\u662f\u4f5c\u7528\u5728factor Xa\nC. dabigatran 80%\u7531\u814e\u81df\u4ee3\u8b1d\nD. edoxaban half life\u662f 9~11 \u5c0f\u6642\nE. \u7121\u6cd5\u85c9\u7531 prothrombin time\u4f86\u76e3\u63a7\u8a72\u85e5\u7269\u6297\u51dd\u8840\u6548\u679c\n": "(A)", "105-21.\n\u4e00\u4f4d65\u6b72\u5973\u6027\u9ad6\u9aa8\u9aa8\u6298\u958b\u5200\u5f8c7\u5929,\u4e3b\u8a34\u547c\u5438\u7a98\u8feb;\u958b\u5200\u524d\u8840\u58d3\u70ba130/80\u6beb\u7c73\u6c5e\u67f1,\u547c\u5438\u7a98\u8feb\u6642\u6e2c\u91cf\u4e4b\u8840\u58d3\u70ba80/50\u6beb\u7c73\u6c5e\u67f1.\u8840\u6c27\u6fc3\u5ea6\u753198%\u964d\u81f370%.\u5fc3\u96fb\u5716\u5982\u5716.\u503c\u73ed\u91ab\u5e2b\u6c92\u62bd\u8840\u6e2cD- dimer \u4fbf\u76f4\u63a5\u5b89\u6392\u5f71\u50cf\u6aa2\u67e5;\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5982\u9644\u5716.\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u5f88\u6709\u53ef\u80fd\u56e0\u958b\u5200\u5f8c\u81e5\u5e8a\u800c\u5c0e\u81f4\u6df1\u90e8\u975c\u8108\u6813\u585e\nB. \u8a72\u503c\u73ed\u91ab\u5e2b\u61c9\u8a72\u62bd\u8840\u7b49D- dimer\u6578\u503c\u6aa2\u6e2c\u51fa\u4f86\u5f8c,\u518d\u9032\u884c\u5b89\u6392\u5f71\u50cf\u6aa2\u67e5\nC. \u8a72\u75c5\u60a3\u4e4b\u8840\u58d3\u964d\u4f4e\u7684\u539f\u56e0\u4e4b\u4e00\u662f\u7531\u65bc\u53f3\u5fc3\u8840\u6db2\u7121\u6cd5\u56de\u5230\u5de6\u5fc3,\u4f86\u63d0\u4f9b\u8db3\u5920\u5fc3\u8f38\u51fa\u91cf\u6240\u81f4\nD. \u6b64\u6642\u62bd\u8840,\u8840\u4e2d\u4e73\u9178\u6703\u5347\u9ad8\nE. D-dimer\u5c0d\u6b64\u80ba\u90e8\u8840\u7ba1\u8b8a\u5316\u7684\u8a3a\u65b7\u654f\u611f\u5ea6(sensitivity)>95%\n": "(B)", "105-22.\n\u4e00\u4f4d75\u6b72\u7537\u6027,\u904e\u53bb\u7f79\u60a3\u7cd6\u5c3f\u75c5,\u4f46\u8840\u7cd6\u63a7\u5236\u4e0d\u4f73.\u62bd\u83f8\u670940\u5e74.\u8840\u58d3\u9ad8\u4f46\u9577\u5e74\u672a\u6cbb\u7642.\u6700\u8fd13\u500b\u6708\u51fa\u73fe\u9593\u6b47\u6027\u8ddb\u884c,\u91ab\u5e2b\u61f7\u7591\u4ed6\u6709\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5 (peripheral arterial occlusive disease),\u56e0\u6b64\u958b\u7acb\u8173\u8e1d\u8207\u80b1\u52d5\u8108\u8840\u58d3\u6bd4\u503c(ankle brachial index, ABI)\u6aa2\u67e5,\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. ABI \u6b63\u5e38\u503c\u57281.0~1.4\nB. ABI<1.0 \u53ef\u4ee5\u78ba\u7acb\u8a3a\u65b7\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\nC. \u904b\u52d5\u5f8c\u7acb\u5373\u6e2c\u91cfABI,\u5982\u679cABI \u6578\u503c\u660e\u986f\u4e0b\u964d,\u53ef\u4ee5\u5354\u52a9\u75c7\u72c0\u6a21\u7a1c\u5169\u53ef\u7684\u75c5\u4eba\u8a3a\u65b7\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\nD. \u9664\u975e\u75c5\u4eba\u6709\u898f\u5283\u9032\u884c\u8840\u7ba1\u91cd\u5efa\u6cbb\u7642 (revascularization), \u78c1\u632f\u8840\u7ba1\u9020\u5f71( Magnetic  Resonance Angiography) \u4e0d\u8981\u88ab\u7576\u6210\u5e38\u898f\u7be9\u6aa2\u5de5\u5177.\nE. ABI\u5c0d\u7f79\u60a3\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\u4e4b\u75c5\u4eba,\u9664\u4e86\u8a3a\u65b7\u7684\u529f\u7528;\u9084\u53ef\u4ee5\u5354\u52a9\u627e\u51fa\u53ef\u80fd\u767c\u751f\u51a0\u72c0\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u75be\u75c5(atherothrombotic event)\u98a8\u96aa\u7684\u4eba\n": "(B)", "106-1.\n53\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u80f8\u75bc\u53ca\u51b7\u6c57\u6025\u5f80\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6c92\u6709\u4efb\u4f55\u65e2\u5f80\u75c5\u53f2\uff0c\u53ea\u6709\u6bcf\u5929\u4e00\u5305\u7159\u7684\u5eff\u4e94\u5e74\u55dc\u597d\u3002\u5c31\u8a3a\u6642\u8840\u58d3165/109 mmHg; \u5fc3\u8df382/min\u3002\u75c5\u53f2\u63a2\u8a62\u6642\u7a81\u7136\u5fc3\u8df3\u505c\u6b62\uff0c\u5fc3\u96fb\u5716\u986f\u793a\u5982\u5716\u3002\u60a8\u7368\u81ea\u5728\u73fe\u5834\uff0c\u8acb\u554f\u60a8\u7684\u7b2c\u4e00\u6b65\u8655\u7f6e\uff0c\u4ee5\u4f55\u8005\u70ba\u5148\uff1f\nA. Amiodarone 150 mg in 50 ml D5W \u975c\u8108\u6ce8\u5c0420\u5206\nB. \u9032\u884cCPR, \u5fc3\u81df\u58d3\u8feb\u6bcf\u5206\u9418100\u6b21\nC. \u7dca\u6025\u7f6e\u653e\u4eba\u5de5\u652f\u6c23\u7ba1\uff0c\u7dad\u6301\u547c\u5438\nD. Intra-cardiac injection, bosmin 1 mg\nE. \u555f\u7528\u8449\u514b\u819c\u652f\u6301\u8840\u58d3\u53ca\u5fc3\u8df3\n": "(B)", "106-2.\n\u5c31\u81e8\u5e8a\u89c0\u5bdf\u800c\u8a00\uff0c\u5fc3\u5f8b\u5feb\u8df3(Tachyarrhythmia)\u8207\u7672\u7647(Seizure)\u6240\u81f4\u4e4b\u6688\u7729(Syncope)\u4e0d\u6613\u9451\u5225\u8a3a\u65b7\uff0c\u552f\u4e0b\u5217\u6578\u9ede\u5177\u6709\u5f37\u5ea6\u53c3\u8003\u50f9\u503c:(1)\u904b\u52d5\u4e2d\u7684\u6688\u7729\uff1b (2)\u5c3f\u5931\u7981\u53ca\u54ac\u820c\uff1b(3)\u75c5\u4eba\u5728\u610f\u8b58\u56de\u5fa9\u5f8c\uff0c\u8fc5\u5373\u56de\u5fa9\u5c0d\u4eba\u3001\u5730\u4e4b\u8fa8\u8b58\u80fd\u529b\uff1b (4)\u54b3\u55fd\u3001\u9589\u6b62\u5438\u6c23\u4e0d\u80fd\u91cb\u89e3\u75c7\u72c0\uff1b(5)\u5e73\u8eba\u9593\u7a81\u767c\u6688\u7729\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u75c5\u53f2\u75c7\u72c0\u504f\u5411\u5fc3\u5f8b\u5feb\u8df3\u81f4\u6688\u7729\u4e4b\u8a3a\u65b7\uff1f\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (2)+(3)+(4)\nD. (1)+(4)+(5)\nE. (1)+(3)+(5)\n": "(E)", "106-3.\n\u8a31\u591a\u5fc3\u96fb\u5716\u6240\u898b\uff0c\u5e38\u5177\u6709\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u81e8\u5e8a\u610f\u7fa9\uff1a(1)PR\u9593\u9694(PR interval) \u5ef6\u9577\u6c92\u6709\u767c\u751f\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u7684\u5371\u96aa\uff1b(2)QRS duration > 0.12 mSec\u7684\u53f3\u675f\u679d\u50b3\u5c0e\u963b\u6eef(Right bundle branch block)\u4e0d\u5177\u751f\u7406\u75c5\u7406\u7684\u610f\u7fa9\uff1b(3)QTc\u5ef6\u9577\u53ef\u767c\u751f\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u60e1\u6027\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u4e0d\u6574(Ventricular tachyarrhythmia)\u4e4b\u5371\u96aa\uff1b(4)\u53cd\u5411QRS\u6ce2\u7684J\u6ce2\u53ef\u5728\u4f4e\u6eab\u3001\u9ad8\u9223\u8840\u53ca\u8166\u90e8\u50b7\u8b8a\u767c\u751f\uff0c\u5177\u9ad8\u5ea6\u60e1\u6027\u5fc3\u5f8b\u4e0d\u6574\u767c\u751f\u7684\u5371\u96aa\uff1b(5)QTc\u7e2e\u77ed\u53ef\u767c\u751f\u60e1\u6027\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u4e0d\u6574\u6216\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8aaa\u6cd5\u662f\u6b63\u78ba\u7684\uff1f\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-4.\n88\u6b72\u7537\u6027\u8001\u5e74\u4e3b\u8a34\u8fd1\u4e09\u500b\u6708\u6642\u6709\u80f8\u60b6\uff0c\u7729\u660f\u53ca\u5fc3\u60b8\u3002\u5f9e\u53bb\u5e74\u5e74\u5e95\u8d77\u65e5\u6f38\u4e0d\u80fd\u81ea\u7406\u751f\u6d3b\uff0c\u4e26\u6709\u8fd1\u671f\u7684\u5931\u61b6\uff0c\u4e0d\u80fd\u8a00\u8a9e\u53ca\u9032\u98df\uff0c\u9010\u65e5\u52a0\u91cd\u5f8c\u4f4f\u9662\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1aBP:112/53 mmHg; HR:46 bpm\uff1bRR,18/min\uff1bSpO2, 98%\uff1b\u610f\u8b58E4M4V5; Muscle power, Normal\uff1b\u9838\u975c\u8108\u6b63\u5e38\uff0c\u7532\u72c0\u817a\u6b63\u5e38\uff1b\u80f8\u90e8\u6709\u7c97\u6fc1\u547c\u5438\u97f3\uff1b\u5fc3\u81df\uff1aS1\u504f\u91cd\uff0c\u5728\u5fc3\u5c16\u53ca\u4e3b\u52d5\u8108\u5340\u6709Grade 2/6 Diastolic murmur\uff1b\u8179\u90e8\u672a\u6709\u809d\u813e\u816b\uff1b\u8173\u6c92\u6709\u6c34\u816b\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u9644\uff1b\u8d85\u97f3\u6ce2\u5fc3\u5716\u986f\u793a\u4e3b\u52d5\u8108\u74e3\u53ca\u4e09\u5c16\u74e3\u4e2d\u5ea6\u9589\u9396\u4e0d\u5168\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u8a3a\u65b7\u662f\uff1a\nA. \u5de6\u5fc3\u5ba4\u8870\u7aed\nB. \u53f3\u5fc3\u5ba4\u8870\u7aed\nC. \u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\nD. \u6bdb\u5730\u9ec3\u4e2d\u6bd2\nE. \u4f4e\u9209\u8840\u75c7\n": "(D)", "106-5.\n\u6709\u95dc\u64f4\u5927\u6027\u5fc3\u808c\u75c5(Dilated cardiomyopathy\uff0c DCM)\u7684\u8fd1\u5e74\u8a3a\u7642\u9032\u5c55\uff0c\u6709\u4e0d\u5c11\u5b9a\u8ad6\uff0c\u8acb\u554f\u4f55\u9ede\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5e7e\u8fd1\u4e00\u534a(20-50%)\u7684DCM\u5177\u6709\u5bb6\u65cf\u6027\uff0c\u5176\u4e2d68%\u662f\u81ea\u9ad4\u986f\u6027\u907a\u50b3(Autosomal dominant inheritance)\u3002\nB. \u81e8\u5e8a\u4e0a\uff0cDCM\u6709\u5169\u7a2e\uff0c\u4e00\u4ee5\u5fc3\u81df\u8870\u7aed\u8868\u73fe\u7684\u55ae\u7d14\u6027(Isolated)DCM, \u53e6\u4e00\u662f\u4f34\u6709\u5fc3\u5f8b\u4e0d\u6574\u6216\u50b3\u5c0e\u963b\u6eef\uff0c\u4e14\u6709\u9aa8\u9abc\u808c\u57fa\u56e0\u75c5\u8b8a\u7684DCM\u3002\nC. X-\u76f8\u9023\u6027DCM(X-linked DCM)\u67092-5%\uff0c\u5982\u6709\u8840\u6e05CK\u5347\u9ad8\uff0c\u5c31\u6709\u53ef\u80fd\u662fDystrophin gene \u7a81\u8b8a\u6240\u81f4\u3002\nD. \u6240\u6709\u7684DCM\uff0c\u4e0d\u8ad6\u5148\u5929\u6216\u5f8c\u5929\u56e0\u7d20\u90fd\u4e0d\u80fd\u5fa9\u539f\uff0c\u5fc3\u81df\u79fb\u690d\u662f\u552f\u4e00\u7684\u6cbb\u7642\u9078\u64c7\u3002\nE. \u6709\u8b02DCM, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, \u6216 Arrhythmogenic RV cardiomyopathy \u90fd\u6709\u5171\u540c\u7684\u57fa\u56e0\u7570\u5e38\uff0c\u56e0\u6b64\u8a8d\u5b9a\u5fc3\u808c\u75c5\u662f\u4e00\u500b\u75c5\u56e0\uff0c\u4e0d\u540c\u7684\u81e8\u5e8a\u5178\u578b\u3002\n": "(D)", "106-6.\n\u75c5\u4eba\uff0c64\u6b72\u5085\u5148\u751f\u5728\u4e0b\u53483:00 PM \u7a81\u7136\u6c23\u4fc3(dyspnea)\uff0c\u5230\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u6162\u6027B\u578b\u809d\u708e\u53ca\u75db\u98a8\u75c5\u53f2\u3002\u5230\u9662\u6642\u8840\u58d3102/73mm Hg; ventricular rate 100/min;\u572810 L/min O2 mask \u4f7f\u7528\u4e0bSpO2 100%\u3002\u5728\u6025\u8a3a\u4e4b\u8eab\u9ad4\u6aa2\u67e5\u672b\u898b\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u53caCxR\u5982\u5716\u3002\u975c\u8108\u8840\u6c27\u6c23\u53ca\u751f\u5316\u6aa2\u67e5\u5982\u8868\uff0c\u8d85\u97f3\u6ce2\u5fc3\u5716\u986f\u793a\u53f3\u5fc3\u64f4\u5927\u53ca\u4e2d\u91cd\u5ea6\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u3002\u672c\u75c5\u4eba\u4e4b\u8a3a\u65b7\u53ca\u6cbb\u7642\u4e4b\u7dca\u6025\u8655\u7f6e\uff0c\u4ee5\u4f55\u65b9\u6848\u6700\u9069\u7576\uff1f\nA. \u6557\u8840\u6027\u4f11\u514b\uff0c\u555f\u7528\u5347\u58d3\u5291\u7dad\u6301\u8840\u58d3\uff0c\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u81f3\u5c11\u4e09\u5957\u5f8c\uff0c\u4f7f\u7528Empirical antibiotics\u3002\nB. \u53f3\u5fc3\u8870\u7aed\uff0c\u63a1\u7528\u5bb9\u7a4d\u91cf\u88dc\u5145\u6cd5\uff0c\u5fc5\u8981\u914d\u7528Dopamine infusion at the rate of 2.5-5.0 microgram/Kg/min\u3002\nC. \u80ba\u6813\u585e\uff0c\u6e2c\u5b9aD-dimer\u53ca\u80f8\u90e8CT\uff0c\u4f9d\u7d50\u679c\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u7642\u6cd5\u53ca\u809d\u7d20\u6ce8\u5c04\u3002\nD. \u6025\u6027\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\uff0c\u7cfb\u5217\u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\u9175\u7d20\u6aa2\u67e5\uff0c\u6309\u7d50\u679c\u6703\u8a3a\u5fc3\u81df\u79d1\u9015\u884cpercutaneous coronary intervention\u3002\nE. \u7e7c\u7e8c\u89c0\u5bdf\uff0c\u7dad\u6301\u751f\u547d\u75c7\u72c0\u7a69\u5b9a\u3002\n": "(C)", "106-7.\n\u6709\u95dc\u9810\u9632\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial Fibrillation\uff1bAf)\u53ef\u81f4\u7684\u8166\u4e2d\u98a8\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u5f9e2014 AHA/ACC,2016 ESC \u53ca2016 CCS\u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6307\u5f15\u4e3b\u5f35\uff0c\u7528\u4ee5\u9810\u9632Af-related stroke?\nA. Aspirin\u6c92\u6709\u9810\u9632\u8166\u4e2d\u98a8\u7684\u89d2\u8272\u3002\nB. AF\u75c5\u4eba\u7684CHA2DS2-VASc\u8a08\u52060\u5206(\u7537)\u6216\u4f4e\u65bc1\u4ee5\u4e0b(\u5973)\uff0c\u5f97\u4e0d\u7528\u6297\u51dd\u8840\u85e5\u7269\u3002\nC. \u4f34\u6709\u814e\u529f\u80fd\u5931\u5168\u7684AF\u5f97\u7528Apixaban\u3002\nD. Apixaban, Edoxaban, \u53caDabigatran 110 mg \u8f03\u591a\u8166\u5167\u51fa\u8840\u3002\nE. \u6b63\u5e38\u74e3\u819c\u6027\u6216\u975e\u74e3\u819c\u6027(Native or non-valvular)AF\u90fd\u5f97\u4f7f\u7528Warfarin \u53caNon-Vitamin K antagonist oral anticoagulation (NOAC)\n": "(D)", "106-8.\n\u4e0b\u5217\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis\uff0cIE)\u7684\u65b0\u8ad6\u8aaa\u6cd5\uff0c\u4e0d\u662f\u6b63\u78ba\u7684\uff1f\nA. \u8fd1\u5e74IE\u591a\u898b\u65bc\u4e94\u5341\u6b72\u5f8c\u7684\u4e2d\u8001\u4eba\uff0c\u4e14\u4ee5\u7537\u6027\u70ba\u591a\u3002\nB. \u88fd\u9020\u4e82\u6d41\u7684\u5fc3\u81df\u7570\u5e38\u7d50\u69cb\uff0c\u5c0e\u81f4\u5fc3\u5167\u819c\u50b7\u8b8a\uff0c\u805a\u7d50\u8840\u5c0f\u677f\u3001\u7e96\u7dad\u7d20\u5f62\u6210\u7121\u83cc\u8d05\u751f\u7269\uff0c\u518d\u7d50\u5408\u83cc\u8840\u75c7\u53ca\u7d30\u83cc\u6027\u884d\u751f\u548c\u4fb5\u900f\u6027\u7d44\u7e54\u8b8a\u5316\u662f\u91cd\u8981\u7684\u75c5\u7406\u751f\u7406\u5b78\u3002\nC. \u5178\u578b\u7684Osler nodes, Janeway\u6216 Roth spots\u5728\u7576\u4eca\u7684\u81e8\u5e8a\u5be6\u4f8b\u4e26\u4e0d\u591a\u898b\u3002\nD. \u5178\u578b\u7684\u967d\u6027\u83cc\u682a\u7d30\u83cc\u57f9\u990a\u5982Streptococcus\u3001 Staphylococcus \u6216HACEK \u8981\u6709\u4e8c\u5957\uff1b\u5176\u4ed6\u6301\u7e8c\u6027\u83cc\u8840\u57f9\u990a\u8981\u6709\u8ddd\u664212\u5c0f\u6642\u4e8c\u5957\u967d\u6027\uff0c\u6216\u56db\u5957\u4ee5\u4e0a\u57f9\u990a\u6709\u4e09\u5957\u967d\u6027\u3002\nE. \u4efb\u4f55IE\u75c5\u4f8b\u90fd\u61c9\u5feb\u901f\u4f7f\u7528Empirical antibiotics,\u4e0d\u5fc5\u4e45\u7b49\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u7d50\u679c\uff1b\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\u4e09\u5929\u672a\u9000\u71d2\u61c9\u8003\u616e\u66ff\u63db\u6297\u751f\u7d20\u3002\n": "(E)", "106-9.\n\u6839\u636e2016\u5e74\u53f0\u7063\u5fc3\u81df\u5b78\u6703\uff0c\u4ee52013- 2014\u5e74\u767b\u9304\u76841509\u540d\u5931\u511f\u6027\u5fc3\u8870\u7aed(Decompensated systolic heart failure, DSHF) \u7684\u5206\u6790\uff0c\u6709\u4e0b\u5217\u8af8\u591a\u7279\u9ede\uff0c\u4f55\u8005\u9664\u5916?\nA. \u5fc3\u808c\u7f3a\u6c27\u3001\u98f2\u98df\u53ca\u7528\u85e5\u9075\u56d1\u6027\u964d\u4f4e\u3001\u611f\u67d3\u53ca\u814e\u5931\u80fd\u90fd\u662f\u89f8\u767c\u5fc3\u8870\u7aed\u7684\u91cd\u8981\u539f\u56e0\u3002\nB. \u9ad8\u905452.3 %\u7684\u5fc3\u8870\u7aed\u4f34\u6709\u4e2d\u7b49\u5ea6\u548c\u56b4\u91cd\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168(Moderate and severe mitral regurgitation) \u3002\nC. \u53f0\u7063\u7684DSHF\u75c5\u4eba\u9060\u6bd4\u6b50\u3001\u7f8e\u3001\u65e5\u591a\u662f\u8001\u4eba\uff0c\u4e14\u4ee5\u5973\u6027\u75c5\u4eba\u70ba\u591a\u3002\nD. \u53f0\u7063\u7684DSHF\u75c5\u4eba\u8f03\u5c11\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation) \u53ca\u9ad8\u8840\u58d3\u3002\nE. \u81e8\u5e8a\u91ab\u5e2b\u5c0d\u53f0\u7063\u7684DSHF\u75c5\u4eba\u8f03\u5c11\u4f7f\u7528mineralocorticoid receptor antagonists\u53caBeta-blockers\u3002\n": "(C)", "106-10.\n\u75c5\u4eba68\u6b72\u7537\u6027\uff0c\u6709\u591a\u5e74\u7cd6\u5c3f\u75c5\u53ca\u9ad8\u8840\u58d3\uff0c\u6cbb\u7642\u4e2d\u3002\u6709\u5bb6\u65cf\u51a0\u5fc3\u75c5\u3002\u5728\u6e05\u6668\u5065\u8eab\u8d70\u8def\u6642\uff0c\u7a81\u7136\u80f8\u60b6\uff0c\u6301\u7e8c\u4e09\u500b\u591a\u5c0f\u6642\uff0c\u4e43\u6025\u8a3a\u8655\u6c42\u91ab\u3002\u6642T/P/R: 36/75/20;BP: 148/85 mmHg\uff0c\u5176\u4ed6\u8eab\u9ad4\u6aa2\u67e5\u672a\u898b\u91cd\u5927\u7570\u5e38\u3002\u5176\u80f8\u90e8X\u5149\u53ca\u5fc3\u96fb\u5716\u5982\u5716\uff0c\u751f\u5316\u53ca\u8840\u6db2\u6aa2\u67e5\u5982\u8868\u3002\u8acb\u554f\u672c\u75c5\u4f8b\u6700\u53ef\u80fd\u7684\u6b63\u78ba\u8a3a\u65b7: (1)STEMI\uff1b(2)NSTEMI ACS\uff1b (3)RCA occlusion\uff1b(4) LAD occlusion\uff1b(5)Inferior wall MI\uff1b(6)Postero-inferior wall MI\nA. (1)+(3)+(5)\nB. (1)+(3)+(6)\nC. (2)+(3)+(5)\nD. (2)+(3)+(6)\nE. (2)+(4)+(6)\n": "(B)", "106-11.\n\u6709\u95dc\u6025\u6027\u4e3b\u52d5\u8108\u75c7\u5019\u7fa4(Acute aortic syndrome)\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b(intraluminal hematoma)\u6210\u56e0\u662f\u71df\u990a\u7ba1\u58c1\u7684\u5c0f\u8840\u7ba1(vasa vasorum)\u7834\u88c2\u6240\u81f4\nB. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b\u4e3b\u8981\u767c\u751f\u65bc\u5347\u4e3b\u52d5\u8108 (ascending aorta)\nC. \u7a7f\u900f\u6027\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6f70\u760d(penetrating atherosclerotic ulcer)\u6210\u56e0\u662f\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6591\u584a\u4fb5\u8755\u81f3\u4e3b\u52d5\u8108\u58c1\u4e2d\u819c (aortic media)\nD. \u7a7f\u900f\u6027\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6f70\u760d\u5e38\u767c\u751f\u65bc\u964d\u80f8\u4e3b\u52d5\u8108\u7684\u4e2d\u7aef\u8207\u9060\u7aef\u90e8(middle and distal portions of descending thoracic aorta)\nE. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b\u53ef\u4ee5\u6f14\u8b8a\u6210\u4e3b\u52d5\u8108\u525d\u96e2\u751a\u81f3\u7834\u88c2\n": "(B)", "106-12.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u6709\u80ba\u764c\u75c5\u53f2,\u4f86\u5230\u6025\u8a3a\u6642,\u5438\u6c23\u6642\u6536\u7e2e\u58d3\u6bd4\u547c\u6c23\u6642\u6536\u7e2e\u58d3\u4e0b\u964d\u8d85\u904e10mmHg\u4ee5\u4e0a,\u5fc3\u96fb\u5716\u5982\u9644\u5716,\u8acb\u554f\u4f55\u8005\u63cf\u8ff0\u70ba\u8aa4?\nA. \u6b64\u75c5\u4eba\u81e8\u5e8a\u4e0a\u61c9\u6709\u4f4e\u8840\u58d3,\u5fc3\u97f3\u5fae\u5f31,\u8207\u9838\u975c\u8108\u6012\u5f35 (Beck's triad )\nB. \u9838\u975c\u8108\u6ce2\u5f62\u6703\u6709\u660e\u986f\u7684 y descent\nC. \u8eab\u9ad4\u6aa2\u67e5\u6642,\u8a72\u75c5\u60a3\u7121Kussmaul's sign\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982\u5716\nE. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u6642\u6703\u51fa\u73fe\u8212\u5f35\u672b\u671f\u53f3\u5fc3\u5ba4\u584c\u9677\u5fb5\u8c61 (right ventricular collapse sign)\n": "(B)", "106-13.\n\u6709\u95dc\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed(Heart failure with preserved ejection fraction)\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u6839\u64da\u6587\u737b[The Candesartan in Heart Failure-Assessment of Mortality and Morbidity (CHARM) Preserved study], Candesartan \u53ef\u4ee5\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u4e4b\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\nB. \u6839\u64da\u6587\u737b[ Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial], Irbesartan\u7121\u6cd5\u660e\u986f\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u4e4b\u81e8\u5e8a\u9810\u5f8c\nC. \u6839\u64da\u6587\u737b[Digitalis Investigation Group (DIG) trial],\u6bdb\u5730\u9ec3 (digoxin)\u5728\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u7684\u6cbb\u7642\u4e0a,\u4e26\u7121\u5e6b\u52a9.\nD. \u6839\u64da\u6587\u737b[Study of The Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS) trial], Nebivolol[\u4e00\u7a2e\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291 (beta-blocker)] , \u7121\u6cd5\u6539\u5584\u66fe\u56e0\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u4f4f\u9662\u5e74\u9577\u75c5\u60a3\u4e4b\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\nE. \u6839\u64da\u6587\u737b [the Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-DHF) study], Spironolactone \u7121\u6cd5\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u7684\u904b\u52d5\u91cf,\u5fc3\u8870\u7aed\u75c7\u72c0\u8207\u751f\u6d3b\u54c1\u8cea.\n": "(A)", "106-14.\n\u6709\u95dc\u5229\u7528\u6539\u5584\u751f\u6d3b\u6a21\u5f0f(Life Style Modification)\u4ee5\u9054\u6210\u9ad8\u8840\u58d3\u63a7\u5236\u76ee\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?(1)\u9ad4\u91cd\u4e0b\u964d9.2\u516c\u65a4,\u7d04\u53ef\u4ee5\u4e0b\u964d\u6536\u7e2e\u58d316.3 mmHg\uff1b(2)\u9ad4\u91cd\u4e0b\u964d9.2\u516c\u65a4,\u7d04\u53ef\u4ee5\u964d\u4f4e\u8212\u5f35\u58d33.1 mmHg\uff1b(3)\u9650\u5236\u98df\u9e7d(NaCl)\u6bcf\u65e5\u651d\u53d6\u91cf4.4~7.4 \u514b[75~125meq],\u53ef\u4ee5\u4e0b\u964d\u6536\u7e2e\u58d3\u7d043.7~4.9 mmHg\uff1b(4)\u9650\u5236\u98df\u9e7d(NaCl)\u6bcf\u65e5\u651d\u53d6\u91cf4.4~7.4\u514b[75~125meq],\u53ef\u4ee5\u4e0b\u964d\u8212\u5f35\u58d3\u7d040.9~2.9 mmHg\uff1b(5)\u6839\u64da\u6587\u737b\u300cDietary Approaches to Stop Hypertension (DASH) trial\u300d,\u98df\u7528\u5bcc\u542b\u6c34\u679c,\u852c\u83dc\u8207\u9ad8\u6cb9\u8102\u985e\u98df\u7269\u6709\u52a9\u65bc\u6539\u5584\u8f15\u75c7\u9ad8\u8840\u58d3\u60a3\u8005\u8840\u58d3\u63a7\u5236\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-15.\n\u6709\u95dc\u8840\u58d3\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u817f(leg)\u7684\u6536\u7e2e\u58d3\u901a\u5e38\u6bd4\u4e0a\u81c2(upper arm)\u7684\u6536\u7e2e\u58d3\u9ad8 20 mmHg\nB. \u817f\u8207\u4e0a\u81c2\u7684\u8840\u58d3\u5dee\u589e\u52a0\u5e38\u898b\u65bc\u91cd\u5ea6\u4e3b\u52d5\u8108\u9589\u9396\u4e0d\u5168(aortic regurgitation)\u6216\u56b4\u91cd\u4e0b\u80a2\u9031\u908a\u8840\u7ba1\u75be\u75c5\nC. \u56b4\u91cd\u4e3b\u52d5\u8108\u9589\u9396\u4e0d\u5168\u60a3\u8005,\u8212\u5f35\u58d3\u6e2c\u91cf\u503c\u6709\u53ef\u80fd\u70ba0 \u6beb\u7c73\u6c5e\u67f1\nD. \u5169\u5074\u4e0a\u81c2\u7684\u6536\u7e2e\u8840\u58d3\u5dee,\u6b63\u5e38\u572810\u6beb\u7c73\u6c5e\u67f1\u4ee5\u5167\nE. \u59ff\u52e2\u6027\u4f4e\u8840\u58d3(Orthostatic hypotension)\u7684\u5b9a\u7fa9\u70ba:\u5f9e\u81e5\u59ff(supine position)\u8b8a\u70ba\u7acb\u59ff(upright posture)\u4e09\u5206\u9418\u5167,\u6536\u7e2e\u58d3\u4e0b\u964d15\u6beb\u7c73\u6c5e\u67f1\u6216\u8212\u5f35\u58d3\u4e0b\u964d5\u6beb\u7c73\u6c5e\u67f1\n": "(E)", "106-16.\n\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84(mitral stenosis)\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u964d\u81f31~1.5\u5e73\u65b9\u516c\u5206\u6642,\u975c\u6b62\u72c0\u614b\u4e0b\u4e4b\u5fc3\u8f38\u51fa\u91cf(cardiac output)\u63a5\u8fd1\u6b63\u5e38\nB. \u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u5c0f\u65bc1\u5e73\u65b9\u516c\u5206\u6642,\u975c\u6b62\u72c0\u614b\u4e0b\u4e4b\u5fc3\u8f38\u51fa\u91cf\u4fbf\u5df2\u7d93\u4f4e\u65bc\u6b63\u5e38(subnormal)\nC. \u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u665a\u671f\u7684\u75c5\u4eba,\u53cd\u8986\u6027\u80ba\u52d5\u8108\u6813\u585e (recurrent pulmonary embolization)\u4e0d\u662f\u9020\u6210\u7f79\u75c5\u8207\u6b7b\u4ea1(morbidity and mortality)\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\nD. \u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u5408\u4f75\u5fc3\u623f\u986b\u52d5\u7684\u75c5\u4eba,\u5168\u8eab\u6027\u6813\u585e(systemic embolization) \u7684\u767c\u751f\u7387(incidence)\u70ba10~20%\nE. \u8f15\u5ea6\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u4e14\u81e8\u5e8a\u7121\u75c7\u72c0\u7684\u75c5\u4eba,\u5168\u8eab\u6027\u6813\u585e\u6709\u53ef\u80fd\u662f\u81e8\u5e8a\u51fa\u73fe\u7684\u8868\u5fb5 (presenting feature)\n": "(C)", "106-17.\n\u4e00\u540d30\u6b72\u7537\u6027\u5230\u9580\u8a3a\u6c42\u8a3a;\u7121\u5fc3\u60b8\u6642\u9580\u8a3a\u5fc3\u96fb\u5716\u5982\u9644\u5716A,\u5fc3\u60b8\u6642\u5fc3\u96fb\u5716\u5982\u9644\u5716B. \u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?(1)\u9644\u5716A \u5fc3\u96fb\u5716\u5448\u73fe\u7e2e\u77ed\u7684PR\u9593\u8ddd (shortened PR interval)\uff1b(2)\u9644\u5716A\u5fc3\u96fb\u5716\u5448\u73fe Epsilon \u6ce2 (Epsilon wave)\uff1b(3)\u9644\u5716B\u70ba\u5fc3\u5ba4\u983b\u8108 (ventricular tachycardia)\uff1b(4)\u7576\u75c5\u4eba\u5fc3\u60b8\u5448\u73fe\u9644\u5716B\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u6642,\u4e0d\u53ef\u4ee5\u65bd\u6253verapamil\uff1b(5)\u7576\u75c5\u4eba\u5fc3\u60b8\u5448\u73fe\u9644\u5716B\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u6642,\u53ef\u4ee5\u65bd\u6253adenosine\nA. (1)+(5)\nB. (2)+(4)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)\nE. (2)+(3)+(5)\n": "(E)", "106-18.\n\u6839\u64da\u7d71\u5408\u5206\u6790(meta-analysis),\u904b\u52d5\u5fc3\u96fb\u5716\u7684\u654f\u611f\u5ea6(sensitivity)\u70ba66%, \u5c08\u4e00\u5ea6(specificity)\u70ba84%. \u6709\u4e00\u4f4d\u75c5\u60a3\u4e4b\u51a0\u5fc3\u75c7\u6e2c\u524d\u6a5f\u7387(pretest probability)\u70ba10%; \u8acb\u554f\u6839\u64da\u8c9d\u6c0f\u5b9a\u7406 (Bayes' Rule), \u7576\u904b\u52d5\u5fc3\u96fb\u5716\u5448\u967d\u6027\u7d50\u679c\u6642,\u8a72\u75c5\u60a3\u4e4b\u6e2c\u5f8c\u6a5f\u7387(posttest probability)\u7d04\u70ba?\nA. 95%\nB. 70%\nC. 50%\nD. 30%\nE. 10%\n": "(D)", "106-19.\n\u6709\u95dcHACEK(Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) \u5fc3\u5167\u819c\u767c\u708e\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u9019\u4e9b\u683c\u862d\u6c0f\u9670\u6027\u7d30\u83cc\u7684\u57f9\u990a\u74b0\u5883\u9700\u8981\u4e8c\u6c27\u5316\u78b3\nB. \u6700\u5e38\u4fb5\u72af\u4e3b\u52d5\u8108\u74e3\u8207\u4e8c\u5c16\u74e3(mitral valve)\nC. \u8207\u975eHACEK\u611f\u67d3\u4e4b\u5fc3\u5167\u819c\u708e(Non-HACEK endocarditis)\u6bd4\u8f03, HACEK\u5fc3\u5167\u819c\u708e\u8f03\u4e0d\u5bb9\u6613\u7522\u751f\u6813\u585e (embolization)\nD. \u7d04\u670985%\u7684HACEK\u5fc3\u5167\u819c\u708e\u75c5\u60a3\u505a\u5fc3\u81df\u8d85\u97f3\u6ce2\u6642,\u53ef\u4ee5\u898b\u5230\u8d05\u751f\u7269(vegetation)\nE. \u96a8\u8457\u57f9\u990a\u6280\u8853\u7684\u6539\u826f,\u5927\u90e8\u5206HACEK\u7d30\u83cc\u7684\u57f9\u990a,\u4e00\u822c\u5728\u7b2c\u4e00\u9031\u4fbf\u6703\u5448\u73fe\u967d\u6027.\n": "(C)", "106-20.\n\u4e00\u4f4d42\u6b72\u5973\u6027\u75c5\u60a3,\u4e3b\u8a34\u8eba\u81e5\u6642\u67d0\u7279\u5b9a\u59ff\u52e2\u6703\u4f34\u96a8\u773c\u524d\u767c\u9ed1\u7684\u5fb5\u5146(black out)\u3002\u81e8\u5e8a\u4e0a\u75c7\u72c0\u9084\u5305\u62ec\u5026\u6020,\u9ad4\u91cd\u6e1b\u8f15\u8eab\u9ad4\u6aa2\u67e5\u6642,\u5fc3\u81df\u807d\u8a3a\u65bc\u5fc3\u5c16\u90e8\u8212\u5f35\u4e2d\u671f\u6709\u4e00\u4f4e\u983b\u5fc3\u97f3,\u4e26\u6709\u8f15\u5fae\u6775\u72c0\u6307 (digital clubbing)\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982\u9644\u5716,A\u5716\u70ba\u5fc3\u5ba4\u6536\u7e2e\u671f\u5448\u50cf,B\u5716\u70ba\u5fc3\u5ba4\u8212\u5f35\u671f\u5448\u50cf [RA=\u53f3\u5fc3\u623f;RV=\u53f3\u5fc3\u5ba4;LV=\u5de6\u5fc3\u5ba4]\u3002\u8acb\u554f\u8a72\u75c5\u60a3\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba?\nA. \u98a8\u6fd5\u6027\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84(Rheumatic mitral stenosis)\nB. \u5de6\u5fc3\u5ba4\u5047\u6027\u5ba4\u58c1\u7624(left ventricular pseudoaneurysm)\nC. \u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u5408\u4f75\u4e8c\u5c16\u74e3\u8d05\u751f\u7269(mitral vegetation)\nD. \u5de6\u5fc3\u623f\u9ecf\u6db2\u7624 (left atrial myxoma)\nE. \u809d\u7d30\u80de\u764c\u5408\u4f75\u53f3\u5fc3\u623f\u8f49\u79fb\n": "(D)", "106-21.\n\u4e0b\u5217\u54ea\u4e9b\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\u53ef\u4ee5\u7528\u4f86\u6539\u5584\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction)\u4e4b\u9810\u5f8c?(1)carvedilol\uff1b(2)bisoprolol\uff1b(3)metoprolol succinate\uff1b(4)xamoterol\uff1b(5)propranolol\nA. (3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (1)+(2)+(5)\nD. (2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "106-22.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u5fc3\u5ba4\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u751f24\u5c0f\u6642\u5167,\u75c5\u60a3\u5e38\u5e38\u7121\u9810\u8b66\u7684\u767c\u751f\u5fc3\u5ba4\u983b\u8108(ventricular tachycardia) \u6216\u5fc3\u5ba4\u986b\u52d5 (ventricular fibrillation)\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u751f24\u5c0f\u6642\u5167,\u5373\u4f7f\u672a\u767c\u751f\u5fc3\u5ba4\u5fc3\u5f8b\u4e0d\u6574,\u4ecd\u61c9\u5e38\u898f\u9810\u9632\u6027\u7d66\u4e88\u75c5\u60a3lidocaine\nC. \u6025\u6027\u5fc3\u808c\u6897\u585e48\u5c0f\u6642\u5f8c,\u5982\u679c\u75c5\u60a3\u56e0\u5fc3\u81df\u8870\u7aed\u800c\u767c\u751f\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5;\u5176\u4f4f\u9662\u6b7b\u4ea1\u7387\u6216\u9577\u671f\u8ffd\u8e64\u4e4b\u6b7b\u4ea1\u7387\u5747\u589e\u52a0\nD. Torsades des pointes \u9019\u7a2e\u5fc3\u5ba4\u983b\u8108,\u53ef\u4ee5\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u767c\u751f\nE. \u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u767c\u751f\u4e4b\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5,\u5982\u679c\u5c0d\u96fb\u64ca(electroshock)\u7121\u6548\u6642,\u7d66\u4e88\u75c5\u60a3amiodarone, \u6709\u53ef\u80fd\u6539\u5584\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5\u5c0d\u96fb\u64ca\u6cbb\u7642\u7684\u53cd\u61c9\n": "(B)", "107-1.\n\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b (cardiogenic shock) \u7684\u81e8\u5e8a\u8a8d\u77e5\uff0c \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5fc3\u56e0\u6027\u4f11\u514b\u8d85\u904e50%\u767c\u751f\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u7684\u7b2c\u4e00\u5929\uff0c\u5176\u5f8c\u7684\u4f11\u514b\u591a\u8207\u5fc3\u808c\u6897\u585e\u64f4\u5927\u3001\u5fc3\u8870\u7aed\u6216\u6a5f\u68b0\u6027\u4f75\u767c\u75c7\u6709\u95dc\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u767c\u751f\u5fc3\u56e0\u6027\u4f11\u514b\u6642\uff0c\u5118\u65e9\u63a1\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66\u7642\u6cd5(Intra-aortic balloon counter-pulsation)\uff0c\u624d\u80fd\u964d\u4f4e\u6b7b\u4ea1\u7387\nC. \u53f3\u5fc3\u5ba4\u5fc3\u808c\u6897\u585e\u5408\u4f75\u4f11\u514b\u61c9\u7a4d\u6975\u4f7f\u7528\u5152\u8336\u915a\u80fa (catecholamine)\uff0c\u66a2\u901a\u6813\u585e\u8840\u7ba1\u53ca\u5145\u5206\u6c34\u5206\u88dc\u91cf\nD. \u5fc3\u5ba4\u4e2d\u9694\u7834\u640d(ventricular septal rupture) \u7684\u4f11\u514b\u591a\u767c\u751f\u5728\u5fc3\u808c\u6897\u585e\u5f8c\u6578\u5929\uff0c\u800c\u975e\u6975\u65e9\u7684\u6578\u5c0f\u6642\u5167\nE. \u904e\u534a\u7684\u5fc3\u56e0\u6027\u4f11\u514b\u591a\u56e0\u524d\u58c1\u5fc3\u808c\u6897\u585e\u800c\u8d77\n": "(B)", "107-2.\n\u88dd\u7f6e\u690d\u5165\u5f0f\u53bb\u986b\u5668(Implantable Cardioverter Defibrillator, ICD) \u53ef\u521d\u7d1a\u9810\u9632 (primary prevention)\u5fc3\u731d\u6b7b (Sudden Cardiac Death, SCD) \u7684\u767c\u4f5c\uff0c\u552f\u4e0b\u5217\u4f55\u8005\u4e4b\u8655\u7f6e\u4e0d\u7b26\u5408\u5be6\u8a3c\u91ab\u5b78\uff1f\nA. \u6025\u6027\u5fc3\u808c\u6897\u585e40\u5929\u5f8c\uff0c\u75c5\u4eba\u67092-3\u7d1aNYHA Heart failure\u4e4b\u75c7\u72c0\uff0c\u4e14\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387 (Left Ventricular Ejection Fraction, LVEF) <=35%\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e40\u5929\u5167\u7684\u75c5\u4eba\u5982\u6709\u975e\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108\r\n(non-sustained ventricular tachycardia), LVEF <40%\u53ca\u96fb\u8a98\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108 (sustained VT) \u5f97\u88dd\u7f6eICD\nC. \u516d\u5341\u6b72\u75c5\u4eba\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\u4e00\u500b\u6708\u5167\uff0cLVEF < 35%\nD. \u975e\u7f3a\u8840\u6027\u64f4\u5927\u6027\u5fc3\u808c(dilated cardiomyopathy)\u75c5\u4eba\u5176LVEF <= 35% \u76842-3\u7d1aNYHA\u5fc3\u8870\u7aed\uff0c\u85e5\u7269\u6cbb\u7642\u4e2d\nE. \u80a5\u539a\u6027\u5fc3\u808c\u75c5\u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u4eba\uff0c\u4e14\u6709\u975e\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108\u8a18\u9304\n": "(C)", "107-3.\n\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (atrial fibrillation, AF) \u7684\u81e8\u5e8a\u89c0\u5bdf\uff0c\u4e0b\u5217\u4f55\u7d44\u7684\u6558\u8ff0\u662f\u6b63\u78ba\u7684\uff1f(1).\tAF\u767c\u4f5c\u6642\u9593\u4e0d\u660e\u6216\u5927\u65bc\u4e8c\u65e5\uff0c\u61c9\u5728\u96fb\u64ca(electric cardioversion)\u524d\u5c31\u555f\u7528\u6297\u51dd\u8840\u85e5\u7269\uff0c\u4ee5\u9632\u8840\u6813\u7684\u7a81\u767c (2).\t\u4e8c\u5c16\u74e3\u72f9\u7a84(mitral stenosis)\u4f75\u6709AF\u7684\u75c5\u4eba\u50c5\u53eawarfarin\u6cbb\u7642\u6709\u6548 (3). warfarin\u9060\u6bd4aspirin + clopidogrel\u66f4\u80fd\u9810\u9632AF\u76f8\u95dc\u8166\u4e2d\u98a8 (4). \u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u9060\u6bd4wafarin\u5b89\u5168\u6709\u6548 (5).\tAF\u7d93\u96fb\u64ca\u56de\u5fa9\u6b63\u5e38\u5fc3\u5f8b\uff0c\u81f3\u5c11\u61c9\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u56db\u9031\uff0c\u5176\u5f8c\u4f9d\u7167CHADS2-VASc\u6c7a\u5b9a\u6297\u51dd\u8840\u85e5\u7269\u4e4b\u4f7f\u7528\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(2)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "107-4.\n\u6709\u95dcST\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e(ST Elevation Myocardial Infarction,STEMI)\u7684\u81e8\u5e8a\u6240\u898b\uff0c\u4e0b\u5217\u4f55\u8005\u8a18\u8ff0\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u75c5\u4eba\u4f4f\u966248\u5c0f\u6642\u5f8c\u5982\u4f75\u5fc3\u5ba4\u6027\u986b\u52d5\u6216\u983b\u8108\uff0c\u5728\u5f8c\u4f86\u7684\u75c5\u7a0b\u6703\u6709\u6975\u9ad8\u7684\u6b7b\u4ea1\u7387\uff0c\u61c9\u7a4d\u6975\u96fb\u6c23\u751f\u7406\u6aa2\u67e5\u53ca\u7f6e\u653e\u690d\u5165\u5f0f\u53bb\u986b\u5668(Implantable Cardioverter Defibrillator)\nB. \u5fc3\u5ba4\u6027\u986b\u52d5\u591a\u767c\u751f\u5728\u6025\u75c5\u5f8c\u7b2c\u4e00\u5929\uff0c\u6709\u904e\u534a\u5728\u7b2c\u4e00\u5c0f\u6642\uff0c\u662f\u9662\u5916\u6025\u6027\u731d\u6b7b\u7684\u4e3b\u56e0\nC. STEMI\u662f\u5fc3\u96fb\u5716\u8a3a\u65b7\uff0c\u5176\u75c5\u7406\u751f\u7406\u7684\u610f\u7fa9\u662f\u8840\u7ba1\u5b8c\u5168\u963b\u585e(complete occlusion)\uff0c\u4e14\u662f\u5fc3\u5ba4\u5fc3\u808c\u7684\u5168\u58c1\u58de\u6b7b(transmural necrosis)\nD. \u80a5\u539a(thick)\u7684\u8102\u8cea\u6838\u5fc3\u6591\u584a(lipid core plaque)\u8f03\u6613\u7834\u88c2\uff0c\u4ee5\u81f4STEMI\u7684\u767c\u751f\nE. \u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u4f5c\u4e00\u5c0f\u6642\u5167, \u524d\u58c1\u6897\u585e\u67091/4\u4f34\u767c\u5feb\u8df3\u53ca\u9ad8\u8840\u58d3\u7684\u4ea4\u611f\u795e\u7d93\u4ea2\u5f35\uff0c\u800c\u4e0b\u58c1\u6897\u585e\u67091/2\u6703\u6709\u6162\u8df3\u53ca\u4f4e\u8840\u58d3\u7684\u526f\u4ea4\u611f\u795e\u7d93\u4ea2\u5f35\n": "(D)", "107-5.\n\u80ba\u52d5\u8108\u9ad8\u58d3\uff08pulmonary hypertension)\u7684\u75c7\u72c0\u4e0d\u4e00\uff0c\u9032\u5c55\u7de9\u6162\uff0c\u81e8\u5e8a\u8a3a\u7642\u6700\u6613\u5ffd\u7565\uff0c\u552f\u65e9\u671f\u75c5\u7a0b\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u662d\u7136\u82e5\u63ed\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8a3a\u5bdf\u8981\u9ede\uff1f\nA. \u9838\u975c\u8108\u6d6e\u5f35\u3001\u4e0b\u80a2\u6c34\u816b\u53ca\u8179\u6c34\nB. P2\u5fc3\u97f3\u91cd\u97ff\uff08accentuation\uff09\u53ca\u53f3\u5fc3S3\u6216S4\nC. \u6709\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u5168\u5fc3\u7e2e\u671f\u96dc\u97f3\u53ef\u805e\nD. \u5de6\u5fc3\u5ba4\u58d3\u529b\u904e\u5ea6\u8ca0\u8f09\uff08left ventricular pressure overloading\uff09\nE. \u6bdb\u7d30\u7ba1\u64f4\u5f35\uff08telangiectasia\uff09\u3001\u767c\u7d3a\uff08clubbing\uff09\u6216\u786c\u76ae\u75c7\uff08sclerodactylia)\n": "(D)", "107-6.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u81df\u96fb\u98a8\u66b4\uff08electrical storm\uff09\u7684\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u7642\u6cd5\u662f\u4e0d\u9700\u8981\u7684\uff1f\nA. \u6025\u7528beta-blocker, amiodarone, lidocaine\nB. \u5fc3\u96fb\u5716\u5448\u73feQT prolongation \u76f8\u95dc\u7684 torsade de pointes \u6642\u53ef\u7528\u975c\u6ce8magnesium\nC. \u6c92\u6709QT prolongation \u7684\u96fb\u98a8\u66b4\u53ef\u4ee5quinidine \u6216isoproterenol\u6cbb\u7642\nD. \u53ef\u63a1\u7528\u5de6\u661f\u72c0\u795e\u7d93\u7d50\u7bc0\u5207\u65b7\u8853(left satellite ganglion block)\nE. \u61c9\u4f7f\u7528\u5de6\u5fc3\u5ba4\u8f14\u52a9\u5668(left ventricular assist device)\n": "(E)", "107-7.\n76\u6b72\u8001\u5148\u751f\u56e0\u6709\u4e00\u500b\u6708\u547c\u5438\u56f0\u96e3\u53ca\u5de6\u4e0b\u8173\u6c34\u816b\u800c\u4f4f\u9662\uff0c\u75c7\u72c0\u56e0\u7528\u529b\u5de5\u4f5c\u800c\u52a0\u5287\uff0c\u8981\u4f11\u606f\u624d\u80fd\u7de9\u89e3\uff0c\u8a3a\u9593\u767c\u73fe\u5de6\u9838\u6709\u816b\u584a\u53ca\u5de6\u9838\u975c\u8108\u6012\u5f35\uff0c\u540c\u6642\u8072\u555e\u72c0\u3002BP:179/79 mmHg; VR:76/min; RR:18/min; SpO2=93%\uff0c\u5fc3\u5c16\u8655\u6709Gr 2/6 systolic murmur;\u80ba\u90e8\u6b63\u5e38\u547c\u5438\u8072\uff0c\u96d9\u4e0b\u80a2\u6c34\u816b\uff0c\u5de6\u908a\u6bd4\u53f3\u908a\u56b4\u91cd\u3002\u8840\u6db2\u6c23\u9ad4\u5206\u6790\u986f\u793a pH\uff1a7.384; pO2: 87.8mmHg; pCO2\uff1a46.7 mmHg; HCO3\uff1a27.2 mmol/L\u3002\u4f4f\u9662\u8840\u6db2\u6aa2\u67e5\uff1aWBC\uff1a3.77x10*3/uL; RBC\uff1a5.1x10*6/uL; Hb:16.4 gm/dL; Platelet: 49x10*3/ul; (\u8a73\u898b\u9644\u8868)\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\uff1aLVEDD 56mm; LVESD 34mm; LVEF: 70%; LA:\r40mm; TR max PG: 35 mmHg; \u9838\u7624\u5207\u7247\u6aa2\u67e5\u75c5\u7406\u8a3a\u65b7\uff1aLymphoma\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\uff1f\nA. Acute myocardial infarction\nB. May-Thurner syndrome with pulmonary thromboembolism\nC. Thoracic aortic dissection\nD. Tumor-associated hypercoagulopathy and pulmonary embolism.\nE. Hypertensive cardiovascular disease with HFpEF\n": "(D)", "107-8.\n\u6709\u95dc\u5fc3\u5167\u819c\u708e\u7684\u81e8\u5e8a\u8a3a\u7642\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u8840\u6db2\u7d30\u83cc\u57f9\u990a\u81f3\u5c11\u9700\u8981\u67093~4\u6b21\u4ee5\u4e0a\u5728\u4e0d\u540c\u4f4d\u7f6e\u7684\u8840\u7ba1\u63a1\u8840\uff0c\u4e14\u7b2c\u4e00\u53ca\u6700\u5f8c\u4e00\u6b21\u81f3\u5c11\u9593\u9694\u4e00\u5c0f\u6642\nB. \u5148\u5929\u6027\u5fc3\u81df\u75c5\u3001\u5fc3\u74e3\u819c\u7f6e\u653e\u624b\u8853\u5f8c\u6216\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u8005\u9032\u884c\u690d\u7259\u624b\u8853\u6642\uff0c\u5b9c\u6709\u9810\u9632\u6027\u6297\u751f\u7d20\u6cbb\u7642\nC. S. aureus \u53caCoagulase negative staphylococcus \u4e0d\u61c9\u50c5\u53ea\u4f7f\u7528methicillin \u6cbb\u7642\nD. \u8840\u6813\u75c7\u72c0\u662f\u5fc3\u5167\u819c\u708e\u7684\u8a3a\u65b7\u91cd\u9ede\uff0c\u5176\u767c\u751f\u90fd\u5728\u6cbb\u7642\u524d\u767c\u751f\uff0c\u76e1\u65e9\u4f7f\u7528\u6709\u6548\u6297\u751f\u7d20\u5c31\u4e0d\u6703\u767c\u751f\u6b64\u4f75\u767c\u75c7\nE. \u5fc3\u5167\u819c\u708e\u4f75\u767c\u8166\u6813\u585e\u61c9\u67094-6\u9031\u6297\u751f\u7d20\u4f7f\u7528\uff0c\u624d\u53ef\u9032\u884c\u5fc5\u8981\u7684\u5916\u79d1\u624b\u8853\n": "(D)", "107-9.\n\u4f9d\u7167\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u53f0\u7063\u9ad8\u8840\u58d3\u5b78\u6703\u65bc2017\u5ea6\u516c\u4f48\u91cd\u9ede\u66f4\u65b0\u9ad8\u8840\u58d3\u6cbb\u7642\u6307\u5f15,\u8acb\u554f\u4ee5\u4e0b\u9805\u76ee\u4f55\u8005\u4e0d\u662f\u53f0\u7063\u91ab\u754c\u964d\u58d3\u76ee\u6a19(Target)\u7684\u4e3b\u5f35\uff1f\nA. \u4e0d\u56e0\u6027\u5225\u6216\u5e74\u9f61\uff0c\u964d\u58d3\u76ee\u6a19\u8a2d\u5728130/80 mmHg\nB. \u521d\u7d1a\u9810\u9632(Primary prevention)\u8a2d\u5728140/90 mmHg \u4ee5\u4e0b\nC. \u8166\u4e2d\u98a8\u75c5\u4eba\u4e4b\u6b21\u7d1a\u9810\u9632(Secondary prevention) \u8a2d\u5728140/90 mmHg \u4ee5\u4e0b\nD. \u7cd6\u5c3f\u75c5\u4eba\u4e4b\u6b21\u7d1a\u9810\u9632\u8a2d\u5728130/80 mmHg\u4ee5\u4e0b\nE. \u51a0\u5fc3\u75c7\u75c5\u4eba\u7684\u6b21\u7d1a\u9810\u9632\u5728130/80  mmHg\u4ee5\u4e0b\n": "(A)", "107-10.\n42\u6b72\u7537\u6027\uff0c\u81ea\u5e74\u8f15\u6642\u5019\u6642\u6709\u611f\u5192\u75c7\u72c0\uff0c\u8fd1\u4f86\u6f38\u6709\u547c\u5438\u56f0\u96e3\uff0c\u9032\u800c\u5c0b\u91ab\u6cbb\u75c5\uff0c\u7d93\u5fc3\u81df\u8d85\u97f3\u6ce2\u8a3a\u65b7\u4e26\u4f4f\u9662\u8655\u7f6e\u3002\u8eab\u9ad4\u6aa2\u67e5: BP\uff1a116/61 mmHg; PR\uff1a61/min; RR\uff1a18/min; \u9838\u975c\u8108\u6b63\u5e38\uff1b\u80ba\u547c\u5438\u97f3\u6b63\u5e38\u6e05\u6f88\uff1b\u5fc3\u81df\u6b63\u5e38\u5927\u5c0f\uff0cS1\u91cd\u97ff\uff0c\u5728\u5fc3\u5c16\u6709 Gr 2-3/6 mid-diastolic murmur \uff1b\u8179\u90e8\u672a\u898b\u809d\u3001\u813e\u816b\u5927\uff1b\u96d9\u817f\u672a\u6709\u6c34\u816b\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\u5176\u8840\u6db2\u53ca\u751f\u5316\u6aa2\u67e5\u672a\u6709\u7570\u5e38\u3002\u552f\u5176\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5982\u5716\u3002\u7d93\u904e\u56db\u5929\u904e\u7a0b\u5e73\u9806\u51fa\u9662\u3002\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u672c\u75c5\u4eba\u7684\u8655\u7f6e\u662f\u6b63\u78ba\u7684\uff1f (1). \u75c5\u4eba\u61c9\u4f7f\u7528beta-blocker \u63a7\u5236\u5fc3\u8df3 (2). \u53e3\u670d\u6297\u751f\u7d20\u9810\u9632\u5fc3\u5167\u819c\u708e\u4e4b\u767c\u751f\u662f\u5fc5\u8981\u7684 (3). \u53e3\u670dwarfarin\u8abf\u63a7INR\r(iInternational normalized ratio) \u4ecb\u65bc1\u00b75 -2\u00b75 \u70ba\u5b9c (4). \u6709\u9ad8\u51fa\u8840\u5371\u96aa\u8005\u5f97\u6309\u7167\u5be6\u8a3c\u91ab\u5b78\uff0c\u4f7f\u7528DOAC(direct oral anti-coagulant)   \u9810\u9632\u8840\u6813\u4e4b\u767c\u751f (5). \u672c\u75c5\u4eba\u4ee5\u9580\u8a3a\u8ffd\u8e64\u8655\u7f6e\u5373\u53ef (6). \u672c\u75c5\u4eba\u4ee5\u5916\u79d1\u7d44\u7e54\u74e3\u819c(tissue valve)\u7f6e\u63db\u624b\u8853\u70ba\u5b9c\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(4)+(6)\nD. (2)+(3)+(5)\nE. (2)+(3)+(6)\n": "(A)", "107-11.\n\u7121\u75c7\u72c0\u7684\u4e3b\u52d5\u8108\u74e3\u819c\u9589\u9396\u4e0d\u5168(aortic regurgitation)\uff0c\u53ef\u4f9d\u64da\u5e8a\u908a\u6240\u898b\u5224\u5b9a\u5176\u56b4\u91cd\u5ea6\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u53ef\uff1f\nA. \u5bec\u5927\u8108\u58d3 (pulse pressure)\u8d85\u904e\u5fc3\u7e2e\u8840\u58d3\u4e4b\u534a\u4ee5\u4e0a\nB. high-pitched blowing decrescendo diastolic murmur \u589e\u5f37\nC. \u51fa\u73feAustin-Flint murmur\nD. \u807d\u5230\u9ad8\u5f37\u5ea6\u7684ejection systolic murmur\nE. \u53f3\u5fc3\u5ba4\u5c04\u51fa\u7387\u4f4e\u65bc50% \u6216\u5de6\u5fc3\u5ba4\u5fc3\u7e2e\u76f4\u5f91\u5927\u65bc5cm\u53ca\u5fc3\u8212\u76f4\u5f91\u5927\u65bc6.5cm\n": "(D)", "107-12.\n\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u53ef\u51fa\u73fe\u5728\u4e0b\u5217\u75c7\u5019\u7fa4\uff0c\u4f55\u8005\u9664\u5916?\nA. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u75c7\u5019\u7fa4\u7b2c\u4e8c\u578bA (multiple endocrine neoplasia type 2A)\nB. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u75c7\u5019\u7fa4\u7b2c\u4e8c\u578b B (multiple endocrine neoplasia, type 2B)\nC. \u9022\u5e0c\u4f2f-\u6797\u9053\u75c7\u5019\u7fa4 (von Hippel-Lindau disease)\nD. \u7b2c\u4e00\u578b\u795e\u7d93\u7e96\u7dad\u7624 (neurofibromatosis type 1)\nE. \u7b2c\u4e8c\u578b\u795e\u7d93\u7e96\u7dad\u7624 (neurofibromatosis type 2)\n": "(E)", "107-13.\n\u5c0e\u81f4\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6591\u584a\u75c5\u7406\u6709\u4e0b\u5217\u7279\u5fb5\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u8584\u7684\u7e96\u7dad\u8868\u76ae\u84cb (thin fibrous cap)\nB. \u6591\u9ede\u72c0\u9223\u5316 (spotty calcification)\nC. \u5411\u5167\u91cd\u5851 (inward  remodeling)\nD. \u5927\u91cf\u7684\u5de8\u566c\u7d30\u80de (a high content of macrophages)\nE. \u76f8\u5c0d\u5927\u91cf\u7684\u8102\u80aa\u6838\u5fc3(relatively large lipid cores)\n": "(C)", "107-14.\n\u6709\u95dc\u98a8\u6fd5\u6027\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u7406\u5b78\u6aa2\u67e5\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u521d\u671f,\u7b2c\u4e00\u5fc3\u97f3\u6703\u52a0\u91cd\nB. \u7b2c\u4e8c\u5fc3\u97f3\u8207\u958b\u74e3\u97f3(opening snap, OS)\u7684\u9593\u8ddd(A2-OS interval), \u8207\u5de6\u5fc3\u623f\u8ddf\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u58d3\u529b\u5dee\u6210\u6b63\u6bd4\nC. \u60a3\u8005\u81c9\u90e8\u53ef\u4ee5\u51fa\u73fe\u9874\u9830\u6f6e\u7d05 (malar rush)\nD. \u5728\u5fc3\u5c16\u90e8\u53ef\u4ee5\u807d\u5230\u4f4e\u983b\u7684\u9686\u9686\u8212\u5f35\u671f\u96dc\u97f3 (a low pitched, rumbling, diastolic murmur)\nE. \u7576\u5408\u4f75\u53f3\u5fc3\u8870\u7aed\u6642\uff0c\u53ef\u4ee5\u51fa\u73fe\u809d\u816b\u5927\u8207\u8173\u8e1d\u6c34\u816b\n": "(B)", "107-15.\n\u6709\u95dc\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4\uff1f\nA. \u901a\u5e38\u4e3b\u52d5\u8108\u74e3\u958b\u53e3\u9762\u7a4d\u5c0f\u65bc1\u5e73\u65b9\u516c\u5206\u4ee5\u4e0b\u624d\u6703\u6709\u75c7\u72c0\nB. \u5230\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84\u672b\u671f\u6642,\u8108\u58d3 (pulse pressure)\u6703\u8b8a\u7a84\nC. \u807d\u8a3a\u6642,\u6709\u6642\u6703\u51fa\u73fe\u7b2c\u4e8c\u5fc3\u97f3\u5947\u7570\u5206\u88c2 (paradoxical splitting of S2),\u610f\u5373\u4e3b\u52d5\u819c\u74e3\u9589\u5408\u5fc3\u97f3\u6703\u6bd4\u80ba\u52d5\u8108\u74e3\u9589\u5408\u5fc3\u97f3\u665a\nD. \u807d\u8a3a\u6642,\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u7684\u6536\u7e2e\u671f\u96dc\u97f3\u6703\u50b3\u905e\u81f3\u5fc3\u5c16\u90e8\u4f4d,\u9020\u6210\u8207\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u96dc\u97f3\u4e0d\u5bb9\u6613\u5340\u5225\uff0c\u7a31\u4e4b\u70baGallavardin effect\nE. \u9223\u5316\u6027\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84(calcified aortic stenosis)\u662f\u4e00\u500b\u6f38\u9032\u60e1\u5316\u7684\u75be\u75c5, \u6bcf\u5e74\u5e73\u5747\u4e3b\u52d5\u8108\u74e3\u58d3\u529b\u5dee(mean aortic valvular pressure gradient)\u589e\u52a07\u6beb\u7c73\u6c5e\u67f1\n": "(D)", "107-16.\n\u6709\u95dc\u653e\u5c04\u7dda\u6cbb\u7642\u764c\u75c7\u6642\uff0c\u7167\u5c04\u5230\u5fc3\u81df\u7684\u5f71\u97ff\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4\uff1f\nA. \u653e\u5c04\u7dda\u5291\u91cf\u8d85\u904e 6000 cGy\u53c8\u5408\u4f75\u5fc3\u6bd2\u6027\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u6709\u8f03\u9ad8\u6a5f\u7387\u767c\u751f\u5fc3\u81df\u50b7\u5bb3\nB. \u6025\u6027\u653e\u5c04\u6027\u5fc3\u5305\u819c\u767c\u708e\u5e38\u5728\u653e\u5c04\u7dda\u6cbb\u76429\u500b\u6708\u5f8c\u767c\u751f\nC. \u6162\u6027\u675f\u7e2e\u6027\u5fc3\u5305\u819c\u708e (constrictive pericarditis)\u4e00\u822c\u5728\u653e\u5c04\u7dda\u6cbb\u76425-10\u5e74\u5f8c\u767c\u751f\nD. \u5e38\u9020\u6210\u4e3b\u52d5\u8108\u74e3\u6216\u4e8c\u5c16\u74e3\u74e3\u819c\u75be\u75c5\nE. \u4e0a\u534a\u8eab\u6597\u7bf7\u5f0f\u653e\u5c04\u7dda\u6cbb\u7642(mantle field radiation)\u4e0d\u6703\u589e\u52a0\u5fc3\u808c\u6897\u585e\u7684\u98a8\u96aa\n": "(E)", "107-17.\n\u4e00\u4f4d70\u6b72\u5973\u6027\u75c5\u60a3\u80f8\u75db1\u5c0f\u6642\u5230\u6025\u8a3a,\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\u8207\u9ad8\u8840\u7cd6;\u4f46\u8840\u58d3\u63a7\u5236\u4e0d\u826f\uff0c\u81f3\u6025\u8a3a\u6642\u8840\u58d3\u70ba160/100\u6beb\u7c73\u6c5e\u67f1\uff0c\u7cd6\u5316\u8840\u8272\u7d20\u6700\u8fd1\u6578\u503c\u70ba8.0%\uff0c\u6700\u8fd1\u7121\u51fa\u8840\u50be\u5411\u6216\u4e0a\u6d88\u5316\u51fa\u8840\u7d00\u9304\uff0c\u8840\u6c27\u98fd\u548c\u6fc3\u5ea6(SpO2) \u70ba98%.\u807d\u8a3a\u5fc3\u81df\u7121S3\u5954\u99ac\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u7121\u6fd5\u56c9\u97f3(moist rales)\u6216\u5598\u9cf4\u97f3(wheezing)\uff0c\u56db\u80a2\u76ae\u819a\u6eab\u6696\u4e14\u4e0b\u80a2\u7121\u6c34\u816b\uff0c\u5fc3\u96fb\u5716\u8207\u80f8\u90e8X\u5149\u7247\u5982\u5716\u4e00\u53ca\u5716\u4e8c\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f (1). \u8a72\u75c5\u60a3\u61c9\u8a72\u7acb\u523b\u81f3\u5fc3\u81df\u79d1\u4e00\u822c\u75c5\u623f\u4f4f\u9662,\u4f4f\u9662\u5f8c\u61c9\u7167\u6703\u5fc3\u81df\u79d1\u91ab\u5e2b (2). \u7d66\u4e88\u8a72\u75c5\u60a3\u963f\u65af\u5339\u9748 (aspirin) (3). \u56e0\u8840\u58d3\u904e\u9ad8,\u7d66\u4e88\u77ed\u6548\u9223\u96e2\u5b50\u963b\u65b7\u5291nifedipine 5mg \u4f86\u964d\u8840\u58d3 (4).\r\u53ef\u7d66\u4e88\u75c5\u4eba\u820c\u4e0bnitroglycerin (5).\u53ef\u7d66\u4e88\u75c5\u4eba\u4e59\u578b\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)+(4)+(5)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(2)+(4)+(5)\n": "(C)", "107-18.\n\u627f\u4e0a\u984c\uff0c\u8a72\u540d\u75c5\u60a3\u65bc\u51fa\u9662\u5f8c3\u500b\u6708\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387 (LVEF)\u70ba25%\uff0c\u8840\u6e05\u808c\u9150\u9178\u70ba1.1 mg/dl\uff0c\u8840\u6e05\u96fb\u89e3\u8cea\u7121\u7570\u5e38\uff0c\u722c\u4e00\u5c64\u6a13\u68af\u4e0d\u5230\u4fbf\u6703\u767c\u751f\u80f8\u60b6\u8ddf\u52d5\u5598\uff0c\u57282\u9031\u5f8c\u767c\u751f\u5230\u9662\u524d\u55aa\u5931\u751f\u547d\u5fb5\u72c0(out of hospital cardiac arrest)\uff0c\u7d93\u9001\u81f3\u6025\u8a3a\u56de\u5fa9\u751f\u547d\u8de1\u8c61\u8207\u610f\u8b58\uff0c\u4f4f\u9662\u5f8c\u505a\u4e86\u5fc3\u81df\u6838\u78c1\u5171\u632f\u6383\u63cf(late gadolinium enhancement)\u5982\u9644\u5716\u3002\u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u7684\u8655\u7406\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u9019\u500b\u75c5\u4eba\u660f\u5012\u7684\u539f\u56e0\u662f\u56e0\u5fc3\u5167\u819c\u4e0b\u7d50\u75a4 (subendocardial scar)\u800c\u767c\u751f\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5\nB. \u8a72\u75c5\u4eba\u63a5\u53d7\u53e3\u670d\u6bcf\u5929amiodarone 200 mg\u5f8c\u5373\u53ef\u56de\u5bb6\nC. \u8a72\u75c5\u4eba\u5982\u6301\u7e8c\u6709\u80f8\u60b6\u75c7\u72c0\uff0c\u61c9\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u51a0\u72c0\u52d5\u8108\u651d\u5f71.\nD. \u8a72\u75c5\u4eba\u61c9\u8a72\u63a5\u53d7\u690d\u5165\u5f0f\u53bb\u986b\u5668 (implantable cardioverter-defibrillator)\nE. \u8a72\u75c5\u60a3\u518d\u767c\u5fc3\u56e0\u6027\u731d\u6b7b\u6a5f\u7387\u9817\u9ad8\n": "(B)", "107-19.\n\u8acb\u554f\u6709\u95dc\u53e3\u670d\u6297\u51dd\u8840\u5291\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f(1). rivaroxaban \u4f5c\u7528\u65bcfactor Xa (2). apixaban\u4f5c\u7528\u65bcThrombin (3). edoxaban\u4f5c\u7528\u65bc factor Xa (4). dabigatran\u4f5c\u7528\u65bcfactor Xa (5).warfarin\u904e\u91cf\u5c0e\u81f4\u51fa\u8840\u4e0d\u6b62\u6642,\u53ef\u4ee5\u4f7f\u7528protamine sulfate\u4f86\u4e2d\u548cwarfarin\u4f5c\u7528\nA. (1)+(2)+(4)\nB. (1)+(3)+(5)\nC. (2)+(4)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(E)", "107-20.\n\u4e00\u4f4d54\u6b72\u5973\u6027\u56e0\u7a81\u767c\u6027\u5fc3\u60b8\u5230\u6025\u8a3a\u6c42\u8a3a\uff0c\u8840\u58d3\u70ba120/80\u6beb\u7c73\u6c5e\u67f1\uff0c\u5148\u524d\u7121\u75c7\u72c0\u6642\uff0c\u5fc3\u96fb\u5716\u5982\u5716\u4e00.\u5230\u6025\u8a3a\u6642\u5fc3\u96fb\u5716\u5982\u5716\u4e8c\u3002\u8acb\u554f\u6709\u95dc\u6b64\u5fc3\u5f8b\u4e0d\u6574\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f (1). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u8a3a\u65b7\u70ba\u5fc3\u5ba4\u983b\u8108(ventricular tachycardia) (2). \u623f\u5ba4\u7d50\u6298\u8fd4 (atrio-ventricular nodal reentry)\u53ef\u4ee5\u662f\u5c0e\u81f4\u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u6a5f\u8f49\u4e4b\u4e00 (3). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u53ef\u4ee5\u7528adenosine\u4f86\u6cbb\u7642 (4). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u53ef\u4ee5\u7528verapamil\u4f86\u6cbb\u7642 (5). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u6cbb\u7642\u61c9\u8a72\u7acb\u5373\u65bd\u884c100\u7126\u8033\u540c\u6b65\u96fb\u64ca\nA. (1)+(2)+(3)+(4)\nB. (2)+(5)\nC. (2)+(3)+(4)\nD. (1)+(5)\nE. (4)+(5)\n": "(D)", "107-21.\n\u4e00\u540d70\u6b72\u5a66\u5973\uff0c\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\uff0c\u9ad8\u8840\u8102\u4f46\u8840\u8102\u63a7\u5236\u4e0d\u826f (\u7e3d\u81bd\u56fa\u9187246 mg/dl\uff0c\u4e09\u9178\u7518\u6cb9\u8102411 mg/dl\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 39 mg/dl) \u7cd6\u5c3f\u75c5\u4f46\u8840\u7cd6\u63a7\u5236\u4e0d\u826f(\u98ef\u524d\u8840\u7cd6134 mg/dl\uff0c\u98ef\u5f8c\u8840\u7cd6304 mg/dl\uff0c\u7cd6\u5316\u8840\u8272\u7d20 8.1%)\uff0c\u904e\u53bb\u7121\u6d88\u5316\u9053\u6f70\u760d\u75be\u75c5\u75c5\u53f2\u6216\u51fa\u8840\u50be\u5411\uff0c\u65bc\u672c\u65e5\u6e05\u6668\u767c\u751f\u5de6\u80f8\u75db\u8f3b\u5c04\u81f3\u4e0b\u5df4\uff0c\u4f34\u96a8\u76dc\u6c57\uff0c\u670d\u7528\u4e09\u9846\u820c\u4e0b\u542b\u7247\u4ecd\u4e0d\u80fd\u7de9\u89e3\u80f8\u75db\uff0c4\u5c0f\u6642\u5f8c\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5e73\u65e5\u5fc3\u96fb\u5716\u5982\u5716\u4e00\uff0c\u81f3\u6025\u8a3a\u5fc3\u96fb\u5716\u5982\u5716\u4e8c\uff0c\u80f8\u90e8X\u5149\u7247\u5982\u5716\u4e09\uff0c\u81f3\u6025\u8a3a\u7b2c\u4e00\u6b21troponin T \u70ba560 ng/L(normal <14)\uff0cMB isoform of  creatine kinase (CKMB) \u70ba10.35 U/L (normal\r<4.88)\uff0c\u5230\u6025\u8a3a\u5f8c\u8840\u58d3\u70ba144 /86 mmHg\uff0c\u8840\u6c27\u6fc3\u5ea6\u70ba96 %\uff0c\u7406\u5b78\u6aa2\u67e5\u5fc3\u81df\u807d\u8a3a\u7121\u7b2c\u4e09\u5fc3\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u7121\u56c9\u97f3\uff0c\u4e0b\u80a2\u4e26\u7121\u6c34\u816b\uff0c\u91dd\u5c0d\u6b64\u75c5\u60a3\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u8a72\u75c5\u60a3\u8a3a\u65b7\u70ba\u4e0d\u7a69\u5b9a\u578b\u5fc3\u7d5e\u75db\uff0c\u800c\u975e\u5fc3\u808c\u6897\u585e\nB. \u8a72\u75c5\u60a3\u4e4b\u8a3a\u65b7\u7121\u6cd5\u78ba\u5b9a\u662f\u5426\u70ba\u6025\u6027\u51a0\u5fc3\u75c7 (acute coronary syndrome)\u56e0\u6b64\u61c9\u8a72\u5b89\u6392\u4e00\u500b\u904b\u52d5\u5fc3\u96fb\u5716\u6aa2\u67e5\nC. \u91dd\u5c0d\u6b64\u75c5\u60a3\u4e4b\u5fc3\u81df\u75be\u75c5\u8a3a\u65b7\uff0c\u8840\u6e05\u5fc3\u808c\u751f\u7269\u6a19\u8a18(serum cardiac biomarker)\u4e2d\uff0cCKMB\u654f\u611f\u5ea6\u9060\u9ad8\u65bctroponin  T\nD. \u8a72\u75c5\u60a3\u61c9\u8a72\u5728\u75c7\u72c0\u767c\u751f6\u5c0f\u6642\u5167\u7acb\u5373\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u8207\u51a0\u72c0\u52d5\u8108\u4ecb\u5165\u6027\u6cbb\u7642\nE. \u8a72\u75c5\u60a3\u61c9\u8a72\u63a5\u53d7\u96d9\u91cd\u6297\u8840\u5c0f\u677f\u85e5\u7269\u6cbb\u7642(dual anti-platelet therapy)\n": "(E)", "107-22.\n\u6709\u95dc\u4eba\u985e\u514d\u75ab\u7f3a\u9677\u75c5\u6bd2(human immunodeficiency virus; HIV)\u611f\u67d3\u5f8c\uff0c\u5fc3\u81df\u8840\u7ba1\u7cfb\u7d71\u5f71\u97ff\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u51a0\u5fc3\u75c7(coronary heart disease)\u662f\u6700\u5e38\u898b\u7684\u5f62\u5f0f (most common form)\nB. \u5728\u611f\u67d3\u665a\u671f\uff0c\u5e38\u767c\u751f\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u5408\u4f75\u9b31\u8840\u6027\u5fc3\u81df\u8870\u7aed\nC. \u53ef\u4ee5\u5fc3\u5305\u819c\u7a4d\u6c34\u4f86\u8868\u73fe\nD. \u53ef\u4ee5\u975e\u7d30\u83cc\u6027\u6813\u585e\u5fc3\u5167\u819c\u708e(nonbacterial thrombotic endocarditis)\u8868\u73fe\nE. \u5728\u6709HIV\u611f\u67d3(advanced HIV infection)\u5408\u4f75\u5fc3\u808c\u75c5\u8b8a\u7684\u75c5\u4eba,\u61c9\u5217\u5165\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5(MRI\u6216CT)\uff0c\u4f86\u6aa2\u67e5\u4e2d\u6a1e\u795e\u7d93\u5f13\u6f3f\u87f2\u611f\u67d3( CNS toxoplamosis)\n": "(B)", "108-1.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7(Acute myocardial infarction, AMI)\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic shock, CS)\u4f75\u767c\u75c7\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?\nA. \u5408\u4f75CS\u7684AMI\u670970%\u7684\u75c5\u4f8b\u5e38\u5448\u73fe\u591a\u689d\u5fc3\u8840\u7ba1\u7684\u56b4\u91cd\u75c5\u8b8a\uff0c\u5176\u4e00\u5e74\u5b58\u6d3b\u7387\u4e5f\u4e0d\u53ca50%\uff0c\u56e0\u6b64\u7dca\u6025\u7d93\u76ae\u51a0\u8108\u963b\u4ecb(PCI) \u6642\uff0c\u61c9\u5c07\u8087\u798d\u75c5\u8b8a(Culprit lesion)\u53ca\u975e\u8087\u798d\u75c5\u8b8a\uff0c\u4e00\u4f75\u540c\u6642\u5be6\u65bd\u5b8c\u6574\u6027\u8840\u7ba1\u518d\u901a\u8853(Complete revascularization)\nB. 80% CS\u90fd\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u800c\u8d77\uff0c STEMI \u6bd4NSTEMI\u591a\u898b\u53c8\u65e9\u898b\u4f75\u767cCS\nC. \u4f7f\u7528\u8449\u514b\u819c(ECMO), \u6709\u52a9\u975e\u8087\u798d\u75c5\u8b8a\u8840\u7ba1\u4e4b\u5fc3\u808c\u704c\u6ce8\uff0c\u53ef\u6e1b\u5c11\u50b7\u8b8a\uff0c\u4f46\u6cbb\u7642CS\u7684\u5b58\u6d3b\u5be6\u8a3c\u53ea\u6709IIb C\nD. \u4f7f\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66(Intra-aortic balloon counter-pulsation,IABP) \u7121\u52a9AMI\u7684CS\uff0c\u56e0\u6b64\u5fc3\u81df\u5b78\u6703\u4e0d\u63a8\u85a6\u5e38\u898f\u4f7f\u7528\nE. \u4f7f\u7528\u6a5f\u68b0\u6027\u8f14\u52a9\u5668(Mechanical support device)\u5982 Impella , TandemHeart\u6cbb\u7642CS\u4ecd\u820a\u672a\u5b9a\u8ad6\n": "(A)", "108-2.\n\u4f9d\u64da\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u9ad8\u8840\u58d3\u5b78\u67032017\u5e74\u516c\u4f48\u7684\u6307\u5f15\uff0c\u6709\u95dc\u9ad8\u8840\u58d3\u7684\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u53d7SPRINT\u81e8\u5e8a\u8a66\u9a57\u7d50\u8ad6\u7684\u5f71\u97ff,\u5169\u6703\u4e3b\u5f35\u63a1\u5f37\u5ea6\u8840\u58d3\u63a7\u5236\u7b56\u7565\nB. \u6210\u5e74\u4eba\u4e4b\u8840\u58d3\u9ad8\u65bc130/80 mmHg\u8996\u70ba\u9ad8\u8840\u58d3\nC. \u51a0\u8108\u786c\u5316\u6027\u5fc3\u81df\u75c5\u53ca\u7cd6\u5c3f\u75c5\u75c5\u4eba\u61c9\u63a7\u5236\u5728\u5c0f\u65bc130/80 mmHg\nD. \u5927\u65bc75\u6b72\u8001\u4eba\u5176\u8840\u58d3\u61c9\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\u70ba\u5b9c\nE. \u8166\u4e2d\u98a8\u75c5\u4eba\u73fe\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u8005\uff0c\u4ee5\u63a7\u5236\u5728130/80 mmHg \u4ee5\u4e0b\u70ba\u5b9c\n": "(B)", "108-3.\n\u6709\u95dc\u5fc3\u81df\u731d\u6b7b\uff08Sudden cardiac death)\u7684\u8aaa\u6cd5\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684?\nA. \u731d\u6b7b\u591a\u898b\u65bc\u6709\u51a0\u5fc3\u75c5\u7684\u7537\u6027\u75c5\u4eba\nB. \u731d\u6b7b\u7684\u767c\u751f\u591a\u898b\u65bc\u5fc3\u808c\u7f3a\u6c27\u6027\u5fc3\u5ba4\u6027\u7e96\u7dad\u986b\u52d5\uff08Ventricular fibrillation)\nC. \u51a0\u5fc3\u75c5\u4eba\u4e00\u500b\u6708\u524d\u7d93\u53d7\u76ae\u51a0\u8108\u4ecb\u5165\u6cbb\u7642(PCI) \uff0c\u5176\u5de6\u5fc3\u5ba4\u5c04\u51fa\u91cf\uff08Left ventricular ejection fraction, LVEF) 35%,\u5728\u96fb\u6c23\u751f\u7406\u6aa2\u67e5\u53c8\u672a\u6709\u8a98\u5c0e\u5fc3\u5f8b\u4e0d\u6574\uff0c\u5bb6\u65cf\u672a\u6709\u731d\u6b7b\u75c5\u53f2\u3002\u4f46\u70ba\u9810\u9632\u731d\u6b7b\u7684\u767c\u751f\uff0c\u5f97\u4ee5ICD (Intra-cardiac defibrillator) \u4f5c\u521d\u7d1a\u6cbb\u7642(Primary prevention)\nD. \u6d3b\u547d\u9810\u671f\u4e0d\u8db3\u4e00\u5e74\u7684\u75c5\u4eba\uff0c\u4e0d\u5fc5ICD \u6cbb\u7642\nE. \u5c31\u731d\u6b7b\u4e4b\u521d\u7d1a\u9810\u9632\uff0c\u4e00\u822c\u76f8\u4fe1\u751f\u6d3b\u65b9\u5f0f\u7684\u6539\u9020\u512a\u65bcICD\n": "(C)", "108-4.\n67\u6b72\u7537\u6027\u75c5\u4eba\u8207\u597d\u53cb\u71ac\u591c\u73a9\u9ebb\u5c07\uff0c\u7fcc\u65e59:13AM\u7a81\u7136\u5012\u5730\u6025\u6551\uff0c\u7d93119 EMT\u65bd\u884cCPR\uff0c26\u5206\u5167\u9001\u62b5\u6025\u8a3a\u8655\u3002\u4e2d\u9593\u6709\u591a\u6b21VT/VF\uff0c\u65bd\u884cDC shock 5\u6b21\uff0c\u5176\u5f8c\u7684\u75c5\u7a0b\u6709CPCR\u517156\u5206\u53ca\u96fb\u64ca9\u6b21\uff0c\u4f7f\u7528amiodarone + Lidocaine+ MgSO4\uff0c\u4e5f\u572850\u5206\u9418\u5167\u653e\u7f6eVA-ECMO\u3002\u7406\u5b78\u6aa2\u67e5: BT 35.4 \u00b0C; HR: 55 /min; RR: 20 /min; BP: 125/68mmHg\u81c9\u8272\u84bc\u767d\uff0c\u7121\u8ca7\u8840\uff0c\u80f8\u90e8\u7121\u7570\u5e38\uff0c\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u5fc3\u5c16\u640f\u672a\u5916\u79fb\uff0cS1\u6b63\u5e38\uff0c\u552f\u5728\u5fc3\u5c16\u53caLLSB\u6709Grade 3/6 systolic murmur\uff0c\u5176\u4ed6\u90e8\u4f4d\u672a\u898b\u7570\u5e38\u3002\r\u65e2\u5f80\u75c5\u53f2:1.2007\u5e74\u8a3a\u65b7\u5fc3\u81df\u75c5\u53ca\u5fc3\u5f8b\u4e0d\u6574\uff0c\u670d\u7528Propranolol\u7528\u30022. \u6bcf\u5929\u62bd\u71591.5\u5305,\u670940\u5e74\u4e4b\u4e45\u30023. \u559c\u597d\u9ad8\u6881\u9152\uff0c\u6bcf\u592930cc\u30024. \u7121\u5bb6\u65cf\u985e\u4f3c\u75c5\u53f2\u3002\u5176\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u651d\u5f71: \u51a0\u72c0\u52d5\u8108\u9020\u5f71\u6aa2\u67e5\u986f\u793a\u4e3b\u5e79\u53ca\u4e09\u5206\u679d\u66a2\u901a\uff0c\u672a\u6709\u8840\u6813\u963b\u585e\u3002\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u8207\u62bd\u8840\u8cc7\u6599(\u5982\u5716)\u6240\u793a\u3002\u4f9d\u4e0a\u8ff0\u75c5\u72c0\u53ca\u521d\u6b65\u6aa2\u67e5\uff0c\u5982\u60a8\u61c9\u6703\u8a3a\u7167\u6703\uff0c\u8acb\u554f\u9019\u4f4d\u75c5\u4eba\u767c\u751fOHCA(Out-hospital cardiac arrest) \u6700\u53ef\u80fd\u7684\u539f\u56e0\u662f:\nA. Acute myocardial infarction\nB. Septic shock\nC. Dilated cardiomyopathy\nD. Hypertrophic cardiomyopathy\nE. Brugada syndrome\n": "(D)", "108-5.\n44\u6b72\u7537\u4eba\u6709\u80f8\u75bc\u534a\u5c0f\u6642\u4e4b\u4e45\uff0c\u516b\u5c0f\u6642\u5f8c\u53c8\u6709\u80f8\u75bc\u4e43\u81f3\u91ab\u9662\u6c42\u8a3a\uff0c\u6025\u8a3a\u5167\u79d1\u91ab\u5e2b\u5728\u5fc3\u96fb\u5716(\u5982\u5716) \uff0c\u96a8\u5373\u555f\u52d5PCI team \u4e26\u7d66\u4e8eTicagrelor + Aspirin + Heparin \u3002\u75c5\u4eba\u6709\u5e73\u65e5\u591a\u62bd\u83f8\uff0c\u4e5f\u6b20\u7f3a\u904b\u52d5\u3002\u7406\u5b78\u6aa2\u67e5:BH: 174 cm, BW: 135 kg, BMI: 44.6 kg/m2; T: 36.3 \u00b0C, P: 97 bpm, R: 16 /min; BP:121/79 mmHg; \u5176\u4ed6\u4e26\u7121\u986f\u8457\u7570\u72c0\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u689d\u51a0\u72c0\u52d5\u8108\u6700\u53ef\u80fd\u7684\u8087\u798d\u8840\u7ba1\u8b8a\u5316(Culprit)\u6240\u5728\u662f?\nA. Normal coronary artery\nB. Left main lesion\nC. Left anterior descending artery\nD. Left circumflex artery\nE. Right coronary artery\n": "(C)", "108-6.\n52 \u6b72\u7537\u6027\u75c5\u4eba\u5f9e\u6628\u665a\u958b\u59cb\u9593\u6b47\u6027\u80f8\u75bc\u75db\uff0c\u521d\u6642\u8f15\u5ea6\u6b77\u7d93\u6578\u5206\u9418\uff0c\u8eab\u9ad4\u904b\u52d5\u53ef\u8a98\u767c\u80f8\u60b6\uff0c\u4eca\u66686:48 AM\u8f49\u6210\u91cd\u5ea6\u80f8\u75bc\uff0c\u540c\u6642\u4f34\u6709\u9838\u9178\u53ca\u5de6\u80a9\u75bc\u800c\u9192\u5e8a\uff0c\u96a8\u5f8c\u81ea\u89ba\u547c\u5438\u56f0\u96e3\u53ca\u982d\u6688\uff0c\u4e43\u6025\u5f80\u91ab\u9662\u3002\u6642\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u6709\u6025\u75c5\u72c0\uff0c\u8eab\u9ad8166cm\uff0c\u9ad4\u91cd80Kg\uff0cBMI 29.07\uff0c\u8840\u58d386/66mmHg\uff0c\u5fc3\u8df370/min\uff0c\u547c\u543820/min\uff0c\u4f53\u6eab35.7\u2103\uff0cSaO2 98%\u3002\u6b64\u5916\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u751f\u5316\u6aa2\u67e5\u3001\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u7d50\u679c(\u5982\u5716)\u6240\u793a\u3002\u6025\u8a3a\u5167\u79d1\u91ab\u5e2b\u91dd\u5c0d\u75c5\u4eba\u7684\u73fe\u6cc1\uff0c\u96a8\u5373\u555f\u52d5PCI team code\u4e26\u9032\u884c\u4e0b\u5217\u8af8\u7a2e\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u7b26\u5408\u6307\u5f15\u8655\u7f6e?(1)O2 inhalation 6 L/min\uff1b(2)IV Nitroglycerin 3\rmcg/min\uff1b(3)Aspirin\u901f\u6548\u5291\u91cf300 mg\u5f8c 100 mg QD\uff1b(4)Atorvastatin 40 mg HS\uff1b(5)Ticagrelor\u901f\u6548\u5291\u91cf180 mg\u5f8c\uff0c90mg/Tab 1# BID PC\uff1b(6)IV bolus Morphine 3mg\uff0c\u8996\u5fc3\u7d5e\u75bc\u75db\u7528\u85e5\uff1b(7)Bisoprolol 1.25mg QD PC\uff1b(8)Amlodipine 5mg BID\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (3)+(4)+(5)\nD. (1)+(3)+(7)\nE. (2)+(4)+(8)\n": "(C)", "108-7.\n\u4f9d\u64da\u7f8e\u570b\u5169\u500b\u5fc3\u81df\u5b78\u6703(AHA/ACC)\u6700\u8fd1\u6709\u95dc\u5fc3\u74e3\u819c\u6027\u5fc3\u81df\u75c5\u4e4b\u5fc3\u5167\u819c\u708e\u8655\u7f6e\u6307\u5f15\u5efa\u8b70\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u61c9\u4f5c\u9810\u9632\u6027\u6297\u751f\u7d20\u7684\u4f7f\u7528?\nA. 56\u6b72\u51a0\u5fc3\u75c5\u4eba\u66fe\u5728\u4e09\u500b\u6708\u524d\uff0c\u7f6e\u653e\u4e94\u652f\u51a0\u8108\u652f\u67b6\uff0c\u5c07\u65bc\u8fd1\u65e5\u5167\u4f5c\u7259\u79d1\u6cbb\u7642\uff0c\u7f6e\u63dborthodontic brackets\u6216orthodontic appliances\nB. 28\u6b72\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u4eba\u5c07\u65bd\u884c\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\nC. 68\u6b72\u75c5\u4eba\u56e0\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u5feb\u8df3\u4e4b\u731d\u6b7b\u6025\u6551\uff0c\u653e\u7f6eIntra-cardiac defibrillater(ICD) \uff0c\u73fe\u5728\u53f3\u4e0a\u80ba\u6709\u73bb\u7483\u72c0\u9670\u5f71(GGO,Ground glass opacity)\uff0c\u5c07\u5be6\u884c\u6c23\u7ba1\u5167\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\nD. 28\u6b72\u5973\u6027\u6709\u80f8\u75bc\u4e3b\u8a34\uff0c\u552f\u7406\u5b78\u6aa2\u67e5\u6b63\u5e38\uff0c\u4f46\u8d85\u97f3\u6ce2\u5fc3\u5716\u5448\u73fe\u4e8c\u5c16\u74e3\u819c\u812b\u5782\u4f75\u6709\u8f15\u5ea6\u9589\u9396\u4e0d\u5168\nE. \u6bd2\u766e\u8005\u5341\u500b\u6708\u524d\u66fe\u6709\u767c\u71d2\uff0c\u552f\u8fd1\u65e5\u8d85\u97f3\u6ce2\u5fc3\u5716\u672a\u6709\u7570\u5e38\u8b8a\u5316\uff0c\u73fe\u5728\u5be6\u65bd\u8180\u80f1\u93e1\u6aa2\u67e5\n": "(C)", "108-8.\n\u4e0b\u9762\u6709\u95dc\u5fc3\u8870\u7aed\u7684\u8655\u7f6e\u6839\u64da\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?\nA. \u5fc3\u8870\u7aed\u5408\u4f75\u4f4e\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u4e0d\u5fc5\u6025\u7528Dopamine, Dobutamine\u6216Nor-epinephrine\uff0c\u56e0\u53ef\u80fd\u591a\u589e\u6b7b\u4ea1\u7387\nB. \u5c31\u75c5\u7406\u751f\u7406\u5b78\u800c\u8a00\uff0c\u53ea\u8981\u80ba\u6c34\u816b\uff0c\u4f7f\u7528\u6301\u7e8c\u6027\u6b63\u58d3\u547c\u5438\u5668(CPAP) \u6709\u52a9\u6539\u5584\u8840\u6db2\u542b\u6c27\u91cf\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4f46\u7121\u52a9\u4f4f\u9662\u7642\u7a0b\u7684\u6b7b\u4ea1\u7387\nC. \u4f9d\u5de6\u5fc3\u5ba4\u5fc3\u81df\u529f\u80fd\u6aa2\u67e5\uff0c\u5fc3\u8870\u7aed\u5206\u62101. HFrEF (Heart failure reduced ejection fraction) 2. HFpEF(Heart failure preserved ejection fraction)\uff0c\u4e0d\u7ba1\u4f4f\u9662\u6216\u51fa\u9662\u7642\u7a0b\uff0c\u524d\u8005\u90fd\u6bd4\u5f8c\u8005\u7684\u6b7b\u4ea1\u7387\u66f4\u9ad8\nD. \u5fc3\u8870\u7aed\u5408\u4f75\u80ba\u6c34\u816b\u5982\u82e5\u8840\u58d3\u504f\u4f4e\uff0c\u8840\u7ba1\u64f4\u5f35\u5291\u4e0d\u662f\u9069\u7576\u7684\u85e5\u7269\u9078\u64c7\nE. \u7dca\u6025\u975c\u8108\u6ce8\u5c04\u5229\u5c3f\u5291\u6709\u52a9\u80ba\u6c34\u816b\u7684\u6539\u5584\n": "(C)", "108-9.\n64\u6b72\u7537\u6027\u96fb\u5b50\u5de5\u7a0b\u5e2b\u57282003\u5e74\u56e0\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u5fc3\u808c\u7f3a\u6c27\uff0c\u5fc3\u5916\u91ab\u5e2b\u96a8\u5373\u9032\u884c\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\uff0c\u8ffd\u8e64\u767c\u73fe\u7e5e\u9053\u8840\u7ba1\u963b\u585e\u4e0d\u901a\uff0c\u6539\u4ee5\u5857\u85e5\u652f\u67b6\u6cbb\u7642\u3002\u81ea2019\u5e741\u6708\u8d77\uff0c\u6642\u6709\u80f8\u75db\uff0c\u7d93\u4fb5\u5165\u6027\u6aa2\u67e5\u767c\u73fe\u5de6\u4e3b\u5e79\u53ca\u5176\u4ed6\u4e09\u689d\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u90fd\u6709\u56b4\u91cd\u72f9\u7a84\uff0c\u5efa\u8b70\u5fc3\u81df\u79fb\u690d\u30022019\u5e747\u670824\u65e5\u56e0\u80f8\u60b6\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u5230\u6025\u8a3a\u6c42\u6cbb\u3002\u9ad4\u6eab37.1\u5ea6\uff1b\u8840\u58d3133/93 mmHg; \u5fc3\u8df3130/\u5206\uff1bSpO2 97%\uff1b \u5176\u5fc3\u96fb\u5716(\u5982\u5716)\u3002\u5176\u7dca\u6025\u751f\u5316\u6aa2\u67e5\uff1a CK :117 U/L; CKMB: 4.25 mg/mL,  Troponin T: 10.41 ng/L\u3002\u8ca0\u8cac\u91ab\u5e2b\u96a8\u5373\u9032\u884c\u4e0b\u5217\u8655\u7f6e\uff0c\u4e5f\u56e0\u6b64\u75c5\u60c5\u7a69\u5b9a\u3002(1)Amiodarone 150 mg IV\uff0c\u96a8\u5f8c 1 mg/ min\r\u6301\u7e8c\u975c\u6ce8\uff1b(2)nitroglycerin 100mg in 500 cc Normal saline ,\u4ee52.5 mcg/Kg/min \u6301\u7e8c\u975c\u6ce8\uff1b(3)\u975c\u8108\u6ce8\u5c04Lanoxin 0.5 mg in 10ml  5% glucose in water\uff1b(4)Heparin 4000U bonus \u5f8c\u6301\u7e8c\u975c\u6ce8\u65e5\u91cf25000U\uff1b(5)DC electric shock 200 joules\uff1b(6)IV 2 Gm Magnesium sulfate\uff1b(7)IV Lasix 20 mg\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8655\u7f6e\u624d\u7b26\u5408\u7576\u4eca\u5fc3\u81df\u5b78\u6703\u5efa\u8b70\u7684\u6307\u5f15\uff1f\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (5)+(6)+(7)\nD. (1)+(2)+(4)\nE. (2)+(3)+(7)\n": "(D)", "108-10.\n\u4e0b\u9762\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff08Atrial fibrillation \uff0cAF)\u7684\u8aaa\u6cd5\uff0c\u8acb\u554f\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u4e0d\u7ba1\u9663\u767c\u6027(paroxysmal)\u6216\u6c38\u4e45(permanent)\u5982\u82e5\u518d\u767cAF\uff0c\u6709\u75c7\u72c0\u7684AF\u6bd4\u6c92\u6709\u75c7\u72c0\u7684AF\u591a12\u500d\nB. \u5c31\u5be6\u8b49\u91ab\u7642\u800c\u8a00\uff0c\u5fc3\u5f8b\u63a7\u5236(Rhythm control)\u4e0d\u6bd4\u5fc3\u8df3\u63a7\u5236(Rate control)\u91cd\u8981\nC. \u80a5\u80d6\u5e38\u6709AF\u7684\u767c\u4f5c\uff0c\u6e1b\u80a5\u6216\u4f7f\u7528ACEi \u6216ARB \u4e5f\u591a\u6703\u6709\u6e1b\u5c11\u767c\u4f5c\u7684\u6548\u679c\nD. \u6025\u6027\u767c\u4f5c\u7684AF\u670940%\u53ef\u81ea\u5df1\u7de9\u89e3\uff0c\u4f46\u670960%\u6703\u6301\u7e8c\u8d85\u904e\u4e00\u5929\uff0c\u5982\u6709\u9700\u8981\u5fc3\u5f8b\u8f49\u6b63\uff08Cardioversion),\u61c9\u6709\u98df\u9053\u8d85\u97f3\u6ce2\u5fc3\u5716\u6392\u9664\u5de6\u5fc3\u623f\u8840\u6813\u4e4b\u53ef\u80fd\uff0c\u6216\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u4e09\u9031\u5f8c\u518d\u8655\u7406\nE. \u6162\u6027AF\u7684\u75c5\u4eba\uff0c\u5176CHADS2VASc\u5927\u65bc2\uff0c\u5c31\u9810\u9632\u8840\u6813\u963b\u585e\u767c\u4f5c\uff0c\u5f9e\u5be6\u8a3c\u91ab\u5b78\u800c\u8a00\uff0c\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269(New oral anticoagulants) \u6bd4Warfarin \u5c11\u898b\u8166\u51fa\u8840\n": "(A)", "108-11.\n78\u6b72\u8001\u592a\u592a\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u6162\u6027\u814e\u75c5\u8b8a\u53ca\u53f3\u4e0a\u80ba\u764c\uff0c\u65bc\u662f\u4f4f\u9662\u505aVATS RUL lobectomy\u958b\u5200, \u8853\u5f8c\u9010\u6f38\u9ad4\u91cd\u589e\u52a0\u3001\u8173\u816b\u3001\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u7d93\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73feAortic valve area 0.7 cm2, Mean aortic pressure gradient 41 mmHg, LVEF 67%,\u6703\u8a3a\u5167\u79d1\u91ab\u5e2b\u3002\u8840\u58d3180/57 mmHg\uff1b \u5fc3\u8df381/min\uff0c\u6162\u6027\u75c5\u5bb9\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u4e3b\u52d5\u74e3\u819c\u72f9\u7a84\uff08Aortic stenosis\uff09\u61c9\u6709\u7684\u7406\u5b78\u6aa2\u67e5\u6240\u898b\uff1f\nA. Mid-systolic; in crescendo-decrescendo at Aortic area\nB. Soft S2 over Aortic area\nC. Bifid apical impulse\nD. S4 audible over the apex\nE. Intensity of cardiac murmur attenuated while on squatting\n": "(E)", "108-12.\n\u4e00\u4f4d\u75c5\u60a3\u56e0\u80f8\u60b6\u5230\u6025\u8a3a,\u80f8\u60b6\u90e8\u4f4d\u70ba\u5de6\u524d\u80f8, \u80f8\u60b6\u6642\u9593\u8d85\u904e30\u5206\u9418,\u91ab\u5e2b\u60f3\u9451\u5225\u8a3a\u65b7\u8a72\u80f8\u75db\u662f\u5426\u70ba\u5fc3\u5305\u819c\u708e\u6216\u5fc3\u808c\u6897\u585e,\u8acb\u554f\u4e0b\u5217\u9673\u8ff0\u4f55\u8005\u932f\u8aa4?(1)\u7576\u60b6\u75db\u5728\u8eba\u4e0b\u6642\u53ef\u4ee5\u8f03\u70ba\u7de9\u89e3;\u5750\u8d77\u4e26\u8eab\u9ad4\u5411\u524d\u50be\u6642\u6703\u52a0\u91cd(1)\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\uff1b(2)\u5fc3\u5305\u819c\u708e\u4e4b\u80f8\u75db\u4e0d\u6703\u8f3b\u5c04\u81f3\u5de6\u4e0a\u81c2\u6216\u4e0b\u5df4\uff1b(3)\u5fc3\u96fb\u5716\u5448\u73fe\u7030\u6f2b\u6027ST -segment elevation,\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\uff1b(4)\u7576\u5fc3\u96fb\u5716ST segment elevation\u70ba\u51f8\u51fa\u72c0(convex pattern),\u5fc3\u5305\u819c\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u512a\u5148\u5217\u5165\u8003\u616e\uff1b(5)\u5fc3\u96fb\u5716\u4e0a\u6709PR segment depression,\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\u3002\nA. (1)+(2)+(4)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (2)+(4)\nE. (4)+(5)\n": "(D)", "108-13.\n\u6709\u95dc\u4f4e\u5c04\u51fa\u5206\u7387\u578b\u5fc3\u81df\u8870\u7aed(heart failure with reduced ejection fraction)\u4e4b\u85e5\u7269\u6cbb\u7642\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u6709\u8aa4?\nA. \u4f7f\u7528beta-blocker \u61c9\u512a\u5148\u65bc angiotensin-converting enzyme inhibitors (ACEI)\nB. Aldosterone antagonist (eplerenone) \u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nC. Direct renin inhibitor (aliskiren)\u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nD. Propranolol  \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nE. Endothelin antagonist (bosentan) \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\n": "(A)", "108-14.\n\u4e0b\u5217\u5728\u6025\u6027\u5fc3\u81df\u8870\u7aed\u6cbb\u7642\u4e4b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642,\u4f7f\u7528ultrafiltration\u4f86\u79fb\u9664\u6c34\u5206 \u53ef\u4ee5\u6e1b\u5c11\u5fc3\u81df\u8870\u7aed\u518d\u4f4f\u9662\u7387\nB. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642,\u4f7f\u7528ultrafiltration \u4f86\u79fb\u9664\u6c34\u5206\u4e0d\u80fd\u6539\u5584\u814e\u81df\u529f\u80fd\nC. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642, \u4f7f\u7528Vasopressin-2 antagonist (tolvaptan) \u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nD. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642, \u4f7f\u7528Calcium sensitizer (levosimendan) \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nE. \u6cbb\u7642\u6025\u6027\u5fc3\u81df\u8870\u7aed,\u4f7f\u7528milrinone\u7576\u4f5c\u5f37\u5fc3\u5291\u6642;\u8981\u6839\u64da\u814e\u529f\u80fd\u4f86\u8abf\u6574\u5291\u91cf.\n": "(C)", "108-15.\n\u4e00\u4f4d46\u6b72\u5973\u6027\u75c5\u60a3\u5448\u73fe\u660f\u53a5\u4f86\u9580\u8a3a\u6c42\u8a3a,\u8a72\u75c7\u72c0\u8207\u7279\u5b9a\u59ff\u52e2\u6709\u95dc.\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982(\u9644\u5716),\u5de6\u5716\u70ba\u5fc3\u5ba4\u6536\u7e2e\u4e8c\u5c16\u74e3\u95dc\u9589\u6642,\u53f3\u5716\u70ba\u5fc3\u5ba4\u8212\u5f35\u6642\u5716\u50cf.\u6709\u95dc\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5fc3\u81df\u807d\u8a3a\u6642,\u6709\u6642\u53ef\u4ee5\u807d\u5230\u4f4e\u983b\u7684\u816b\u7624\u64b2\u843d\u97f3(tumor-plop)\nB. \u75c5\u4eba\u53ef\u4ee5\u6709\u767c\u71d2,\u9ad4\u91cd\u6e1b\u8f15\u7b49\u75c7\u72c0\nC. \u75c5\u4eba\u53ef\u4ee5\u6709\u96f7\u8afe\u6c0f\u73fe\u8c61 (Raynauld's phenomenon)\nD. \u75c5\u4eba\u4e0d\u6703\u6709\u6775\u72c0\u6307(clubbing finger)\u7684\u75c7\u72c0\nE. \u5efa\u8b70\u5176\u4ed6\u4e00\u7b49\u89aa\u4e4b\u89aa\u5c6c(first-degree relatives)\u4e5f\u9032\u884c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(D)", "108-16.\n\u690e\u52d5\u8108\u4e00\u5171\u5206\u6210\u56db\u6bb5,\u7b2c\u4e00\u6bb5(V1)\u5f9e\u53f3\u7121\u540d\u52d5\u8108(innominate artery)\u6216\u5de6\u9396\u9aa8\u4e0b\u52d5\u8108\u5206\u51fa\u5f8c\u81f3\u7b2c\u4e94\u6216\u7b2c\u516d\u9838\u690e\u6a6b\u7a81\u5b54(transverse foramen).\u7b2c\u4e8c\u6bb5(V2)\u5f9e\u4e0a\u8ff0\u9838\u690e\u6a6b\u7a81\u5b54\u81f3\u7b2c\u4e8c\u9838\u690e(C2)\u6a6b\u7a81\u5b54.\u7b2c\u4e09\u6bb5\u5f9e\u7b2c\u4e8c\u9838\u690e\u6a6b\u7a81\u5b54\u7d93\u7b2c\u4e00\u9838\u690e\u7a7f\u904e\u6795\u9aa8\u5927\u5b54(foramen Magnum)\u4e4b\u786c\u8166\u819c,\u7b2c\u56db\u6bb5(V4)\u8207\u5c0d\u5074\u690e\u52d5\u8108\u5408\u6210\u57fa\u5e95\u52d5\u8108(Basilar artery)\u3002\u6709\u95dc\u690e\u52d5\u8108\u5206\u679d\u75be\u75c5\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u52d5\u8108\u786c\u5316\u8840\u6813\u75c5\u7076 (atherothrombotic lesions)\u6700\u5e38\u5728V1\u53caV4\u767c\u751f.\nB. V2\u8207V3\u8f03\u5e38\u767c\u751f\u690e\u52d5\u8108\u525d\u96e2\nC. V4\u4f9b\u61c9\u8166\u5e79\u8207\u5c0f\u8166\u4e4b\u8840\u6d41\nD. \u52d5\u8108\u72f9\u7a84\u5728V3\u8655\u6703\u9020\u6210subclavian steal syndrome\nE. V4\u767c\u751f\u8840\u7ba1\u963b\u585e\u53ef\u4ee5\u7522\u751fWallenberg's syndrome\n": "(D)", "108-17.\n\u6709\u95dc\u5fc3\u81df\u8eab\u9ad4\u8a3a\u5bdf\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4? (1)\u5fc3\u81df\u89f8\u8a3a\u51fa\u73fe\u9707\u986b (thrill )\u4ee3\u8868\u5fc3\u96dc\u97f3\u5f37\u5ea6\u70ba\u7b2c\u4e09\u7d1a\uff1b(2)\u5fc3\u623f\u4e2d\u8188\u7f3a\u640d\u6642,\u53ef\u4ee5\u807d\u5230\u5438\u6c23\u8207\u547c\u6c23\u6642\u56fa\u5b9a\u7b2c\u4e00\u5fc3\u97f3\u5206\u5c94(fixed split of S1)\uff1b(3)\u4e3b\u52d5\u8108\u80ba\u52d5\u8108\u958b\u653e\u6027\u5c0e\u7ba1(patent ductus arteriosus)\u53ef\u4ee5\u807d\u5230continuous murmur\uff1b(4)\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\u75c5\u60a3\u5728\u4f5cValsalva maneuver \u6642,\u6536\u7e2e\u671f\u96dc\u97f3\u6703\u8b8a\u5927\u8072\uff1b(5)\u4e8c\u5c16\u74e3\u812b\u5782(mitral valve prolapse)\u6703\u807d\u5230\u8212\u5f35\u671f\u96dc\u97f3(diastolic click)\nA. (2)+(4)+(5)\nB. (3)+(4)\nC. (3)+(5)\nD. (1)+(2)+(3)\nE. (1)+(2)+(5)\n": "(E)", "108-18.\n\u6709\u95dc\u5fc3\u81df\u8870\u7aed\u8840\u6e05\u6a19\u8a18B-type natriuretic peptide (BNP) \u8207N-terminal pro-BNP  (NT-proBNP)\u7684\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?\nA. \u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u4f7f\u7528ARNI (angiotensin receptor neprilysin inhibitor) \u5f8c, BNP\u7684\u6fc3\u5ea6\u6703\u964d\u4f4e\nB. \u5e74\u9f61\u589e\u52a0\u6642,NT-proBNP\u8840\u6e05\u6fc3\u5ea6\u6703\u589e\u52a0\nC. \u814e\u529f\u80fd\u8b8a\u5dee\u6642, NT-proBNP\u8840\u6e05\u6fc3\u5ea6\u6703\u589e\u52a0\nD. \u80a5\u80d6\u6703\u9020\u6210BNP\u6fc3\u5ea6\u5047\u6027\u964d\u4f4e(falsely low)\nE. \u9019\u4e9b\u8840\u6e05\u6a19\u8a18\u5728\u53f3\u5fc3\u8870\u7aed\u6642,\u4e5f\u6703\u5347\u9ad8.\n": "(A)", "108-19.\n\u4e00\u4f4d75\u6b72\u62bd\u83f8\u7537\u6027\u75c5\u60a3\u81f3\u9580\u8a3a,\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\u8207\u9ad8\u8840\u8102,\u4e3b\u8a34\u9593\u6b47\u6027\u8ddb\u884c.\u767c\u751f\u7684\u90e8\u4f4d\u70ba\u81c0\u90e8\u8207\u4e0b\u80a2\u808c\u8089.\u75c5\u4eba\u53e6\u6709\u967d\u840e(impotence)\u7684\u75c7\u72c0.\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u80a1\u52d5\u8108\u7121\u8108\u640f.\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u7b26\u5408Leriche's syndrome\nB. \u8a72\u75c5\u7076\u662f\u56e0left common iliac vein  \u53d7\u5230right common iliac artery \u58d3\u8feb\u6240\u81f4\nC. \u807d\u8a3a\u6642,\u5728\u809a\u81cd\u4e0b\u65b9\u7684\u8179\u90e8\u5e38\u53ef\u4ee5\u807d\u5230bruit\nD. \u75c5\u4eba\u7684\u75c7\u72c0\u56b4\u91cd\u5ea6\u8207\u5074\u679d\u5faa\u74b0(collateral circulation)\u6709\u95dc\nE. \u8eab\u9ad4\u8a3a\u5bdf\u53ef\u89c0\u5bdf\u5230\u4e0b\u80a2\u76ae\u819a\u840e\u7e2e\u8207\u4e0b\u80a2\u51b0\u51b7\n": "(B)", "108-20.\n\u4e00\u4f4d65\u6b72\u7537\u6027,\u6709\u9ad8\u8840\u58d3,\u7cd6\u5c3f\u75c5\u8207B\u578b\u809d\u708e\u5408\u4f75\u809d\u786c\u5316\u75c5\u53f2.\u6b64\u6b21\u5c31\u8a3a\u4e4b\u4e3b\u8a34\u70ba\u975c\u6b62\u6642\u5598\u4e0d\u904e\u6c23\u4f86,\u4e14\u6709\u7aef\u5750\u547c\u5438\u8207\u4e0b\u80a2\u6c34\u816b.\u904e\u53bb4\u500b\u6708\u6709\u4e7e\u54b3,\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\u8207\u5026\u6020\u611f.\u9ad4\u6eab\u70ba\u651d\u6c0f37\u5ea6,\u5fc3\u8df3\u70ba\u898f\u5247\u5fc3\u5f8b,\u6bcf\u5206\u941878\u8df3,\u547c\u5438\u70ba\u6bcf\u5206\u941817\u6b21.\u8840\u58d3\u70ba158/95\u6beb\u7c73\u6c5e\u67f1.\u80f8\u90e8X \u5149\u5448\u73fe\u5fc3\u81df\u64f4\u5927,\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5448\u73fe\u5927\u91cf\u5fc3\u5305\u819c\u7a4d\u6db2.\u5fc3\u5305\u819c\u7a7f\u523a\u53d6\u5fc3\u5305\u819c\u6db2\u9001\u6aa2\u5f8c\u5448\u73fe\u5982(\u9644\u8868). 3\u5929\u4e4b\u5f8c, \u5fc3\u5305\u819c\u6db2adenosine deaminase \u6fc3\u5ea6\u70ba118.1 U/L (\u6b63\u5e380.0~11.3 U/L).\u8acb\u554f\u5efa\u8b70\u4e0b\u5217\u4f55\u8005\u8655\u7f6e?\nA. \u9032\u884c\u53e6\u4e00\u6b21\u5fc3\u5305\u819c\u7a7f\u523a,\u518d\u9001\u4e00\u6b21\u5fc3\u5305\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\u8207\u7d30\u83cc\u57f9\u990a\nB. \u7d66\u4e88\u6297\u7d50\u6838\u83cc\u85e5\u7269\u6cbb\u7642\nC. \u7d66\u4e88\u79cb\u6c34\u4ed9\u7d20\u6cbb\u7642\nD. \u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nE. \u9032\u884c Interferon-gamma  release assay\n": "(B)", "108-21.\n\u6709\u95dc\u7c92\u7dda\u9ad4\u75be\u75c5(mitochondria disease)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u75c5\u60a3\u53ef\u4ee5\u6709\u807d\u529b\u969c\u7919 (sensorineural hearing impairment)\nB. \u75c5\u60a3\u53ef\u4ee5\u5448\u73fe\u7cd6\u5c3f\u75c5\nC. \u75c5\u60a3\u53ef\u4ee5\u5448\u73fe\u4e73\u9178\u4e2d\u6bd2 (lactic acidosis)\nD. \u75c5\u60a3\u53ef\u4ee5\u6709\u5fc3\u81df\u50b3\u5c0e\u969c\u7919\nE. \u7c92\u7dda\u9ad4\u75c5\u60a3\u7684\u5152\u5b50\u4e5f\u6703\u7f79\u60a3\u9019\u500b\u75be\u75c5,\u4e26\u6703\u5c07\u6b64\u907a\u50b3\u75be\u75c5\u50b3\u905e\u81f3\u4ed6\u7684\u4e0b\u4e00\u4ee3\n": "(E)", "108-22.\n\u4e00\u540d65\u6b72\u7537\u6027,\u56e0\u51a0\u72c0\u52d5\u8108\u75c5\u63a5\u53d7\u7e5e\u9053\u624b\u8853.\u75c5\u4eba\u56e0\u5fc3\u60b8\u81f3\u6025\u8a3a\u5c31\u8a3a,\u5fc3\u96fb\u5716(\u5982\u5716).\u75c5\u4eba\u8840\u58d3\u70ba100/50\u6beb\u7c73\u6c5e\u67f1,\u610f\u8b58\u6e05\u695a\u4f46\u865b\u5f31,\u4e0d\u6642\u6253\u5475\u6b20.\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u80f8\u524d\u5c0e\u6975\u6c92\u6709\u540c\u76f8 (concordance)\u8b8a\u5316\nB. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u6709\u623f\u5ba4\u89e3\u96e2(AV dissociation)\nC. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716QRS duration >140 msec\nD. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u5224\u8b80\u70ba\u5fc3\u5ba4\u4e0a\u5fc3\u640f\u904e\u901f (supraventricular tachycardia) \u5408\u4f75\u53f3\u675f\u652f\u50b3\u5c0e\u963b\u65b7\nE. \u6b64\u75c5\u60a3\u4e4b\u62bd\u8840\u6aa2\u67e5\u61c9\u6db5\u84cbtroponin T, creatine kinase , \u8207 creatine kinase  MB\n": "(D)", "109-1.\u5c31\u75be\u75c5\u4e4b\u9810\u9632\u53ca\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u500b\u6848\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u4e0d\u7576\u4e4b\u8209\uff1f    \nA.78\u6b72\u8001\u7fc1\u6709\u5fc3\u96fb\u5716\u5448\u73feST -T\u8b8a\u5316\uff0c\u75c5\u4eba\u8840\u58d3128 /74 mmHg, \u5fc3\u8df374 /min, \u6b63\u5e38\u5f8b\u52d5 \uff0c\u5c1a\u7121\u80f8\u75db\u6216\u5fc3\u60b8\n\u7b49\u75c5\u72c0\uff0c\u53ef\u505a\u5167\u79d1\u9580\u8a3a\u6cbb\u7642 \uff0c\u4e0d\u5fc5\u7acb\u523b\u505a\u7d93\u76ae\u51a0\u72c0\u52d5\u8108\u4ecb\u5165\u6cbb\u7642 (Percutaneous coronary \nintervention )\nB.32\u6b72\u5a66\u4eba\u6bcf\u9022\u6708\u7d93\u4f86\u81e8\u90fd\u6709\u5fc3\u60b6\u75c7\u72c0 \uff0c\u7d93\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u53ca\u8d85\u97f3\u6ce2\u5fc3\u5716\u90fd\u986f\u793a\u6b63\u5e38\u7d50\u69cb\u53ca\u529f\u80fd \uff0c\u70ba\u5b89\n\u5168\u8d77\u898b\u4ecd\u61c9\u8acb\u6bcf\u516d\u500b\u6708\u56de\u8a3a\u8ffd\u8e64\nC.56\u6b72\u7537\u6027\u516c\u53f8\u7d93\u7406\u4eba \uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u9ad8\u8102\u8840 \u3002\u4f46\u70ba\u9632\u6cbb\u5fc3\u8840\u7ba1\u75c5 \uff0c\u61c9\u505a\u98a8\u96aa\u8a55\u4f30 \uff0c\u4e26\u5728\u9580\u8a3a\u8ffd\u8e64\u4f5c\u751f\n\u6d3b\u65b9\u5f0f\u77ef\u6b63 (Lifestyle  modification )\nD.48\u6b72\u7537\u6027\u5f9e\u5546 \uff0c\u80f8\u60b6\u7d93\u7531\u7406\u5b78\u6aa2\u67e5\u53ca\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5f8c \uff0c\u4e26\u7121\u4efb\u4f55\u5fc3\u8840\u7ba1\u75be\u75c5\u53ca\u98a8\u96aa \uff0c\u4e0d\u5fc5\u5efa\u8b70\u4f5c\u5168\u8eab\n\u5065\u5eb7\u6aa2\u67e5\nE.102\u6b72\u8001\u5a66\u4eba30\u5e74\u524d\u56e0\u9ad8\u8840\u58d3\u5230\u9580\u8a3a\u6cbb\u7642 \uff0c\u4e94\u5e74\u524d\u958b\u59cb\u6709\u9ad4\u529b\u4e0d\u652f \u3001\u5bb9\u6613\u75b2\u5026 \u3001\u672a\u6709\u80f8\u60b6 \u3001\u7729\u6688\u3001\u547c\n\u5438\u56f0\u96e3\u7b49\u75c7\u72c0 \uff0c\u7d93\u78ba\u8a3a\u70ba\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168 \uff0c\u4f7f\u7528\u85e5\u7269\u6cbb\u7642 \uff0c\u75c7\u72c0\u6539\u5584 \u3002\u61c9\u5efa\u8b70\u9019\u4f4d\u8001\u5a66\u4eba\u6bcf 6\u621612\u500b\n\u6708\u56de\u8a3a\u8a55\u4f30 \uff0c\u5982\u6709\u60e1\u5316 \uff0c\u624d\u5efa\u8b70\u4f4f\u9662\u505a\u5916\u79d1\u624b\u8853\u6cbb\u7642\n": "[B]", "109-2.\u6709\u4f4d38\u6b72\u6797\u5c0f\u59d0\u56e0\u5fc3\u60b8\u53ca\u5931\u7720\u591a\u500b\u6708\u800c\u6c42\u8a3a \uff0c\u7d93\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38 \uff0c\u552f\u6709\u5de6\u80f8\u9aa8\u4e0b\u7de3\u8655\u6709\u8f15\u5ea6 (Gr \n1-2/6)\u4e2d\u671f\u5fc3\u7e2e\u96dc\u97f3 (Mid-systolic murmur )\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u78ba\u5b9a\u8a3a\u65b7\u7684\u5fc5\u8981\u8655\u7f6e \uff1f\n(1) \u5fc3\u96fb\u5716(Electrocardiogram )\n(2) \u80f8\u90e8X\u5149(Chest X-ray)\n(3) \u8d85\u97f3\u6ce2\u5fc3\u5716 (Echocardiogram )\n(4) \u5fc3\u81df\u78c1\u632f\u9020\u5f71 (Cardiac MRI )\n(5) Thallium 201 \u5fc3\u808c\u704c\u6ce8\u5f71\u50cf (Thallium 201 Perfusion Scan )\n(6) \u5fc3\u81df\u5c08\u79d1\u6703\u8a3a   \nA.(1)+(2)+(3)\nB.(2)+(4)+(6)\nC.(1)+(3)+(5)\nD.(4)+(5)+(6)\nE.(1)+(2)+(5)\n": "[A]", "109-3.\u5fc3\u8870\u7aed(Heart failure, HF )\u662f\u81e8\u5e8a\u5f88\u91cd\u8981\u7684\u8ab2\u984c \uff0c\u53ef\u5206\u6210\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6bd4\u7387\u4f4e\u9000\u5fc3\u8870\u7aed (Heart Failure reduced \nEjection Fraction ,HFrEF)\u53ca\u5c04\u51fa\u6bd4\u7387\u6b63\u5e38\u5fc3\u8870\u7aed (Heart Failure preserved Ejection Fraction ,HFpEF) \uff0c\u8acb\n\u554f\u4e0b\u5217\u4f55\u9805\u7684\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u516b\u5341\u4e94\u6b72\u4ee5\u4e0a\u8001\u4eba\u7d0440%\u6709\u5404\u7a2e\u4e0d\u540c\u7a0b\u5ea6\u7684\u5fc3\u8870\u7aed\nB.\u6025\u6027\u5fc3\u8870\u7aed\u75c5\u4eba\u7684\u75c5\u6cc1\u60e1\u5316\u591a\u8207\u539f\u59cb\u75c5\u56e0\u8f49\u5287\u6709\u95dc \uff0c\u4f46\u4e0d\u80fd\u5ffd\u8996\u75c5\u4eba\u56e0\u5176\u4ed6\u6162\u6027\u75be\u75c5\u8a98\u767c \uff0c\u7528\u85e5\u9806\u5f9e\n\u6027\u4e0d\u4f73\u6216\u85e5\u7269\u4ea4\u4e92\u4f5c\u7528\u5c0e\u81f4\nC.\u5de6\u5fc3\u5ba4HFrEF \u7d04\u4f54\u5fc3\u8870\u7aed\u7684\u534a\u6578\u4ee5\u4e0a\nD.\u5de6\u5fc3\u5ba4HFrEF\uff0c\u591a\u898b\u5728\u5973\u6027\u3001\u8001\u5e74\u4eba\u7279\u5225\u5408\u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2\u8005\nE.\u5de6\u5fc3\u5ba4HFpEF \u4e4b\u6b7b\u4ea1\u7387\u9060\u6bd4\u5de6\u5fc3\u5ba4HFrEF\u70ba\u4f4e\uff0c\u4f46\u4ecd\u6bd4\u540c\u5e74\u9f61\u7684\u6b63\u5e38\u4eba\u70ba\u9ad8\n": "[D]", "109-4.\u96a8\u8457\u91ab\u7642\u74b0\u5883\u53ca\u91ab\u5b78\u7684\u9032\u6b65 \uff0c\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e (Infective endocarditis ,IE )\u7684\u81e8\u5e8a\u5be6\u6cc1\u6709\u8a31\u591a\u8b8a\u5316 \uff0c\u8acb\n\u554f\u4ee5\u4e0b\u7684\u8aaa\u6cd5\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u96a8\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u76db\u884c\u4e4b\u6e1b\u5c11\uff0c\u7f79\u60a3IE\u7684\u75c5\u4eba\u591a\u504f\u5411\u8001\u9f61\u5316\nB.\u5fc3\u81df\u74e3\u819c\u75c5\u8b8a\u7522\u751f\u7684\u5fc3\u5167\u4e82\u6d41(Turbulent flow) \u8207IE\u767c\u751f\u8d05\u751f\u7269(Vegetation)\u7684\u5f62\u6210\u6709\u95dc\nC.\u4e8c\u5c16\u74e3\u812b\u5782\u53ca\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u90fd\u6709\u767c\u751fIE\u7684\u98a8\u96aa\nD.\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (Systemic lupus erythematosus, SLE )\u7684\u6d88\u8017\u6027\u8d05\u7269 (Marantic vegetation )\u4e0d\u5177\u8840\u7ba1\n\u71df\u990a, \u53ef\u662f\u4e00\u65e6\u7d30\u83cc\u9644\u7740\u611f\u67d3 \uff0c\u4e0d\u6613\u6297\u751f\u7d20\u6cbb\u597d   \nE.46\u6b72\u5973\u6027\u75c5\u4eba\u4e3b\u8a34\u611f\u5192 \u3001\u767c\u71d2\u53ca\u8f15\u5ea6\u547c\u5438\u56f0\u96e3 \uff0c\u6709\u5169\u9031\u4e4b\u4e45 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u6709\u5fc3\u81df\u96dc\u97f3, \u624b\u638c\u6709\u985e\u4f3c\n\u7684Osler node, \u7d93\u63a1\u8840\u4e00\u6b21 ,\u7d30\u83cc\u57f9\u990a\u6709\u91d1\u9ec3\u8272\u8461\u8404\u7403\u7d30\u83cc \uff0c\u6309Duke criteria \uff0c\u672c\u75c5\u4f8b\u61c9\u53ef\u78ba\u8a3a\u611f\u67d3\u6027\n\u5fc3\u5167\u819c\u708e\n": "[E]", "109-5.\u5fc3\u5ba4\u983b\u8108 (Ventricular tachycardia, VT) \u662f\u5a01\u8105\u751f\u547d\u6027\u5fc3\u5f8b\u4e0d\u6574 (Life-threatening arrhythmia )\uff0c\u6709\u95dc\u5176\u8a3a\u65b7\n\u53ca\u6cbb\u7642\u7684\u8aaa\u6cd5 \uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba \uff1f   \nA.\u6709\u5668\u8cea\u6027\u5fc3\u81df\u75c5 (Organic heart disease )\u7684\u6301\u7e8c\u6027 (Sustained )VT\u6642\uff0c\u61c9\u7f6e\u653e\u5fc3\u5167\u53bb\u986b\u5668 (Intra-cardiac \ndefibrillator )\nB.\u9577\u671f\u4f7f\u7528\u6297\u5fc3\u5f8b\u4e0d\u6574\u85e5\u7269\u53ef\u6cbb\u7642\u7279\u767c\u6027\u5fc3\u5ba4\u5feb\u8df3 (Idiopathic VT )\uff0c\u552f\u5b9c\u5148\u63a1\u7528\u5c0e\u7ba1\u71d2\u707c\u8853 (Catheter \nablation)\nC.\u6709VT\u767c\u4f5c\u75c5\u4eba\uff0c\u4e00\u5b9a\u6709\u91cd\u5ea6\u5668\u8cea\u6027\u5fc3\u81df\u75c5\nD.\u5bec\u95ca\u5947\u7570\u72c0QRS \u6ce2(Wide,Bizarre QRS waves )\uff0c\u878d\u548c\u8df3(Fusion beat) \u3001\u6355\u6349\u8df3(Capture beat) \u53ca\u623f\u5ba4\n\u8df3\u89e3\u96e2 (A-V dissociation )\u662f\u8a3a\u65b7VT\u7684\u5fc3\u96fb\u5716\u689d\u4ef6 (Criteria) \uff0c\u4f46\u50c5\u53ea\u623f\u5ba4\u8df3\u89e3\u96e2\u662f\u552f\u4e00\u53ef\u9760\u7684\u6839\u64da\nE.\u96a8\u8457\u51a0\u8108\u8840\u7ba1\u518d\u901a\u8853\u4e4b\u767c\u9054 \uff0cST\u6ce2\u4e0a\u6607\u578b\u7684\u6025\u6027\u5fc3\u808c\u6897\u585eST elevation acute myocardial \ninfarction )\u4f75\u767cVT\u591a\u5728\u6025\u6027\u51a0\u5fc3\u75c7\u4e00\u9031\u5167\n": "[C]", "109-6.\u7531\u65bc\u91ab\u7642\u79d1\u6280\u7684\u9032\u6b65\u53ca\u81e8\u5e8a\u5be6\u4f8b\u7684\u7d93\u9a57\u7d2f\u7a4d \uff0c\u4e0b\u5217\u6709\u95dc\u80a5\u539a\u6027\u5fc3\u808c\u75c5 (Hypertrophic cardiomyopathy) \u7684\u81e8\n\u5e8a\u7279\u8cea\uff0c\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5 \uff1f   \nA.\u5176\u5728\u4eba\u53e3\u7684\u76db\u884c\u7387\u662f1/500\uff1b\u6b7b\u4ea1\u7387< 1%\nB.\u4e09\u5206\u4e4b\u4e00\u7684\u5e74\u8f15\u4eba\u731d\u6b7b (sudden cardiac deaths) \u662f\u56e0\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u800c\u8d77 \uff0c\u4e14\u591a\u898b\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u7e96\u7dad\n\u986b\u52d5(Ventricular tachycardia or fibrillation )\nC.\u5229\u7528\u96fb\u6c23\u751f\u7406\u53ca\u57fa\u56e0\u6aa2\u6e2c\u5df2\u80fd\u9810\u671f\u5176\u731d\u6b7b\u4e4b\u98a8\u96aa\nD.\u904b\u52d5\u5f8c\u4f4e\u8840\u58d3 \u3001\u5fc3\u5ba4\u4e2d\u9694\u539a\u5ea6 >3cm\u3001\u6709\u7729\u6688\u75c5\u53f2\u6216\u5fc3\u5ba4\u5feb\u8df3\u4e4b\u5fc3\u96fb\u5716\u8a18\u9304 \uff0c\u90fd\u662f\u5224\u5b9a\u731d\u6b7b\u98a8\u96aa\u7684\u6307\n\u6a19\nE.Gadolinium\u78c1\u632f\u5f71\u50cf\u53ef\u986f\u793a\u5fc3\u808c\u7e96\u7dad\u5316(Fibrosis) \u7a0b\u5ea6\u662f\u56b4\u91cd\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u53ef\u9760\u9810\u6e2c\u6307\u6a19\n": "[C]", "109-7.\u75c5\u4eba58\u6b72\u5a66\u5973 \uff0c\u4e3b\u8a34\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \u3001\u9ad4\u91cd\u4e00\u661f\u671f\u9593\u5f9e84\u516c\u65a4\u589e\u52a0\u81f387\u516c\u65a4 \uff0c\u96d9\u8173\u6c34\u816b\u6709\u4e00\u9031\u4e4b\u4e45 \uff0c\u6b65\n\u5c65\u96e3\u884c\uff0c\u521d\u6b65\u6aa2\u67e5\u5448\u73fe\u5fc3\u81df\u64f4\u5927 \uff0c\u4e43\u524d\u5f80\u91ab\u5b78\u4e2d\u5fc3\u8a3a\u7642 \uff0c\u5728\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5Chest X -ray\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u548c\u5fc3\n\u96fb\u5716(\u5982\u5716)\uff0c\u65cb\u5373\u4f4f\u9662 \u3002\u75c5\u4eba\u4e03\u5e74\u524d\u6709\u5de6\u4e73\u764c\u7d93\u5207\u9664\u624b\u8853 \uff0c\u81f3\u4eca\u4e26\u672a\u5b8c\u5168\u7de9\u89e3 \u3002\u75c5\u4eba\u8fd1\u4e94\u5e74\u4f86 \uff0c\u6709\u9ad8\u8840\u58d3\n\u53ca\u7cd6\u5c3f\u75c5 \uff0c\u90fd\u85e5\u7269\u6cbb\u7642\u4e2d \u3002\u751f\u547d\u5fb5\u8c61 \uff1aT: 36.2\u00b0C,P:81/min,R:20/min,BP:150/84mmHg ,Pain score :0\u3002\u75c5\n\u53f2\u8a62\u554f\u53ca\u8eab\u9ad4\u7406\u5b78\u6aa2\u67e5 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u5fc3\u8840\u7ba1\u75c5\u7406\u5b78\u6aa2\u67e5 (Cardiovascular approach )\uff0c\u662f\u60a8\u61c9\u8a72\u89c0\u5bdf\u7684\u6a19\n\u7684\uff1f\n(1) \u6d88\u6c88\u7684S1 and /or S2\n(2) S3 and S4\n(3) Pericardial friction\n(4) Mid-systolic murmur and pansystolic murmur\n(5) Kussmaul sign\n(6) Pulsating congestive liver   \nA.(1)+(2)+(3)\nB.(2)+(4)+(6)\nC.(1)+(3)+(5)\nD.(4)+(5)+(6)\nE.(3)+(4)+(5)   \n": "[C]", "109-8.86\u6b72\u8001\u592a\u592a\u56e0\u6709\u4e8c\u5c0f\u6642\u7684\u80f8\u60b6\u524d\u5f80\u91ab\u9662\u6025\u8a3a\u6c42\u6cbb \u3002\u75c5\u4eba\u5728\u5341\u5e74\u524d\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u800c\u4f4f\u9662 \uff0c\u5728\u5de6\u524d\u964d\u652f\u51a0\u72c0\n\u52d5\u8108(Left anterior descending artery )\u7f6e\u653e\u51a0\u72c0\u52d5\u8108\u652f\u67b6 \u3002\u75c5\u4eba\u5c1a\u6709\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u53ca\u8001\u9f61\u5931\u667a\u8a3a\u65b7 \u3002\u7406\u5b78\n\u6aa2\u67e5\u767c\u73fe \uff1aBH\uff1a156 cm, BW \uff1a48 kg\uff1bBMI\uff1a19.7 kg/m\u00b2\uff1bT/P/R\uff1a 36.2/66/22\uff1bBP\uff1a158/90 mmHg \uff1b\u5728\n\u6025\u8a3a\u7684\u5176\u4ed6\u6aa2\u9a57\u5c1a\u7121\u91cd\u5927\u7570\u5e38 \uff0c\u5176\u7cfb\u5217\u7684\u751f\u5316\u6aa2\u9a57 \u3001Chest X ray \u3001\u5fc3\u96fb\u5716\u5982\u9644\u5716 \uff1a   \nA.\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5\nB.\u5de6\u8ff4\u65cb\u51a0\u8108\u6813\u585e\u4e4bNon-STE acute myocardial infarction\nC.\u5de6\u524d\u964d\u652f\u51a0\u8108\u6813\u585e\u4e4bNon-STE acute myocardial infarction\nD.\u5de6\u524d\u964d\u652f\u51a0\u8108\u6813\u585e\u4e4bSTE acute myocardial infarction\nE.\u5de6\u8ff4\u65cb\u51a0\u8108\u6813\u585e\u4e4bSTE acute myocardial infarction\n": "[D]", "109-9.\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u9589\u9396\u4e0d\u5168 (Mitral regurgitation, MR) \u53ef\u5206\u539f\u59cb\u6027\u53ca\u7e8c\u767c\u6027 (Primary and Secondary MR )\u5169\n\u7a2e\uff0c\u5f9e\u8af8\u591a\u81e8\u5e8a\u5be6\u8a3c \uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7e8c\u767c\u6027MR\u7684\u6b63\u78ba\u8aaa\u6cd5 \uff1f   \nA.\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6bd4\u7387\u4f4e\u9000\u7684\u5fc3\u8870\u7aed (Heart Failure reduced Ejection Fraction, HFrEF) \u7684\u75c5\u4eba\u5927\u670975 %\u7684\u6709\n\u7e8c\u767c\u6027MR\nB.\u7e8c\u767c\u6027MR\u591a\u8087\u56e0\u65bc\u4e8c\u5c16\u74e3\u74b0\u64f4\u5927 (Mitral annular dilatation )\u53ca\u4e73\u982d\u808c\u7570\u5e38 \uff0c\u5f71\u97ff\u4e8c\u5c16\u74e3\u9589\u5408 \uff0c\u5916\u79d1\u5fa9\n\u539f\u624b\u8853\u6709\u826f\u597d\u6cbb\u7642\u6210\u7e3e\nC.\u5f9e\u81e8\u5e8a\u75c7\u72c0\u4e4b\u60e1\u5316\u53ca\u807d\u8a3a\u7570\u5e38\u4e4b\u5f37\u5ea6\u4e0d\u53ef\u70baMR\u7684\u56b4\u91cd\u5ea6\u53c3\u8003\nD.\u4e8c\u5c16\u74e3\u819c\u7684\u75c5\u8b8a\u4e0d\u662f\u6c7a\u5b9a\u7e8c\u767c\u6027MR\u7684\u95dc\u9375\u56e0\u7d20\nE.\u4f7f\u7528\u5fc3\u81df\u518d\u540c\u6b65\u5316\u6cbb\u7642 (Cardiac resynchronization therapy) \u6539\u5584\u5de6\u5fc3\u5ba4\u5fc3\u808c\u5931\u80fd \uff0c\u6709\u52a9\u7e8c\u767c\u6027MR \u7684\n\u56b4\u91cd\u5ea6\n": "[B]", "109-10.\u4f9d\u636e2016 \u5e74Taiwan Society of Cardiology\u6709\u95dc\u975e\u74e3\u819c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation) \u75c5\u4eba\u4e4b\u9810\u9632\u8166\u4e2d\u98a8\n\u7684\u6cbb\u7642\u6307\u5f15 \uff0c\u8acb\u554f\u4f55\u7a2e\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684 \uff1f   \nA.Aspirin\u5c0d\u8166\u4e2d\u98a8\u7684\u9810\u9632\u662f\u7121\u7642\u6548\nB.\u5305\u62ec\u53f0\u7063\u5728\u5167\u7684\u4e9e\u6d32\u4eba \uff0c\u81e8\u5e8a\u5be6\u8a3c\u767c\u73fe\u4ee5\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (New Oral Anti -Coagulants, NOACs) \n\u6bd4 Warfarin \u5c0d\u8166\u4e2d\u98a8\u7684\u9810\u9632\u66f4\u5177\u7642\u6548\nC.\u4e03\u5341\u4e94\u6b72\u8001\u5e74\u4eba\u5408\u4f75\u6709\u4e2d -\u91cd\u5ea6\u6162\u6027\u814e\u8870\u7aed\u6642 \uff0c\u5efa\u8b70\u53ef\u4f7f\u7528\u4f4e\u5291\u91cfNOAC \uff0c\u4f46\u82e5\u4f7f\u7528Warfarin \uff0cTime \nto therapeutic range > 70 %\u6642\uff0c\u53ef\u6539\u7528Warfarin\nD.\u5c31\u4e9e\u6d32\u75c5\u4eba\u800c\u8a00\uff0c\u4f7f\u7528\u4f4e\u5291\u91cfNOACs \u53ef\u4f5c\u70ba\u5982Warfarin\u4e00\u6a23\u5b89\u5168\u7684\u6cbb\u7642\u9078\u64c7\nE.\u4e9e\u6d32\u75c5\u4eba\u4f7f\u7528Warfarin \u6216NOAC\u90fd\u6709\u8f03\u9ad8\u8166\u4e2d\u98a8 \u3001\u5927\u51fa\u8840\u53ca\u9871\u5167\u51fa\u8840\u7684\u767c\u751f \uff0c\u662f\u4ee5\u5efa\u8b70\u542bAspirin \u53ca \nClopidogrel\u7684\u96d9\u91cd\u6297\u8840\u5c0f\u677f\u6cbb\u7642 (Dual antiplatelet therapy, DAPT) \u4ee3\u66ff\n": "[E]", "109-11.\u6709\u95dc\u5fc3\u808c\u708e(Myocarditis)\u7684\u6700\u8fd1\u9032\u5c55\uff0c\u4e0b\u5217\u4f55\u5247\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5\u7684\uff1f    \nA.\u5f9e\u4eba\u53e3\u63a8\u4f30\uff0c\u5fc3\u808c\u708e\u7684\u767c\u751f\u7387\u7d04\u842c\u5206\u4e4b\u4e00\u81f3\u5341\u842c\u5206\u4e4b\u4e00\uff0c\u4f46\u5728\u5e74\u9752\u731d\u6b7b\u75c5\u4eba\u7684\u75c5\u7406\u89e3\u5256\u537b\u9ad8\u905412%\nB.\u75c5\u7406\u8a3a\u65b7\u5fc3\u808c\u708e\u5fc5\u9808\u5fc3\u808c\u7121\u7f3a\u8840\u6027\u7684\u7d30\u80de\u640d\u50b7 \u3001\u9000\u5316\u6216\u58de\u6b7b (Injury, degeneration or necrosis )\u53ca\u767c\u708e\n\u7d30\u80de\u4fb5\u6f64\u8b8a\u5316 \uff0c\u4f46\u771f\u5be6\u7684\u81e8\u5e8a\u4e16\u754c\u88e1 \uff0c\u5927\u90e8\u4efd\u5fc3\u808c\u708e\u662f\u81e8\u5e8a\u8a3a\u65b7 \uff0c\u4e0d\u662f\u75c5\u7406\u8a3a\u65b7\nC.\u975c\u8108\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d (Intravenous immunoglobulin, IVIG )\u5c0d\u5e74\u9752\u4eba\u7684\u6025\u6027\u5fc3\u808c\u708e\u6709\u6548 \uff0c\u552f\u5176\u7d50\u8ad6\u6709\u5f85\n\u5b8c\u6574\u7684\u81e8\u5e8a\u8a66\u9a57\u7684\u9a57\u8a3c\nD.\u611b\u6ecb\u75c5\u6bd2\u53ca\u6dcb\u5df4\u5fc3\u808c\u708e\u90fd\u662f\u9810\u5f8c\u56b4\u91cd\u7684\u5fc3\u808c\u708e\nE.\u5de8\u7d30\u80de\u5fc3\u808c\u708e\u591a\u898b\u8001\u5e74\u4eba \uff0c\u6642\u4ee5\u80f8\u75db \u3001\u5fc3\u8870\u7aed\u3001\u60e1\u6027\u5fc3\u5f8b\u4e0d\u6574\u6216\u50b3\u5c0e\u963b\u6eef \uff0c\u6709\u8cf4\u81e8\u5e8a\u8b66\u89ba\u65e9\u671f\u5207\u7247\u8a3a\n\u65b7\uff0c\u76e1\u65e9\u514d\u75ab\u6cbb\u7642\u6709\u6548 \uff0c\u552f\u6b7b\u4ea1\u7387\u9ad8 \uff0c\u6709\u8cf4\u5fc3\u81df\u79fb\u690d\u6cbb\u7642\n": "[E]", "109-12.\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic shock)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f    \nA.\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u5fc3\u56e0\u6027\u4f11\u514b\u767c\u751f\u7387\u5df2\u56e0\u65e9\u671f\u4f7f\u7528\u518d\u704c\u6ce8\u6cbb\u7642\uff08Reperfusion therapy)\u800c\u6e1b\u5c11\u4e865-10%   \nB.\u6709\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4ee5\u591a\u689d\u51a0\u72c0\u52d5\u8108\u75c5\u8b8a\u70ba\u591a \uff0c\u4e14\u7d0480%\u662f\u4ee5ST\u6ce2\u6bb5\u4e0a\u6607\u5fc3\u808c\u6897\u585e \uff08ST \nelevation myocardial infarction \uff09\u7684\u5fc3\u96fb\u5716\u8868\u73fe\nC.\u5728\u81e8\u5e8a\u5be6\u8b49\u4e0a\uff0c\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b\u4ee5\u7dca\u6025\u5916\u79d1\u51a0\u8108\u7e5e\u9053\u624b\u8853\u70ba\u5b9c\nD.\u5728\u8af8\u591a\u7684\u5927\u578b\u81e8\u5e8a\u8a66\u9a57 \uff0c\u5229\u7528\u8840\u7ba1\u4f5c\u7528\u5291 \uff08Vasoactive agents) \u5982Norepinephrine, Dopamine, \nDobutamine \u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b \uff0c\u7121\u52a9\u9810\u5f8c\u4e4b\u6539\u5584\nE.\u4f7f\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66 \uff08Intra-aortic balloon pump \uff0cIABP\uff09\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b \uff0c\u5728\u81e8\u5e8a\u8a66\u9a57\u8cc7\u6599\u4e26\u4e0d\n\u986f\u793a\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\n": "[C]", "109-13.\u9ad8\u5b89\u6c0f\u8840\u7ba1\u708e(Takayasu arteritis)\uff0c\u6700\u5e38\u5f71\u97ff\u7684\u8840\u7ba1\u70ba\uff1f    \nA.\u814e\u52d5\u8108(renal artery)\nB.\u8179\u4e3b\u52d5\u8108(abdominal aorta)\nC.\u9396\u9aa8\u4e0b\u52d5\u8108(subclavian artery)\nD.\u51a0\u72c0\u52d5\u8108(coronary artery)\nE.\u4e3b\u52d5\u8108\u5f13(aortic arch)\n": "[C]", "109-14.\u6709\u95dc\u7ae0\u9b5a\u58fa\u5fc3\u808c\u75c7(Takotsubo cardiomyopathy)\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u80ba\u6c34\u816b\uff0c\u4f4e\u8840\u58d3\u8207\u5178\u578b\u5fc3\u7d5e\u75db\nB.\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u53ef\u4ee5\u5728\u6578\u5929\u5230\u6578\u9031\u5f8c\u7de9\u89e3\nC.\u60a3\u8005\u4e4b\u5fc3\u96fb\u5716\u5e38\u5448\u73fe\u5178\u578b\u5fc3\u808c\u6897\u585e\u4e4b\u8b8a\u5316\nD.\u9020\u6210\u4e4b\u56e0\u7d20\u5e38\u70ba\u5f37\u70c8\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u6216\u5152\u82ef\u915a\u80fa\u6bd2\u6027(catecholamine toxicity)\nE.\u53e3\u670d\u6297\u51dd\u8840\u5291\u662f\u5fc5\u8981\u4e4b\u85e5\u7269\u6cbb\u7642\n": "[E]", "109-15.\u6709\u95dc\u6297\u51dd\u8840\u5291\u7684\u89e3\u85e5(antidote)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Heparin\u7684antidote\u662fprotamine\nB.Warfarin \u7684antidote\u662fvitamin K\nC.Dabigatran \u7684antidote\u662fidarucizumab\nD.Rivaroxaban \u7684antidote\u662fandexanet\nE.Apixaban \u7684antidote\u662fidarucizumab\n": "[E]", "109-16.\u6709\u95dc\u80ba\u52d5\u8108\u9ad8\u58d3\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u4e00\u6c27\u5316\u78b3\u7030\u6f2b\u91cf (Diffusing capacities of the lungs for carbon monoxide DLCO) \u5728\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005\u6703\n\u4e0b\u964d\nB.\u5fc3\u81df\u8d85\u97f3\u6ce2\u7684\u5f71\u50cf(\u5982\u9644\u5716)\nC.\u5728\u7121\u7761\u7720\u547c\u5438\u969c\u7919\u7684\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005,\u591c\u9593\u7f3a\u6c27(nocturnal desaturation)\u4e26\u4e0d\u5e38\u898b\nD.\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005\u5747\u61c9\u63a5\u53d7\u6297\u6838\u6297\u9ad4 (antinuclear antibody )\uff0c\u985e\u98a8\u6fd5\u56e0\u5b50 (rheumatoid factor )\uff0cScl \n70\u6297\u9ad4 (anti-scl-70 antibody )\u6aa2\u6e2c\nE.\u5fc3\u97f3\u807d\u8a3a\u6642\uff0c\u7b2c\u4e8c\u5fc3\u97f3\u80ba\u52d5\u8108\u74e3\u6210\u5206\u6703\u52a0\u91cd(accentuated P2)\n": "[C]", "109-17.\u6709\u95dc\u6025\u6027\u814e\u640d\u50b7(acute kidney injury)\u9020\u6210\u5fc3\u81df\u8870\u7aed\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u51fa\u9662\u5f8c\uff0c\u56e0\u5fc3\u81df\u8870\u7aed\u518d\u4f4f\u9662\u98a8\u96aa\u660e\u986f\u589e\u52a0\nB.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u51fa\u9662\u5f8c\uff0c\u56e0\u5fc3\u8840\u7ba1\u75be\u75c5\u6b7b\u4ea1\u6216\u6162\u6027\u5fc3\u81df\u8870\u7aed\u6bd4\u7387\u660e\u986f\u589e\u52a0\nC.\u6025\u6027\u814e\u640d\u50b7\u91cd\u75c7\u60a3\u8005\uff0c\u534a\u4e73\u7cd6\u51dd\u96c6\u7d20-3 (galectin 3)\u8207\u5fc3\u808c\u50b7\u5bb3\u6709\u76f8\u95dc\nD.\u5728\u6025\u6027\u814e\u640d\u50b7\u6642\uff0c\u7528\u6c28\u57fa\u672b\u7aef\u8166\u9209\u80bd\u524d\u9ad4(NT-proBNP)\u53ef\u4ee5\u8a3a\u65b7\u5fc3\u81df\u8870\u7aed\u7684\u56b4\u91cd\u5ea6   \nE.\u55dc\u4e2d\u6027\u767d\u8840\u7403\u660e\u81a0\u76f8\u95dc\u6027\u8102\u8cea\u904b\u8f09\u86cb\u767d (neutrophil gelatinase \u2013associated lipocalin /NGAL)\u8207\u6025\u6027\u814e\n\u640d\u50b7\u9020\u6210\u4e4b\u5fc3\u808c\u7e96\u7dad\u5316\u6709\u76f8\u95dc\n": "[D]", "109-18.\u6709\u95dc\u5fc3\u81df\u7406\u5b78\u6aa2\u67e5\u4e4b\u63cf\u8ff0 ,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5fc3\u623f\u986b\u52d5\u6642 ,\u807d\u8a3a\u6642\u4e0d\u6703\u51fa\u73fe\u7b2c\u56db\u5fc3\u97f3 (S4)\n(2) \u807d\u8a3a\u6642,\u7b2c\u4e09\u5fc3\u97f3 (S3)\u5728\u53ea\u5728\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u4e4b\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u51fa\u73fe ,\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\u4e4b\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u4e0d\u6703\u51fa\u73fe\n(3) Allen's test\u662f\u7528\u4f86\u5075\u6e2c\u80b1\u52d5\u8108 (brachial artery) \u8840\u6db2\u5faa\u74b0\n(4) \u5927\u6d41\u91cf\u4e4b\u52d5\u975c\u8108\u5ed4\u7ba1 (arteriovenous fistula )\u53ef\u4ee5\u9020\u6210\u975e\u5e38\u4f4e\u4e4b\u8212\u5f35\u58d3\n(5) \u5728\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u60a3\u8005 ,\u628a\u8108\u6642\u53ef\u4ee5\u6478\u5230\u96d9\u5cf0\u8108\u6ce2 (bifid pulse )\n(6) \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u4e4b\u6536\u7e2e\u671f\u96dc\u97f3\u807d\u8a3a\u5340\u5728\u80f8\u9aa8\u53f3\u5074\u7b2c\u4e8c\u808b\u9593 ,\u5fc3\u96dc\u97f3\u6703\u50b3\u905e\u81f3\u9838\u52d5\u8108   \nA.(1)+(2)+(3)+(6)\nB.(1)+(4)+(6)\nC.(2)+(4)+(5)\nD.(1)+(2)+(4)\nE.(4)+(5)+(6)\n": "[B]", "109-19.\u4e0b\u5217\u54ea\u4e00\u500b\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291 (beta-blocker)\uff0c\u9664\u4e86\u4ea4\u611f\u795e\u7d93\u6291\u5236\u5916 \uff0c\u9084\u5177\u5099\u8840\u7ba1\u64f4\u5f35\u529f\u80fd (additional \nvasodilator actions )   \nA.Nebivolol\nB.Atenolol\nC.Metoprolol\nD.Propranolol\nE.Bisoprolol\n": "[A]", "109-20.\u4e00\u4f4d70\u6b72\u5973\u6027 \uff0c\u4e3b\u8a34\u660f\u53a5\u75c5\u53f2 \uff0c24 \u5c0f\u6642Holter ECG (\u5982\u9644\u5716)\uff0c\u7121\u75c7\u72c0\u4e4b\u5fc3\u96fb\u5716\u70ba\u4e0a\u5716 \uff0c\u767c\u751f\u660f\u53a5\u4e4b\u5fc3\u96fb\n\u5716\u70ba\u4e0b\u5716 \u3002\u8a72\u5fc3\u96fb\u5716\u4e4b\u5fc3\u81df\u7bc0\u5f8b\u6b63\u78ba\u8a3a\u65b7\u70ba \uff1f   \nA.\u7b2c\u4e00\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\nB.\u7b2c\u4e8c\u5ea6\u7b2c\u4e00\u578b\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08Mobitz I\uff09\nC.\u7b2c\u4e8c\u5ea6\u7b2c\u4e8c\u578b\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08Mobitz II\uff09\nD.\u7b2c\u4e09\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\nE.\u75c5\u7ac7\u75c7\u5019\u7fa4\n": "[D]", "109-21.\u6709\u95dc\u5fc3\u623f\u986b\u52d5\u8207\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction)\u4e4b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5fc3\u623f\u986b\u52d5\u8207\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u5169\u8005\u5408\u4f75\u767c\u751f\u6642\uff0c\u6703\u5c0e\u81f4\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u9810\u5f8c\u4e0d\u826f\nB.\u5728\u4e2d\u81f3\u91cd\u5ea6\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u60a3\u8005\uff0c\u4f7f\u7528dronedarone \u4e0d\u6703\u5c0e\u81f4\u6b7b\u4ea1\u7387\u589e\u52a0\nC.\u53ef\u4ee5\u4f7f\u7528dofetilide\u4f86\u9032\u884c\u7bc0\u5f8b\u63a7\u5236(rhythm control)\nD.\u53ef\u9032\u884c\u5c0e\u7ba1\u71d2\u707c\u8853(catheter ablation and pulmonary vein isolation)\nE.\u53ef\u4ee5\u4f7f\u7528amiodarone\u4f86\u9032\u884c\u7bc0\u5f8b\u63a7\u5236(rhythm control)\n": "[B]", "109-22.\u6709\u95dc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e (infective aortitis )\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624 (mycotic aneurysm )\u597d\u767c\u90e8\u70ba\u5728infrarenal abdominal aorta\n(2) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624\u597d\u767c\u65bc\u5e74\u8f15\u4eba\n(3) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624\u597d\u767c\u65bc\u7537\u6027\n(4) \u6885\u6bd2\u6027\u4e3b\u52d5\u8108\u708e (syphilitic aortitis) \u597d\u767c\u65bc\u5347\u4e3b\u52d5\u8108 (ascending aorta )\uff0c\u5c24\u5176\u662f\u4e3b\u52d5\u8108\u6839\u90e8 (aortic root )\n(5) \u6885\u6bd2\u6027\u4e3b\u52d5\u8108\u708e\u6703\u9020\u6210\u8840\u7ba1\u6ecb\u990a\u7ba1 (vasa vasorum) \u7684\u9589\u585e\u6027\u52d5\u8108\u5167\u819c\u708e( obliterative endarteritis )      \nA.(1)+(2)\nB.(2)+(3)\nC.(2)+(4)\nD.(1)+(4)\nE.(3)+(5)\n": "[A]", "110-1.\u4f9d\u64da2019\u5e74\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u9812\u4f48\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u7684\u8655\u7f6e\u662f\u4e0d\u6b63\u78ba\u7684?    \nA.\u50e7\u5e3d\u74e3\u72f9\u7a84 (Mitral stenosis) \u53ca\u91d1\u5c6c\u985e\u74e3\u819c\u61c9\u4f7f\u7528Warfarin\u4f5c\u6297\u51dd\u8840\u85e5\u7269 (Anti-coagulant) \u4ee5\u6cbb\u7642\u5fc3\u623f\n\u7e96\u7dad\u986b\u52d5 \u3002\nB.\u672b\u671f\u814e\u75c5\u4eba\u6216\u4f7f\u7528\u8840\u6db2\u900f\u6790\u75c5\u4eba\u4e0d\u5408\u9069\u4f7f\u7528Dabigatran \uff0cRivaroxaban \u6216Edoxaban\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\n\u52d5\u3002\nC.\u6cbb\u7642\u975e\u74e3\u819c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u4ee5\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (NOACs, \u5982dabigatran, rivaroxaban, apixaban, \n\u53ca edoxaban) \u6bd4warfarin\u66f4\u597d \u3002\nD.\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation, AF )\u6709\u77ed\u9663\u5f0f (paroxysmal ), \u6301\u7e8c\u5f0f(persistent ), \u53ca\u6c38\u4e45\u5f0f (permanent) \n\u7b49\u4e09\u7a2e\uff0c\u53ea\u6709permanent AF\u624d\u9700\u8981\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u6cbb\u7642 \u3002\nE.\u5973\u6027\u75c5\u4eba\u6709\u5fc3\u623f\u64b2\u52d5 (Atrial flutter) \u5176CHA\u2082DS\u2082VASc\u662f 2\u5206\u6642\uff0c\u53ef\u4e0d\u5fc5\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u6cbb\u7642 \u3002\n": "[D]", "110-2.\u4f9d\u64da2020\u53f0\u7063\u9ad8\u8840\u58d3\u5b78\u6703\u53ca\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u7684\u5c08\u5bb6\u5171\u8b58\u800c\u9812\u4f48\u7684\u8a3a\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?    \nA.\u9996\u6b21\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u9ad8\u8840\u58d3 \uff0c\u61c9\u65bc2\u500b\u661f\u671f\u5f8c\u56de\u8a3a \uff0c\u5982\u82e5\u8840\u58d3\u4e0d\u7372\u5f97\u63a7\u5236 \uff0c\u61c9\u5728\u4e00\u500b\u6708\u5f8c\u56de\u8a3a \uff0c\u5982\u82e5\u8840\n\u58d3\u7372\u5f97\u63a7\u5236 \uff0c\u5f97\u5728\u4e09\u500b\u6708\u5f8c\u56de\u8a3a \u3002\nB.\u9ad8\u8840\u58d3\u5408\u4f75\u4e09\u7a2e\u4ee5\u4e0a\u5371\u96aa\u56e0\u7d20(\u5982\u7cd6\u5c3f\u75c5\u3001\u51a0\u5fc3\u75c5)\uff0c\u61c9\u5c07\u8840\u58d3\u63a7\u5236\u5728130/80 mmHg \u4ee5\u4e0b\u3002\nC.\u5927\u65bc75\u6b72\u7684\u8001\u5e74\u9ad8\u8840\u58d3\u75c5\u4eba\uff0c\u8840\u58d3\u61c9\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\u3002\nD.\u9ad8\u8840\u58d3\u5408\u4f75\u8166\u4e2d\u98a8\u6216\u6162\u6027\u814e\u75c5\u8b8a\u7684\u75c5\u4eba\uff0c\u5b9c\u5c07\u8840\u58d3\u63a7\u5236\u5728140/90 mmHg \u4ee5\u4e0b\u3002\nE.\u5e74\u8f15\u4eba(<30\u6b72)\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u8a3a\u9593\u8840\u58d3120/75 mmHg\uff0c\u5f97\u5efa\u8b70\u4e0d\u5fc5\u5b9a\u671f\u56de\u8a3a\u3002\n": "[D]", "110-3.\u6709\u95dcCOVID-19\u7684\u5fc3\u8840\u7ba1\u4f75\u767c\u7684\u75c5\u60c5\u5831\u544a\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?    \nA.\u611f\u67d3COVID-19\u75c5\u4eba\u6bd4\u6d41\u884c\u6027\u611f\u5192(Influenza)\u8005\u70ba\u591a\u3002\nB.COVID-19\u75c5\u6bd2\u9032\u5165\u4eba\u9ad4\u7d30\u80de\u63a1\u5167\u541e\u65b9\u5f0f (Endocytosis) \uff0c\u90fd\u7d93\u7d30\u80de\u819c\u4e0aACE -2\u86cb\u767d\u4e4b\u5f15\u4ecb \uff0c\u5fc3\u808c\u7d30\u80de\n\u4ea6\u67097.5%\u7684ACEI-2 Expression \uff0c\u662f\u4ee5\u5fc3\u808c\u50b7\u8b8a\u5728\u6240\u96e3\u514d \u3002\nC.\u5fc3\u808cTroponin T\u53ef\u56e0\u4f75\u767c\u51a0\u8108\u8840\u7ba1\u50b7\u8b8a\u3001\u5fc3\u808c\u708e\u6216\u5fc3\u8840\u7ba1\u75d9\u6523\u800c\u6607\u9ad8\u3002\nD.\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u80a5\u80d6\u75c7\u53ca\u5fc3\u8840\u7ba1\u75c5\u7684COVID-19\u75c5\u4eba\u6b7b\u4ea1\u7387\u504f\u9ad8\u3002\nE.\u5fc3\u5f8b\u4e0d\u6574\uff0cSTEMI \u53caNSTEMI\uff0c\u4f11\u514b\u90fd\u53ef\u80fd\u767c\u751f\u5728COVID-19\u75c5\u4eba\uff0c\u7279\u5225\u5e74\u8001\u591a\u75c5\u8005\u3002\n": "[A]", "110-4.73\u6b72\u8001\u592a\u592a\u5728\u4e09\u5929\u524d\u6642\u6709\u77ed\u9663\u80f8\u60b6\u5f8c\u81ea\u7136\u7de9\u89e3\u4e0d\u75db \uff0c\u4e0d\u610f\u6709\u6b21\u904b\u52d5\u5f8c\u7a81\u767c\u80f8\u75db\u6301\u7e8c\u4e8c\u5c0f\u6642\u4e0d\u505c \uff0c\u540c\u6642\u4f34\u6709\n\u76dc\u6c57\u53ca\u5641\u5fc3 \uff0c\u4e43\u524d\u5f80\u6025\u8a3a\u6c42\u91ab \u3002\u6642TPR 35.9\u2070C / 75/min / 22/min; BP 152 / 70 mmHg; SpO2 100 %\u3002\u75c5\u4eba\n\u5144\u5f1f\u59ca\u59b9\u591a\u4eba\u6709\u9ad8\u8102\u8840\u75c7 \uff0c\u4f46\u672a\u6709\u9ad8\u8840\u58d3\u6216\u7cd6\u5c3f\u75c5 \u3002\u8eab\u9ad4\u7406\u5b78\u6aa2\u67e5\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u767c\u73fe \u3002\u63a1\u8840\u9032\u884c\u751f\u5316\u53ca\u8840\n\u6db2\u6aa2\u67e5\u4e2d \uff0c\u96a8\u5373\u4f5c\u5fc3\u96fb\u5716\u6aa2\u67e5 \uff0c\u5982\u5716\u3002\u8acb\u554f\u9019\u4f4d\u75c5\u4eba\u7684\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f :   \nA.\u5de6\u524d\u964d\u679d\u51a0\u8108\u8fd1\u7aef\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u7684ST elevation myocardial infarction(STEMI)\u3002\nB.\u5de6\u524d\u964d\u679d\u51a0\u8108\u9060\u7aef\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u7684STEMI\u3002\nC.\u5de6\u8ff4\u65cb\u679d\u51a0\u8108\u9060\u7aef\u8840\u7ba1\u963b\u585e\u7684STEMI\u3002\nD.\u53f3\u51a0\u8108\u8fd1\u7aef\u8840\u7ba1\u963b\u585e\u7684STEMI\u3002\nE.\u591a\u8840\u7ba1\u51a0\u5fc3\u75c5\u4ee5(non-STEMI)\u81e8\u5e8a\u8868\u73fe\u3002\n": "[A]", "110-5.\u6709\u95dc\u4e3b\u52d5\u8108\u7624 (Aortic aneurysms \uff0cAA)\u4e43\u6cdb\u6307\u4e3b\u52d5\u8108\u76f4\u5f91\u64f4\u592750 %\u4e4b\u8b02\uff0c\u81e8\u5e8a\u7684\u8a8d\u77e5\u5e38\u662f\u7a2e\u7121\u75c7\u72c0 \uff0c\u4f46\u537b\n\u9032\u884c\u64f4\u5c55\u4e2d\u7684\u75be\u75c5 \uff0c\u6709\u4e3b\u52d5\u8108\u7834\u88c2\u6025\u6551\u7684\u5371\u96aa \uff0c\u4e0b\u5217\u4f55\u9805\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u6700\u8fd1\u7814\u7a76\u8a8d\u5b9a AA\u8207\u8102\u86cb\u767d\uff0c\u7279\u5225\u904e\u4f4e\u7684\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187(HDL-C)\u6709\u95dc\u3002\nB.\u4f9d\u64da\u7814\u7a76\u767c\u73fe\u7cd6\u5c3f\u75c5\u4eba\u7684AA\u8f03\u4e0d\u6613\u64f4\u5927\uff0c\u4e14\u8207HbA1c\u7684\u60aa\u5316\u5ea6\u6210\u53cd\u6bd4\u95dc\u4fc2\u3002\nC.\u8179\u90e8AA\u591a\u898b\u65bc\u7537\u6027\u53ca\u5e74\u8001\u75c5\u4eba\u3002   \nD.\u81e8\u5e8a\u7814\u7a76 \uff0c\u80f8\u90e8AA\u6bd4\u8179\u90e8AA\u591a\u898b ,\u524d\u8005\u8207\u57fa\u56e0 \u3001\u62bd\u7159\u3001\u9ad8\u8840\u58d3\u53ca\u6162\u6027\u80ba\u963b\u585e\u75c5\u7b49\u98a8\u96aa\u6709\u95dc \uff0c\u5f8c\u8005\u8207\u5e74\n\u9f61\u3001\u7537\u6027\u3001\u62bd\u7159\u53ca\u8840\u7ba1\u7ca5\u72c0\u786c\u5316\u7b49\u98a8\u96aa\u6709\u95dc \u3002\nE.\u8179\u90e8AA\u61c9\u5b9a\u671f\u6aa2\u67e5, 3-3.9\u516c\u5206\u76f4\u5f91\u6642\u6bcf\u4e09\u5e74\u8ffd\u8e64\u4e00\u6b21 \uff0c4-4.4\u516c\u5206\u6642\u6bcf\u4e8c\u5e74\u8ffd\u67e5\u4e00\u6b21 \uff0c\u800c4.5-5.4 \u516c\u5206\n\u8005\u6bcf\u5e74\u4e00\u6b21\u8ffd\u67e5 \uff0c\u8d85\u904e5.5\u516c\u5206\u61c9\u4e8e\u6cbb\u7642 \u3002\n": "[D]", "110-6.\u6025\u6027\u5fc3\u808c\u6897\u585e\u4f75\u767c\u5fc3\u56e0\u6027\u4f11\u514b (Cardiogenic shock )\u7684\u767c\u751f\u7387\u7d04\u5728 3-13%\uff0c\u76ee\u524d\u63a1\u884c\u76e1\u65e9\u51a0\u8108\u518d\u901a\u624b\n\u8853(Coronary Revascularization )\u4f7f\u6b7b\u4ea1\u7387\u5f9e70 -80%\u4e0b\u964d\u523040 -50%\uff0c\u4f46\u8fd1\u5e74\u7684\u7814\u7a76\u986f\u793a\u6b7b\u4ea1\u7387\u4e0d\u964d\u53cd\u800c\u5fae\n\u5347\uff0c\u4ecd\u6709\u6539\u5584\u7684\u7a7a\u9593 \u3002\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u5be6\u8a3c\u91ab\u5b78\u7684\u8655\u7f6e \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u4f9d\u64da2018\u5e74\u6b50\u6d32\u5fc3\u81df\u91ab\u5b78\u6703\u7684\u6307\u5f15\u5efa\u8b70 \uff0c\u50c5\u53ea\u8655\u7406\u8087\u59cb\u75c5\u8b8a (Culprit lesion )\uff0c\u4e0d\u5efa\u8b70\u5e38\u898f\u540c\u6642\u591a\u689d\u51a0\n\u8108\u518d\u901a\u624b\u8853 \u3002\nB.\u4f9d\u64da\u73fe\u6709\u7684\u6578\u500b\u81e8\u5e8a\u7814\u7a76 \uff0c\u7dca\u6025\u51a0\u8108\u8840\u7ba1\u7e5e\u9053\u624b\u8853 \uff08CABG)\u6216\u7d93\u76ae\u51a0\u8108\u518d\u901a\u8853 (PCI)\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\n\u514b\uff0c\u4f55\u8005\u70ba\u4f73 \uff0c\u96e3\u6709\u7d50\u8ad6 \u3002\nC.\u5fc3\u808c\u6897\u585e\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u75c5\u4eba\u4e4b\u8840\u6d41\u7570\u5e38\u53ca\u7121\u6cd5\u53e3\u670d\u6297\u8840\u677f\u85e5\u7269 \uff0c\u5f97\u975c\u8108\u6ce8\u5c04GP IIb /IIIb-inhibitors or \nCangrelor \u3002\nD.\u5e7e\u4e4e90%\u5fc3\u56e0\u6027\u4f11\u514b\u75c5\u4eba\u5927\u591a\u4f7f\u7528\u8840\u7ba1\u4f5c\u7528\u5291 (Vasoactive agents ),\u7531\u65bc\u8840\u7ba1\u6536\u7e2e\u5f71\u97ff\u5fae\u8840\u7ba1\u5faa\u74b0\u53ca\n\u589e\u52a0\u5fc3\u808c\u8017\u6c27\u91cf \uff0c\u61c9\u4ee5\u4f4e\u91cf\u6ce8\u5c04\u70ba\u4e3b \u3002\nE.\u4e3b\u52d5\u8108\u5167\u9006\u5411\u5e6b\u9001\u8f14\u52a9\u7642\u6cd5(IABP)\u662f\u5fc3\u56e0\u6027\u4f11\u514b\u8655\u7f6e\u7684\u5fc5\u8981\u9078\u64c7\u3002\n": "[E]", "110-7.\u904e\u53bb20-30\u5e74\u6709\u95dc\u6025\u6027\u5fc3\u808c\u708e(Myocarditis)\u7684\u8a3a\u7642\u8ad6\u9ede\u5df2\u6709\u91cd\u5927\u7684\u6539\u8b8a\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u6b63\u78ba\u7684\u505a\u6cd5\uff1f    \nA.\u4e0d\u8ad6\u9ad8\u6216\u4f4e\u98a8\u96aa\u7684\u5fc3\u8870\u75c5\u4f8b\uff0c\u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\u662f\u5fc5\u9808\u7684\u8a3a\u65b7\u65b9\u6cd5\u3002\nB.\u5fc3\u808c\u78c1\u632f\u9020\u5f71\u7528\u65bc\u8fa8\u8b58\u5fc3\u808c\u6c34\u816b\u53ca\u7e96\u7dad\u75c5\u8b8a\uff0c\u53ef\u5e6b\u52a9\u5fc3\u808c\u708e\u9451\u5225\u3002\nC.\u514d\u75ab\u7642\u6cd5\u5c0d\u5de8\u7d30\u80de\u5fc3\u808c\u708e (Giant Cell myocarditis )\u6216\u55dc\u7d05\u767d\u8840\u7403\u5fc3\u808c\u708e (Eosinophilic myocarditis )\u6709\n\u6548\u3002\nD.\u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u75c5\u6bd2\u57fa\u56e0\u9ad4(Virus genome)\u4e0d\u4e00\u5b9a\u80fd\u78ba\u5b9a\u5fc3\u808c\u708e\u7684\u8a3a\u65b7\u3002\nE.\u5553\u7528\u8af8\u5982IABP \u53caECMO\u6709\u52a9\u8655\u7406\u6025\u6027\u5fc3\u808c\u708e\u65e9\u671f\u4e4b\u8840\u884c\u529b\u5b78(Hemodynamic)\u4e4b\u7570\u5e38\u3002\n": "[A]", "110-8.40\u6b72\u4f01\u696d\u4e3b\u7ba1\u56e0\u6709\u5fc3\u60b8\u53ca\u547c\u5438\u56f0\u96e3\u6709\u4e00\u500b\u661f\u671f\u4e4b\u4e45 \uff0c\u4e43\u524d\u5f80A\u9662\u6c42\u8a3a\uff0c\u8a8d\u5b9a\u662f\u4e0a\u547c\u5438\u9053\u611f\u67d3 \uff0c\u4f46\u8655\u7f6e\u7121\n\u6548\uff0c\u4e09\u5929\u5f8c\u81f3 B\u9662\u3002\u75c5\u4eba\u57282009\u5e74\u8a3a\u65b7\u7a81\u767c\u6027\u4e0a\u5fc3\u5ba4\u5feb\u8df3 \uff0c\u4e14\u6709\u591a\u5e74\u80a5\u80d6 (BMI=41.5 Kg/m\u00b2,) \u3002\u7406\u5b78\u6aa2\u67e5: \nBP: 156/91  mmHg, HR :141/min, RR:28/min, Temp: 36 .90\u2103, SpO2: 97%\uff0c\u7121\u8ca7\u8840\uff0c\u9838\u975c\u8108\u6b63\u5e38 \uff0c\u7532\u72c0\n\u817a\u672a\u6709\u7570\u5e38 \uff0c\u80f8\u90e8\u6709\u6df7\u6fc1\u547c\u5438\u8072 \uff0c\u5fc3\u81df\u7a0d\u5927 \uff0c\u4e0d\u6b63\u5e38\u5f8b\u52d5 \uff0c\u672a\u6709S3\u53ca\u5fc3\u96dc\u97f3 \uff0c\u809d\u813e\u4e0d\u5927 \uff0c\u7121\u8179\u6c34\uff0c\u96d9\u4e0b\n\u80a2\u5fae\u816b\u3002\u6642\uff0c\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X-\u5149\u53ca\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716 \u3002\u5176\u751f\u5316\u53ca\u8840\u6db2\u6c23\u9ad4\u6aa2\u9a57\u5982\u8868 \u3002\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u8a3a\u65b7\u6700\n\u6b63\u78ba?   \nA.\u51a0\u72c0\u52d5\u8108\u6813\u585e\u75c7\u3002\nB.\u9ad8\u8840\u58d3\u5fc3\u8840\u7ba1\u75c5\u3002\nC.\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u3002\nD.\u80ba\u52d5\u8108\u6813\u585e\u75c7\u3002\nE.\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u3002\n": "[D]", "110-9.\u75c5\u4eba\u738b\u5148\u751f\u73fe\u5e7488 \u6b72\uff0c\u6709\u5169\u500b\u6708\u7684\u96d9\u8173\u6d6e\u816b\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u6578\u5ea6\u524d\u5f80\u591a\u5bb6\u91ab\u9662\u6c42\u8a3a \uff0c\u8a3a\u7642\u7f54\u6548 \u3002\u75c5\u4eba\n\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u8102\u8840\u3001\u6162\u6027\u814e\u81df\u75c5\u53ca\u651d\u8b77\u817a\u80a5\u5927\u7b49\u904e\u5f80\u75c5\u53f2 \u3002\u5230\u8a3a\u6642\u610f\u8b58\u6e05\u9192\uff0c T/P/R: 35.5 \u00b0C/99/18; \nBP: 121/73 mmHg; SpO 2: 92%\u3002(ambient air ); BH: 165 cm; BW: 66 kg; BMI: 24 .2 kg/m2   \u7406\u5b78\u6aa2\u67e5\u5b8c\n\u6210\u5f8c\uff0c\u6709\u5fc3\u96fb\u5716 \u3001\u80f8\u90e8X\u5149\u53ca\u5176\u4ed6\u5f71\u50cf\u6aa2\u67e5\u5982\u5716 :\u8acb\u554f\u4e0b\u5217\u6578\u500b\u6a19\u7684\u4e4b\u7406\u5b78\u6aa2\u67e5 (Targeted physical \nexamination) \u6240\u898b: ( 1)\u5168\u8eab\u6c34\u816b (2)\u80ba\u6c34\u816b\u986f\u8457 (3)\u5927\u8108\u58d3(Pulse pressure) ( 4)\u809d\u813e\u816b\u5927 (5)Pericardial \nknock (6)Kussmaul sign \u3002\u90a3\u7d44\u662f\u6b63\u78ba\u8a3a\u65b7\u7684\u6839\u64da ?   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002   \nC.(1)+(4)+(6)\u3002\nD.(2)+(3)+(4)\u3002\nE.(2)+(4)+(6)\u3002\n": "[C]", "110-10.\u6709\u95dc\u8eab\u9ad4\u8a3a\u5bdf\u5167\u9838\u975c\u8108\u7684\u8108\u5716,\u4e0b\u5217\u54ea\u4e00\u500b\u6558\u8ff0\u932f\u8aa4?    \nA.\u5728\u5fc3\u623f\u5fc3\u5ba4\u89e3\u96e2(AV dissociation)\u6642,\u6703\u51fa\u73fe\u5de8\u5927\u7684 A\u6ce2(Cannon A wave)\u3002\nB.\u5fc3\u623f\u986b\u52d5\u6642,\u6703\u51fa\u73feA \u6ce2\u3002\nC.Wide QRS complex tachycardia\u6642\u51fa\u73feA wave,\u4ee3\u8868\u662f\u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u8d77\u6e90\u4f86\u81ea\u5fc3\u5ba4\u3002\nD.\u4e09\u5c16\u74e3\u91cd\u5ea6\u9589\u9396\u4e0d\u5168\u6642,V \u6ce2\u6703\u8b8a\u5927\u3002\nE.\u6b63\u5e38\u5438\u6c23\u6642,\u9838\u975c\u8108\u58d3\u61c9\u4e0b\u964d\u7d043\u6beb\u7c73\u6c5e\u67f1\u3002\n": "[B]", "110-11.\u60a3\u8005\u5fc3\u808c\u6897\u585e\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u6642,\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?    \nA.\u5fc3\u808c\u6897\u585e\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u6642,\u7d04\u670980%\u75c5\u4eba\u5448\u73fe\u5de6\u5fc3\u8870\u7aed\u3002\nB.\u5728\u524d\u80f8\u9396\u9aa8\u4e0b\u807d\u5230\u7b2c\u4e09\u7d1a\u8212\u5f35\u671f\u96dc\u97f3 ,\u8981\u8003\u616e\u5fc3\u5ba4\u4e2d\u8188\u808c\u8089\u56e0\u5fc3\u808c\u6897\u585e ,\u9020\u6210\u6025\u6027\u5fc3\u5ba4\u4e2d\u8188\u88c2\n\u640d(ventricular septal rupture )\u3002\nC.\u6025\u6027\u5fc3\u5ba4\u4e2d\u8188\u88c2\u640d\u6642,\u53f3\u5fc3\u623f\u8207\u53f3\u5fc3\u5ba4\u8212\u5f35\u671f\u7684\u58d3\u529b\u6703\u4e0a\u5347\u3002\nD.\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ef\u4ee5\u5354\u52a9\u5206\u8fa8\u662f\u5426\u6709\u5fc3\u5305\u819c\u586b\u585e,\u4e8c\u5c16\u74e3\u8171\u7d22\u65b7\u88c2\u3002\nE.Lead aVR \u5448\u73feST segment elevation ,\u540c\u6642\u6709\u591a\u5c0e\u6975\u5448\u73feST depression \u6642,\u8981\u8003\u616e\u5de6\u4e3b\u51a0\u72c0\u52d5\u8108\u91cd\u5ea6\n\u72f9\u7a84\u3002\n": "[B]", "110-12.\u4e0b\u5217\u54ea\u4e00\u7a2e\u5fc3\u5305\u819c\u767c\u708e\u75c7\u72c0\u8f03\u5e38\u6709\u660e\u986f\u80f8\u75db?    \nA.\u80ba\u7d50\u6838\u5fc3\u5305\u819c\u708e (tuberculous pericarditis)\u3002\nB.\u816b\u7624\u5fc3\u5305\u819c\u767c\u708e(neoplastic pericarditis)\u3002\nC.\u5c3f\u6bd2\u6027\u5fc3\u5305\u819c\u767c\u708e (uremic pericarditis)\u3002\nD.\u653e\u5c04\u6cbb\u7642\u5f8c\u5fc3\u5305\u819c\u767c\u708e( post-irradiation pericarditis)\u3002\nE.\u5fc3\u808c\u6897\u585e\u5f8c\u5fc3\u5305\u819c\u767c\u708e (Dressler's syndrome)\u3002\n": "[E]", "110-13.\u6162\u6027\u91cd\u5ea6\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168\u4e4b\u75c5\u60a3,\u4e0b\u5217\u54ea\u4e00\u7a2e\u7406\u5b78\u6aa2\u67e5\u4e4b\u63cf\u8ff0\u70ba\u932f\u8aa4?    \nA.\u6703\u51fa\u73fewater-hammer pulse\u3002\nB.\u6703\u5728\u6307\u5c16\u51fa\u73fe Quincke's pulse\u3002\nC.\u6703\u51fa\u73feTraube's sign\u3002\nD.\u7576\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168 ,\u662f\u7531\u4e3b\u52d5\u8108\u6839\u90e8\u7624\u72c0\u64f4\u5f35 (aneurysmal dilation of the aortic root )\u6240\u5c0e\u81f4\u6642 ,\u8212\u5f35\n\u671f\u4e4b\u96dc\u97f3\u5728\u80f8\u9aa8\u5de6\u5074\u6bd4\u53f3\u5074\u660e\u986f \u3002\nE.\u6703\u51fa\u73feDuroziez's sign\u3002\n": "[D]", "110-14.\u6709\u95dc\u9209-\u8461\u8404\u7cd6\u5171\u540c\u8f49\u904b\u86cb\u767d\u6291\u5236\u5291 (Sodium-Glucose Co -Transporter 2 [SGLT2] inhibitor )\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\n\u8005\u6b63\u78ba?(1)SGLT2 inhibitor\u662f\u6291\u5236\u9060\u7aef\u814e\u5c0f\u7ba1\u7684\u9209 -\u8461\u8404\u7cd6\u5171\u540c\u8f49\u904b\u86cb\u767d (2)SGLT2 inhibitor\u6703\u5c0e\u81f4\u5c3f\u4e2d\u8461\n\u8404\u7cd6\u6392\u51fa\u91cf\u964d\u4f4e (3)SGLT2 inhibitor\u7684\u964d\u8840\u7cd6\u6548\u679c\u662finsulin independent (4)SGLT2 inhibitor \u6703\u5c0e\u81f4\u9ad4\u91cd\u964d\n\u4f4e (5)SGLT2 inhibitor (Empagliflozin and canagliflozin )\u5728\u6709\u7cd6\u5c3f\u75c5\u5408\u4f75\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005 ,\u6703\u589e\u52a0\u5fc3\u81df\u8870\u7aed\n\u7684\u518d\u4f4f\u9662\u7387   \nA.(3)+(4)\u3002\nB.(1)+(5)\u3002\nC.(4)+(5)\u3002   \nD.(1)+(2)+(3)\u3002\nE.(2)+(3)+(5)\u3002\n": "[A]", "110-15.ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e (ST segment elevation myocardial infarction )\u75c5\u60a3\u63a5\u53d7\u8840\u6813\u6eb6\u89e3\u5291\u7684\u6558\u8ff0\u4f55\u8005\u932f\n\u8aa4?   \nA.\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u5291\u5f8c ,\u9020\u6210\u6897\u585e\u4e4b\u51a0\u72c0\u52d5\u8108\u5982\u80fd\u9054TIMI (Thrombolysis in Myocardial Infarction )\u5206\u985e\u7b2c\u4e09\n\u7d1a\u8840\u6d41,\u5176\u9810\u5f8c\u8f03\u4f73 .\u76f8\u8f03\u65bcstreptokinase ,\u4f7f\u7528tPA ( tissue plasminogen activator )\u80fd\u66f4\u6709\u6548\u7387\u8b93\u9020\u6210\n\u6897\u585e\u4e4b\u51a0\u72c0\u52d5\u8108\u9054TIMI \u5206\u985e\u7b2c\u4e09\u7d1a\u8840\u6d41 \u3002\nB.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u8981\u6ce8\u610f\u51fa\u8840\u7684\u98a8\u96aa ,\u5927\u898f\u6a21\u7814\u7a76 (large-scale trials )\u986f\u793a:\u76f8\n\u8f03\u65bcstreptokinase ,\u4f7f\u7528tPA\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u9020\u6210\u9871\u5167\u51fa\u8840\u4e4b\u98a8\u96aa\u660e\u986f\u964d\u4f4e \u3002\nC.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e ,\u572870\u6b72\u4ee5\u4e0a\u9020\u6210\u9871\u5167\u51fa\u8840\u7684\u98a8\u96aa\u7d04\u70ba65\u6b72\u4ee5\u4e0b\u75c5\u60a3\n\u76842\u500d\u3002\nD.\u4f7f\u7528streptokinase\u8981\u6ce8\u610f\u904e\u654f\u53cd\u61c9\u3002\nE.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u8981\u6ce8\u610f\u75c5\u60a3\u8840\u58d3\u4e0d\u80fd\u904e\u9ad8 (\u5982\u6536\u7e2e\u58d3 >180 mmHg ,\u8212\u5f35\n\u58d3>110mmHg )\u3002\n": "[B]", "110-16.\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u60a3\u56e0\u7aef\u5750\u547c\u5438\u8207\u52d5\u5598\u4e00\u9031\u800c\u4f86\u4f4f\u9662 \u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8840\u58d390 /56\u6beb\u7c73\u6c5e\u67f1 ,\u5fc3\u8df3\u6bcf\u5206\n\u9418102\u4e0b,\u9838\u975c\u8108\u6012\u5f35 ,\u5fc3\u97f3\u4f4e\u9060\u4f75\u7b2c\u4e09\u5fc3\u97f3 \uff0c\u80ba\u90e8\u6709\u56c9\u97f3 \uff0c\u96d9\u4e0b\u80a2\u5c0f\u817f\u8207\u8173\u90e8\u6c34\u816b \u3002\u5fc3\u96fb\u5716\u5982\u5716\u4e00 \u3002\u5fc3\u81df\n\u8d85\u97f3\u6ce2\u5448\u73fe\u5de6\u5fc3\u5ba4\u64f4\u5927 ,\u7030\u6f2b\u6027\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u7570\u5e38 ,\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387 (left ventricle ejection \nfraction)\u70ba25%\u3002\u5fc3\u81df\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u5982\u5716\u4e8c A\u8207B\u3002\u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u5982\u5716\u4e8c C\u8207D\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\n\u8aa4?(1)\u8a72\u75c5\u60a3\u7684\u5fc3\u96fb\u5716\u5448\u73fe low voltage in frontal leads (2)\u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u986b\u52d5 (3)\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u78c1\n\u632f\u9020\u5f71\u5f71\u50cf\u6aa2\u67e5\u5448\u73fe\u5de6\u5fc3\u5ba4\u5fc3\u808c\u7dfb\u5bc6\u5316\u4e0d\u5168 (left ventricular non -compaction) ( 4)\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u78c1\u632f\u9020\u5f71\u5f71\n\u50cf\u6aa2\u67e5\u5448\u73fe\u6025\u6027\u5fc3\u808c\u767c\u708e (5)\u8a72\u75c5\u60a3\u61c9\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u5291 (6)\u9019\u7a2e\u75be\u75c5\u6709\u6642\u662f\u56e0\u808c\u7bc0 (sarcomere )\u57fa\u56e0\u7570\u5e38\n\u5f15\u8d77   \nA.(1)+(3)+(6)\u3002\nB.(2)+(3)+(5)\u3002\nC.(2)+(4)\u3002\nD.(2)+(4)+(5)\u3002\nE.(2)+(6)\u3002\n": "[C]", "110-17.\u6709\u95dc\u5229\u7528\u5fc3\u81df\u518d\u540c\u6b65\u5316\u7bc0\u5f8b\u5668 (cardiac resynchronization therapy, CRT )\u6cbb\u7642\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart \nfailure with reduced ejection fraction )\u7684\u6558\u8ff0,\u4f55\u8005\u6b63\u78ba ?   \nA.Cardiac Resynchronization in Heart Failure Study (CARE-HF) trial \u986f\u793aCRT \u4e0d\u80fd\u6539\u5584\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\n\u7387(all cause mortality )\u3002\nB.\u5728\u5fc3\u96fb\u5716 QRS complex width  >149 ms \u4e14\u5408\u4f75\u53f3\u675f\u652f\u50b3\u5c0e\u963b\u65b7\u60a3\u8005\u6548\u679c\u6700\u597d\u3002\nC.\u5de6\u53f3\u5fc3\u5ba4\u7684\u4e0d\u540c\u6b65\u6536\u7e2e,\u5e38\u5c0e\u81f4\u529f\u80fd\u6027\u7684\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168,\u9032\u800c\u52a0\u91cd\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u3002\nD.\u7576\u4f7f\u7528CRT \u5728\u9019\u985e\u75c5\u4eba\u6539\u5584\u5de6\u5fc3\u5ba4\u6536\u7e2e\u5206\u7387\u5f8c,\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u56b4\u91cd\u5ea6\u537b\u5e38\u7121\u6cd5\u6539\u5584\u3002\nE.CRT\u7684\u5de6\u5fc3\u5ba4\u5c0e\u7dda\u5e38\u7d93\u7531\u51a0\u72c0\u975c\u8108\u7ac7(coronary sinus)\u7f6e\u653e\u3002\n": "[E]", "110-18.\u6709\u95dcMarfan syndrome\u7684\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?    \nA.\u7576\u5b55\u5a66\u5408\u4f75 Marfan syndrome\u6642,\u5982\u679c\u4e3b\u52d5\u8108\u6839\u90e8>40 mm,\u5247\u4e3b\u52d5\u8108\u525d\u96e2\u7684\u98a8\u96aa\u589e\u52a0\u3002\nB.Marfan syndrome\u60a3\u8005\u4f7f\u7528propranolol\u4f86\u964d\u8840\u58d3,\u7121\u6cd5\u6e1b\u7de9\u6216\u9810\u9632\u4e3b\u52d5\u8108\u64f4\u5927\u3002\nC.\u88c2\u9699\u71c8\u6aa2\u67e5(slit-lamp examination) \u5c0d\u8a3a\u65b7Marfan syndrome\u5f88\u91cd\u8981\u3002\nD.\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5c0d\u8a3a\u65b7Marfan syndrome\u5f88\u91cd\u8981\u3002\nE.\u6839\u64daGhent criteria\u8a3a\u65b7\u7684Marfan syndrome\u60a3\u8005,\u8d85\u904e90% \u90fd\u6709FBN1\u57fa\u56e0\u7684\u7a81\u8b8a\u3002   \n": "[B]", "111-1.\u75c5\u4eba58\u6b72\u7537\u6027 \uff0c\u6709\u50f5\u76f4\u6027\u810a\u690e\u708e \uff0c\u8fd1\u6708\u4f86\u9010\u6f38\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u4e43\u81f3\u91ab\u9662\u6c42\u8a3a \u3002\u7d93\u7cfb\u5217\u5fc3\u81df\u6aa2\u67e5\u78ba\u8a3a\u4e3b\u52d5\n\u8108\u9589\u9396\u4e0d\u5168 (Aortic regurgitation )\uff0c\u4f9d\u64da\u6a19\u7684\u7406\u5b78\u6aa2\u67e5 (Targeted physical examination) \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u624d\n\u662f\u6b63\u78ba\u7684\u807d\u8a3a ?\n(1) \u5728\u5fc3\u5c16\u8655 (Apical area )\u6709Gr 2/6 mid-systolic click and late systolic murmur \uff0c\n(2) \u5728\u53f3\u80f8\u9aa8\u7de3 (Right sternal border )\u6709Gr3/6 decrescendo, early diastolic murmur\uff0c \n(3) \u5728\u5fc3\u5c16\u8655\u6709Gr 1-2/6 mid-diastolic murmur \uff0c\n(4) \u5728\u53f3\u80f8\u9aa8\u7de3\u4e0b\u7aef\u6709 S3 gallop\uff0c\n(5) \u5728\u5fc3\u5c16\u8655\u6709Open Snap \uff0c\n(6) \u5728\u4e3b\u52d5\u8108\u5340 (Aortic area )\u6709Ejection click \u3002   \nA.(1)+(2)+(3)\u3002\nB.(2)+(4)+(6)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[D]", "111-2.\u4f9d\u64da1991\u5e74\u4e16\u754c\u885b\u751f\u7d44\u7e54\u7684\u8a8d\u5b9a \uff0c\u9ad8\u8840\u58d3\u662f\u5168\u7403\u75be\u75c5\u8ca0\u64d4\u4e4b\u91cd \uff0c\u6709\u95dc\u9ad8\u8840\u58d3\u7684\u8a3a\u7642\u4e4b\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\n\u8ad6\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5 ?\n(1) SARS-CoV-2 \u7684\u611f\u67d3\u8207\u68d8\u86cb\u767d (Spike protein) \u7684ACE\u6709\u95dc \uff0c\u4f46ACEi \u53caARB\u7684\u4f7f\u7528 \uff0c\u4e26\u672a\u6709\u6703\u5f71\u97ff\u8a72\u75c5\n\u6bd2\u611f\u67d3\u53ca\u75c5\u60c5\u60e1\u5c55\n(2) Sodium glucose co -transporter 2 (SGLT2) inhibitors \u53ca Glucagon -like peptide -1 receptor agonists \n(GLP1-RA) \u662f\u7cd6\u5c3f\u75c5\u53ca\u975e\u7cd6\u5c3f\u75c5\u4eba\u7684\u6709\u5229\u964d\u58d3\u5291\n(3) \u5e74\u9f61\u9ad8\u65bc85\u6b72\u8001\u4eba\u4e4b\u8840\u58d3\u76ee\u6a19\u662f <150/90 mmHg \uff0c\u592a\u9ad8\u53ca\u592a\u4f4e\u90fd\u589e\u52a0\u5fc3\u8840\u7ba1\u75c5 \u3001\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u5fc3\u8870\n\u7684\u767c\u751f\u7387  \n(4) \u814e\u795e\u7d93\u5207\u9664\u624b\u8853 (Renal nerve denervation )\u662f\u9811\u56fa\u6027\u9ad8\u8840\u58d3 (Resistant hypertension) \u6cbb\u7642\u7684\u552f\u4e00\u9078\u64c7\n(5) \u4f9d\u64da\u6301\u7e8c\u602724\u5c0f\u6642\u8840\u58d3\u8a18\u9304 \uff0c\u5982\u82e5\u55aa\u5931\u591c\u9593\u8840\u58d3\u4e0b\u964d (Night dipping) \u8207\u5fc3\u8870\u53ca\u5fc3\u8840\u7ba1\u75c5\u6709\u91cd\u5927\u7684\u76f8\u95dc \n(6) \u6b63\u5e38\u8840\u58d3\u8005\u5982\u82e5\u6709\u904b\u52d5\u6027\u5fc3\u7e2e\u9ad8\u8840\u58d3 >200 mmHg \uff0c\u4e5f\u4e0d\u5177\u5fc3\u8840\u7ba1\u75c5\u7684\u98a8\u96aa   \nA.(1)+(3)+(5)\u3002\nB.(2)+(4)+(6)\u3002\nC.(2)+(3)+(5)\u3002\nD.(1)+(2)+(3)\u3002\nE.(1)+(3)+(6)\u3002\n": "[B]", "111-3.\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation, AF) \u662f\u500b\u9032\u5c55\u6027\u7684\u5fc3\u5f8b\u4e0d\u6574 \uff0c\u5e38\u898b\u65bc\u8001\u4eba \u3001\u5fc3\u81df\u75c5\u3001\u5fc3\u8870\u3001\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\n\u9032\u75c7\u75c5\u4eba \uff0c\u4e14\u6642\u8207\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u3001\u80a5\u80d6\u75c7\u547c\u5438\u4e2d\u6b62\u75c5\u76f8\u4f34 \uff0c\u5176\u8207\u4e2d\u98a8 \u3001\u5931\u667a\u7684\u767c\u751f\u53ca\u6b7b\u4ea1\u7387\u7684\u591a\u898b\u6709\n\u95dc\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u6709\u95dcAF\u7684\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 ?   \nA.\u5728\u5be6\u8a3c\u91ab\u5b78\u986f\u793a\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (NOAC)\u5982dabigatran, rivaroxaban, apixaban, \u53ca edoxaban \u6bd4 \nWarfarin \u5c0d\u975e\u74e3\u819c\u6027AF (Nonvalvular AF) \u75c5\u4f8b\u6709\u6548\u6e1b\u5c11\u6b7b\u4ea1\u7387 \uff0c\u4e5f\u5c11\u6709\u4e2d\u98a8 \u3001\u5927\u51fa\u8840\u6216\u9871\u5167\u51fa\u8840\u7684\n\u526f\u4f5c\u7528\u3002\nB.AF\u6301\u7e8c\u8d85\u904e30\u79d2\u5c31\u6709\u8840\u6813\u5f62\u6210\u7684\u53ef\u80fd \uff0c\u662f\u4ee5\u8655\u7f6e\u6307\u5f15\u8a8d\u5b9aAF\u767c\u751f\u572848\u5c0f\u6642\u5167 \uff0c\u5f97\u4ee5\u96fb\u64ca\u6216\u85e5\u7269\u5f8b\u52d5\n\u8f49\u56de(Cardioversion) \uff0c\u552f\u61c9\u5148\u78ba\u5b9a\u5de6\u5fc3\u8033\u672a\u6709\u8840\u6813\u7684\u5b58\u5728 \u3002\nC.\u5fc3\u623f\u7570\u5e38\u5feb\u8df3\u7d93\u6b77\u591a\u6642\u6050\u81f4\u5fc3\u808c\u7d30\u80de\u8b8a\u7570 \uff0c\u884d\u6210\u7d44\u7e54\u518d\u5851 (Remodeling) \uff0c\u81f4\u6709\u7570\u5e38\u50b3\u5c0e \uff0c\u6539\u8b8a\u5fc3\u623f\n\u7d44\u7e54\u4e4b\u4e0d\u61c9\u671f \uff0c\u9020\u6210\u591a\u8655\u518d\u8ff4\u5165 (Re-entry)\u7684\u96fb\u6c23\u751f\u7406\u8b8a\u5316 \uff0c\u662f\u5fc3\u623f\u5fc3\u808c\u75c5 (Atrial cardiomyopathy )\u7684\n\u75c5\u56e0\u3002\nD.\u75c5\u4eba\u6709\u50e7\u5e3d\u74e3\u72f9\u7a84\u7f6e\u63db\u91d1\u5c6c\u6027\u4eba\u5de5\u74e3\u819c\uff0c\u4f7f\u7528Clopidogrel + Aspirin \u6bd4 Warfarin\u66f4\u5b89\u5168\u6709\u6548\u3002\nE.\u96fb\u6c23\u71d2\u707c(Electric ablation) \u5408\u9069\u5e74\u8f15\u4eba\u7684\u9663\u767c\u6027AF\u3002   \n": "[D]", "111-4.\u75c5\u4eba36\u6b72\u7537\u6027\u7a81\u7136\u55aa\u5931\u610f\u8b58\u6709\u4e00\u500b\u5c0f\u6642\u4e4b\u4e45 \uff0c\u4e43\u6025\u5f80\u91ab\u9662\u6c42\u8a3a \uff0c\u6642\u8840\u58d396 /56 mmHg \u5fc3\u8df3: 105 /min\uff0c\u547c\n\u5438: 20/min\u53ca\u9ad4\u6eab: 36 .2\u2103\u3002\u75c5\u4eba\u65e5\u524d\u7259\u75bc\u81f3\u8a3a\u6240\u6cbb\u7642 \uff0c\u4f7f\u7528ibuprofen, cephalexin \u53ca\u80c3\u85e5 \uff0c\u5341\u9ede\u5165\u7761 \uff0c\u5728\n\u6df1\u591c\u88e1\u807d\u898b\u547c\u5438\u5598\u9cf4 \uff0c4 AM\u4e0d\u9192\u4eba\u4e8b\u4e26\u6709\u7672\u7647\u767c\u4f5c\u53ca\u5c3f\u5931\u7981 \u3002\u7406\u5b78\u6aa2\u67e5\u986f\u793a E1M4V2\uff0c \u534a\u5c0f\u6642\u5f8c\u6e05\n\u9192\uff0c\u6709\u5614\u5410\u53ca\u982d\u75db\u4e4b\u8868\u793a \uff0c\u672a\u6709\u795e\u7d93\u53ca\u5176\u4ed6\u7570\u5e38\u6240\u898b \u3002CXR \u53ca\u5fc3\u96fb\u5716\u5982\u5716 \uff0c\u524d\u5f8c\u76f8\u9694\u4e8c\u5c0f\u6642 \u3002\u8840\u6db2\u751f\u5316\n\u6709K\u207a 2.8 mEq/L, Na\u207a 141 mEq /L,  AST 79 U/L,  ALT 98 U/L,  Cr 0.97 mg/dL, BUN 13 mg /dL, Sugar 132 \nmg/dL, Troponin I 0.04 ng/mL\u3002(\u9644\u5fc3\u96fb\u5716 \u3001\u80f8\u90e8X\u5149)\u3002\u5f9e\u75c5\u4eba\u7684\u5e74\u9f61 \u3001\u6027\u5225\u3001\u75c5\u53f2\u3001\u767c\u4f5c\u6642\u9593 \u3001\u5fc3\u96fb\u5716\n\u6240\u898b\u3001\u751f\u5316\u6aa2\u9a57\u548c\u7406\u5b78\u6240\u898b \uff0c\u672c\u75c5\u4f8b\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f \uff1a   \nA.Long QT syndrome with Torsades de Pointes\u3002\nB.Brugada syndrome with Electrical Storm and Incessant Ventricular Tachycardia\u3002\nC.Wolf-Parkinson-White syndrome with event of atrial fibrillation\u3002\nD.Early Repolarization J Wave Syndromes\u3002\nE.Arrhythmogenic RV cardiomyopathy\u3002\n": "[B]", "111-5.\u6709\u95dc\u6025\u6027\u5fc3\u8870\u7aed\u7684\u6cbb\u7642\u6307\u5f15\u4e26\u4e0d\u591a\u898b\uff0c\u90e8\u4efd\u7814\u7a76\u7684\u4e3b\u5f35\u6709\u81e8\u5e8a\u5be6\u7528\u50f9\u503c\uff0c\u4e0b\u5217\u7684\u4f55\u8005\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684?    \nA.\u96a8\u91ab\u5b78\u7684\u9032\u6b65 \uff0c\u6025\u6027\u5fc3\u8870\u6b7b\u4ea1\u7387\u4ecd\u820a\u5c45\u9ad8\u4e0d\u4e0b \uff0c\u5c24\u5176\u4e00\u500b\u6708\u5167\u53ca\u534a\u5e74\u5167\u518d\u4f4f\u9662\u7387\u5206\u5225\u9ad8\n\u905425%\u53ca50%\uff0c\u8017\u8cbb\u91ab\u7642\u8cc7\u6e90\u9817\u5927 \u3002\nB.\u6162\u6027\u5fc3\u8870\u6025\u6027\u60e1\u5316 \uff0c\u6bd4\u6025\u6027\u521d\u767c\u5fc3\u8870\u66f4\u591a \uff0c\u56e0\u6b64\u627e\u51fa\u8a98\u767c\u5fc3\u8870\u7684\u539f\u56e0\u8af8\u5982\u6025\u6027\u7f3a\u8840\u8b8a\u5316 \u3001\u611f\u67d3\u3001\u5fc3\u81df\n\u7d50\u69cb\u8b8a\u5316 \u3001\u5fc3\u5f8b\u4e0d\u6574 \u3001\u6216\u75c5\u4eba\u7528\u85e5\u9806\u5f9e\u7b49\u56e0\u7d20\u6700\u662f\u91cd\u8981 \u3002\nC.\u5f37\u529b\u7684\u5229\u5c3f\u5291\u662f\u5145\u8840\u6027\u5fc3\u8870\u7684\u95dc\u9375\u6cbb\u7642\u3002\nD.\u5c31\u5be6\u8a3c\u91ab\u5b78\uff0c\u73fe\u7528\u7684\u8840\u7ba1\u4f5c\u7528\u5291(Vasoactive agents)\u53ca\u5f37\u5fc3\u5291(Inotropes) \u90fd\u662f\u5dee\u5f37\u4eba\u610f\u7684\u6cbb\u7642\u3002\nE.\u6c27\u6c23\u7642\u6cd5\u6700\u70ba\u91cd\u8981 \uff0c\u7dad\u6301\u6108\u9ad8\u6c27\u6c23\u6fc3\u5ea6\u6709\u52a9\u7d44\u7e54\u6d3b\u529b \uff0c\u9ad8\u6d41\u91cf\u6c27\u6c23\u5438\u5165 \uff0c\u751a\u81f3\u5167\u7f6e\u6c23\n\u7ba1(Endotracheal intubation )\u4f9b\u6c27\u90fd\u662f\u61c9\u8a72\u7684\u8655\u7f6e \u3002\n": "[E]", "111-6.\u75c5\u4eba64\u6b72\u5bb6\u5ead\u4e3b\u5a66 \uff0c\u8fd1\u4e09\u500b\u6708\u4f86\u6709\u9593\u6b47\u6027\u80f8\u60b6\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \u3002\u75c5\u4eba\u6709\u6c23\u5598\u53ca\u9ad8\u8840\u58d310\u5e74\u75c5\u53f2 \uff0c\u898f\u5247\n\u670d\u7528Ipratropium \u6216Furosemide + Aldactone + Digoxin + Aspirin \u3002\u4e8b\u5be6\u4e0a\u75c5\u4eba\u904e\u53bb10\u5e74\u524d\u5c31\u6709\u985e\u4f3c\u75c7\n\u72c0\uff0c\u518d\u591a\u52a0\u670d\u7528\u4e0a\u5217\u85e5\u7269 \uff0c\u4e5f\u5c31\u6539\u5584 \u3002\u53ea\u662f\u8fd1\u6708\u4f86\u5168\u8eab\u5026\u6020 \uff0c\u98df\u617e\u4e0d\u632f \uff0c\u4e0a\u8179\u5fae\u75db\u53ca\u9ad4\u91cd\u6e1b\u8f15\u4e03\u516c\u65a4 \uff0c\u4e43\n\u65bc\u4e03\u6708\u5eff\u516d\u65e5\u4f4f\u9662\u8a3a\u7642 \u3002\u75c5\u4ebaHeight: 156 cm  Weight: 68kg ; T/P/R:37.1/88/16;\u3002 BP: 110 /73 \nmmHg\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38 \uff0c\u898f\u5247\u5f8b\u8df3 \uff0c\u552f\u5fc3\u5c16\u8655 (Apical area) \u6709\u96d9\u5cf0\u8108\u6ce2bifid pulse) \u53ca\u5728\u5de6\u4e0a\n\u80f8\u7de3\u53ca\u5fc3\u5c16\u8655\u6709Gr 4/6 Pansystolic murmur \uff0c\u4e0b\u80a2\u67092\u5ea6\u6d6e\u816b\uff0c\u4f46\u5176\u4ed6\u5668\u5b98\u4e26\u672a\u6709\u7570\u5e38 \u3002\u8840\u7403\u6aa2\n\u67e5:WBC,10.14k/uL; RBC, 4.79 M/uL; Platelet, 169 K/uL\u3002\u8840\u6db2\u751f\u5316\u7d50\u679c: Albumin, 4.2 gm/dL; T-Bil, 0.86 \nmg/dL; BUN, 16 .8 mg/dL; Cre1.0 mg/dL; ALT, 90 U/L\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8 \uff38\u5149\u5982\u5716\u3002\u7d93\u5fc3\u5c0e\u7ba1\u6aa2\u67e5: \u5927\u52d5\u8108\n\u8840\u58d3, 142 /68 mmHg; \u5de6\u5fc3\u5ba4\u51fa\u53e3\u90e8( LVOT ), 158/28 mmHg; \u5de6\u5fc3\u5ba4\u5fc3\u5c16\u90e8, 198 /32 mmHg. \u5176\u5de6\u5fc3\u5ba4\u9020\u5f71\n\u53caCardiac CT\u5982\u5716 \u3002\u8acb\u554f\u75c5\u4eba\u7684\u6b63\u78ba\u5fc3\u81df\u8a3a\u65b7\u662f \uff1a   \nA.\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5(Hypertensive cardiovascular disease)\u3002\nB.\u5de6\u5fc3\u5ba4\u5fc3\u5c16\u80a5\u539a\u6027\u5fc3\u808c\u75c5(LV apical hypertrophic cardiomyopathy)\u3002\nC.\u5de6\u5fc3\u5ba4\u4e2d\u90e8\u5fc3\u808c\u80a5\u539a\u75c5(Mid-LV hypertrophic cardiomyopathy)\u3002\nD.\u7f3a\u8840\u6027\u5fc3\u81df\u75c5(Ischemic cardiomyopathy)\u3002\nE.\u64f4\u5927\u6027\u5fc3\u808c\u75c5(Dilated cardiomyopathy)\u3002\n": "[C]", "111-7.\u96a8\u8457\u75c5\u7406\u751f\u7406\u6a5f\u8f49\u7684\u8a8d\u77e5 \uff0c\u5fc3\u8870\u6cbb\u7642\u53ca\u5fc3\u81df\u5f71\u50cf\u9032\u6b65 \uff0c\u5fc3\u5167\u5916\u624b\u8853\u6cbb\u7642\u7684\u6f14\u9032 \uff0c\u6709\u95dc\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\n\u5168(Mitral regurgitation, MR) \u6709\u8af8\u591a\u65b0\u5c55 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u7684\u4e3b\u5f35\u662f\u4e0d\u5408\u7576\u4eca\u6642\u5b9c ?   \nA.\u56e0\u4e8c\u5c16\u74e3\u74b0 (Mitral annulus )\u3001\u4e73\u7a81\u808c(Papillary muscles )\u53ca\u5de6\u5fc3\u5ba4\u7570\u5e38\u9020\u6210\u7684\u9589\u9396\u4e0d\u5168\u662f\u539f\u767c\n\u6027MR(Primary MR )\uff0c\u800c\u56e0\u4e8c\u5c16\u74e3\u8449 (Mitral leaflet )\u53ca\u8171\u7d22\u7570\u5e38 (Chordae tendineae )\u800c\u81f4\u7684\u9589\u9396\u4e0d\u5168\u662f\n\u7e8c\u767c\u6027MR (Secondary MR )\u3002   \nB.\u4e0d\u8ad6\u75c7\u72c0\u4e4b\u6709\u7121 \uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u76f4\u5f91 >40 mm\u53ca\u5de6\u5fc3\u5ba4\u5c04\u51fa\u91cf <60%\u662f\u5167\u5916\u79d1\u4ecb\u5165\u624b\n\u8853(Intervention )\u7684\u95dc\u9375\u6839\u64da \u3002\nC.\u7f3a\u8840\u6027MR (Ischemic MR )\u5e38\u56e0\u5de6\u5fc3\u5ba4\u5f8c\u58c1\u5931\u80fd \uff0c\u5de6\u5fc3\u5ba4\u64f4\u5927 \uff0c\u5c0e\u81f4\u8171\u7d22\u53ca\u4e73\u982d\u808c\u5931\u80fd\u800c\u8d77 \uff0c\u662f\u6df7\u5408\n\u6027MR(\uff2dixed MR) \uff0c\u4ee5\u5916\u79d1\u7e5e\u9053\u624b\u8853\u53ca\u4e8c\u5c16\u74e3\u819c\u7f6e\u63db\u70ba\u4f73 \u3002\nD.\u7d93\u5c0e\u7ba1\u7de3\u5c0d\u7de3\u593e\u5408(Trans-catheter edge to edge mitral clip) \u5c0d\u539f\u767c\u6027\u53ca\u7e8c\u767c\u6027MR\u90fd\u662f\u5408\u9069\u7684\u6cbb\u7642\u3002\nE.\u56e0\u5de6\u5fc3\u623f\u64f4\u5927\u5c0e\u81f4\u7684\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\u53ca\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u90fd\u662f\u6c7a\u5b9a\u5fc3\u81df\u5167\u5916\u79d1\u624b\u8853\u7684\u6839\u64da\u3002\n": "[A]", "111-8.\u731d\u6b7b\u7684\u767c\u751f \uff0c\u4f54\u5fc3\u8840\u7ba1\u75c5\u6b7b\u4ea1\u768450 %\uff0c \u4e5f\u662f\u5065\u5eb7\u4eba\u7684\u7b2c\u4e00\u6b21\u5fc3\u81df\u75c5\u767c\u4f5c\u768450 %\u3002\u5728\u53f0\u7063\u6bcf\u5e74\u6709\u9662\u5916\u731d\u6b7b\n\u5728\u9662\u5167\u7684\u6551\u6d3b\u800c\u7121\u795e\u7d93\u50b7\u8b8a\u8005\u50c5\u53ea21 .7%\uff0c\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u731d\u6b7b\u7684\u8aaa\u6cd5 \uff0c\u4f55\u8005\u4e0d\u6b63\u78ba ?   \nA.\u51a0\u5fc3\u75c5\u53ca\u5fc3\u8870\u662f\u731d\u6b7b\u6700\u91cd\u8981\u7684\u5371\u96aa\u56e0\u7d20\u3002\nB.\u731d\u6b7b\u5e38\u898b\u7684\u5fc3\u8df3\u9589\u6b62 (Asystole) \u53ca\u7121\u8108\u6027\u96fb\u6c23\u6d3b\u6027 (Pulseless electric activity) \uff0c\u524d\u8005\u5e38\u56e0\u96fb\n\u64ca(Electric cardioversion )\u7d50\u679c\uff0c\u5f8c\u8005\u591a\u56e0\u5931\u8840 \u3001\u7f3a\u6c27\u3001\u4ee3\u8b1d\u7570\u5e38\u6216\u80ba\u52d5\u8108\u6813\u585e\u800c\u8d77 \u3002\nC.\u5bec\u8f3bQRS\u578b\u5feb\u8df3\u5e38\u662f\u5fc3\u5ba4\u6027\u7570\u8df3\uff0c\u61c9\u7dca\u6025\u8655\u7f6e\u3002\nD.\u6b63\u5e38QRS\u578b\u5feb\u8df3\u5982\u82e5\u4f34\u6709\u7729\u6688\u6216\u4f4e\u8840\u58d3\uff0c\u4ea6\u61c9\u7dca\u6025\u8655\u7f6e\u3002\nE.\u4ee5\u85e5\u7269\u4e4b\u6cbb\u7642\u6162\u6027\u5fc3\u5ba4\u6027\u671f\u5916\u6536\u7e2e\u53ef\u9632\u6b62\u731d\u6b7b\u767c\u751f\u3002\n": "[E]", "111-9.\u75c5\u4eba\u738b\u5148\u751f\u73fe\u5e7488 \u6b72\uff0c\u6709\u5169\u500b\u6708\u7684\u96d9\u8173\u6d6e\u816b\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u6578\u5ea6\u524d\u5f80\u591a\u5bb6\u91ab\u9662\u6c42\u8a3a \uff0c\u8a3a\u7642\u7f54\u6548 \u3002\u75c5\u4eba\n\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u8102\u8840\u3001\u6162\u6027\u814e\u81df\u75c5\u53ca\u524d\u5217\u817a\u80a5\u5927\u7b49\u904e\u5f80\u75c5\u53f2 \u3002\u5230\u8a3a\u6642\u610f\u8b58\u6e05\u9192\uff0c T/P/R: 35.5 \u00b0C/99/18; \nBP: 106/83 mmHg; SpO 2: 92%\u3002(ambient air ); BH: 165 cm; BW: 66 kg; BMI: 24 .2 kg/m2 \u7406\u5b78\u6aa2\u67e5\u767c\u73fe\n\u984f\u9762\u5fae\u816b \uff0c\u9838\u975c\u8108\u4e2d\u5ea6\u6012\u5f35 \uff0c\u8108\u640f\u7a0d\u5f31 \uff0c\u4e26\u672a\u6709\u986f\u8457Paradoxical pulse, \u53caKussmaul sign \uff0c\u547c\u5438\u8072\u6e05\n\u6de8\uff0c\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38 \uff0c\u5fc3\u97f3\u7565\u9060 \uff0cP2\u7a0d\u5f37\uff0cPericardial friction\u53ef\u7591 \uff0c\u7121\u809d\u3001\u813e\u816b\u5927\uff0c\u96d9\u8173\u5fae\u816b \u3002\u5176\u5fc3\u96fb\n\u5716\u3001\u80f8\u90e8X\u5149\u53ca\u5176\u4ed6\u5f71\u50cf\u6aa2\u67e5\u5982\u5716 \uff1a\u8acb\u554f\u4f9d\u7167\u4e0a\u5217\u6578\u500b\u6a19\u7684\u4e4b\u7406\u5b78\u6aa2\u67e5 (Targeted physical examination) \n\u53ca\u5be6\u9a57\u5ba4\u6240\u898b \uff0c\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f   \nA.Non-ST elevation myocardial infarction\u3002\nB.Pericardial disease\u3002\nC.Hypertrophic cardiomyopathy\u3002\nD.Dilated cardiomyopathy\u3002\nE.Fabry disease\u3002\n": "[B]", "111-10.65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u81ea\u5e74\u8f15\u6642\u5373\u8a3a\u65b7WPW\u75c7\u5019\u7fa4 (Wolff-Parkinson -White syndrome )\uff0c\u591a\u5e74\u4f86\u76f8\u5b89\u7121\u4e8b \u3002\u4e00\u500b\n\u5c0f\u6642\u524d\u7a81\u767c\u5fc3\u623f\u986b\u52d5\u5408\u4f75\u5fc3\u640f\u904e\u901f\u4f86\u6025\u8a3a \u3002\u6025\u8a3a\u6aa2\u67e5\u767c\u73fe\u8840\u58d3\u7a69\u5b9a \uff0c\u5fc3\u8df3\u901f\u5ea6\u7d04\u6bcf\u5206\u9418180 \u4e0b\u3002\u4f60\u70ba\u7576\u65e5\n\u503c\u73ed\u91ab\u5e2b \uff0c\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u975c\u8108\u6ce8\u5c04adenosine\u3002\nB.\u975c\u8108\u6ce8\u5c04digoxin\u3002\nC.\u975c\u8108\u6ce8\u5c04amiodarone\u3002\nD.\u7d66\u4e88\u53e3\u670dbeta-blockers\u3002\nE.\u7d66\u4e88\u93ae\u975c\u9ebb\u9189\u5f8c\uff0c\u5be6\u65bd\u96fb\u64ca(electric cardioversion)\u3002\n": "[E]", "111-11.\u5fc3\u81df\u8870\u7aed\u5408\u4f75\u5fc3\u623f\u986b\u52d5 (atrial fibrillation )\u7684\u75c5\u4eba\uff0c\u5982\u679c\u63a1\u53d6\u5fc3\u5f8b\u63a7\u5236 (rhythm control )\u7b56\u7565\uff0c\u4ee5\u4e0b\u4f55\u8005\u662f\u9996\n\u9078\u85e5\u7269\uff1f   \nA.Propafenone\u3002\nB.Flecainide\u3002\nC.Dronedarone\u3002\nD.Amiodarone\u3002   \nE.Quinidine\u3002\n": "[D]", "111-12.\u5c0d\u65bc\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u4e4b\u5fc3\u8870\u7aed\u4e4b\u6cbb\u7642\uff0c\u4f55\u7a2e\u85e5\u7269\u7121\u6cd5\u589e\u52a0\u5b58\u6d3b\u7387\uff1f    \nA.\u8840\u7ba1\u6536\u7e2e\u7d20\u8f49\u5316\u9176\u6291\u5236\u5291 \uff08angiotensin -converting enzyme inhibitor \uff0c\nACEI\uff09\u3002\nB.\u74b0\u7ba1\u5229\u5c3f\u5291 (loop diuretic)\u3002\nC.\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u62ee\u6297\u5291\uff08\u03b2-blockers\uff09\u3002\nD.\u919b\u56fa\u916e\u62ee\u6297\u5291\uff08spironolactone\uff09\u3002\nE.\u8840\u7ba1\u6536\u7e2e\u7d20\u53d7\u9ad4\u963b\u65b7\u5291(angiotensin receptor blocker)\u3002\n": "[B]", "111-13.\u4e0b\u5217\u6709\u95dcST\u7bc0\u6bb5\u4e0a\u5347\u7684\u5fc3\u808c\u6897\u585e\uff08ST-elevation myocardial infarction\uff0cSTEMI\uff09\u7684\u654d\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u4e3b\u8981\u7684\u767c\u75c5\u6a5f\u8f49\u70ba\u8840\u7ba1\u5167\u7ca5\u72c0\u786c\u5316\u6591\u7470\u7834\u88c2\uff0c\u7522\u751f\u6025\u6027\u8840\u6813\u5c07\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u3002\nB.\u6297\u8840\u677f\u85e5\u7269clopidogrel\u6548\u679c\u7684\u81e8\u5e8a\u6548\u679c\u8207ticargrelor, prasugrel\u76f8\u4f3c\u3002\nC.\u75c5\u767c\u5982\u572812\u5c0f\u6642\u5167\uff0c\u8981\u7167\u6703\u5fc3\u81df\u79d1\u5118\u5feb\u9032\u884c\u5fc3\u5c0e\u7ba1\u6253\u901a\u8840\u7ba1\u3002\nD.\u53ef\u4f7f\u7528\u809d\u7d20(heparin)\u6216\u4f4e\u5206\u5b50\u91cf\u809d\u7d20(low-molecular-weigth heparin, LMWH)\u6cbb\u7642\u3002\nE.\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\u5408\u4f75\u53f3\u5fc3\u6897\u585e\u6642\uff0c\u5982\u8840\u58d3\u4e0d\u7a69\uff0c\u53ef\u8003\u616e\u8f38\u6db2\u6cbb\u7642\u3002\n": "[B]", "111-14.\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f    \nA.\u6700\u5e38\u898b\u7684\u6301\u7e8c\u6027\u5fc3\u5f8b\u4e0d\u6574\uff0c\u4e00\u822c\u800c\u8a0080\u6b72\u4ee5\u4e0a\u76db\u884c\u7387\u7d0410\uff05\u3002\nB.\u5f15\u8d77\u5fc3\u623f\u986b\u52d5\u7684\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u5e74\u8001\uff0c\u9ad8\u8840\u58d3\uff0c\u7cd6\u5c3f\u75c5\uff0c\u80a5\u80d6\uff0c\u547c\u5438\u7d42\u6b62\u75c7\u7b49\u3002\nC.\u5fc3\u623f\u986b\u52d5\u7d04\u589e\u52a05\u500d\u4e2d\u98a8\u7684\u6a5f\u6703\u3002\nD.\u6297\u51dd\u8840\u5291\u5982aspirin\u7b49\u80fd\u6709\u6548\u9810\u9632\u4e2d\u98a8\u767c\u751f\u3002\nE.\u7d0430\uff05\u7684\u958b\u5fc3\u624b\u8853\u60a3\u8005\u8853\u5f8c\u53ef\u80fd\u7522\u751f\u9577\u77ed\u4e0d\u7b49\u7684\u9663\u767c\u6027\u5fc3\u623f\u986b\u52d5\u3002\n": "[D]", "111-15.70\u6b72\u9673\u5148\u751f \uff0c\u56e0\u70ba\u767c\u71d2\u5408\u4f75\u5598\u8207\u7aef\u5750\u547c\u5438\u81f3\u6025\u8a3a \uff0c\u8eab\u9ad4\u6aa2\u67e5\u5728\u5fc3\u5c16\u90e8\u4f4d\u807d\u5230\u7b2c\u56db\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3 \uff0c\u4e14\u80ba\u90e8\u6709\n\u56c9\u97f3(rales\uff09\u3002 \u5fc3\u81df\u8d85\u97f3\u6ce2\u5728\u4e8c\u5c16\u74e3\u767c\u73fe\u8d05\u751f\u7269 (vegetation )\uff0c\u4e09\u5957\u8840\u6db2\u57f9\u990a\u5448\u73festreptococcus \ngallolyticus \u3002\u8acb\u554f\u9664\u4e86\u5fc3\u5167\u819c\u708e\u5916 \uff0c\u4e0b\u5217\u75be\u75c5\u5fc5\u9808\u5217\u5165\u8003\u616e \uff1f   \nA.\u8166\u819c\u75c5\u8b8a\u3002\nB.\u814e\u7d50\u77f3\u5f15\u767c\u814e\u6c34\u816b\u3002\nC.\u5927\u8178\u606f\u8089\u6216\u5927\u8178\u764c\u3002\nD.\u80ba\u90e8\u75c5\u8b8a\u3002\nE.\u651d\u8b77\u817a\u767c\u708e\u3002\n": "[C]", "111-16.\u738b\u8001\u592a\u592a\u4e09\u500b\u6708\u524d\u63a5\u53d7\u5fc3\u81df\u74e3\u819c\u7f6e\u63db\u624b\u8853 \uff0c\u8fd1\u4e00\u500b\u6708\u4f86 \uff0c\u904b\u52d5\u6642\u547c\u5438\u56f0\u96e3\u9010\u6f38\u52a0\u91cd\u4e14\u6709\u4e0b\u80a2\u6c34\u816b \u3002\u7d93\u6aa2\u67e5\n\u809d\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u7d66\u4e88\u5229\u5c3f\u5291\u6cbb\u7642\u4f46\u9838\u975c\u8108\u4ecd\u6709\u986f\u8457\u64f4\u5f35 \u3002\u9580\u8a3a\u80f8\u90e8 X\u5149\u986f\u793a\u5fc3\u81df\u4e26\u672a\u64f4\u5927 \uff0c\u8eab\u9ad4\u8a3a\u5bdf\u7121\u5fc3\n\u96dc\u97f3\uff0c\u809d\u81df\u7a0d\u816b\u5927 \uff0c\u6709\u8179\u6c34\u53ca\u96d9\u5074\u4e0b\u80a2\u6c34\u816b \u3002\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u53f3\u5fc3\u623f\u5e73\u5747\u58d3\u529b\u589e\u52a0\u4e14\u53f3\u5fc3\u623f\u58d3\u529b\u66f2\u7dda\u5448\u73fe\u660e\u986f\n\u7684Y\u4e0b\u964d\u6ce2\u3002\u4ee5\u4e0b\u6709\u95dc\u672c\u75c5\u4eba\u7684\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u8840\u58d3\u4e0a\u5347\u4e14\u8108\u640f\u58d3\u8b8a\u5bec\u3002\nB.\u80f8\u90e8X\u5149\u7247\u5448\u73fe\u80ba\u9b31\u8840\uff08lung congestion\uff09\u73fe\u8c61\u3002\nC.\u5de6\u53f3\u5fc3\u5ba4\u8212\u5f35\u672b\u671f\u58d3\u529b(end-diastolic pressure)\u4e0d\u7b49\u3002\nD.\u807d\u8a3a\u6642\u6709\u53ef\u80fd\u6703\u6709\u5fc3\u5305\u6572\u64ca\u97f3\uff08pericardial knock\uff09\uff0c\u6709\u4e9b\u6703\u51fa\u73fe\uff62\u5947\u8108\uff63\uff08paradoxical pulse\uff09\u3002\nE.\u547c\u6c23\u6642\uff0c\u9838\u52d5\u8108\u64f4\u5f35\u53ef\u80fd\u66f4\u5f62\u986f\u8457\u3002\n": "[D]", "111-17.\u6709\u95dc\u5fc3\u81df\u8870\u7aed (Heart failure) \u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u6b63\u78ba\uff1f       \nA.\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387\u4fdd\u7559\u5fc3\u81df\u8870\u7aed (heart failure with preserved ejection fraction, HFpEF )\u75c5\u60a3\uff0c\u7d66\u4e88\u8840\u7ba1\u6536\n\u7e2e\u7d20\u8f49\u5316\u9176\u6291\u5236\u5291 \uff08angiotensin -converting enzyme inhibitor \uff0cACEI\uff09\u53ef\u6709\u6548\u6539\u5584\u9810\u5f8c \u3002\nB.\u6bdb\u5730\u9ec3(digoxin)\u56e0\u7121\u6cd5\u6539\u5584\u75c5\u4eba\u9810\u5f8c\uff0c\u76ee\u524d\u50c5\u5728\u5176\u5b83\u85e5\u7269\u5145\u5206\u4f7f\u7528\u5f8c\u4ecd\u6709\u660e\u986f\u75c7\u72c0\u6642\u8003\u616e\u7d66\u4e88\u3002\nC.\u5f37\u5fc3\u85e5\u7269 (inotropic agents )\u7121\u6cd5\u6539\u5584\u9810\u5f8c \uff0c\u751a\u81f3\u53ef\u80fd\u589e\u52a0\u6b7b\u4ea1\u7387\u53ca\u4f75\u767c\u75c7 \uff0c\u76e1\u91cf\u5728\u6709\u9700\u8981\u6642\u77ed\u671f\u4f7f\n\u7528\u3002\nD.\u6025\u6027\u5931\u8abf\u6027\u5fc3\u81df\u8870\u7aed (Acute decompensated heart failure \uff0cADHF)\u53ef\u80fd\u6703\u4f75\u767c\u5fc3\u814e\u75c7\u5019\n\u7fa4(Cardio-renal syndrome )\uff0c\u4f7f\u7528\u5229\u5c3f\u91cf\u589e\u52a0\u6b64\u985e\u75c5\u4eba\u4e4b\u6392\u5c3f\u91cf\u4e0d\u76e1\u6709\u6548 \u3002\nE.\u5728\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6e1b\u5c11\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction, HFrEF )\u75c5\n\u60a3\uff0cLCZ696(Sacubitril /Valsartan )\u8f03Ramipril\u66f4\u80fd\u6709\u6548\u6e1b\u5c11\u6b7b\u4ea1\u7387 \u3002\n": "[A]", "111-18.\u5433\u5148\u751f\u70ba\u6162\u6027\u814e\u81df\u75c5\u75c5\u4eba \uff0c\u56e0\u70ba\u5168\u8eab\u7121\u529b\u5c31\u8a3a \uff0c\u62bd\u8840\u767c\u73fe\u8840\u6e05\u808c\u9178\u9150 \uff08creatinine \uff09\u70ba5.0 mg/dL \uff0c\u8840\n\u9240\uff08K\uff097. 2 mmol/L\uff0c\u6709\u95dc\u5fc3\u96fb\u5716\u53ef\u80fd\u7684\u8b8a\u5316\u4e0b\u5217\u4f55\u8005\u6709\u8aa4 \uff1f   \nA.\u9ad8\u5c16T\u6ce2\uff08peaked T wave\uff09\u3002\nB.PR\u671f\u9593\u8b8a\u9577\u3002\nC.QRS\u6ce2\u8b8a\u5bec\u3002\nD.QT\u671f\u9593\u8b8a\u9577\u3002\nE.P\u6ce2\u8b8a\u6241\u3002\n": "[D]"}